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Summary 
Coronary heart disease (CHD) leading to myocardial infarction (MI) is the primary 
cause of morbidity and mortality globally. Following an MI, a number of 
structural and functional changes to the myocardium occur, known as cardiac 
remodelling. Initially, these changes are adaptive. Inflammation and deposition 
of extracellular matrix (ECM) components and collagen occurs in order to form 
the scar tissue, and in response to the rise in wall stress cardiomyocytes undergo 
adaptive hypertrophy in order to maintain contractile performance of the heart. 
There are also alterations in the electrical properties of the heart, including 
dysregulation of a variety of Ca2+-handling proteins. In the long term these 
processes become maladaptive. Reactive fibrosis stiffens the ventricular wall, 
eccentric hypertrophy contributes to expansion of the left ventricle (LV) and the 
electrical changes lead to reduced contraction and increased propensity to 
arrhythmia, all of which can contribute to the development of heart failure (HF) 
and the possibility of sudden cardiac death (SCD). Dysregulation of the renin-
angiotensin system (RAS) is one of the factors responsible for driving these 
adaptive and maladaptive remodelling processes. The main effector peptide of 
the RAS, Angiotensin II (Ang II), acting via the Angiotensin type 1 receptor (AT1R) 
mediates the majority of the maladaptive changes which occur post-MI. The 
counter-regulatory axis of the RAS has been found to counteract many of 
deleterious effects associated with Ang II signalling. The peptide Ang-(1-7), 
signalling via Mas, has been found to exert anti-fibrotic and anti-hypertrophic 
effects and improve LV function post-MI. Less is known about the peptide Ang-
(1-9), however there is evidence that it too is able to exert anti-hypertrophic 
and anti-fibrotic effects post-MI, however improvements on cardiac function 
have not been previously demonstrated. Therefore, the main aim of this thesis 
was to investigate the therapeutic potential of Ang-(1-9) via a gene transfer 
approach on adverse remodelling in a mouse model of MI, with a focus on 
cardiac functional parameters.  
First, the mouse model of MI was established and characterised for adverse 
structural and functional remodelling parameters. Haemodynamic and functional 
measurements using echocardiography and pressure-volume (PV) loops 
demonstrated a reduction in contractility and ejection fraction (EF) following MI. 
This was also associated with an increase in concentric cardiomyocyte 
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hypertrophy, fibrosis and collagen deposition. Moreover, alterations in 
expression of cardiac AT1R, Angiotensin type 2 receptor (AT2R), Angiotensin 
converting enzyme (ACE) and Angiotensin converting enzyme 2 (ACE2) were 
detected. Following characterisation, this model was utilised to assess the 
effects of viral-mediated Ang-(1-9) delivery.  
Initially, an adenoviral vector (Ad) expressing a biological peptide pump enabling 
the synthetic production of Ang-(1-9) [RAdAng-(1-9)] was utilised in order to 
assess the effects of the peptide following MI. Efficient transduction of the 
healthy myocardium following MI was demonstrated using direct intramyocardial 
Ad injection. Initially, it was found that administration of RAdAng-(1-9) reduced 
the mortality rate associated with the MI procedure, with a reduction in deaths 
from unknown causes and cardiac rupture. Functional cardiac parameters were 
monitored using echocardiography for a 4 week period, with RAdAng-(1-9) 
administration found to be associated with increased LV fractional shortening 
(FS) compared to MI controls from 1 to 4 wks. PV loop measurements confirmed 
this improved function, with increased end systolic pressure (ESP) and 
normalised EF found in RAdAng-(1-9) administered animals. Post-mortem analysis 
and histology demonstrated an anti-hypertrophic effect of RAdAng-(1-9) 
delivery, with reduced heart weight and cardiomyocyte thickness in MI animals 
over-expressing Ang-(1-9). An anti-fibrotic effects was also evident, with a 
reduction in total LV fibrosis demonstrated, primarily due to reduced collagen I 
expression.  
Next, an adeno-associated virus serotype 9 (AAV9) vector expressing the Ang-(1-
9) fusion protein expression cassette [AAVAng-(1-9)] was utilised in the same 
mouse MI model in order to assess the effects of Ang-(1-9) 8 wks post-MI. Global 
transduction of the healthy myocardium in MI hearts using a single tail vein 
injection of AAV9 was demonstrated, with transgene expression detectable as 
early as 1 wk post-MI. Similarly to the previous study, AAVAng-(1-9) delivery 
demonstrated a reduction in the incidence of cardiac rupture following MI. 
Echocardiography also demonstrated improvements in cardiac contractility, with 
increased FS evident from 1 to 8 wks post-MI in AAVAng-(1-9) transduced 
animals. Again, PV loop measurements found that AAVAng-(1-9) increased ESP 
and normalised EF. Moreover, CO was significantly elevated in Ang-(1-9) 
expressing animals. Due to the more advanced 8 wk time-point, a reduction in 
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LV stiffness was detectable in AAVAng-(1-9) animals compared to controls as 
measured by the end diastolic pressure-volume relationship (EDPVR). In contrast 
to RAdAng-(1-9) administration at 4 wks post-MI, no anti-hypertrophic effect was 
detectable, with an increase in heart weight and cardiomyocyte thickness found 
in AAVAng-(1-9) animals equivalent to control MI groups. However, AAVAng-(1-9) 
administration was associated with a reduction in total fibrosis in MI animals, 
which was attributable to reduced collagen I expression. Moreover, gene 
expression analysis in MI animals found AT2R expression was elevated in the 
myocardium of AAVAng-(1-9) administered animals, which had not previously 
been identified.  
Finally, in order to attempt to elucidate the mechanism of action of Ang-(1-9), 
single cardiomyocyte Ca2+-handling measurements were utilised in order to 
assess its effects on Ca2+-handling protein function. Pre-treatment of isolated 
mouse cardiomyocytes with 1 µM Ang-(1-9) increased cardiomyocyte Ca2+-
transient amplitude and shortening compared to control, equivalent to the 
effects seen using 1 µM of Ang II. However, only Ang II induced an increase in 
spontaneous rises in intracellular Ca2+. Ang-(1-9) pre-treatment was also 
associated with increased sarcoplasmic reticulum (SR) Ca2+ content.   
Overall the findings from this thesis have demonstrated for the first time that 
Ang-(1-9) exerts beneficial effects on cardiac function post-MI, which may in 
part be due to modulation of cardiomyocyte Ca2+-handling. These findings 
provide the impetus to further investigate the potential of Ang-(1-9) as a 
possible therapeutic agent to prevent progression of adverse cardiac remodelling 
and HF post-MI.  
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Chapter 1: General introduction 
  
 
  
Chapter 1  2 
1.1 The heart 
The mammalian heart can be thought of as two muscular pumps that function by 
operating in series in order to pump blood from the systemic veins into the 
pulmonary circulation via contraction of the right atrial and ventricular 
chambers, and deliver this oxygenated blood to the systemic circulation from 
the pulmonary veins via the contraction of the left atrial and ventricular 
chambers (Katz, 2010). The contraction of the heart is initiated and controlled 
by electrical impulses generated and conducted by specialised myocardial cells. 
The muscle is composed of working contractile cardiomyocytes of the atria and 
ventricles, which, combined with the conduction system cardiomyocytes, 
account for 70 % of the heart’s overall cellular mass, with non-cardiomyocyte 
cells such as vascular smooth muscle cells (VSMCs), endothelial cells (ECs) and 
cardiac fibroblasts accounting for the remainder (Katz, 2010). Fibroblasts 
secrete and maintain the fibres required for the hearts framework and 
contribute to stiffness and tensile strength (Katz, 2010). SMCs and ECs form the 
network of coronary vessels (Irani, 2000). The contraction of the heart and the 
maintenance of blood flow is one of the most essential mammalian physiological 
processes. As such, understanding the physiological processes and mechanisms 
underlying the regulation of normal heart function, and determining the 
pathophysiological changes that occur during disease, has proved essential in the 
development of treatment for contractile dysfunction and HF.  
1.2 Normal function of the heart 
1.2.1  Excitation-contraction coupling 
Excitation-contraction coupling (ECC) is the process by which electrical signals 
are translated into mechanical movement of the heart via the utilisation of the 
second messenger molecule calcium (Ca2+) in order to enable the cardiac 
chambers to contract and relax (Maier and Bers, 2007). Central to this is the 
concept of Ca2+-induced Ca2+-release (CICR) brought about by depolarisation of 
the cardiomyocyte cell membrane (Bers, 2002; Fabiato, 1983).  
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1.2.1.1 The ventricular cardiomyocyte action potential 
The fast-response cardiomyocyte action potential (AP) is the mechanism by 
which extracellular Ca2+ enters ventricular cardiomyocytes via activation of the 
depolarization-activated Ca2+ channels (Bers, 2002). It begins with generation of 
an electrical signal at the sinoatrial (SA) node which is propagated through the 
atrial conduction system to the atrioventricular (AV) node. The AV node slowly 
conducts the electrical signal before it is rapidly passed through the His-Purkinje 
system to the cardiomyocytes where it coordinates ventricular contraction 
(Downey, 2003). The cardiomyocyte AP varies between species but can generally 
be divided into 5 main stages: 
 Phase 0- Rapid upstroke or depolarization 
 Phase 1- Early rapid repolarization 
 Phase 2- Plateau 
 Phase 3- Late repolarization 
 Phase 4- Resting membrane potential/diastolic depolarization 
The rapid depolarization of the cell is initiated by the electrical current 
delivered by the Purkinje system. This stimulus opens the voltage-gated sodium 
(Na+) channels, generating the inward Na+ current (INa) which dramatically alters 
membrane potential from a resting state at approximately -90 mV to 
approximately +20 mV (Bers, 2002). The early repolarization in phase 1 is 
brought about by inactivation of the Na+ channels and activation of the rapid IKto 
current [outward potassium (K+) channels]. The plateau phase is brought about 
by the balance between delaying repolarization via the inward movement of Ca2+ 
(ICaL) through the L-type Ca2+ channels and the outward movement of K+ through 
the delayed rectifier currents (Iks). Acceleration of repolarization occurs in phase 
3 where the L-type Ca2+ channels are closed but the rectifying K+ currents 
remain active. The resting membrane potential is then restored in phase 4 and 
equilibrium is maintained mainly by the inward rectifying K+ currents (Ik1) (Bers, 
2002) (Figure 1.1)  
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Figure 1.1 The ventricular cardiomyocyte action potential. 
Depolarization of membrane (phase 0) stimulated via INa+, which is deactivated in phase 1 upon 
activation of IKto. Ca2+ enters via ICaL during plateau/phase 2. Deactivation of ICaL in phase 3 induces 
repolarization while IK remains active. Resting membrane potential (phase 4) maintained by IK. INa= 
inward Na+ current, IKto= outward K+ current, ICaL= L-type Ca2+ channel current, IK= rectifying K+ 
currents (Klabunde, 2011).  
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1.2.1.2 Cardiomyocyte Ca2+-handling 
Entry of Ca2+ into the cell via the L-type Ca2+ channel, increasing cytosolic 
[Ca2+], triggers CICR. The L-type Ca2+ channels are located in the cardiomyocyte 
T-tubules, co-localized with the ryanodine receptor (RyR) situated on the cell’s 
intracellular store of Ca2+, the sarcoplasmic reticulum (SR) (Sah et al., 2003). 
The RyR is the SR Ca2+ release complex. When [Ca2+]i is raised via entry through 
the L-type Ca2+ channel, it stimulates the opening of the SR via the RyR, 
resulting in a synchronous release of Ca2+, further raising [Ca2+]i. It is thought 
that 2-4 Ca2+ ions binding per RyR is enough to stimulate release (Bers, 2001). 
Neighbouring RyRs are then stimulated either by the increase in local [Ca2+]i or 
by coupled-gating between RyRs (Bers, 2002). The increase in local [Ca2+]i also 
turns off the L-type Ca2+ channels via a positive-feedback loop. The amount of 
Ca2+ release upon stimulation of the RyR depends on its sensitivity, which is 
reliant on SR [Ca2+]. If Ca2+ is high, the RyR has increased Ca2+ sensitivity as there 
is increased availability of SR Ca2+. Conversely, if SR Ca2+ content is low, the RyR 
may become so desensitized to Ca2+ that it may fail to be triggered by Ca2+ entry 
via the L-type Ca2+ channel. In response to depleted SR [Ca2+] other Ca2+-
handling protein functions are altered to address the imbalance. L-type activity 
is increased to promote entry of Ca2+ into the cell, the sodium-calcium 
exchanger (NCX) which extrudes Ca2+ is down-regulated and Ca2+ uptake into the 
SR is enhanced via the phosphorylation of phospholamban (PLB) by cyclic AMP 
(cAMP), protein kinase A (PKA) or calcium/calmodulin-dependent protein kinase 
II (CaMKII), which relieves inhibition of the SR Ca2+-ATPase (SERCA), promoting 
influx of Ca2+ into the SR (Bers, 2002; Brittsan and Kranias, 2000). 
After release of Ca2+ from the SR, CICR is switched off by inactivation of the RyR. 
Ca2+ then binds to troponin C found on the cardiomyocyte myofilaments, 
activating cellular contraction which produces rapid shortening in order to 
facilitate ventricular contraction and ejection of blood from the chamber (Bers, 
2002). The force of cellular contraction is directly related to the [Ca2+]i and the 
sensitivity of the myofilaments to Ca2+. Following contraction, [Ca2+]i must be 
reduced in order to facilitate dissociation of Ca2+ from the myofilaments to allow 
for relaxation. This requires extrusion of Ca2+ from the cytoplasm, achieved via 
two mechanisms; extrusion from the cell via the NCX, or back into the SR via 
SERCA, with the majority returned to the SR from where it originated (Sah et 
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al., 2003). The exact proportions of Ca2+ extrusion by each channel varies 
between species, with SERCA responsible for removal of 70 % of [Ca2+]i in rabbit 
and human cardiomyocytes compared to 92 % in rat and mouse (Bers, 2002; 
Hove-Madsen and Bers, 1993). The slow Ca2+ extrusion systems of the 
sarcolemmal Ca2+-ATPase and mitochondrial Ca2+ uniporter account for only 1 % 
of extrusion in each case (Bers, 2002). An equivalent amount of Ca2+ is required 
to be extruded from the cell as entered at each contraction to maintain a steady 
state (Bers, 2002; Eisner et al., 2000), with [Ca2+]i  rising from a diastolic resting 
concentration of approximately 0.1 µM up to approximately 1 µM with each 
contraction (Sah et al., 2003) (Figure 1.2). 
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Figure 1.2 Cardiomyocyte Ca2+-handling. 
The process of cardiomyocyte Ca2+-handling that occurs during ECC to facilitate cardiomyocyte 
contraction. Ca2+= calcium, RyR= ryanodine receptor, PLB= phospholamban, SERCA= 
sarcoplasmic reticulum Ca2+-ATPase, NCX= sodium-calcium exchanger, AP= action potential. 
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1.3 The diseased heart 
According to the World Health Organisation (WHO), cardiovascular disease (CVD) 
is the primary cause of death globally, with 17.5 million people dying as a result 
of CVD complications in 2012, accounting for 31 % of all deaths. Of these, 7.4 
million were attributable to CHD (WHO, 2015). CHD occurs through the 
development of a myocardial ischemia, or MI, formed as a result of a stenosis, or 
narrowing, of the coronary artery, reducing or blocking blood flow to a region of 
the myocardial tissue itself (Libby and Theroux, 2005). Although the overall 
mortality rate of CHD has shown a decline since 1998, the burden of the disease 
remains high due to the increased survival rates following MI leading to 
increased development of HF (Roger et al., 2012). 
1.3.1 Structural remodelling processes post-MI 
Following infarction and loss of myocardium there is an abrupt increase in wall 
stress triggering a number of LV structural changes in an attempt to normalise 
increased wall stress and maintain LV contraction (Sutton and Sharpe, 2000). 
These processes following MI, termed adaptive remodelling, can be divided into 
2 phases; the early phase (<72 hr following infarction) where scar expansion and 
potential cardiac rupture can occur (Erlebacher et al., 1984), and the late phase 
(>72 hr following infarction) where global alterations in cardiac architecture 
occur including LV dilation, distortion of the LV shape, cardiomyocyte 
hypertrophy and collagen scar formation (Pfeffer and Braunwald, 1990). Failure 
of these alterations to normalise wall stress results in further LV expansion and 
deterioration of contractile function (Pfeffer and Braunwald, 1990).  
1.3.1.1 Early remodelling and scar formation 
Immediately following infarction and cardiomyocyte necrosis there is an influx of 
macrophages, monocytes and neutrophils into the infarcted region, followed by 
the appearance of myofibroblasts within the scar. Macrophages facilitate the 
removal of necrotised cardiomyocytes and cellular debris, and the rapid 
degradation of cardiomyocyte collagen struts occurs through the activation of 
collagenases, serine proteases and matrix metalloproteases (MMPs) released 
from infiltrating neutrophils, with the normal collagen structure of the infarcted 
myocardium completely removed by 1 week post-MI (Cleutjens et al., 1995b; Ertl 
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and Frantz, 2005). MMPs are crucial in the regulation of the cardiac extracellular 
matrix (ECM) during this process as they are the only enzymes capable of 
breaking down the proteolytic-resistant helical structure of collagens (Mann and 
Spinale, 1998). MMP1 cleaves the collagens into fragments which are then 
unfolded and degraded by MMP2, MMP3 and MMP9 (Mann and Spinale, 1998). This 
degradation process results in infarct expansion, which occurs within 24 hr of 
injury and elevates diastolic and systolic wall stress (Warren et al., 1988). Scar 
expansion is a permanent and disproportionate regional thinning, dilation and 
elongation of the infarct zone which occurs prior to collagen scar formation and 
causes a distortion in the LV shape (Weisman and Healy, 1987). Following the 
degradation of the collagen network and prior to the formation of a stable scar, 
a reduction in the number of cardiomyocytes across the infarcted region as a 
result of slippage between muscle bundles can occur and also contributes to 
expansion (Pfeffer and Braunwald, 1990). This extreme wall-thinning during 
expansion can result in cardiac rupture and mortality in 5-30 % of MI cases (Anzai 
et al., 1997). The extent of expansion appears to be directly related to infarct 
size, with larger expansion indicating poor prognosis due to the further increase 
in LV cavity exerting increased wall stress and work-load on the non-infarcted 
myocardium (Pfeffer et al., 1991; Weisman and Healy, 1987).  
The final early remodelling stage of scar formation is facilitated by the 
myofibroblasts, which are modified fibroblasts with SMC-like features, including 
the presence of functional gap junctions and the expression of α-SM actin, and 
are characterised by the presence of contractile apparatus consisting of actin 
myofilament bundles (Tomasek et al., 2002). The myofibroblasts construct a new 
collagen network, requiring several weeks to form a solid, stable collagen scar 
interspersed with some remaining myofibroblasts which contribute to collagen 
turnover and scar contraction (van den Borne et al., 2010; Willems et al., 1994). 
Myofibroblasts do not exist in healthy myocardium (Porter and Turner, 2009), 
and only following myocardial injury are normal cardiac fibroblasts stimulated to 
differentiate into myofibroblasts in response to a change in the mechanical 
microenvironment. Migration of the myofibroblasts to the site of injury is then 
facilitated by chemotactic factors such as transforming growth factor β (TGF-β) 
(Porter and Turner, 2009; van den Borne et al., 2010). Myofibroblast 
proliferation, migration and secretion of ECM components is regulated by various 
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stimuli including mechanical stretch, vasoactive peptides such as Ang II, 
autocrine/paracrine factors and pro-inflammatory cytokines (Porter and Turner, 
2009). At the site of infarction myofibroblasts deposit new ECM proteins, first in 
the border zone between the infarcted and non-infarcted myocardium before 
expanding into the central region of the scar (van den Borne et al., 2010). The 
myofibroblasts produce interstitial collagens. Initially collagen III is produced, 
with levels found to be elevated as early as 3 days post-MI in the rat MI model 
(Cleutjens et al., 1995a), with collagen I deposition occurring more slowly and to 
lower levels than that of collagen III. Cross-linking of multiple collagen I fibres 
confers tensile strength to the scar (Cleutjens et al., 1999) (Figure 1.3). 
1.3.1.2 Cardiac hypertrophy 
Adaptive eccentric and concentric cardiomyocyte hypertrophy occurs in response 
to increased wall stress and myocardial loss following scar formation (Janssens 
et al., 2004). In response to pro-hypertrophic signals, cardiomyocytes can 
increase in size by up to 70 % (Sutton and Sharpe, 2000) as a result of increased 
contractile protein synthesis (Carabello, 2002). Where eccentric and concentric 
hypertrophy differ is in what arrangement the contractile proteins are 
assembled. Eccentric hypertrophy occurs primarily in response to volume 
overload and involves the assembly of sarcomeric proteins in a series, resulting 
in cell lengthening, whereas concentric hypertrophy results from pressure 
overload and results in the parallel assembly of sarcomeric proteins, resulting in 
an increase in cardiomyocyte width (Kehat et al., 2011). Pressure overload 
results from the heart having to contract while experiencing excessive afterload, 
or stress, on the LV wall, whereas volume overload occurs when the LV has an 
excessive blood volume, adversely affecting function due to increased 
myocardial stretch (Gotzmann et al., 2012; Pang and Levy, 2010; Peterson, 
2002). As there is a combined increase in volume and pressure overload post-MI 
as a result of increased strain on the surviving myocardium, scar expansion and 
increased wall stress, both concentric and eccentric hypertrophy have been 
shown to occur (Force and Molkentin, 2006; Opie et al., 2006; Runge and 
Patterson, 2007). 
Hypertrophy is triggered by a range of factors post-MI, including increased 
myocardial stretch, activation of the local tissue RAS, and paracrine/autocrine 
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factors (Sutton and Sharpe, 2000). Ca2+ signalling can also trigger hypertrophy, 
with it demonstrated in animal models that increased L-type Ca2+ channel, NFAT 
and calcineurin expression and decreased Ca2+ release from the SR induce 
cardiomyocyte hypertrophy (Berridge et al., 2003). Increased norepinephrine 
(NE) release stimulates a hypertrophic response directly and indirectly by raising 
plasma Ang II and endothelin-1 (ET-1) levels (Ju et al., 1998). Local Ang II and 
ET-1 release stimulates the synthesis of sarcomeric contractile proteins 
(Sadoshima et al., 1992). The activation of the G-protein-coupled receptor AT1R 
by Ang II activates multiple signalling pathways including tyrosine kinases, 
protein kinase C (PKC), mitogen activated protein kinases (MAPKs) and S6 kinase 
(Ju et al., 1998), which stimulates further Ang II release and activation of foetal 
gene expression such as α-actin, β-myosin heavy chain (β-MyHC), and ANP 
(Yamazaki et al., 1995). Cardiomyocyte hypertrophy is initially a cardio-
protective response, attenuating progressive LV dilation and stabilising 
contraction (Garza et al., 2015). However, over time the chronic neurohormonal 
activation, myocardial stretch, RAS activation and presence of 
autocrine/paracrine factors promotes eccentric, pathological hypertrophy over 
concentric hypertrophy (Garza et al., 2015). Transition from concentric to 
eccentric hypertrophy is a marker of transition from compensatory to 
pathological remodelling. It causes severe chamber dilation, a reduction in 
ventricular contraction and progression to HF (Lemmens et al., 2007) (Figure 
1.3). 
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Figure 1.3 Phases and mechanisms of structural remodelling post-MI. 
Signalling pathways activated during the early, adaptive and maladaptive phases of myocardial remodelling post-MI. MMP= matrix metalloprotease, TGF-β= 
transforming growth factor-β, PKC- protein kinase-C, AT1R= angiotensin type 1 receptor, ANP= atrial natriuretic peptide, BNP= brain natriuretic peptide, MAPK= 
mitogen activated protein kinase, ACE= angiotensin converting enzyme, LV= left ventricle, TIMP= tissue inhibitors of metalloproteases. Figure adapted from (Seropian 
et al., 2014; Takemura et al., 2009; van den Borne et al., 2010).
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1.3.1.3 Cardiac fibrosis and collagen deposition 
While collagen deposition and a high percentage of ECM components in the scar 
is essential for effective healing, collagen deposition and fibrosis in the non-
infarcted myocardium is detrimental to cardiac function (Cleutjens et al., 1999). 
This reactive fibrosis involving collagen deposition within the interstitial space of 
the non-infarcted myocardium is a result of sustained elevation of Ang II-induced 
TGF-β release (Sun et al., 2002). TGF-β is primarily involved in the regulation of 
myofibroblast collagen secretion and is able to diffuse into the interstitial spaces 
of the myocardium, remote from the infarct region. In doing so it promotes the 
chemotaxis of myofibroblasts and collagen deposition within the interstitial 
space (Sun et al., 2002). This increased ECM has adverse effects on cardiac 
function, with a 2- to 3- fold increase in collagen content of the non-infarcted 
myocardium being sufficient for the development of myocardial stiffness and 
dysfunction (Covell, 1990). Not only does this progressive increase in collagen 
deposition exaggerate mechanical stiffness and promote diastolic dysfunction, it 
also disrupts electrical conductivity between cardiomyocytes, increasing the 
possibility of re-entrant arrhythmias (Brown et al., 2005). Perivascular fibrosis 
around cardiac arterioles also occurs, which can impair cardiomyocyte oxygen 
availability, promoting further cardiomyocyte apoptosis (Brown et al., 2005) 
(Figure 1.3). 
1.3.1.4 Late remodelling and systolic HF 
HF is a complication of MI owing to adverse cardiac remodelling processes which 
occurs in 22 % of males and 46 % of females within 6 years of the initial 
infarction (Lloyd-Jones et al., 2009). HF is an end-stage heart disease where the 
heart no longer compensates for the loss of myocardium and as a result cardiac 
performance is so impaired that it is no longer able to meet systemic energy 
requirements (Chiariello and Perrone-Filardi, 1998; Kannel and Belanger, 1991). 
The structural alterations which the heart undergoes during the compensatory 
phase are the very mechanisms which contribute to eventual development of HF 
(van den Borne et al., 2010). The initial compensatory hypertrophic response 
become progressively more eccentric (Lemmens et al., 2007). The 
cardiomyocytes lengthen and the LV chamber becomes progressively more 
dilated, exerting further wall-stress on the myocardium. This effect may be 
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initially compensatory in an effort to maintain stroke volume (SV), however this 
eventually promotes further ventricular enlargement and dysfunction (van den 
Borne et al., 2010). HF hearts are often associated with a reduced number of 
myofibroblasts in the scar region, which is indicative of poor ECM maintenance 
and also allows further expansion of the scar (van den Borne et al., 2010). This 
combined with accumulation of collagen in the non-infarcted myocardium, 
stiffening the muscle wall, promoting diastolic dysfunction and resulting in 
cardiomyocyte apoptosis all contribute to the HF phenotype (Figure 1.3).  
1.3.2 Electrical remodelling processes post-MI 
ECC in ventricular cardiomyocytes isolated from hearts of HF patients is 
dramatically altered, with abnormal Ca2+-handling (Gwathmey et al., 1987) and 
a prolongation of the AP (Gwathmey et al., 1990). It has been further postulated 
that the haemodynamic and contractile dysfunction observed in diseased 
myocardium is associated with a common pattern of electrophysiological 
changes within ventricular cardiomyocytes. This has been studied extensively in 
both failing human hearts and animal models of cardiac dysfunction, with 
specific proteins that contribute to this altered state identified (O’Rourke et al., 
1999). Abnormal Ca2+-handling features associated with the ventricular 
cardiomyocytes of diseased hearts include increased diastolic [Ca2+]i, a slower 
decline of the Ca2+-transient, a reduced Ca2+-transient amplitude and reduced 
cellular contractility, as observed in HF patients and animal models of HF 
(Beuckelmann et al., 1992; Beuckelmann et al., 1995; Gomez et al., 2001; 
Houser et al., 2000; O’Rourke et al., 1999; Piacentino et al., 2003).  
Dysregulation of SERCA is a main contributor to Ca2+-handling abnormalities, 
with decreased SERCA expression or activity coupled with reduced SR [Ca2+] 
being a feature found in animal and human cardiomyocytes from failing hearts 
(Beuckelmann et al., 1995; del Monte et al., 2001; Frank et al., 2002; Hobai and 
O’Rourke, 2001; Levitsky et al., 1991; Piacentino et al., 2003). Reduced SERCA 
activity may explain the reduced SR [Ca2+], a common feature in cardiac 
contractile dysfunction, and reduced release of Ca2+ from the SR during CICR, 
reducing the amplitude of the Ca2+-transient (Bers, 2002; Gomez et al., 2001; 
Piacentino et al., 2003). Expression of the regulator of SERCA, PLB (which has an 
inhibitory effect on SERCA), appear to remain unchanged in diseased hearts 
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(Frank et al., 1998; Hasenfuss et al., 1994; Huang et al., 1999; Schwinger et al., 
1995), however its phosphorylation does change, with a decrease in 
phosphorylation at Ser16 and Thr17 (Huang et al., 1999; MacLennan and Kranias, 
2003; Schwinger et al., 1999), leading to increased inhibition of SERCA and a 
decrease in Ca2+ uptake into the SR (Kadambi et al., 1996).  
Another characteristic of cardiomyocytes from diseased hearts is the increased 
incidence of spontaneous diastolic Ca2+ release, or Ca2+ sparks, from the SR as a 
result of increased RyR sensitisation (Litwin et al., 2000; Shannon et al., 2003). 
As well as increasing the loss of Ca2+ from the SR, further depleting its 
concentration, the production of Ca2+ sparks can spread through the cell causing 
abnormal Ca2+ wave propagation, resulting in delayed afterdepolarizations 
(DADs). These DADs have been associated with development of ventricular 
arrhythmias and increased incidence of SCD, which accounts for 50 % of all CV-
related mortality (Chen et al., 2009; Gilmour and Moïse, 1996; Lehnart et al., 
2006; Pogwizd and Bers, 2002; Wang et al., 2014b). 
Identifying the mechanisms and pathways driving adverse structural and 
functional remodelling changes post-MI is crucial in the development of novel 
therapeutic strategies that can attenuate the decline in cardiac function and 
prevent progression to HF. One such pathway is the RAS. 
1.4 The classical RAS 
A central pathway crucial in the regulation of cardiovascular function and many 
other basic physiological processes is the RAS. Traditionally, the ‘classical RAS’ 
axis was described in the 1940’s as a sequential, endocrine system revolving 
around the main RAS effector molecule Ang II, which was identified as a 
vasoactive peptide whose primary role was thought to be blood pressure 
regulation (Braun-Menendez et al., 1940; Bumpus et al., 1954). Our 
understanding of the RAS has evolved considerably since, with it now also 
appreciated as a local system in individual tissues whose components have been 
identified in every organ, and consequentially the signalling and function of the 
RAS is far more complex than the basic sequential pathway (Paul et al., 2006). 
Moreover, an alternative ‘non-classical’ or counter-regulatory RAS axis has also 
been identified, which blocks many actions of the classical axis (Chappell et al., 
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1989). The RAS is now implicated in the regulation of a variety of physiological 
processes including those in renal, neuronal, cardiac, pancreatic, vascular, 
adrenal, pituitary, cognitive, aging, inflammatory and reproductive functions 
(Paul et al., 2006). 
The classical axis of the RAS begins with angiotensinogen; a 453 amino acid 
protein that is the source of all RAS peptides (Chappell, 2012b). It is primarily 
synthesised by the liver and secreted into the circulation (Navar, 2014), where it 
is hydrolysed between residues 10 and 11 by the aspartyl protease renin to 
produce the inactive peptides Ang I [or angiotensin-(1-10)] and (des-Ang I)-
angiotensinogen (Chappell, 2012b). Renin was the first RAS component identified 
in 1898 when it was isolated from rabbit renal cortex lysates (Tigerstedt and 
Bergman, 1898). It is produced in the kidney by the juxtaglomerular (JG) cells 
that line the arterioles of the afferent renal glomerulus in response to changes 
in renal perfusion pressure, tubular sodium chloride concentration, activation of 
the sympathetic nervous system and negative feedback of Ang II on the JG cells 
(Atlas, 2007; Persson, 2003). Angiotensinogen is renin’s only known substrate, 
however other proteases including chymase, tonin, kallikrein and cathepsin D 
hydrolyse angiotensinogen within tissues (Chappell, 2012b; Ihara et al., 1999). 
The conversion of angiotensinogen to Ang I is the rate-limiting step of the RAS 
and is primarily dependent on renin activity as plasma angiotensinogen levels 
remains relatively constant (Morgan et al., 1996). The inactive decapeptide Ang I 
is further hydrolysed by the metallopeptidase ACE, which cleaves Ang I between 
residues 8 and 9 to form the active effector peptide Ang II and the dipeptide His-
Leu (Chappell, 2012b) (Figure 1.5). ACE is a membrane-bound dipeptidyl 
carboxy-peptidase located on the endothelial surface of pulmonary vessels and 
on renal, intestinal and choroid epithelial cells (Bruneval et al., 1986). 
1.5 Ang II 
Ang II has an important function in renal physiology and blood pressure 
homeostasis through regulation of sodium and blood volume (Hall, 1986), 
including effects on haemodynamics and peripheral vascular tone, stimulation of 
sodium reabsorption in the kidney, stimulation of the adrenal glands for the 
production of aldosterone, inhibition of renin release from the kidneys and 
activation of the sympathetic nervous system (Ito et al., 1995; Phillips et al., 
Chapter 1   17 
 
1993). Through the promotion of vasoconstriction and sodium reabsorption by 
the nephron, Ang II increases blood pressure and volume thus restoring renal 
perfusion, which in turn reduces renin release, maintaining homeostasis (Atlas, 
2007). Within tissues Ang II also has roles in the regulation of cell growth, 
proliferation and apoptosis, the inflammatory response and oxidative stress 
(Ferrario, 2006). Ang II has a very short circulating half-life of approximately 30 
s (van Kats et al., 1997), therefore it is thought that the ubiquitous endothelial 
cell membrane-bound nature of ACE makes it possible for Ang II to be 
synthesised close to its site of action (Atlas, 2007). Local synthesis of Ang II 
within tissues is thought to occur through uptake of renin and/or 
angiotensinogen from the circulation into the tissue (Carey and Siragy, 2003). 
Ang II signals via two receptor subtypes; the AT1R and the AT2R, with the former 
mediating the majority of the physiological and pathophysiological effects of Ang 
II (Carey and Siragy, 2003). Both receptors belong to the seven-transmembrane G 
protein-coupled receptor superfamily (Mehta and Griendling, 2007) (Figure 1.5). 
1.5.1 AT1R 
The AT1R is a 40 KDa protein composed of 349 amino acids and is found widely 
distributed throughout the body (Mehta and Griendling, 2007). Four cysteine 
residues on the extracellular binding domain form disulphide bridges crucial in 
Ang II signalling (Ohyama et al., 1995). G-protein coupling occurs at the NH2 
terminus of the transmembrane portion of the receptor and the first and third 
extracellular loops (Bumpus, 1991). The cytoplasmic tail of the receptor contains 
serine and threonine residues which can be phosphorylated by G-protein 
receptor kinases (Mehta and Griendling, 2007). It is these phosphorylation sites 
which are believed to play a role in receptor desensitisation (Du et al., 2004). 
Following stimulation by Ang II, AT1Rs are endocytosed within approximately 10 
min, with 25 % of these recycled back to the cell surface and the remainder 
degraded (Griendling et al., 1987). Regulation of the AT1R is under the control of 
a tight negative feedback loop with Ang II, with an acute increase in Ang II 
increasing the expression of the AT1R, but chronic Ang II activation leading to 
receptor down-regulation (Lassegue et al., 1995). Its expression is also regulated 
by a variety of other factors including glucocorticoids and mineralocorticoids, 
insulin, nitric oxide, LDL and epidermal growth factor (Kaschina and Unger, 
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2003). Its regulation also changes under pathophysiological conditions, including 
in MI and HF (Nio et al., 1995; Yamamoto et al., 2000; Zhu et al., 1999).  
Ang II signalling via the AT1R mediates the majority of its physiological actions. 
The ‘classical’ actions mediated through the stimulation of the AT1R include 
generalised vasoconstriction (Unger, 2000). Activation of the AT1R on VSMCs by 
Ang II promotes vasoconstriction which is further enhanced by the release of 
noradrenaline and ET-1 (Hahn et al., 1993). AT1R-induced vasoconstriction is 
strongest in the kidney, where it also facilitates reabsorption of sodium ions in 
the kidney proximal tubes (Unger, 2000) and also modulates renal glomerular 
filtration and cellular growth and differentiation (Kaschina and Unger, 2003). 
AT1R stimulation promotes the release of aldosterone from the adrenal cortex 
and in the heart it stimulates cell growth in the LV and exerts a positive 
inotropic effect by increasing the rate and force of contraction by initiating 
noradrenaline release from the sympathetic nerve terminals (Unger, 2000). The 
AT1R is also deemed to exert the detrimental effects of Ang II in 
pathophysiological cardiac remodelling and HF, including roles in cardiac 
hypertrophy, fibrosis, inotropy and arrhythmogenisis, which will be discussed 
later (Opie and Sack, 2001). 
1.5.1.1 AT1R signalling 
Following Ang II binding to the AT1R, a number of signalling cascades are 
activated which can be divided into G-protein and non-G-protein pathways 
(Mehta and Griendling, 2007). The primary signalling pathways activated and the 
physiological effects resulting from AT1R stimulation are summarised in Table 
1.1. 
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Table 1.1 AT1R signalling pathways 
 
 
PLC= Phospholipase C, PLD= Phospholipase D, PLA2= Phospholipase A2, IP3= Inositol trisphosphate, PKC= Protein kinase C, DAG= 2,3-diamino-2,3-dideoxyglucose, 
VSMC= Vascular smooth muscle cells, MyHC= Myosin heavy chain, MEK/MAPK= Mitogen-activated protein kinase kinase, ERK= Extracellular-signal-related-kinase, 
PA= Phosphatidic acid, AA= Arachidonic acid, NADPH= Nicotinamide adenine dinucleotide phosphate, ROS= Reactive oxygen species, Akt= Protein kinase B, Src= 
Proto-oncogene tyrosine-protein kinase Src, EGFR= Epidermal growth factor receptor, NF-κβ= Nuclear factor κβ, AP-1= Activator protein 1, NRF= Nuclear respiratory 
factor, PDGF= Platelet-derived growth factor, FAK= Focal Adhesion Kinase, JAK-STAT= Janus kinase-signal transducer and activator of transcription.
Pathway 
Downstream 
effector 
Signalling 
molecules 
Factors/pathways regulated Effect References 
G-protein coupled 
(Gαq11, Gα12/13  
and Gβу subunits) 
PLC 
IP
3
, PKC  
and  
DAG 
VSMC MyHC phosphorylation; 
aldosterone release; phosphorylation of 
Na
+
/H
+
 pump;  
Ras, Raf, MEK and ERK activation 
Vasoconstriction and  
cell growth 
Yan et al., 2003;  
Yasunari et al., 1999  
 
 
PLD DAG and PKC 
Hydrolysis of phosphatidly choline  
and PA production 
Cell contraction and growth Touyz and Schiffrin, 2000 
  
PLA
2
 
AA production 
and NADPH 
oxidation 
AA metabolites (e.g.  
hydroxyeicosatetraenoic acids)  
and ROS 
Pro-hypertensive, regulation of 
vascular tone, vasoconstriction 
Griendling et al., 2000; 
Sarkis et al., 2004 
Non-G-protein  
coupled 
ROS 
Nox-1 and Nox-4 
membrane 
NADPH, 
superoxide, H
2
O
2
 
p38MAPK, Akt, Src and EGFR,  
and transcription factors  
NF-κB, AP-1 and NRF 
Development of vascular injury and 
atherosclerosis 
Lassègue et al., 2001; 
Papaiahgari et al., 2006; 
Pueyo et al., 2000 
 
Tyrosine-kinase 
cross-talk 
EGFR, PDGF, 
insulin receptor, 
c-Src, Pyk-2 and 
FAK 
Ras/Raf/MAPK cascade  
activation and MAPK  
translocation to the nucleus 
Cell growth, apoptosis,  
contraction and differentiation 
Bucher et al., 2001;  
Kaschina and Unger, 2003 
 
  JAK-STAT  
Induction of early response genes  
c-fos, c-jun and c-myc  
Activated in MI and hypertrophy; cell 
growth, adhesion, migration and ECM 
secretion; adaptive and maladaptive 
changes in heart and vasculature 
during injury 
Mascareno and Siddiqui, 
2000;  
Omura et al., 2001 
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1.5.2 AT2R 
The AT2R is a 41 KDa protein consisting of 363 amino acids, which only shares 34 
% homology with the AT1R (Mukoyama et al., 1993). Despite the lack of similarity 
between the two receptors, Ang II has a similar affinity for both (Steckelings et 
al., 2011). Unlike the AT1R, the AT2R is expressed only at very low levels in adult 
tissues, in contrast it is widely expressed in foetal tissues, with expression 
dropping dramatically after birth, suggesting it plays a crucial role in foetal 
development (Shanmugam et al., 1996). After birth AT2R expression is restricted 
to a few organs including the brain, adrenal glands, heart, kidney, myometrium 
and ovary, with expression predominantly in mesenchymal tissues, suggesting 
the receptor may be involved in developmental and differentiation processes 
(Kaschina and Unger, 2003; Shanmugam et al., 1995).  
Regulation of AT2R expression occurs in response to a variety of factors. It is 
down-regulated in response to Ang II, norepinephrine and growth factors 
including endothelial growth factor (EGF) and fibroblast growth factor (FGF) and 
glucocorticoids (Kijima et al., 1996; Matsubara and Inada, 1998). It is stimulated 
by insulin, interferon regulatory factors and interleukin-1β, however the 
majority of this has been observed in vitro (Unger, 1999). Limited in vivo 
evidence has suggested it is increased in certain cell types in response to 
oestrogen and decreased in response to aldosterone and NO (Bucher et al., 2001; 
Mancina et al., 1996; Wang et al., 1998). The most well documented change in 
expression of the AT2R has been shown to occur during pathological conditions 
(Mehta and Griendling, 2007). Its expression is significantly increased following 
MI, and in CHF there is significant down-regulation of the AT1R in relation to the 
normal expression levels of the AT2R (Tsutsumi et al., 1998). Normal receptor 
expression on rat cardiomyocytes has been reported to consist of 10 % of total 
ventricular cardiomyocytes expressing AT2R and 40 % of total ventricular 
cardiomyocytes expressing the AT1R. Following MI, the percentage of 
cardiomyocytes expressing the AT2R increases to 60 % (Busche et al., 2000). 
The AT2R regulates a variety of processes which generally counteract the effects 
exerted through Ang II-AT1R signalling (Nouet and Nahmias, 2000). Disruption of 
the Atrg2 gene encoding for the AT2R has demonstrated its role in negatively 
regulating blood pressure (Ichiki et al., 1995), with its over-expression exerting 
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anti-pressor activity and a strong negative inotropic effect (Masaki et al., 1998). 
It is also the first G-protein coupled receptor to be identified as a receptor-
specific antagonist, capable of inhibiting AT1R-mediated responses via 
heterodimerisation in vitro (AbdAlla et al., 2001). Like the AT1R, the AT2R is able 
to form a stable heterodimer with the BK2R which is functional and thought to 
possibly promote vasodilation through NO and cGMP release (Abadir et al., 
2006). 
AT2R stimulation is also associated with anti-proliferative and pro-apoptotic 
effects (Nouet and Nahmias, 2000). It has been demonstrated to mediate 
apoptosis and broad anti-growth effects in a variety of cultured cell models 
(Dimmeler et al., 1997; Li et al., 1998) (Meffert et al., 1996; Tsuzuki et al., 
1996), and is pro-apoptotic in VSMCs and in the cerebral cortex following stroke 
in vivo (Zhu et al., 2000). Unlike Ang II-AT1R signalling, the AT2R is thought to be 
anti-proliferative but able to promote cellular differentiation (Kaschina and 
Unger, 2003). Although its exact mechanism of action is unclear, one study in 
endothelial cells suggested it is able to inhibit growth via the up-regulation of 
thrombospondin-1, a modulator of endothelial cell adhesion, motility and growth 
(Fischer et al., 2001). In vivo the AT2R has been demonstrated to inhibit 
angiogenesis and promote vasodilation, counter-acting the effects associated 
with the AT1R (Munzenmaier and Greene, 1996).  
However, some of the established effects of the AT2R in the heart have been 
disputed due to publication of varying results. Studies in adult cardiomyocytes in 
vivo have produced conflicting evidence for the role the AT2R in hypertrophy. 
Loss-of-function studies using the AT2R-deficient mouse have shown there is no 
hypertrophic response observed in AT2R KO mice in response to pressure 
overload or Ang II infusion, suggesting the receptor is required for the 
hypertrophic response and protein synthesis (Akishita et al., 2000; Ichihara et 
al., 2001; Senbonmatsu et al., 2000). However, gain-of-function studies utilising 
overexpression of the AT2R have reported results which dispute this. Lentiviral 
over-expression of the AT2R in the rat has been demonstrated to exert an anti-
hypertrophic response to Ang II infusion (Falcón et al., 2004). Similarly, 
transgenic mice selectively over-expressing the AT2R in ventricular 
cardiomyocytes show an attenuated hypertrophic response following aortic 
banding compared to WT controls (Yan et al., 2008). Moreover, in cultured adult 
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rat cardiomyocytes there is no evidence for a pro-apoptotic effect of the AT2R, 
but rather apoptosis appears to be mediated by the AT1R (Cigola et al., 1997; 
Kajstura et al., 1997). Therefore, due to conflicting results produced by these 
studies the precise role of the AT2R in the heart remains controversial (Avila et 
al., 2011). Moreover, despite its evident up-regulation in pathological 
conditions, the exact role the AT2R plays in this setting is unclear (Mehta and 
Griendling, 2007). Following MI in the rat, an increase in numbers of progenitor 
cells characterised as c-kit+AT2R+ have been identified, suggesting a role for the 
receptor in regeneration and tissue repair (Ludwig et al., 2012). AT2R expression 
in human HF appears to be primarily in interstitial fibroblasts (Tsutsumi et al., 
1998), however the exact physiological effects of the receptor following MI 
remain to be elucidated.  
Despite this, the AT2R remains a promising therapeutic target. It is thought to 
mediate the cardio-protective effects of AT1R blockers (Oishi et al., 2006) and 
the synthetic AT2R agonist C21 has been found to exert potent cardio-protective 
effects post-MI through anti-inflammatory and anti-oxidant mechanisms 
(Kaschina et al., 2008). Moreover, C21 has recently been identified as exerting 
cerebro-protective effects following ischaemic stroke in the rat and therefore is 
being pursued as a potential novel therapeutic for CVD (Joseph et al., 2014). 
1.5.2.1 AT2R signalling 
Unlike Ang II stimulation of the AT1R, the signalling cascades involved in AT2R 
stimulation are far less characterised (AbdAlla et al., 2001). Although classed as 
a G-protein coupled receptor, the AT2R has atypical signal transduction and G-
protein coupling, with initial studies failing to show it was G-coupled (Nahmias 
and Strosberg, 1995; Porrello et al., 2008). It has since been shown that coupling 
of the AT2R to Giα2/3 or an unknown G-protein does occur (Buisson et al., 1995; 
Horiuchi et al., 1997; Jones et al., 2008; Zhu et al., 1998). There is also 
evidence to suggest the AT2R can signal in the absence of Ang II due to its 
constitutively active nature (Porrello et al., 2008). The primary signalling 
pathways activated and physiological effects of AT2R stimulation that have been 
characterised are summarised in Table 1.2. 
 
 
 
 
 
Chapter 1           23 
 
Table 1.2 AT2R signalling pathways 
 
MKP-1= Mitogen-activated protein kinase phosphatase-1, PP2A= Protein phosphatase 2, MAPK= Mitogen activated protein kinase, ERK= Extracellular-signal-related-
kinase, JNK= c-Jun kinase, NO= Nitric oxide, cGMP= Cyclic guanosine monophosphate, PKA= Protein kinase A, eNOS= Endothelial nitric oxide synthase, PLA2= 
Phospholiapse A2, AA= Arachidonic acid.  
 
Pathway Downstream effector Signalling molecules Factors/pathways regulated Effect References 
G-protein 
coupled (Giα2/3  
or unknown 
subunit) 
Protein phosphatases 
MKP-1, SHP-1 and  
PP2A activation 
MAPK and ERK inactivation;  
dephosphorylation of Bcl-1 and  
activation of the JNK pathway  
Anti-growth and anti-
proliferation, pro-apoptotic 
Bedecs et al., 1997;  
Horiuchi et al., 1997; 
Kaschina and Unger, 2003; 
Shenoy et al., 1999 
 
Kinin/NO/cGMP 
Increased cGMP and  
PKA activation 
eNOS phosphorylation,  
bradykinin activation 
Vasodilation, sodium 
excretion and anti-
proliferation 
Gohlke et al., 1998;  
Liu et al., 1997;  
Siragy et al., 1996;  
Yayama et al., 2006 
  
PLA
2
 AA and PP2A MAPK and ERK activation 
Myocyte pH regulation, 
proximal tubule sodium 
excretion and neuronal cell 
current regulation 
Dulin et al., 1998;  
Haithcock et al., 1999;  
Kohout and Rogers, 1995;  
Zhu et al., 1998 
Constitutive  
activation 
unknown unknown p38MAPK and caspase 3  Cell growth and apoptosis 
D’Amore et al., 2005;  
Miura and Karnik, 2000;  
Porrello et al., 2008 
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1.6 The RAS in cardiac remodelling 
1.6.1 Ang II in structural remodelling 
Using animal models it has been demonstrated that immediately following MI 
there are dramatic changes in the levels of RAS hormones, enzymes and 
receptors which correlate with the dramatic changes that occur in the cardiac 
architecture (Sun, 2010). In the infarcted rat myocardium, renin, which is not 
found in the healthy rat heart, is significantly up-regulated along with ACE and 
AT1R expression, which are both usually expressed at low levels under normal 
conditions (Passier et al., 1996; Sun and Weber, 1996; Yamagishi et al., 1993). 
Renin, ACE and AT1R are expressed by macrophages, myofibroblasts and vascular 
cells, which locally produce the high levels of Ang II also found in the infarct 
region, further promoting the early inflammatory response and influx of 
inflammatory cells (Falkenhahn et al., 1995; Sun and Weber, 1996). During this 
acute phase post-MI, circulating RAS effector molecule expression has been 
shown to be unaltered in the rat, suggesting local cardiac RAS activation 
promotes early remodelling independent of the systemic RAS (Hodsman et al., 
1988). Chronic RAS activation also contributes significantly to the pathogenesis 
of HF. Within the myocardium of animals with experimental HF, increased levels 
of renin have been identified in the myocardium along with increased expression 
of ACE and AT1R (Pieruzzi et al., 1995). Similarly, in human HF, uptake of renin 
from the circulation into the myocardium is enhanced, as is expression of ACE 
from both endothelial cells and other cells types within the heart (Wollert and 
Drexler, 1999). An inverse correlation between renin levels and angiotensinogen 
has also been identified in failing hearts, indicating enhanced cleavage of 
angiotensinogen and an increase in local Ang II production (Danser et al., 1997). 
Elevated local Ang II expression regulates macrophages, endothelial cells and 
myofibroblasts during the acute post-MI phase (Sun, 2010). Ang II activates 
macrophages in an autocrine manner, promoting the removal of necrotic 
cardiomyocytes and facilitating the inflammatory response via inducing 
expression of NF-κB through ROS generation, thus promoting the activation of 
monocyte chemoattractant protein 1 (MCP-1) which further recruits 
macrophages and monocytes to the infarct region (Takahashi et al., 2008). ROS, 
produced primarily by NADPH oxidase in the heart, can be produced through Ang 
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II/AT1R signalling through up-regulation of several components of NADPH, which 
has been found to be most elevated 2 weeks post-MI (Wolf, 2000). Following MI, 
vascular endothelial cell expression of ACE and AT1R increases, with it proposed 
that Ang II facilitates angiogenesis in the scar region through increased 
expression of VEGF (Skaletz-Rorowski et al., 2004). Although Ang II has been 
shown to promote neovascularisation post-MI in mice (Toko et al., 2004), it has 
also been shown to inhibit neovascularisation post-MI in transgenic rats over-
expressing the AT1R in a cardiac-specific manner (de Boer et al., 2003). Ang II is 
also locally released by myofibroblasts (Sun and Weber, 1996). Myofibroblast-
released Ang II regulates the myofibroblasts in an autocrine manner, signalling 
via the AT1R and significantly increasing TGF-β expression, which as previously 
described is required for myofibroblast differentiation, chemotaxis towards the 
infarct region and collagen secretion for synthesis of the scar (Sun et al., 1998). 
Ang II also activates tissue inhibitors of metalloproteinases (TIMPs), thus 
inhibiting MMP activity to stop collagen degradation at the infarct (Lijnen et al., 
2000). This demonstrates that Ang II is integral in facilitating inflammation and 
scar healing in the acute remodelling phase post-MI.  
1.6.1.1 Ang II signalling in hypertrophy 
Ang II is the primary regulatory of the pro-hypertrophic response of the 
myocardium post-MI (Lijnen and Petrov, 1999). Although associated with pro-
hypertrophic effects, studies in vitro suggest that Ang II does not promote 
cardiomyocyte hypertrophy directly in adult cardiomyocytes as it only produces 
a small hypertrophic response through AT1R-mediated ERK activation (Ruf et al., 
2002). Therefore it has been proposed that Ang II promotes hypertrophy in vivo 
through the activation of various growth factors which then act locally via 
paracrine/autocrine mechanisms in order to promote cardiomyocyte hypertrophy 
(Sadoshima and Izumo, 1993). Growth factor expression has been demonstrated 
to occur through the activation of various second messenger pathways including 
phospholipases C, D, and A2, PKC, tyrosine kinases, p21Ras, MAPKs, S6 kinase, c-
Jun NH2-terminal kinase, ERKs and Raf-1 kinase (Kudoh et al., 1997; Sadoshima 
et al., 1993; Zou et al., 1996) which are thought to be activated through either 
Ang II-induced G-coupling of the AT1R or ROS signalling (Frey et al., 2004; Mehta 
and Griendling, 2007).  
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One of the factors thought to be crucial in the pro-hypertrophic effects exerted 
by Ang II is TGF-β. Ang II can induce TGF-β release from myofibroblasts in an 
autocrine manner (Sun et al., 1998). In vitro experiments on rat cardiomyocytes 
have also demonstrated that Ang II signalling via the AT1R can induce TGF-β 
activation, however whether its release occurs from myofibroblasts, 
cardiomyocytes or both in vivo is yet to be clarified (Gray et al., 1998). Another 
factor crucial in the regulation of Ang II-induced hypertrophy is ET-1. In vitro 
experiments have shown that exposing cardiomyocytes to Ang II increases 
prepro-ET-1 mRNA expression in a PKC-dependent manner (Ito et al., 1993). 
Increased expression has also been demonstrated in cardiomyocytes subjected to 
mechanical stretch (Yamazaki et al., 1996). ET-1 itself has been shown to be a 
potent pro-hypertrophic factor for cardiomyocytes via signalling of the ETA 
receptor and activation of the Raf-1 kinase and MAPK second messenger 
pathways and a resulting increase in protein synthesis and expression of the 
proto-oncogenes c-fos and ANP, which in turn regulate cell growth and gene 
expression (van Wamel et al., 2001).  
Studies performed in AT1R over-expressing transgenic animals and in vitro have 
demonstrated that Ang II is able to directly induce cardiomyocyte hypertrophy 
via the transactivation of the epidermal growth factor receptor (EGFR) and 
subsequent activation of MAPKs, independent of growth factor activation (Shah 
and Catt, 2003). Ang II signalling has been shown to cause AT1R-EGFR association 
in lipid rafts on VSMC membranes and promotion of the tyrosine phosphorylation 
of the EGFR (Ushio-Fukai et al., 2001). Activation of the AT1R by Ang II 
stimulates PLC and subsequent signalling molecules including PKC, Ca2+, ROS and 
tyrosine kinase (Eguchi et al., 2001). This activates the MMP-a disintegrin and 
metalloprotease domain (ADAM) which converts pro-heparin binding EGF to its 
active form which subsequently binds, phosphorylates and activates the EGFR 
(Asakura et al., 2002). This activates the MAPK signalling cascade and promotes 
cardiomyocyte hypertrophy through activation of Raf, ERK 1/2 and JAK-STAT 
(Saito and Berk, 2001; Thomas et al., 2002) (Figure 1.4). 
1.6.1.2 Ang II signalling in fibrosis 
Ang II signalling is crucial in orchestrating pro-fibrotic pathways in the heart 
following MI through driving differentiation of cardiac fibroblasts to 
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myofibroblasts and promoting synthesis of collagen I and collagen III. Activation 
of the AT1R on cardiac fibroblasts has been shown to activate the PKC-NADPH-
oxidase pathway, promoting production of ROS and inducing fibroblast 
differentiation and collagen I and III production in vitro (Bai et al., 2013). 
Interstitial cardiac fibrosis is also induced through ROS-dependent Ang II 
signalling. Ang II infusion in mice induces severe interstitial fibrosis through 
activation of Nox-2-containing NADPH oxidase which increases cardiac 
fibronectin and pro-collagen I expression and increases MMP-2 and NF-κB activity 
(Johar et al., 2006). Activation of NF-κB has been found to be associated with 
increased expression of collagen I and connective tissue growth factor (CTGF) 
genes in response to Ang II through cross-talk with integrin-linked kinase (ILK) 
(Thakur et al., 2014).  
Ang II also promotes the proliferation of cardiac fibroblasts through AT1R-
dependent activation of MAPK, MEK and ERK1/2 (Stockand and Meszaros, 2003), 
as well as inducing autocrine production of TGF-β in cardiac fibroblasts (Lee et 
al., 1995; Olson et al., 2005). MAPK regulation by Ang II in cardiac fibroblasts is 
thought to be through modulation of Ca2+-calmodulin activated phosphatase, or 
calcineurin, and its downstream transcriptional effector nuclear factor of 
activated T-cells (NFAT) (White et al., 2012). Ang II activation of this pathway 
increases fibroblast proliferation, fibronectin and pro-collagen expression and 
inducible nitric oxide synthase production (iNOS) (White et al., 2012). AP-1-
dependent activation of the immediate-early genes c-jun and c-fos was 
previously described as being important in Ang II-mediated pro-hypertrophic 
signalling, however it is also important in the pro-fibrotic response to Ang II 
(Huang et al., 2009).  
Treatment of cardiac fibroblasts with Ang II promotes DNA binding of AP-1, c-jun 
and c-fos through the activation of JNK in a poly(ADP-ribose) polymerase-1 
(PARP-1)-dependent manner which in turn promotes expression of pro-collagen, 
MMPs, TGF-β and other ECM proteins (Chen and Mehta, 2006; Huang et al., 
2009). Infusion of rats with Ang II induces perivascular fibrosis through promotion 
of adventitial and interstitial fibroblast proliferation within intramyocardial 
coronary arterioles in an AT1R-depdendent manner (McEwan et al., 1998). TGF-β 
is is responsible for enhancing ECM synthesis by myofibroblasts, increasing the 
secretion of collagens, fibronectin and proteoglycans, and preventing ECM 
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breakdown through the inhibition of MMP activity and induction of Plasminogen 
Activator Inhibitor (PAI)-1 and TIMP synthesis (Schiller et al., 2004). Many of 
these functions are mediated by the activation of the Smad3 signalling pathway 
(Verrecchia and Mauviel, 2002). As well as activation of TGF-β, Ang II also 
induces the phosphorylation of Smad3 in fibroblasts through promoting 
production of IL-6, thus promoting the pro-fibrotic effects of TGF-β (Ma et al., 
2012) (Figure 1.4).  
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Figure 1.4 Ang II signalling in structural remodelling post-MI. 
Signalling pathways involved in Ang II-induced myocardial remodelling post-MI. P= phosphorylated, AT1R= angiotensin type 1 receptor, MCP-1= monocyte 
chemoattractant protein 1, VEGF= vascular endothelial growth factor, ACE= angiotensin converting enzyme, ROS= reactive oxygen species, TNF- α= tumor necrosis 
factor-α, NADPH=  nicotinamide adenine dinucleotide phosphate-oxidase, TGF-β= transforming growth factor-β, TIMP= tissue inhibitors of metalloproteases, MMP= 
matrix metalloprotease, NF-κB= nuclear factor κB, EGF= endothelial growth factor, EGFR= endothelial growth factor receptor, PH-EGF=  pro-heparin binding 
endothelia growth factor,  ET-1= endothelin   1, ETAR= endothelin type A receptor, PKC= protein kinase C, MAPK= mitogen-activated protein kinases,  JNK= c-Jun N-
terminal kinases, PA-I= plasminogen activator inhibitor, CTGF= connective tissue growth factor, NFAT= nuclear factor of activated T-cells, ERK= extracellular signal-
regulated kinases, IL-6= interleukin 6, ECM= extracellular matrix, PLC= phospholipase C, BNP= brain natriuretic peptide, ANP= atrial natriuretic peptide, gp130= 
glycoprotein 130, AP-1= activator protein-1, PARP-1= poly(ADP-ribose) polymerase-1, CaMKII= Ca2+/calmodulin-dependent protein kinase, ILK= integrin-linked kinase, 
iNOS= inducible nitric oxide synthase, ADAM= a disintegrin and metalloprotease domain, JAK-STAT= janus kinase/signal transducers and activators of transcription, 
β-MyHC= β-myosin heavy chain.
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1.6.2 Ang II in electrical remodelling 
Ang II activation has also been linked directly to dysfunctional regulation of Ca2+-
handling proteins in various animals models of cardiac dysfunction and in 
isolated cardiomyocytes (Mehta and Griendling, 2007). In vivo this has been 
demonstrated in the TG1306/1R transgenic mouse model of cardiac-specific Ang 
II over-expression. These animals develop progressive cardiac hypertrophy as a 
result of chronic cardiac Ang II overexpression, which was shown to be 
accompanied by the dysregulation of Ca2+-handling proteins. Initially an up-
regulation of NCX was observed, which was thought to be an adaptive change in 
response to the pro-hypertrophic signals. However, in older animals with a 
chronic form of the disease, a maladaptive reduction in SR [Ca2+] and 
sensitisation of the RyR was seen in response to the shift towards NCX Ca2+ 
extrusion, resulting in reduced cardiomyocyte function (Gusev et al., 2009). 
Transgenic mice over-expressing the human AT1R in a cardiac-specific manner 
also develop cardiac hypertrophy and contractile dysfunction. This was again 
associated with abnormal Ca2+-handling, with cardiomyocytes showing decreased 
Ca2+-transient amplitude, reduced SR [Ca2+] and a prolongation in transient 
decay as well as reduced ICaL and reduced Cav1.2 and SERCA expression (Rivard 
et al., 2011). Inhibition of the RAS in the rat MI model of CHF shows 
normalisation of sarcolemmal NCX and Na+-K+-ATPase exchanger activity and 
expression, combined with an improvement in cardiac function, suggesting a role 
of the RAS in modulating the expression and activity of ion channels in the 
normal Ca2+-handling and function of cardiomyocytes (Shao et al., 2005). 
In vitro Ang II-AT1R signalling is also associated with an increased Cl- current and 
increased inward rectifying K+ current in rabbit ventricular cardiomyocytes, 
resulting in a biphasic modulation of the AP, with an initial reduction and then 
an increase in AP duration (Morita et al., 1995). ATP-sensitive K+ channels, which 
regulate AP duration and cardiac contractility, close in response to Ang II 
signalling in isolated guinea pig ventricular cardiomyocytes as a result of AT1R-
mediated adenylate cyclase inhibition which increases subsarcolemmal ATP 
concentration. This can have the detrimental effect of prolonging the AP and 
can lead to larger infarct sizes in animal models of MI (Tsuchiya et al., 1997). 
Ang II also mediates the AP in isolated rat cardiomyocytes through a reduction in 
the outward rectifying K+ current (Ito). Interestingly, this was found to be 
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mediated by the AT2R rather than the AT1R, which activated serine/threonine 
phosphatase type 2A (PP2A) resulting in a decrease in the current (Caballero et 
al., 2004). Ito is also modulated by Ang II in isolated canine cardiomyocytes, 
where it shows a slower recovery from inactivation in an AT1R-dependent 
manner, thus prolonging the AP (Yu et al., 2000). In isolated rabbit 
cardiomyocytes, Ang II increases the L-type Ca2+-current via modulation of the 
Na+-H+ antiporter in a AT1R-dependent manner (Kaibara et al., 1994). In 
cardiomyocytes isolated from cardiomyopathic hamsters, AP prolongation by Ang 
II is also associated with increased L-type Ca2+ activity via PKC activation (De 
Mello and Monterrubio, 2004).  
Various studies have demonstrated a pro-arrhythmogenic effect of Ang II, with 
RAS blockade shown to significantly reduce the incidence of ischemia-induced 
ventricular arrhythmia (Lee et al., 1997). Transgenic mice with cardiac-specific 
over-expression of ACE succumb to sudden cardiac death as a result of 
arrhythmia, with no associated structural cardiac remodelling due to atrial 
arrhythmia and cardiac block (Xiao et al., 2004). In isolated rat cardiomyocytes, 
Ang II induces cellular arrhythmia through a Nox-2 mediated increase in RyR 
Ca2+-leak via CaMKII activation (Wagner et al., 2014) and Ang II-induced cardiac 
hypertrophy in mice is associated with a high incidence of arrhythmia-induced 
SCD (Wang et al., 2014b). Perturbation of electrical synchronisation between 
cardiomyocytes by Ang II through modulation of gap junctions has also been 
demonstrated. Ang II has been shown to reduce junctional conductance between 
rat ventricular cardiomyocyte pairs in a PKC-dependent manner (De Mello and 
Altieri, 1992). A similar effect is also seen in cells from failing hamster hearts, 
where junctional conductance is reduced by Ang II in an AT1R-dependent manner 
(De Mello, 1996). Connexin 43 (Cx43) is a major component of the mammalian 
gap junction, with its reduction shown to be a major contributor to ventricular 
tachycardia (VT) (Efimov, 2006; Iravanian and Dudley, 2008). Cardiomyocyte-
specific over-expression of ACE in mouse hearts and a resulting increase in Ang II 
caused a significant loss of total Cx43 and elevated levels of dephosphorylation, 
thus deactivation, of the protein, with the result of elevated incidence of VT 
and sudden death in these animals (Kasi et al., 2007). Rats expressing humanized 
RAS genes also showed a high incidence of sudden death which was attributable 
to significantly reduced Cx43 expression and increased susceptibility to VT 
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(Fischer et al., 2007). Interestingly, mice with a cardiac-specific over-expression 
of ACE2, which is usually associated with cardio-protective effects, were found 
to die suddenly also as a result of VT, presumed to be a result of down-
regulation of both Cx43 and Cx40 (Donoghue et al., 2003).  
Ang II signalling is able to modify the properties and function of various Ca2+-
handling proteins through redox modification via increasing cardiac ROS in a 
Nox-2-dependent manner (Akki et al., 2009; Garrido and Griendling, 2009; 
Hingtgen et al., 2006). In HF, Ang II levels are high while SERCA is generally 
found to be suppressed through modulation of NADPH oxidase-activation and ROS 
(Li et al., 2006a) (Hasenfuss, 1998). Chronic Ang II treatment of H9c2 cells 
mediates a reduction in Na+ channel current associated with a decrease in 
expression of the Na+ channel scn5a (Shang et al., 2008). Ang II also increases L-
type Ca2+ channel activity through up-regulation of the α1c subunit in HL-1 cells 
in a NADPH-oxidase-dependent manner (Tsai et al., 2007). Ang II-induced 
modulation of K+ channel current and expression and Cl- current in rat and rabbit 
cardiomyocytes has also been demonstrated (Ren et al., 2008; Shimoni et al., 
2005; Zhou et al., 2006). Other studies have identified a role for PKC and MAPK 
in the effects of Ang II, with these pathways implicated in the negative inotropic 
effects observed in isolated rat cardiomyocytes in response to Ang II (Palomeque 
et al., 2006) and the Ang II-induced increase seen in the L-type Ca2+ channel (De 
Mello and Monterrubio, 2004). 
Overall these studies show the complex regulatory relationship between the RAS 
and modulators of cardiac function and how activation of the RAS can be a 
primary stimulus driving the development of contractile dysfunction and 
progression to HF post-MI. 
1.7 The counter-regulatory RAS 
The counter-regulatory axis of the RAS revolves around a homologue of the ACE 
enzyme known as ACE-related cardoxypeptidase, or ACE2 (Donoghue et al., 
2000). Initially, ACE2 was identified as having the primary role of facilitating the 
hydrolysis of Ang I to the peptide Ang-(1-9) through the removal of a C-terminal 
leucine residue (Donoghue et al., 2000), however it was later demonstrated that 
the preferred substrate of ACE2 is Ang II, to which it has a 400 times greater 
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affinity than Ang I, facilitating the conversion of Ang II to the peptide Ang-(1-7) 
(Tipnis et al., 2000; Vickers et al., 2002). Prior to the identification of ACE2, a 
variety of other enzymes were identified as being capable of generating Ang-(1-
7) via the hydrolysis of Ang I or Ang II. Prolyl-endopeptidase (PEP), neutral-
endopeptidase (NEP) and thimet oligopeptidase (TOP) are all capable of 
producing Ang-(1-7) in an ACE2-independent manner (Chappell et al., 1994; 
Greene et al., 1982; Yamamoto et al., 1992). Moreover, Ang-(1-7) can be formed 
from the hydrolysis of Ang-(1-9) by ACE, which cleaves a phenylalanine and a 
histidine residue from the N-terminus of the peptide, and which can also occur 
through the activity of NEP (Vickers et al., 2002). Ang-(1-9) formation has also 
been demonstrated to occur from Ang I through the activity of carboxypeptidase 
A or cathepsin A in human heart extracts (Jackman et al., 2002; Kokkonen et al., 
1997). In cytosolic extracts of the rat kidney and lung, Ang-(1-9) has been shown 
be converted into Ang II in an ACE-independent manner by aminopeptidase and 
N-like carboxypeptidase activity (Drumme et al., 1988). Ang-(1-7) and Ang-(1-9) 
both facilitate the actions of the counter-regulatory axis of the RAS by signalling 
via the Mas and AT2R, respectively, counter-acting Ang II signalling via the AT1R 
(McKinney et al., 2014) (Figure 1.5).  
1.7.1 ACE2 
Unlike ACE, ACE2 has only one active enzymatic site that shares 42 % homology 
with ACE, therefore it functions as a carboxypeptidase rather than a dipeptidyl 
carboxypeptidase (Burrell et al., 2004). Its high affinity for Ang II suggests it 
plays a role in limiting the vasoconstrictor function of Ang II through its 
inactivation and counteracting its effects through the production of Ang-(1-7) 
(Burrell et al., 2004). ACE2 has a far more restricted distribution throughout the 
body compared to ACE, with it primarily identified in the heart, kidneys and 
testis of humans on vascular and proximal tubule epithelial cells, as well as in 
the brain, GI tract and lung (Donoghue et al., 2000; Harmer et al., 2002; Tipnis 
et al., 2000).  
ACE2 has been shown to be an important regulator in the heart. Studies in ACE2 
knockout mice have suggested an essential regulatory role for the enzyme, as 
ACE2 deficient mice have abnormal heart function with impaired contractility, 
combined with increased Ang II levels, enhanced cardiac hypertrophy and 
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elevated hypoxia marker expression such as PAI-1 and hypoxia-inducible factor 1 
(HIF-1) (Crackower et al., 2002). ACE2 deletion also enhances pathological 
remodelling in the TAC model of cardiac pressure-overload, with the 
development of more pronounced hypertrophy, dilation and decreased 
contractility (Yamamoto et al., 2006). ACE2 is also found up-regulated following 
MI in rats and humans, and it is thought to play a role in negatively regulating 
the RAS to degrade Ang II following injury (Burrell et al., 2005). However, 
despite the evidence for a potent cardio-protective effect of ACE2, the 
production of a transgenic mouse over-expressing ACE2 revealed that it induced 
a high rate of SCD due to the increased risk of ventricular tachycardia as a result 
of connexin down-regulation (Donoghue et al., 2003). Moreover, ACE2 expression 
is significantly increased in the LV of patients with idiopathic and ischemic 
cardiomyopathic HF, however the functional consequence of this remains to be 
identified (Goulter et al., 2004). However, the dual benefits of ACE2 of both 
degrading Ang II and producing Ang-(1-7) means it remains a promising 
therapeutic target for CVD (Ferreira et al., 2012). 
1.7.2 Ang-(1-7) 
Upon its identification, the heptapeptide Ang-(1-7) was initially thought to be an 
inactive peptide product of RAS metabolism (Greene et al., 1982; Santos et al., 
1988). However, in 1988 a study assessing its effects on neurohypophysial 
explants found it was as potent as Ang II for promoting the release of vasopressin 
(Schiavone et al., 1988). The biological activity of Ang-(1-7) was further 
confirmed when it was found to decrease arterial pressure following injection 
into the nucleus of the solitary tract (Campagnole-Santos et al., 1989). Since 
then there has been an abundant body of work produced detailing the 
physiological effects and signalling mechanisms of Ang-(1-7). A major step in 
deciphering the physiological mechanism by which Ang-(1-7) exerts its effects 
was upon the identification of its receptor. Early studies demonstrated that the 
potent pressor and diuretic effects elicited by Ang-(1-7) treatment were blocked 
using a specific angiotensin antagonist A-779, but its effects were still observed 
upon AT1R or AT2R antagonism, suggesting a specific receptor was facilitating its 
actions (Fontes et al., 1994; Santos et al., 1994). The receptor was identified 
using radioligand binding assays and transgenic mice and found to be the 
‘orphan’ seven transmembrane G-protein coupled receptor Mas (Santos et al., 
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2003). Although much is known regarding the functional effects of Mas 
stimulation by Ang-(1-7), the signalling mechanisms still remain poorly 
understood. There is evidence to suggest Akt activation and eNOS are involved in 
Mas signalling following Ang-(1-7) stimulation in the heart. In the rat, Ang-(1-7)-
mediated stimulation of Mas has been demonstrated to phosphorylate JAK2 and 
Akt specifically at threonine 308 and serine 473 in a PI3K-dependent manner 
(Giani et al., 2007; Muñoz et al., 2010). Mas activation in the heart has also been 
shown to inhibit the NF-κB signalling pathway, with a reduction in inflammatory 
marker expression (Al-Maghrebi et al., 2009) and inhibition of growth promoting 
pathways induced by Ang II through inhibition of the phosphorylation of ERK1/2 
and Rho kinase (Giani et al., 2008).  
The physiological effects of Ang-(1-7) have been demonstrated to counteract 
those exerted by Ang II signalling via the AT1R, including promoting vasodilation, 
exerting anti-thrombotic effects, increasing sodium excretion in the kidney and 
inhibiting cell proliferation and angiogenesis (Santos et al., 2008). Moreover, it 
has been found to counteract the adverse cardiac remodelling processes exerting 
by Ang II, especially fibrosis and hypertrophy, in a variety of disease models, 
making it a promising alternative therapeutic for adverse cardiac remodelling 
post-MI.  
1.7.2.1 Ang-(1-7) in structural remodelling 
The anti-hypertrophic and anti-fibrotis effects of Ang-(1-7) have been 
demonstrated in transgenic [TGR(A1–7)3292] rats, which over-express a fusion 
protein form of Ang-(1-7) in the heart resulting in a doubling of circulating Ang-
(1-7), and [TG(hA-1-7)L7301] rats, which over-expresses a cardiac-specific Ang-
(1-7) fusion protein, and both demonstrated resistance to isoproterenol-induced 
stress, with reductions in cardiac hypertrophy and cardiac fibronectin and 
collagen III deposition (Ferreira et al., 2010a; Santos et al., 2004). In adult rat 
cardiac fibroblasts, Ang-(1-7) inhibits collagen synthesis and fibroblast growth in 
response to growth factors, (Iwata et al., 2005) and in the Ang-(1-7) cardiac 
over-expressing transgenic mouse, cardiac hypertrophy and fibrosis was 
significantly attenuated in response to hypertensive challenge, as was impaired 
cardiac contractility (Mercure et al., 2008). This was found to be mediated via 
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Mas activation which modulated TGF-β expression through inhibition of p38 
MAPK phosphorylation (Mercure et al., 2008).  
In models of MI and HF, Ang-(1-7) has been demonstrated to exert therapeutic 
effects. Minipump infusion of Ang-(1-7) in the rat MI model was found to 
preserve cardiac function through increased LVEDP and LVESP, thus preventing 
progression to HF (Loot et al., 2002a). Increased circulating levels of Ang-(1-7) in 
MI animals was also found to prevent cardiac hypertrophy, which was associated 
with the stimulation of bone-marrow derived progenitor cells which increased 
the level of c-kit and VEGF-positive cells in the infarcted hearts (Wang et al., 
2010b). In the mouse ACE2-null model of pressure-overload induced HF, Ang-(1-
7) infusion was able to recover systolic function, suppress NADPH oxidase 
activation and normalise pathological signalling pathways similar to the effects 
exerted by the ARB irbesartan (Patel et al., 2012). An oral formulation of Ang-(1-
7), HPβCD/Ang-(1–7), administered to infarcted rats improved cardiac FS and EF 
and exerted an anti-fibrotic effect via downregulation of TGF-β and collagen I, 
thus further confirming the therapeutic potential of the peptide (Marques et al., 
2012). Moreover, using the Mas receptor blocker A-779, Ang-(1-7) signalling 
following MI in the rat was observed to be crucial in facilitating the healing 
process in the heart via the promotion of angiogenesis in the infarcted region 
through stimulating the expression of VEGF-D and MMP-9 (Zhao et al., 2013). 
Ventricular function was also impaired in animals treated with the Mas receptor 
blocker (Zhao et al., 2013). Therefore Ang-(1-7) can not only be utilised in a 
therapeutic capacity, but also appears to be essential for the normal healing 
process of the heart following MI.  
1.7.2.2 Ang-(1-7) in electrical remodelling 
There is an accumulation of evidence in the isolated rat heart I/R model that 
Ang-(1-7) exerts cardio-protective effects including improved post-ischemic 
cardiac function, reduced incidence and duration of arrhythmias and activation 
of the Na+ pump, with its effects demonstrated to be exerted in a Mas-
dependent manner and associated with increases in prostaglandin and bradykinin 
release. This was shown to result in re-established impulse propagation through 
Na+ pump activation, with prostaglandin and bradykinin release facilitating 
cardio-protective and vasodilatory effects as well as activation of EP3 receptors 
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which activates repolarising currents (De Mello, 2004; Ferreira et al., 2001; 
Santos and Almeida, 2002). These effects were further demonstrated in I/R 
injury of hearts isolated from transgenic TGR(A1–7)3292 rats over-expressing 
circulating Ang-(1-7), which also showed improved function and reduced 
duration of arrhythmias (Santos et al., 2004), and in hearts from Mas knock-out 
mice which demonstrated worse post-I/R function compared to WT animals 
(Castro et al., 2006). As I/R injury-induced arrhythmias and contractile 
dysfunction are related to a disturbance in Ca2+ homeostasis, this suggests Ang-
(1-7) may regulate intracellular Ca2+-handling directly. This was demonstrated in 
a recent study which utilised an isolated rat ventricular cardiomyocyte model of 
I/R to show that Ang-(1-7) attenuated the increase in cytosolic Ca2+ during 
reperfusion, restored the decrease in peak systolic Ca2+ and reversed the 
decrease in Ca2+-transient amplitude, which was combined with decreased ROS 
production during ischemia (Wang et al., 2014a). 
Similar to the effects seen in I/R injury, in the dog pacing model of atrial 
tachycardia Ang-(1-7) significantly reduced incidence of atrial fibrillation which 
was associated with decreased atrial interstitial fibrosis as a result of ERK 
modulation (Liu et al., 2010a). In this model, Ang-(1-7) also attenuated the 
decrease in AP duration, characteristically observed in atrial cardiomyocytes 
during AF, as well as prevented the decrease in expression of the L-type Ca2+ 
channel and outward K+ channel observed in the model (Liu et al., 2010a). A 
later study demonstrated in the same AF model that this improvement was also 
associated with increased density of the Na+ current which improved atrial 
conductance, similar to the effects Ang-(1-7) exerts in the ventricle during I/R 
injury (Wang and Li, 2014). A recent in vitro study utilising dye-coupling 
experiments between rat cardiomyocyte cell pairs demonstrated that Ang-(1-7) 
was able to re-establish dye-coupling following a decrease in gap junction 
permeability induced by hypertonic saline treatment, suggesting that during 
instances such as myocardial ischemia, Ang-(1-7) may be able to prevent 
impairment of cell communication and impulse propagation, therefore reduce 
the incidence of re-entrant arrhythmias (De Mello, 2014). These studies suggest 
the protective effects of Ang-(1-7) are multi-faceted, with beneficial effects on 
cardiac structural, electrical and functional remodelling all having been 
demonstrated. 
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1.7.3 Ang-(1-9) 
Similarly to Ang-(1-7), Ang-(1-9) was originally thought to be an inactive product 
of RAS metabolism, with any biological actions observed thought to be as a 
result of conversion to Ang-(1-7) (Greene et al., 1982; Ocaranza and Jalil, 2012). 
In human heart tissue, the main products of Ang I degradation are Ang-(1-9) and 
Ang II (Jackman et al., 2002). However, although Ang-(1-9) can be produced 
from Ang I via ACE2 activity, this is extremely inefficient compared to Ang-(1-7) 
production from Ang II (Rice et al., 2004). Therefore it is more likely that the 
activity of carboxypeptidases enzymes such as CxA and CpA have a more 
prominent role in Ang-(1-9) production (Jackman et al., 2002; Kokkonen et al., 
1997). The peptide is found in the plasma of healthy humans and rats at 
concentrations of 2 to 6 fmol/mL (Campbell et al., 1993), with levels in the 
kidney found to be at higher concentrations than Ang II (Campbell et al., 1991). 
Its levels are also found increased in some pathological conditions, such as 
following MI (Ocaranza et al., 2006), and in animals treated with ACEIs and ARBs 
(Johnson et al., 1989; Ocaranza et al., 2006; Ocaranza and Jalil, 2012). The 
plasma half-life of Ang-(1-9) is also thought to be longer than other RAS 
peptides, with its hydrolysis shown to occur 18 times slower in vitro compared to 
Ang I (Chen et al., 2005). 
Much more recently than for Ang-(1-7), Ang-(1-9) has now been identified as a 
biologically active molecule. The first study to indicate the potential activity of 
Ang-(1-9) was performed as recently as 2005, where RAS peptide metabolism 
was studied in CHO cells transfected with human ACE and the BK2R (Chen et al., 
2005). This study suggested Ang-(1-9) was able to enhance bradykinin activity, 
which is associated with cardio-protective effects, through competitive 
inhibition of ACE and re-sensitisation of the BK2R (Chen et al., 2005). A later 
study found that at 1 week post-MI, levels of Ang II, ACE, ACE2 and Ang-(1-9) 
were found to be up-regulated compared to controls, however at 8 weeks only 
Ang II and ACE remained high, with circulating levels of ACE2 and Ang-(1-9) 
dropping lower than the control group, with Ang-(1-7) levels remaining 
unchanged (Ocaranza et al., 2006). Treatment with the ACE inhibitor Enalapril 
exerted cardio-protective effects, associated with the inhibition of the down-
regulation of circulating ACE2 and Ang-(1-9) 8 weeks post-MI, suggesting ACE2 
Chapter 1   39 
 
acting via Ang-(1-9) was potentially able to counter-regulate the actions of Ang II 
signalling (Ocaranza et al., 2006). 
1.7.3.1 Signalling and effects in the heart 
One of the most notable studies performed for Ang-(1-9) to date was that which 
identified the receptor for Ang-(1-9). Using radioligand binding studies, Flores-
Muñoz et al., demonstrated that Ang-(1-9) was able to bind the AT2R, albeit with 
lower affinity than that reported for Ang II (Flores-Muñoz et al., 2011). 
Moreover, using H9c2 cells and primary rabbit cardiomyocytes they 
demonstrated that the peptide exerted anti-hypertrophic effects, shown via 
reduction of hypertrophy marker expression (ANP, BNP, β-MHC and MLC), in 
response to Ang II and vasopressin and that this could be attenuated using the 
AT2R blocker PD123319 (Flores-Muñoz et al., 2011). The importance of this, and 
other similar studies, was the separation of the actions of Ang-(1-9) from those 
of Ang-(1-7). Although demonstrated to exert similar anti-hypertrophic and anti-
fibrotic effects, their actions are blocked by completely different receptor 
antagonists; PD123319 for Ang-(1-9) and A-779 for Ang-(1-7), with no effect of 
Mas antagonism on the function of Ang-(1-9), suggesting it mediates its effects 
independently of Ang-(1-7) conversion (Flores-Muñoz et al., 2012; Flores-Muñoz 
et al., 2011; Flores-Munoz et al., 2012; Ocaranza et al., 2014). 
Similarly to Ang-(1-7), the actions of Ang-(1-9) appear to counter-act those of 
Ang II signalling via the AT1R. The physiological effects primarily reported for 
Ang-(1-9) have been anti-hypertrophic and anti-fibrotic effects it exerts on 
cultured cardiomyocytes and in the hearts of hypertensive animal models of 
cardiac remodelling. The first of these studies demonstrated that Ang-(1-9) was 
able to counter-act norepinephrine and insulin-like growth factor-1 induced 
cardiomyocyte hypertrophy in an Ang-(1-7)-independent manner (Ocaranza et 
al., 2010). This in vitro evidence for an anti-hypertrophic effect of the peptide 
led to further in vivo studies using the rat MI model, where Ang-(1-9) infusion via 
minipump was again found to attenuate cardiac hypertrophy, an effect which 
correlated with decreased plasma Ang II levels (Ocaranza et al., 2010). 
Moreover, treatment of MI animals with enalapril or candesartan, which also 
attenuated LV hypertrophy, was associated with increased plasma Ang-(1-9) 
levels (Ocaranza et al., 2010). However, no beneficial effects of cardiac 
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contraction was observed in MI through the infusion of Ang-(1-9) (Ocaranza et 
al., 2010).  
Despite the identification of its receptor the signalling mechanisms for Ang-(1-9) 
remain elusive. The identification of the AT2R as the primary receptor for Ang-
(1-9) suggests it may trigger the signalling pathways associated with this 
receptor, thus exerting counter-regulatory effects to Ang II-AT1R signalling. 
Experiments using aortic wire myography revealed that Ang-(1-9) was able to 
improve endothelial cell function, demonstrated by decreased vascular 
resistance, in an AT2R-dependent manner through increasing NO bioavailability, 
possibly via increased expression of Nox-4 (Flores-Munoz et al., 2012). Ang-(1-9) 
minipump infusion was also associated with beneficial anti-fibrotic effects in the 
SHRSP model of hypertensive cardiac fibrosis, with it found to significantly 
reduce cardiac fibrosis by 50 % through inhibition of cardiac collagen I deposition 
(Flores-Munoz et al., 2012). Moreover, Ang-(1-9) was demonstrated to improve 
function in small mesenteric arteries of the SHRSP in an AT2R-dependent manner 
through up-regulation of endothelial NO-synthase with associated decreases in 
oxidative stress and TGF-β expression (Ocaranza et al., 2014). It is possible this 
occurs through stimulation of the bradykinin NO/cGMP pathway and/or a direct 
increase in NO release triggered by Ang-(1-9)-AT2R signalling (Jackman et al., 
2002). Incubation of CHO cells with Ang-(1-9) triggers the release of AA, 
increases intracellular Ca2+ and re-sensitises the BK2R (Erdös et al., 2002). It has 
also been demonstrated in CHO cells and human primary endothelial cells that 
Ang-(1-9) is more active than Ang-(1-7) and is able to enhance the effects of a 
BK analogue, also promoting the release of NO and AA by kinins (Jackman et al., 
2002). This increased AA release is most likely a result of increased PLA2 activity 
triggered by Ang-(1-9), which also appears to be able to act as an ACE-BK2R 
complex allosteric modifier (Chen et al., 2005). In vivo studies using the DOCA 
salt model of hypertension has also suggested that modulation of the Rho kinase 
signalling pathway may be involved in the improved vascular function and 
increased NO release seen using Ang-(1-9) (Ocaranza et al., 2011). The use of a 
ROCK inhibitor in this experimental model of hypertension was associated with 
increased plasma Ang-(1-9) levels as a result of increased ACE2 activity 
(Ocaranza et al., 2011). Moreover, as well as increasing vascular eNOS 
expression, ROCK inhibition was associated with normalisation of vascular TGF-β, 
Chapter 1   41 
 
MCP-1 and PAI-1 expression (Ocaranza et al., 2011). Another recent study found 
that Ang-(1-9) increases ANP secretion in isolated atria subjected to stretch, 
without affecting contraction in vivo via an AT2R dependent mechanism (Cha et 
al., 2013). Stimulation of the AT2R was found to activate PI3K, Akt and stimulate 
the NO/cGMP signalling pathway, leading to increasing ANP secretion which may 
play a role in the beneficial effects it exerts on the heart (Cha et al., 2013).   
To date, only one study has demonstrated protective functional effects of Ang-
(1-9) on the heart. Minipump infusion of Ang-(1-9) was shown to exert cardio-
protective effects, including anti-hypertrophic and anti-fibrotic effects and 
decreased expression of cardiac pro-hypertrophic markers, TGF-β and collagen I 
in the STZ-induced mouse model of diabetic cardiomyopathy (Zheng et al., 
2015). Moreover, Ang-(1-9) was shown to exert beneficial functional effects, 
with Ang-(1-9) treated animals showing improved EF (Zheng et al., 2015). There 
was also reduced cardiac ROS and an anti-inflammatory effect of the peptide 
(Zheng et al., 2015). Mechanistically Ang-(1-9) was found to suppress cardiac 
NADPH oxidase activity, reduce NF-κB and MPO activation and decrease 
expression of TGF-β and IL-1β. These effects were associated with suppressed 
ACE activity and decreased cardiac Ang II levels, further affirming the counter-
regulatory effects of Ang-(1-9) (Zheng et al., 2015).  
One particular group has performed studies which suggest caution is needed with 
regards to the therapeutic potential of the Ang-(1-9). In experiments assessing 
the effects of Ang-(1-9) they found that it was pro-thrombotic in models of 
electrically stimulated arterial thrombosis and stasis-induced venous thrombosis 
via increased expression of PAI-1 (Kramkowski et al., 2010; Mogielnicki et al., 
2013). However, this was found to occur in a AT1R-dependent manner without 
the direct interaction of Ang-(1-9) with the AT1R receptor, suggesting it was 
acting through conversion to Ang II (Kramkowski et al., 2010; Mogielnicki et al., 
2013). This highlights the importance of further research into the dynamics and 
physiological effects of the counter-regulatory axis of the RAS. Overall the 
effects that Ang-(1-9) has been shown to exert in vitro and in vivo suggests it 
would make an ideal alternative therapeutic for adverse cardiac remodelling 
post-MI.
 
 
 
 
 
Chapter 1           42 
 
 
Figure 1.5 The classical and counter-regulatory axis of the RAS. 
The classical axis of the RAS requires the production of Ang II from the precursor molecules Angiotensinogen and Ang I by the action of renin and ACE, respectively. 
Ang II signals via the AT1R and the AT2R. The counter-regulatory axis revolves around ACE2 which converts Ang I and Ang II into Ang-(1-9) and Ang-(1-7), 
respectively. Ang-(1-7) signals via the Mas receptor, whereas Ang-(1-9) signals via the AT2R. ACE= angiotensin converting enzyme, AT1R= angiotensin type I receptor, 
AT2R= angiotensin type 2 receptor, CxpA= carboxypeptidase A, CpA= cathepsin A, AP= aminopeptidase, NEP= neutral-endopeptidase, PEP= Prolyl-endopeptidase, 
TOP= thimet oligopeptida
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1.7.4 Other peptide metabolites 
As well as the primary counter-regulatory RAS effector peptides, other peptide 
cleavage products of the RAS have been identified, some of which appear to 
exert biological functions (Atlas, 2007), including Ang-(1-12), Ang-(2-10), Ang III, 
Ang IV, Ang-(3-7), Ang A and Alamandine, the details of which are summarised in 
Table 1.3. 
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Table 1.3 RAS peptide metabolites 
Peptide Formation Receptor Role/effect References 
Ang-(1-12) 
2 extra aa on C-
terminus of Ang I. 
Possibly formed from 
angiotensinogen. 
none 
Alternative non-renin 
dependent precursor 
for RAS peptides. Any 
effects facilitated via 
conversion to Ang II.  
Ahmad et al., 
2013; Nagata et 
al., 2010  
Ang-(2-10) 
Hydrolysis of Ang I by 
aminopeptidase A. 
AT1R 
Anti-hyperplasic and 
anti-hypertrophic 
effects in VSMCs. 
Protective vascular 
effects in SHRSP 
 Min et al., 2000; 
Mustafa et al., 
2004; Velez et 
al., 2009 
Ang III 
[Ang-(2-8)] 
Removal of N-terminus 
aa of Ang II via 
aminopeptidase A. 
AT4R 
Acts in CNS 
regulating BP. 
Stimulates PAI-1 
secretion from 
endothelium. 
Reudelhuber, 
2005; Stanton, 
2003 
Ang VI 
[Ang-(3-8)] 
Removal of N-terminus 
aa of Ang III via 
aminopeptidase N and 
hydrolysis of Ang II via 
dipeptidyl 
aminopeptidase IV.  
AT4R and 
AT1R 
Co-operative role in 
Ang II signalling. 
Stimulates PAI-1 
secretion from 
endothelium. 
 Chappell, 2012a; 
Reudelhuber, 
2005; Stanton, 
2003 
Ang-(3-7) 
Derived from Ang II, 
Ang-(1-7) or Ang IV 
through the activity of 
aminopeptidases and 
carboxypeptidases.  
AT4R 
Regulatory role in 
sympathetic drive 
and BP in CNS. 
Ferreira et al., 
2007; Handa, 
2000; Welches et 
al., 1991  
Ang A 
Decarboxylation of the 
first aspartate residue 
of Ang II to form an 
alanine through the 
activity of a leukocyte-
derived aspartate 
decarboxylase  
AT1R and 
AT2R 
Pressor effects.  
 Coutinho et al., 
2014; Jankowski 
et al., 2007; 
Yang et al., 2011 
Alamandine 
ACE2 conversion of Ang 
A or carboxylase action 
of Ang-(1-7) 
MrgD 
Regulates eNOS 
dependent 
vasodilation. Exerts 
anti-fibrotic and 
anti-hypertensive 
effects. 
Dell’Italia and 
Ferrario, 2013; 
Habiyakare et 
al., 2014; 
Lautner et al., 
2013  
 
AA= archadonic acid, aa= amino acid, RAS= renin angiotensin system, VSMC= vascular smooth 
muscle cell, SHRSP= spontaneously hypertensive stroke-prone rat, CNS= central nervous system, 
BP= blood pressure, eNOS= endothelial nitric oxide synthase, PAI-1= plasminogen activator 
inhibitor 1.
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1.8 CVD therapeutics 
The development of surgical intervention and pharmacological management of 
patients following an acute MI has dramatically reduced the mortality associated 
with the initial infarction (Sarmento-Leite et al., 2001). This however has the 
potential to increase the number of patients developing HF, which despite 
optimised medical therapy has a high mortality and morbidity rate (DiGiorgi et 
al., 2005). Therefore more effective therapies are required to prevent the 
progression to HF following MI. 
1.8.1 Coronary reperfusion 
It was in the 1970s that the idea of reperfusion of the infarcted region of the 
myocardium through removal of the blockage was a successful way of salvaging 
the myocardium and improving survival rates post-MI (Chazov et al., 1976). This 
was initially achieved pharmacologically, using intravenous infusion of 
streptokinase, a thrombolytic agent (Markis et al., 1981). Following this, more 
potent thrombolytic agents, tissue plasminogen activators, were developed as 
were ways to surgically clear the blockage (Ganz, 1985). These included 
percutaneous coronary angioplasty which was combined with deployment of a 
stent later, and thrombus aspiration which is carried out prior to stent 
deployment (Keeley et al., 2003; Svilaas et al., 2008; Zhu et al., 2001). These 
interventions have proved successful in halving mortality rates following acute 
MI, from 15 to 7.5 % (Braunwald, 2012). However, myocardial reperfusion is not 
100% effective as whilst it minimises ischaemic death, it also injures the 
surviving myocardium in a process known as reperfusion injury (Braunwald and 
Kloner, 1985; Yellon and Hausenloy, 2007). This is thought to result from 3 main 
phenomena: the Ca2+ paradox where there is an intracellular influx of Ca2+; the 
oxygen paradox where myocardial ROS is increased, and the pH paradox where 
the pH is suddenly increased to normal following acidosis in the ischaemic zone, 
all of which is thought to damage the myocardial mitochondria leading to 
cardiomyocyte death (Braunwald, 2012; Yellon and Hausenloy, 2007). Although 
research into minimising reperfusion injury, such as myocardial pre-conditioning, 
is in progress it is not currently used clinically (Longacre et al., 2011). Moreover, 
revascularisation using stenting has the added complications of stent thrombosis 
and restenosis (Serruys et al., 2006).  
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1.8.2 RAS-targeted therapeutics 
To date, the most successful treatments for CVD have involved the inhibition or 
blockade of the RAS. The idea of ACE inhibitors (ACE-I) was triggered in the 
1960’s when peptides found in snake venom were shown to reduce blood 
pressure and produce beneficial haemodynamic effects in HF patients through 
degradation of ACE (Ferrario, 2006). Captopril, the first orally active ACE-I, was 
designed based on carboxypeptidase A (Brown and Hall, 2005; Wong et al., 
2004). However, unwanted side-effects led to the development of a range of 
drugs such as lisinopril, benazepril, quinapril, ramipril, perindopril, cilazapril, 
trandolapril and fosinopril (Brown and Hall, 2005; Wong et al., 2004). ACE-I 
competitively blocks ACE activity thus reduce Ang II levels by preventing the 
conversion of Ang I (Lopez-Sendon et al., 2004). Short term use of ACE-I induces 
a dose-dependent reduction in cardiac pre-load and after-load and lowers blood 
pressure (Lopez-Sendon et al., 2004). Early trials in patients who had suffered an 
MI demonstrated that ACE-I attenuated LV remodelling and progression to HF 
and alleviated the symptoms of developed HF, including pulmonary congestion, 
and prolonged life (Investigators, 2003; Lopez-Sendon et al., 2004; Yusuf et al., 
2000). Although generally well tolerated and effective, there are some 
disadvantages and side-effects associated with ACE-I treatment (Wong et al., 
2004). Prolonged use of ACE-I leads to elevated Ang I levels and renin activity 
that can potentially overcome the blockade (Atlas et al., 1984). Kininase II, 
which has an identical structure to that of ACE, is also inhibited and can lead to 
accumulation of substance P which leads to dry cough (Wong et al., 2004). This 
can also lead to the more serious side-effects of angioedema and foetal 
developmental abnormalities (Wong et al., 2004). Other side-effects include 
hypotension, deterioration of renal function, hyperkalemia, hepatic toxicity and 
proteinuria (Wong et al., 2004).  
The development of selective AT1R inhibitors (ARBs) began in the 1990s in the 
hope they would be more specific than ACE-I by blocking Ang II signalling via its 
primary receptor rather than one of its synthesis pathways (Ferrario, 2006). 
Losartan was the first of these, with others including valsartan, irbesartan, 
candesartan, eprosartan, telmisartan, and olmesartan developed thereafter 
(Ferrario, 2006). ARB usage results in an increase in Ang II levels due to the 
negative feedback loop of the RAS (Hernandez-Hernandez et al., 2002), with it 
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postulated that increased Ang II binding to the AT2R may mediate further 
beneficial effects (Atlas, 2007). Although there is no clinical data to suggest this 
is the case, evidence produced using valsartan in the mouse model of MI and 
AT2R knock-out transgenic animals suggests the AT2R does mediate some of the 
protective effects exerted by ARBs, including reduction in LV dimensions, 
reduced LV hypertrophy and alleviated pulmonary congestion (Carey and Siragy, 
2003; Oishi et al., 2006). ARB therapy has been shown in clinical trials to confer 
benefits to hypertensive patients as well as reducing the inflammatory response 
in patients with atherosclerosis (Ibrahim, 2006; Koh et al., 2003; Navalkar et al., 
2001). It has also been shown to confer reduced cardiovascular risk, with a 
reduced likelihood of suffering from cardiovascular death, stroke and MI (Dahlöf 
et al., 2002). In HF, ARB treatment reduces incidence of mortality (Maggioni et 
al., 2002; Pfeffer et al., 2003) and following MI it reduces risk of recurrent MI, 
SCD, and all-cause mortality (Dickstein et al., 2002). ARBs are generally better 
tolerated than ACE-I, however their use is also associated with abnormal foetal 
development during pregnancy and instances of hypotension, hyperkalemia and 
deteriorating renal function as with ACE-I (Atlas, 2007). 
Despite the successes of the various established treatments for CVD, the overall 
mortality rate as a result of MI and HF remain high (WHO, 2015) and therefore 
new, more effective therapies are needed.  
1.9 Gene therapy 
Advances in molecular cardiology have made it possible to identify a number of 
novel cardiac gene therapy targets which are promising for the treatment of 
acute MI and HF (Müller et al., 2007). However, the implementation of this has 
required the development and optimisation of gene delivery vectors (Müller et 
al., 2007). Viral-vector based gene delivery is one such approach which utilises 
the natural viral infection pathway in order to gain access to human tissue cells 
in order to express therapeutic genes (Thomas et al., 2003). This requires the 
deletion of enough of the viral genome in order to insert the gene of interest 
while maintaining the ability of the particles to infect target cells (Thomas et 
al., 2003). There are currently 5 main viral vectors in development for 
therapeutic use; oncoretroviruses, lentiviruses, herpes simplex-1 viruses (HSV-
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1s), Ad and AAVs; with Ad and AAV being the most commonly used (Thomas et 
al., 2003).   
1.9.1 Adenoviral gene transfer vectors 
In 2012 over 1800 gene therapy clinical trials had been completed, were ongoing 
or had been approved worldwide. Of these, the vast majority (23.3 %) were 
utilising Ad vectors (Ginn et al., 2013). Ad gene therapy has also been utilised 
for the treatment of a variety of diseases such as cancer, cystic fibrosis (Bellon 
et al., 1997), muscular dystrophy (Cerletti et al., 2003) and macular 
degeneration (Campochiaro et al., 2006). 
After cancer and monogenic disease, the third most popular disease for gene 
therapy research is cardiovascular disease (Ginn et al., 2013). To date, the most 
common form of cardiovascular gene therapy has been aimed at promoting 
therapeutic myocardial angiogenesis in ischemic heart disease. Intramyocardial 
delivery of an E1/ E3 deleted Ad expressing the pro-angiogenic factor VEGF121 
(AdVEGF121) has been utilised in clinical trials for the treatment of ischemic 
heart disease, and so far has demonstrated improvements in exercise tolerance 
and angina class in treated patients (Rosengart et al., 1999; Stewart et al., 
2006). VEGF165 has also been utilised in the KAT (Kuopio angiogenesis trial) 
clinical trial which utilised an Ad (VEGF-AdV) delivered via catheter to the heart 
during a standard angioplasty and stenting procedure. Six month follow-ups of 
patients receiving the virus showed no change in restenosis compared to 
placebo, however myocardial perfusion rates were significantly increased in the 
treated patient group (Hedman et al., 2003). The AGENT phase I-II clinical trials 
investigated the effects of an E1 deleted Ad5 vector expressing FGF-4 (Ad5FGF-
4) on the perfusion of ischemic myocardium in patients with stable angina and 
reversible ischemia. Similarly to the VEGF121 studies, patients demonstrated a 
higher tolerance for exercise testing, which was combined with evidence for 
increased perfusion of the ischemic tissue with smaller infarct size reported 
(Grines et al., 2002; Grines et al., 2003). However, when this was expanded into 
phase III clinical trials neither of these improvements were noted (Henry et al., 
2007). What all these trials have demonstrated, regardless of outcome, is that 
delivery of an Ad vector to the heart is safe and shows sufficient transgene 
expression. 
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1.9.2 AAV 
AAVs suitability as a gene therapy vector means it is currently in use in clinical 
trials for a variety of diseases, with its use accounting for 5 % of all gene therapy 
clinical trials in 2012 (Ginn et al., 2013). Their potential use in the treatment of 
metabolic diseases has received a lot of attention in recent years (Alexander et 
al., 2008), with the very first licencing of an AAV1-based gene therapy vector, 
alipogene tiparvovec (or Glybera ©), in Europe in 2012 for treatment of 
lipoprotein lipase deficiency (LPLD), a rare genetic disorder (Flemming, 2012). 
Other diseases for which AAV vectors are being pursued as potential treatments 
include cystic fibrosis (Moss et al., 2007), haemophilia B (Manno et al., 2006), 
muscular dystrophy (Bowles et al., 2011), rheumatoid arthritis (Evans et al., 
2005), ophthalmic diseases (Buch et al., 2008) and disease of the CNS including 
Alzheimer’s (Mandel, 2010) and Parkinson’s disease (Carter et al., 2008; LeWitt 
et al., 2011). 
Similarly to Ad vectors, pre-clinical studies have looked at the potential of AAVs 
to promote angiogenesis in ischemic hearts through the delivery of transgenes 
carrying pro-angiogenic factors. An AAV vector expressing human VEGF165 
injected directly into the infarcted mouse heart has been shown to promote 
neoangiogenesis without the induction of an inflammatory response (Su et al., 
2000). Moreover, transgene expression was demonstrated to be able to be 
controlled through the use of a cardiac-specific, hypoxia-inducible promotor 
cardiac myosin light chain 2v (MLC-2v) and the hypoxic-response element, which 
restricted VEGF transgene expression to ischemic mouse hearts, showing greater 
vascularisation, smaller infarcts and improved cardiac function (Su et al., 2004). 
Direct myocardial delivery of an AAV2 vector expressing a p53-inducible human 
VEGF-A transgene in the rat TAC-model of pressure-overload promoted 
neovascularisation, significantly improved cardiac function and decreased 
fibrosis. As p53 is induced in the heart during chronic hypoxia and is associated 
with the transition to de-compensatory cardiac hypertrophy, the gene therapy 
restricted transgene expression to the target tissue and stimulated VEGF-A 
expression in the heart when it was required (Bajgelman et al., 2015). Genes 
other than pro-angiogenic factors have also been targeted for AAV gene therapy. 
AAV-mediated delivery of microdystrophin to the hearts of the mdx mouse 
muscular dystrophy model has been shown to restore cardiac dystrophin-
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glycoprotein complex levels thus stabilising the sarcolemmal integrity of the 
heart, which demonstrated therapeutic potential for cardiomyopathy in patients 
with Duchenne’s muscular dystrophy (Yue et al., 2003). The long-term 
expression properties of AAV have been exploited as a potential therapy for 
hypertension. AAV-mediated systemic delivery of the serine protease kallikrein 
has been shown to ameliorate hypertension in the SHRSP model. This was 
associated with confirmation of long-term expression of the protein in various 
tissues and reduced renal damage and collagen deposition in the heart (Wang et 
al., 2004).  
The direct targeting of Ca2+ handling proteins for the treatment of cardiac 
contractile dysfunction has also received great interest. S100A1, a positive 
inotropic regulator of cardiac function, was delivered via a rAAV6 vector under 
the control of a cardiac-selective promotor through catheter-mediated delivery 
into the aortic root of HF rats (Pleger et al., 2007). It was shown to have chronic 
HF-rescuing properties, mediated by improved SR Ca2+ handling, improved 
cardiac contraction and ameliorated LV remodelling, with improved beneficial 
effect over β-adrenergic blockade (Pleger et al., 2007). Administration of the 
same vector in a large animal pre-clinical pig model of HF resulted in a reversal 
of adverse structural and functional myocardial changes and a complete 
normalisation of cardiomyocyte and SR Ca2+-handling (Pleger et al., 2011). 
Transcoronary delivery of a rAAV vector expressing a pseudo-phosphorylated PLB 
mutant (S16EPLN) has also been shown to attenuate contractile dysfunction in a 
hamster model of dilated cardiomyopathy and the rat MI HF model through 
chronic PLB inhibition resulting in increased LV EF, lower EDP and a reduction in 
cardiac hypertrophy (Hoshijima et al., 2002; Iwanaga et al., 2004). An AAV9 
vector has also recently been utilised to investigate the possibility of inhibiting 
protein phosphatase 1 (PP1) β, a catalytic subunit involved in inhibition of Ca2+ 
uptake into the SR, by expressing a short hairpin RNA molecule of PP1β under 
control of a HF-inducible BNP promotor. This approach was shown to have 
beneficial effects on LV diastolic function and remodelling, with reduction in 
BNP expression and cardiac interstitial fibrosis deposition in a mouse model of 
cardiac dysfunction (Miyazaki et al., 2012).  
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1.9.3 SERCA gene therapy  
Of all the Ca2+-handling proteins targeted for viral-mediated gene therapy, 
SERCA2a has perhaps generated the most interest, with its effects in small 
animal CVD models first assessed in 2000. A gene therapy approach using 
catheter-based delivery of an Ad vector expressing the SERCA2a gene directly to 
the heart of the aortic banding HF rat model (del Monte et al., 2001; Miyamoto 
et al., 2000) and the senescent rat heart (Schmidt et al., 2000) was used to 
assess the effects of SERCA2a overexpression on contractile dysfunction and 
diastolic function in vivo. In the rat HF model, overexpression of SERCA was 
associated with improved SR pump function and normalisation of LV systolic 
pressure indices and an increased rate of isovolumetric relaxation back to near 
sham levels compared to animals receiving control virus (Miyamoto et al., 2000). 
As well as improved haemodynamic parameters, restoration of SERCA in the 
failing rat heart was also shown to produce an improved phosphocreatine/ATP 
ratio which is found reduced in failing hearts. As phosphocreatine is the heart’s 
major energy reserve molecule, this showed that SERCA overexpression 
maintained the energy potential of the heart, with resulting metabolomic and 
functional effects (del Monte et al., 2001). The senescent rat heart shows 
unaltered systolic functional parameters, however it shows severe diastolic 
dysfunction with significantly increased EDP and decreased isovolumetric 
relaxation. Restoration of SERCA expression has also been shown to significantly 
improve these parameters in comparison to control vector administered animals 
(Schmidt et al., 2000). Despite these successes, overexpression of SERCA in vivo 
was shown to have some disadvantages, with it being demonstrated in the rat MI 
model that in transgenic rats overexpressing SERCA, although enhanced 
myocardial function post-MI was evident in the transgenic animals, there was 
also an increased incidence of ventricular arrhythmia (Chen et al., 2004). This 
may indicate that overexpression of SERCA in every cardiomyocyte from birth 
may have detrimental side effects later in life following cardiac insult. 
More recently, studies utilising large animal models have produced convincing 
pre-clinical trial data demonstrating similar benefits to what was observed in the 
small animal models. In sheep with pacing-induced HF, delivery of an AAV 
serotype 1 (AAV2/1) vector overexpressing SERCA demonstrated a dose-
dependent improvement on cardiac contractility as assessed by left ventricular 
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pressure measurements and echocardiography when administered via a cardiac-
directed recirculating delivery approach (Byrne et al., 2008). Pigs with volume-
overload induced HF administered with a rAAV1 vector overexpressing SERCA via 
intracoronary infusion again demonstrated improved left ventricular function 
combined with positive effects on left ventricular remodelling (Kawase et al., 
2008). In both cases, levels of BNP expression remained stable or reduced 
compared to control animals (Byrne et al., 2008; Kawase et al., 2008). 
These data paved the way for AAV-mediated gene delivery of SERCA2a in human 
clinical trials for the treatment of HF. The ‘Calcium Up-Regulation by 
Percutaneous Administration of Gene Therapy in Cardiac Disease’, or CUPID, 
multicentre phase I/II clinical trial was launched in the US in 2007 (Hajjar et al., 
2008; Jaski et al., 2009). The study recruited 9 patients with advanced HF who 
underwent intracoronary infusion of an AAV1 vector expressing the SERCA2a 
protein, with patients receiving the highest dose demonstrating improvement 
from baseline symptomatic and functional parameters at 6 month follow-up 
(Jaski et al., 2009). Phase II trials involving 39 patients further demonstrated the 
efficacy and safety of the virus as well as its beneficial effects, with decreased 
frequency of cardiovascular events compared to placebo group at 12 month 
follow-up (Jessup et al., 2011). Three year follow up of these 39 patients 
demonstrated long-term transgene expression and an 82 % reduction in recurrent 
cardiovascular events in the group receiving the high dose (Zsebo et al., 2014). 
This initial success of the CUPID inspired 2 further trials utilising AAV delivery of 
SERCA2a; the ‘AAV-CMV-Serca2a GENe Therapy Trial in Heart Failure’ (AGENT-
HF) in the UK and a parallel study in the UK and France in patients using LV 
assist devices, both of which were recruiting patients for phase I/II trials as of 
2011 (Kawase et al., 2011). Following the success of the initial trial, the CUPID2 
Phase 2b 243-patient intention-to-treat population trial was undertaken which 
was a randomized, double-blind, placebo-controlled, multinational trial 
evaluating a single intracoronary infusion of the SERCA2a gene using the AAV 
vector which is now termed ‘MYDICAR®’ on primary and secondary outcomes in 
HF patients (Celladon, 2015). The most recent data from this trial as of April 
2015 reported no adverse effect of vector delivery, however the vector itself 
failed to show any difference in endpoint comparison with the placebo groups 
with no differences in heart failure-related hospitalizations, ambulatory 
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treatment for worsening heart failure, all-cause death, need for a mechanical 
circulatory support device or heart transplant (Celladon, 2015). 
1.9.4 Gene therapy approaches for targeting the counter-
regulatory RAS  
RAS gene therapy for CVD has primarily utilised over-expression of ACE2 or Ang-
(1-7). Huentelman et al (2005) were the first to develop an ACE2-expressing 
lentiviral vector (Huentelman et al., 2005). Administration of this vector directly 
into the LV cavity of 5 day old rats demonstrated that ACE2 over-expression 
could attenuate cardiac hypertrophy and fibrosis following Ang II minipump 
infusion 10 weeks post-lentiviral delivery (Huentelman et al., 2005). This same 
vector utilised in the SHR was shown to significantly reduce BP, LV wall thickness 
and perivascular fibrosis 4 months following transduction (Díez-Freire et al., 
2006). More recently, an Ad vector over-expressing ACE2 was developed and 
utilised in the Streptozocin (STZ) rat model of diabetic cardiomyopathy (Dong et 
al., 2012). Animals administered with the Ad showed increased cardiac MMP-2 
activity, increased LV EF, decreased LV EDV and ESV, reduced LV fibrosis and 
reduced expression of cardiac ACE, Ang II and collagens (Dong et al., 2012). 
Lentiviral vectors have also been utilised for the delivery of Ang-(1-7) in rat 
models of pulmonary fibrosis (PF) and pulmonary hypertension (PH) (Shenoy et 
al., 2010). Intra-tracheal delivery of this vector was demonstrated to reduce ACE 
and AT1R expression, decrease collagen deposition and attenuate expression of 
pro-inflammatory cytokine and TGF-β in the lungs of PF animals and reduce RV 
hypertrophy, fibrosis and systolic pressure in PH animals, all of which was 
mediated via the Mas receptor (Shenoy et al., 2010). 
Intracardiac injection of a lentiviral vector expressing ACE2 in the rat model of 
MI exerts cardio-protective effects, including increased EF and cardiac 
contractility and reduced wall-thinning (Der Sarkissian et al., 2008). Cardiac 
ACE2 over-expression using intracardiac injection of an Ad vector also shows 
cardio-protective effects in the rat MI model, with reduced LV dilation, 
increased EF, attenuated LV fibrosis and decreased expression of ACE, Ang II and 
collagen I all associated with Ad-administered animals (Zhao et al., 2010). The 
effects of Ang-(1-7) following MI have also been characterised in the rat using 
lentiviral-mediated cardiac overexpression (Qi et al., 2011). Lentiviral 
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administration ameliorated a variety of MI associated pathologies, including 
improved EF, improved LVEDP, reduced LV hypertrophy, decreased ACE 
expression, increased ACE2 and BK2R expression, decreased wall-thinning and 
decreased pro-inflammatory cytokine expression (Qi et al., 2011). These studies 
demonstrate how viral-vector mediated gene therapy can be an effective, 
translational method by which to harness the cardio-protective potential of the 
counter-regulatory RAS for the treatment of CVD. 
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1.10 Hypothesis and aims 
Ang-(1-9) is emerging as a potential novel therapeutic peptide for adverse 
cardiac remodelling. Little is known about its mechanism of action and there is 
currently only one study to suggest it confers a beneficial effect functionally in 
the heart. All in vivo studies performed have also only utilised minipump infusion 
as the method of Ang-(1-9) delivery. The beneficial structural remodelling 
effects of the peptide combined with the evidence of a functional effect through 
counteracting Ang II signalling in the heart via activation of the counter-
regulatory RAS axis suggest Ang-(1-9) may confer cardio-protective effects in an 
animal model of acute cardiac dysfunction such as in MI. Therefore we 
hypothesised that viral vector-mediated over-expression of Ang-(1-9) in the 
mouse MI model would attenuate adverse structural and functional cardiac 
remodelling. 
The principle aim of this thesis was to assess the effects of cardiac over-
expression of Ang-(1-9) on structural and functional cardiac parameters 
following MI. This was achieved through the following experimental aims: 
 Develop a technique for the successful cardiac over-expression of Ang-(1-
9) in the mouse MI model using viral vector-mediated gene transfer. 
 Assess changes in functional and structural cardiac parameters post-MI in 
Ang-(1-9) over-expressing animals compared to controls. 
 Investigate the effect of Ang-(1-9) on the Ca2+-transient in isolated adult 
cardiomyocytes.  
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Chapter 2: Materials and methods 
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2.1 Materials 
All chemicals for mouse cardiomyocyte studies, histological and biochemical 
applications were purchased from Sigma-Aldrich (Poole, UK) unless otherwise 
stated. Chemicals used for cardiomyocyte isolation were dissolved in double 
distilled water (ddH2O, 18 MΩ/cm) filtered via a Purelab Option-R 15 purification 
system (Cole-Parmer, London, UK) to ensure solutions were nominally calcium-
free. Angiotensin peptides were purchased from Phoenix Pharmaceuticals 
(Karlsrhue, Germany) or Sigma-Aldrich (Poole, UK) and Losartan and PD123319 
were purchased from Sigma-Aldrich, all of which were also re-suspended in 
sterile ddH2O. DNA mini- and maxi-prep kits, RNA extraction kits, DNA gel 
extraction kits and DNase were purchased from Qiagen (Manchester, UK). 
Reverse transcription and quantitative real-time polymerase chain reaction 
(qRT-PCR) reagents were purchased from Invitrogen (Paisley, UK). Restriction 
endonucleases were purchased from New England Biolabs (NEB) (Hertfordshire, 
UK) or Promega (Southampton, UK). Luria broth (LB) and LB-agar were purchased 
from Sigma-Aldrich. All western immunoblot reagents, buffers and gels were also 
purchased from Invitrogen. Normal goat serum and rabbit IgG for 
immunohistochemistry (IHC) were purchased from Dako (Cambridge, UK). 
2.1.1 Solutions 
 1 x Krebs-Henseleit solution (in mmol/L): NaCl 130.0, KCl 5.4, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 25.0, NaH2PO4 0.4, 
MgCl2 0.5, glucose 22.0. pH 7.4 at 37 °C with NaOH. 
 10 x HEPES buffered perfusate (in mmol/L): NaCl 140.0, KCl 4, MgCl2 1.0, 
HEPES 5.0, glucose 11.1, CaCl2 1.8. pH 7.4 at 37 °C with NaOH. 
 10 x Tris-buffered saline (TBS) (in mmol/L): Tris-HCL 162.6, Tris-base 46.0, 
NaCl 1505.0. pH 7.6 at room temperature. 
 10 x Phosphate-buffered saline (PBS) (in mmol/L): NaCl 1370.0, KCl 27.0, Na2-
HPO4 100.0, KH2PO4 18.0. pH 7.4 at room temperature. 
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 50 mM Tris-buffered tween (Tbt) (in mmol/L): Tris-HCl 40.3, Tris-base 9.7, 
NaCl 150.0. pH 7.5 at room temperature. 0.5 mL Tween-20/L. 
 10 mM Sodium citrate (in mmol/L): Trisodium citrate 11.4. pH 6 at room 
temperature. 0.5 mL Tween-20/L. 
 10 x Citric saline (in mmol/L): KCl 13.4, sodium citrate 1.7. 
 10 x Tris-EDTA (TE) buffer (in mmol/L): Tris-base 100.0, EDTA 1.3. pH 8 with 
HCl at room temperature. 
 1 x Tris density (TD) buffer (in mmol/L): NaCl 750.0, KCl 50.0, Tris-HCl 250.0, 
Na2HPO4 10.0. pH 7.4 at room temperature. 
 1 x Protein lysis buffer (in mmol/L): Tris-HCl 50.0, NaCl 150.0, EDTA 2.5, 
EGTA 2, Triton X-100 200 µL/L, PMSF 0.2, NaF 100.0. 1 x complete mini 
protein inhibitor cocktail tablet (Roche, Welwyn, UK). 
2.2 Cell culture 
2.2.1 Cell lines and maintenance 
Both H9c2 (immortalised rat heart myoblast cell line) and HeLa (immortalised 
human cervical epithelial carcinoma cell line) cells were purchased from the 
European Collection of Animal Cell Cultures (Wiltshire, UK). 293 cells are a 
human embryonic kidney cell line transformed with the left-hand fragment of 
the adenovirus serotype 5 (Ad-5) genome which transcomplements the E1 Ad-5 
genomic region to allow propagation of replicant-deficient rAd vectors in vitro 
(Mahmood and Yang, 2012). They were purchased from Microbix Biosystems 
(Toronto, Canada). All cell culture work was performed in a sterile class II 
microbiological safety cabinet under laminar flow (Thermo Scientific, 
Basingstoke, UK). Tissue culture plastics were purchased from Corning, Fisher 
Scientific (Loughborough, UK). Cells were maintained in minimal essential media 
(MEM, Gibco, Paisley, UK) supplemented with 10 % foetal bovine serum (FBS), 2 
mM L-Glutamine, 1 IU/ mL Penicillin, 100 µg/µL Streptomycin and 100 mM 
Sodium Pyruvate in a humidified incubator at 37 °C and 5 % CO2. Cells were 
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grown in a monolayer and passaging (or sub-culturing) was performed when cells 
reached 60-70 %, 90-100 % and 80-90 % confluency for H9c2, HeLa and 293 cell 
lines, respectively (Section 2.2.2).   
Frozen cell stocks of all cell lines were stored long term in liquid nitrogen and 
replenished from live stocks as needed. Briefly, a confluent 150 cm2 vented-lid 
flask (T150) of cells were passaged as described in Section 2.2.2. Media was 
removed from the cell pellet and discarded. Cells were re-suspended in 4-6 mL 
of supplemented MEM containing 5 % (v/v) dimethyl sulfoxide (DMSO). Cells were 
divided into 1 mL aliquots into cryovials and frozen gradually in order to avoid 
cellular rupture by submerging tubes in 100 % isopropanol and placing in a -80 °C 
freezer for 24 hr before transfer to liquid nitrogen. To recover cells from frozen 
stocks an aliquot was thawed rapidly at 37 °C in a water bath and transferred to 
a sterile tube which was centrifuged at 500 x g for 10 min at room temperature. 
DMSO contaminated media was removed and discarded and the cell pellet re-
suspended in fresh MEM and placed in a T150 cm2 flask to recover.  
2.2.2 Cell passaging and plating 
Cells (in T150 cm2 flasks) were passaged by washing twice with sterile PBS 
before 5 mL of pre-warmed trypsin-ethylenediamine tetra-acetic acid (trypsin-
EDTA, for HeLa and H9c2 cells) or 5 mL 1 x citric saline (293) was added to the 
flask, followed by incubation at 37 °C for approximately 5 min or until cells 
detached from the flask. Approximately 10 mL of pre-warmed 10 % FCS-
supplemented MEM was added to the flask in order to avoid over-digestion of the 
cells. The entire contents of the flask were transferred to a sterile tube and 
centrifuged for 10 min at 500 x g. The media was decanted and the cell pellet 
re-suspended in 4-8 mL of fresh MEM, depending on the density to be seeded. 
Finally, 1 mL of the cell suspension was added to a new T150 cm2 flask and the 
total volume adjusted to 25 mL using MEM.  
In order to plate cells at a specific density for experimentation, they were 
counted following re-suspension in fresh MEM. This was performed by loading 12 
µL of cell suspension into a haemocytometer, the number of cells in each of the 
four quadrants counted and an average number of cells per quadrant 
determined. The number of cells per mL equalled the average number of cells 
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per quadrant x 104. In order to calculate the volume of cell suspension required 
to plate a specific density the following calculation was used: 
volume required =
cell density required
number of cells per mL
× 1000 = volume in µL per well 
The appropriate volume of cell suspension was then added to each well and MEM 
added to adjust the volume to 2 mL, 1 mL, 0.5 mL or 200 µL for a 6-, 12-, 24- or 
96-well plate, respectively.  
2.2.3 Transfections 
Transfections were performed using Xfect transfection reagent (Clontech, 
California, USA) as per the manufacturer’s instructions. Cells were seeded in 6 
well plates at a density of 3 x 105 cells/well (HeLa) or 6 x 104 cells/well (H9c2) 
24 hr prior to transfection. Plasmid DNA was diluted in Xfect reaction buffer to 
achieve 2.5, 5 or 7.5 µg of DNA in a total volume of 100 µL. An equivalent 
volume of Xfect polymer was diluted in the same reaction buffer with 0.3 µL of 
polymer added per µg of DNA. Tubes were vortexed well before the DNA and 
polymer was mixed and vortexed again. A polymer-only mix was prepared as a 
control for toxicity. Samples were incubated at room temperature for 10 min to 
allow biodegradable DNA-polymer nanoparticles to form. Media was removed 
from cells and 1 mL of fresh MEM added to each well before the entire 200 µL of 
nanoparticle preparation was added to the well drop-wise in triplicate. A set of 
triplicate wells remained un-transfected as a control. Plates were incubated at 
37°C for 4 hr before media and nanoparticles were removed via aspiration and 
replaced by 2 mL of fresh media. Media was changed again at 24 hr and cells 
harvested 48 hr post-transfection. 
2.3 Adenovirus purification 
The method for preparation of high-titre recombinant adenoviral (RAd) stocks is 
described in detail elsewhere (Nicklin and Baker, 1999). First, 25 x T150 cm2 
flasks of 293 cells at 80-90 % confluence were infected with an in-house viral 
seed stock (a gift from SA Nicklin) at a multiplicity of infection (MOI) of between 
0.1-10 per flask. Cells were incubated for 3-4 days until cytopathic effect 
became apparent. Next, media and cells were collected and cells harvested via 
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centrifugation at 2000 x g for 10 min at 4°C. Media was discarded and the cell 
pellet re-suspended in ~6 mL of sterile PBS. An equivalent volume of 
trichlorotrifluoroethane (Arklone P, ICI Ltd., Cheshire, UK) was added, followed 
by inversion for approximately 10 s and then shaking for 5 s. These steps were 
repeated to release the viral particles and the preparation was centrifuged at 
3000 x g for 10 min. The upper aqueous layer containing the virus was 
transferred to a fresh sterile tube and either immediately underwent 
purification or was stored at -80°C. 
2.3.1 Double caesium chloride gradient purification 
Double caesium chloride (CsCl) gradient ultracentrifugation is used in order to 
remove cellular contaminants from viral preparations. CsCl solutions were 
prepared via dissolving the required mass of CsCl in 50 mL of TD buffer in order 
to achieve the correct density solutions; 1.25 g/mL (18.08 g), 1.34 g/mL (31.1 g) 
and 1.4 g/mL (25.6 g). Solutions were then filter sterilised and all subsequent 
steps of the extraction performed under sterile conditions in a class II 
microbiological safety cabinet under laminar flow (Thermo Scientific, 
Basingstoke, UK). A sterilised thin-walled 14 mL 14 x 95 mm centrifuge tube 
(Beckman Coulter, High Wycombe, UK) suitable for use in an SW40 centrifuge 
rotor was filled with 2.5 mL of the 1.4 g/mL CsCl solution. A further 2.5 mL of 
the 1.25 g/mL CsCl solution was carefully layered on top followed by the crude 
virus preparation. Tubes were carefully sealed in a SW40 rotor tube and 
centrifuged at 90000 x g for 1.5 hr at 18 °C in an Optima L-80 XP ultracentrifuge 
(Beckman Coulter, High Wycombe, UK). Tubes were then carefully removed from 
the rotor tube and mounted in a clamp stand (Figure 2.1 A). The lower virus 
particle band was extracted using a 21 gauge needle and a 5 mL syringe. The 
needle was inserted through the tube wall and the virus band withdrawn into the 
syringe. The viral preparation then underwent a second round of purification 
using another density gradient. A sterilised centrifuge tube was filled with 5 mL 
of the 1.34 g/mL CsCl solution. The extracted virus was carefully layered on top 
and the tube filled with sterile PBS. The preparation was centrifuged at 90000 x 
g at 18 °C for 18 hr. The single virus band (Figure 2.1 B) was extracted in an 
identical manner as described previously. 
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Figure 2.1 Separation of viral particles after CsCl density gradient ultracentrifugation. 
Schematic of polypropylene centrifuge tubes showing separation of fractions after CsCl density 
gradient ultracentrifuge. (A) Separation after spin at 90000 x g for 1.5 hr using 1.25 g/mL and 1.4 
g/mL density CsCl solutions. Viral capsid layer forms between 1.25 g/mL and 1.4 g/mL CsCl 
solutions, with viral capsid proteins forming a second band slightly above. Cellular protein debris 
and PBS form the upper layer (Nicklin and Baker, 1999). (B) Separation after second 90000 x g 
spin for 18 hr showing formation of viral particle layer directly on top of 1.34 g/mL CsCl solution 
(Alba et al., 2012). 
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2.3.2 Dialysis 
In order to remove any CsCl contamination from the preparation, the virus was 
loaded into a Slide-A-Lyser dialysis cassette (Perbio Science, Northumberland, 
UK) with a molecular weight cut off of 10 000 kDa. The preparation was dialysed 
in 2 L of sterile 1 x TE buffer for 2 hr, the buffer replaced and the dialysis 
continued for a further 2 hr. Finally the preparation was dialysed overnight in 1 
x TE supplemented with 10 % glycerol. The virus was then removed, aliquoted 
and stored at -80 °C. 
2.3.3 Recombinant adenoviral vector titration 
Infectious viral particle titres were assessed via end point dilution, and total 
viral particles via micro-Bicinchoninic Acid (BCA) assay, allowing a ratio of 
infectious virions: total particles to be determined. 
2.3.3.1 Titration by end-point dilution assay 
One x T150 cm2 flask of 293 cells were passaged as described in Section 2.2.2 
and re-suspended in 25 mL MEM. Three mL of the cell solution was then diluted 
into a final volume of 20 mL MEM and 200 µL of this added to each well of a 96 
well plate to achieve 50-60% confluence. 24h later viral dilutions were prepared 
in media with dilutions ranged from 10-2 to 10-12. Media was removed from each 
well and replaced starting at the bottom of the plate where 100 µL of media was 
added to each well as a negative control. Each subsequent row was replaced 
with 100 µL of increasing viral concentrations. This process was also repeated 
identically using a 96-well plate containing HeLa cells in order to assess whether 
there was replication competent adenovirus present in the preparation. Media 
was replaced on the cells after 24 hr and then every 2 days for 8 days. When 
viral plaques became apparent, the wells were marked and the media was no 
longer replaced. In order to calculate titre accurately, one dilution must present 
with no plaques, one with less than 50 % of wells presenting with plaques and 
one with greater than 50 %. Plaque forming units (pfu)/mL was then calculated 
using the equations as follows: 
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The proportionate distance (PD) from the 50 % end-point = 
% positive above 50 % - 50 %
% positive above 50 % - % positive below 50 %
 
and logID50 (infectivity dose) = log dilution above 50 % + (PD x -1) x dilution 
For example; for a plate with 7 positive wells out of 10 (70 %) at 10-10 dilution 
and 1 positive well out of 10 (10 %) at 10-11 dilution, the calculation would be as 
follows: 
PD = 
70 - 50
70 - 10
 = 0.33 
logID50 = -10 + (0.33 x -1) = -10.33 
ID50 = 10-10.33 therefore, TCID50 = 
1
10-10.33
 = 1010.33 x by dilution factor (10) 
= TCID50/mL = 1011.33 = 2.14 x 1011 
Where ID50 = infectivity dose 50 and TCID50 = tissue culture infectivity dose 50. As 
1 TCID50/mL is equivalent to 0.7 pfu, multiply by 0.7 to get the final titre, 
2.14 x 1011 x 0.7 = 1.5 x 1011 pfu/mL 
Viral tires ranged from 1.88 x 1010- 5.176 x 1011 pfu/mL. 
2.3.3.2 Particle titration by micro-BCA assay 
Micro-BCA was performed using a micro-BCA protein assay kit (Thermo Scientific, 
Basingstoke, UK) as per the manufacturer’s instructions. First, a 2000 µg/mL BSA 
stock was serially diluted in 1 x PBS to produce a set of standards ranging from 
0.5 µg/mL to 200 µg/mL of protein. Next, 150 µL of each standard was added in 
duplicate to a well of a clear, flat-bottomed 96-well plate (Corning, 
Loughborough, UK) with 150 µl of 1 x PBS also added in duplicate to act as a 
negative control. Next, 1, 3 and 5 µL of adenoviral vectors was added in 
duplicate to the 96-well plate and the total volume adjusted to 150 µL with PBS. 
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The BCA working solution was prepared via mixing reagents MA, MB and MC in 
the ratio 25: 24: 1, respectively. Next, 150 µL of working solution was added to 
each well using a multi-channel pipette and the plate incubated in the dark at 
37°C for 2 hr. Absorbance at 562 nm was then determined using a Wallac 
VICTOR2 plate reader (PerkinElmer, Wallac, Finland). The total number of virus 
particles per mL was then calculated by identifying the protein standard with 
the closest absorbance to that of the sample and using the following formula: 
(
Total protein in BSA standard well (µg)
Absorbance of standard
 ×
Absorbance of sample well
Virus volume in µL
) ×(4 ×109) 
= particle titre in µg/mL 
This was performed for each volume of virus and the values averaged to give the 
final viral particle titre (VP)/mL. 
2.3.4 Virus infections 
Cells were seeded in 6 well plates as described in Sections 2.2.2 and 2.2.3 24 hr 
prior to viral transduction. Adenovirus aliquots were thawed on ice, diluted in 
MEM where required and added directly to each well to achieve the desired 
multiplicity of infection (MOI). MOI is the ratio of infectious viral particles per 
cell. The volume of virus required to achieve a specific MOI is calculated based 
on both cell density and virus pfu titre (Section 2.3.3.1), and is determined using 
the following formula: 
Volume of virus= {(
Cell density
Desired MOI
) ÷ virus pfu} × 1000 = volume in µL 
Cells were harvested 48 hr post-virus transduction. 
2.4 AAV production 
AAV9-Ang-(1-9) and AAV9-eGFP vectors were prepared at the AAV Vector-Unit 
(AVU) Core facility at the International Centre for Genetic Engineering and 
Biotechnology (ICGEB) in Trieste, Italy and were provided as a gift by Professor 
Mauro Giacca.  
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2.5 Nucleic acid extraction 
2.5.1 DNA extraction 
2.5.1.1 Mini-preparation 
A small-scale plasmid preparation was utilised to isolate up to 20 µg plasmid DNA 
from 1-10 mL of bacterial preparation. Prior to purification, 5 mL of the selected 
bacterial colony was produced via incubation in liquid growth media over-night 
(Section 2.6). Next, 4 mL of the bacterial culture was harvested at 6800 x g in a 
table-top centrifuge for 3 min at room temperature. The bacterial pellet was re-
suspended in buffer P1 containing 0.1 mg/mL RNase A, followed by addition of 
250 µL of cell lysis buffer P2. The tubes were inverted to mix. Next, 350 µL of 
precipitation buffer N3 was added to the tube followed by mixing. The sample 
was subjected to centrifugation in a table-top micro-centrifuge at 17900 x g for 
10 min at room temperature. The resulting supernatant was transferred to the 
spin column, avoiding the pellet of cellular debris. The spin columns were 
subjected to centrifugation at maximum speed for 1 min to bind the DNA to the 
silica membrane, and the flow-through discarded. The membrane was washed 
using 0.5 mL of buffer PB followed by a further wash using 0.75 mL of ethanol-
containing wash buffer PE and centrifugation for a further min to dry the 
membrane. The column was transferred to a collection tube and the DNA eluted 
from the column via the addition of 50 µL nuclease-free H2O followed by 
incubation at room temperature for 1 min and a subsequent 1 min centrifugation 
at 17900 x g. DNA concentration was determined via nanodrop (Section 2.5.3) 
and DNA was stored at -20 °C. 
2.5.1.2 Maxi-preparation 
Large-scale maxi preparations allow purification of up to 100-500 µg of plasmid 
DNA from 100-500 mL of bacterial culture. Overnight-incubation of 500 mL of 
bacterial culture was carried out (Section 2.6) and harvested the following day 
via centrifugation at 6000 x g for 15 min at 4 °C. The bacterial pellet was re-
suspended in 10 mL of RNase A containing buffer P1 followed by the addition of 
10 mL of lysis buffer P2. After a 5 min incubation at room temperature, 10 mL of 
pre-chilled neutralisation buffer P3 was added, followed by vigorous inversion of 
the tube to ensure thorough mixing and incubated on ice for 20 min before 
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centrifugation at 20000 x g for 30 min at 4 °C. The cleared supernatant 
containing the DNA was removed from the tube immediately, avoiding the cell 
debris pellet, and loaded onto a QIAGEN-tip 500 which had been equilibrated 
previously using 10 mL of QBT buffer. The supernatant was allowed to enter the 
column resin by gravity flow. The bound DNA was then washed twice using 30 mL 
of medium-salt concentration QC buffer, again under gravity flow. Elution was 
performed under gravity flow via addition of 15 mL of buffer QF to the column 
which was collected in a centrifuge tube. DNA was precipitated via the addition 
of 10.5 mL of room-temperature isopropanol followed by immediate 
centrifugation at 15000 x g for 30 min at 4 °C. The isopropanol was then 
discarded and the DNA pellet washed in 5 mL of 70 % ethanol before a final 
centrifugation step for 10 min at 15000 x g. Finally the pellet was air-dried and 
re-suspended in an appropriate volume of nuclease-free H2O. DNA concentration 
was determined by Nanodrop (Section 2.5.3) and DNA was stored at -20 °C and 
thawed on ice as needed.  
2.5.2 RNA extraction 
Filter pipette tips and RNase-free plastics were used throughout the RNA 
purification protocol. 
2.5.2.1 Cell and tissue lysis 
Tissue samples (10-20 mg), preserved in liquid nitrogen and stored at -80 °C 
(Section 2.10.5), were placed in 2 mL Eppendorfs on dry ice and a 5 mm 
stainless steel bead added to each tube. The tubes were placed at room 
temperature and 700 µL of QIAzol reagent added immediately to each tube. 
Tubes were placed in a Tissue Lyser (Qiagen, Manchester, UK) 2 x 24 Adaptor Set 
and lysed at 30 Hz for 2 x 2 min in order to rupture the cell membranes of the 
tissue. RNA extraction was performed immediately following lysis (Section 
2.5.2.2).  
Cells were washed twice with PBS, followed by the addition of 700 µL of QIAzol 
directly to each well. Cell lysis was facilitated via physical removal of cells from 
the plate surface using a 2 mL syringe plunger. The entire contents of each well 
was aspirated and placed in a 1.5 mL Eppendorf. Tubes were vortexed to ensure 
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complete homogenisation and samples were either stored at -80 °C until 
required or RNA extracted immediately following lysis (Section 2.5.2.2).  
2.5.2.2 Purification 
QIAzol homogenates had 140 µL of chloroform added to each tube before 
vigorous shaking for 15 s. The tubes were incubated at room temperature for 2-3 
min before centrifugation for 15 min at 12000 x g at 4 °C. The upper aqueous 
phase was removed to a fresh tube and 525 µL of 100 % ethanol was added in 
order to facilitate RNA binding to the mini column membrane. RNA was bound to 
the column via centrifugation at 8000 x g for 15 s. At this stage the on-column 
DNase digest was performed (Section 2.5.2.3). Following DNase treatment, the 
membrane was washed with 2 x 500 µL of the ethanol-based RPE wash buffer. 
The column was then subjected to centrifugation at 16000 x g for 1 min to dry 
the membrane. The spin column was placed in a collection tube and RNA eluted 
using 30 µL of nuclease free water and centrifugation at 8000 x g for 1 min. RNA 
concentration was determined using Nanodrop (Section 2.5.3) and was stored at 
-80 °C and thawed on ice as needed.  
2.5.2.3 DNase treatment 
The spin column membrane was washed with 350 µL of the ethanol-based wash 
buffer RWT. DNase I was prepared as per the manufacturer’s instructions (10 µL 
of DNase I diluted in 70 µL of buffer RDD). The entire 80 µL was then added 
directly to the mini spin column membrane and incubated for at least 15 min at 
room temperature. The DNase I was then removed by a further wash with 350 µL 
of RWT buffer. The RNA extraction procedure was then completed as described 
(Section 2.5.2.2).  
2.5.3 Nucleic acid quantification 
DNA and RNA concentrations were determined using a ND-1000 Nanodrop full-
spectrum (220-750 nm) spectrophotometer (Thermo Scientific, Loughborough, 
UK). The Nanodrop is operated by 1-2 µL of sample being placed on the fibre 
optic cable and a second cable lowered down on an arm so the sample forms a 
column between the two. A near-monochromatic pulse of light is then produced 
from a xenon flash lamp at 260 nm which passes through the sample. The light 
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that passes through the sample is analysed by a linear charged-coupled device 
(CCD) array and the absorbance at 260 nm used to correlate the absorbance with 
nucleic acid concentration using the Beer-Lambert equation which is as follows: 
c=A/(E×b) 
Where, c= nucleic acid concentration (mol/L), A= absorbance (log10 P0/P) , E= 
extinction coefficient (L/mol/cm) and b= path length of sample (cm). 
The extinction coefficients for nucleic acids are as follows: dsDNA= 50, ssDNA= 
33, RNA= 40. The absorbance ratio at 260/280 was used to assess nucleic acid 
purity, with a ratio of ≥ 1.8 considered pure.  
2.6 Molecular cloning  
2.6.1 Bacterial culture and antibiotic selection 
Escherichia Coli (E.coli) Top10 cells were produced in-house and with efficiency 
>1 x 108 cfu/mL. Following transformation (Section 2.6.6), bacteria were grown 
on solid antibiotic containing-Luria Broth (LB) agar plates. As the density of 
bacterial growth cannot always be anticipated, 20 and 200 µL of bacterial 
culture were plated on 2 individual plates per transformation and distributed 
evenly across the plate’s surface using a sterile spreader. Plates were incubated 
at 37 °C overnight to allow bacterial colonies to form. 
2.6.1.1 Cryopreservation of bacterial stocks 
1 mL of bacterial culture carrying the plasmid of interest was placed in a 2 mL 
cryovial and mixed via pipetting with 200 µL of sterile 100 % glycerol to achieve 
a 20 % final glycerol content (v/v). The vial was stored at -80 °C. In order to 
expand a clone from a glycerol stock for DNA extraction, the vial was thawed on 
ice and 20 µL spread onto an agar plate containing the appropriate antibiotic 
and the plate incubated as described. A single colony was picked and cultured as 
described (Section 2.6). 
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2.6.2 Restriction endonuclease digestion 
All restriction endonuclease reactions were performed as per manufacturer’s 
instructions. Multiple 20 µL restriction digest reactions containing 1 µg of 
plasmid DNA were performed in order to confirm plasmid integrity and for 
screening clones. 50 µg plasmid DNA was utilised in restriction endonuclease 
reactions to purify fragments for sub-cloning. DNA was mixed with the 
appropriate volume of enzyme and buffer diluted to 1 x using sterile water in a 
1.5 mL Eppendorf and incubated at 37 °C in a water bath for 1-4 hr (20 µL 
reaction) or overnight (100 µL reaction). Fragments could then be visualised 
using gel electrophoresis (Section 2.6.3).  
2.6.3 Agarose gel electrophoresis 
A 0.8 % agarose gel (w/v) was made by dissolving the required weight of agarose 
in 1 x TE buffer by heating. The liquid agarose was allowed to cool for 5 min 
before the addition of 0.01 µL/mL of ethidium bromide. The agarose was poured 
into a gel mould and a comb put in place to form the sample wells. The gel was 
allowed to set at room temperature for 1 hr. Samples were prepared by the 
addition of 6 x gel loading dye (New England Biolabs, Hertfordshire, UK) directly 
to the restriction endonuclease reaction to achieve a final concentration of 1 x 
(e.g. 3.33 µL in a 20 µL reaction). Each sample (and 1kb Ladder) was loaded and 
the gel electrophoresed at 100 volts for 45 min (or until the loading dye 
approached the bottom of the gel). DNA bands were visualised and photographed 
using a Bio-Rad ChemiDoc XRS ultra violet (UV) transilluminator and 
accompanying software (Bio-Rad, Hertfordshire, UK).  
2.6.4 DNA gel purification 
The DNA bands were visualised using UV light and excised using a clean, sharp 
scalpel blade. Bands were weighed and placed in a 2 mL Eppendorf tube and 3 
volumes of buffer QG added to 1 volume of gel (100 mg of gel ~ 100 µL of 
buffer). The tubes were heated on a heat block at 50°C for 10 min, or until the 
gel slices had completely dissolved, with frequent vortexing. One gel volume of 
isopropanol was added to the tubes and the contents immediately loaded onto 
spin columns. The tubes were centrifuged for 1 min at 17900 x g. The membrane 
was washed with a further 0.5 mL of buffer QG to ensure removal of salt 
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contamination followed by 0.75 mL of buffer PE. The membrane was then dried 
via centrifugation for 1 min before DNA elution using 50 µL of nuclease free H2O. 
The H2O was incubated on the membrane for 4 min at room temperature prior to 
centrifugation of the columns in a collection tube via centrifugation for 1 min at 
17900 x g.  
2.6.5 Ligation of DNA fragments into plasmid vectors 
T4 DNA ligase (New England Biolabs, Hertfordshire, UK) was used as per 
manufacturer’s instructions. The amount of backbone DNA was kept constant at 
50 ng per reaction, with the amount of DNA insert varied at 25, 50, 100 and 150 
ng per reaction. A backbone only reaction was performed as a negative control. 
Components were mixed as follows in a well of a 96-well plate: 1 µL insert DNA, 
1 µL 10 x T4 DNA ligase buffer, 1 µL vector DNA, 6 µL sterile H2O and 1 µL T4 
DNA ligase. The plate was sealed and incubated on a PCR heat block at 16 °C for 
16 hr.  
2.6.6 DNA transformation and clone screening 
Following ligation DNA was transformed into bacteria. Top10 cells were 
defrosted slowly on ice, with all steps carried out on ice unless otherwise 
specified and 50 µL of cells used per reaction. 5 µL of each chilled ligation 
reaction was added to the cells which were mixed gently and incubated on ice 
for 30 min. Sterile H2O was used as a negative control and an intact plasmid 
carrying the same antibiotic resistance gene used as a positive control. Tubes 
were placed in a water bath at 42 °C for exactly 30 s and immediately placed 
back on ice for 2 min. Next, 250 µL of sterile SOC media was added to each 
reaction and tubes were incubated at 37 °C and shaken at 200 rpm for 1 hr. 
Cells were then plated on selective growth media overnight as described in 
Section 2.6. Following transformation and culture, clone screening was 
performed to identify those which carry the successfully ligated plasmid.  
2.6.7 Polymerase chain reaction 
PCR reactions were prepared on ice in a 96-well plate using Taq DNA polymerase 
with a Thermopol buffer (New England Biolabs, Hertfordshire, UK) following the 
manufacturer’s instructions for 25 µL reactions. For each reaction 100 ng of 
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cDNA was used. The sequences of the forward and reverse primers used are 
shown in Table 2.1. Reverse transcription (RT) reactions performed without the 
addition of reverse transcriptase were used as a negative control and also to 
check for genomic DNA contamination. PCR reactions were also established using 
100 ng of intact original pBluescript plasmid DNA to act as a positive control. 
Reaction components were as follows: 2.5 µL 10x reaction buffer, 0.5 µL 10 mM 
dNTPs, 0.5 µL of each primer (of 10 µM stocks, forward and reverse), 0.125 µL of 
5 units/µL Taq polymerase and nuclease free H2O to make the final reaction 
volume up to 25 µL. The plate was sealed well and placed on a PCR heat block 
set at the cycling temperatures shown in Table 2.2. PCR reactions were resolved 
on an agarose gel as described in Section 2.6.3. 
2.6.8 DNA sequencing 
Sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing 
Kit (Invitrogen, Paisley, UK) which performs fluorescence-based cycle sequencing 
reactions for double-stranded DNA. The sequencing protocol was performed in 2 
steps. First a PCR reaction was carried out which was then loaded onto an ABI 
Prism 377 laser DNA sequencer (Invitrogen, Paisley, UK) which determines the 
base sequence. 
The sequencing protocol was carried out as per the manufacturer’s instructions. 
For the PCR step, 100 ng of plasmid DNA in a total volume of 1-2 µL was mixed in 
a total reaction volume of 20 µL. Sequencing of the original pBluescript plasmid 
was performed as a positive control. Multiple reactions were set up for each 
plasmid to be sequenced; one for each sequencing primer. Each reaction 
contained the following components: 4 µL BigDye sequencing buffer, 1 µL BigDye 
ready reaction mix, 2 µM of sequencing primer (1 µL of a 10 µM stock) and the 
template DNA, with the total reaction volume made up to 20 µL with Millipore 
filtered H2O. The plate was sealed and heated on a PCR block at the cycling 
temperatures shown in Table 2.3. Prior to sequencing, the PCR reaction 
underwent a clean-up to remove any remaining enzyme and other reagents. This 
was performed by the addition of 10 µL of room-temperature, well-agitated 
Agencourt CleanSEQ (Beckman-Coulter, High Wycombe, UK) to each reaction 
well. Next, 62 µL of 85 % ethanol was added to each well before the plate was 
re-sealed and carefully vortexed to mix. The plate was centrifuged briefly 
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before being placed on an Agencourt 96-well magnet plate (Beckman-Coulter, 
High Wycombe, UK) for 2 min. The DNA, now attached to the beads, remained in 
the plate as long as it was placed on the magnet. The plate, still on the magnet, 
was then blotted upside down to remove the ethanol. The DNA was washed by 
the addition of 150 µL of 85 % ethanol to each well and the magnet-blot process 
repeated. The plate, still in the magnet block and upside down, was subjected 
to centrifugation briefly to remove excess ethanol. The plate was left to air dry 
for 10 min at room temperature. The beads were then re-suspended in 40 µL of 
Millipore filtered H2O (with the plate now removed from the magnet block). With 
the DNA now removed from the beads and in solution, the plate was placed on 
the magnet block one last time and the DNA carefully removed, avoiding any of 
the beads. The DNA was either transferred directly onto a sequencing plate or 
into a sterile Eppendorf tube to be stored at -20 °C prior to sequencing. For 
sequencing, 20 µL of purified PCR product was added to a well of a 96-well ABI 
sequencing plate (Invitrogen, Paisley, UK) which was subsequently loaded onto 
the ABI Prism 377 laser DNA sequencer. Electropherograms were imported into 
CLC Genomics Workbench 7.0 software and analysed compared to a reference 
sequence.   
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Steps 2-4 
repeated 
for 30 
cycles. 
Steps 2-4 
repeated for 
30 cycles. 
Table 2.1 Primer sequences for PCR and sequencing of expression cassette. 
 
Table 2.2 PCR cycling conditions. 
 
 
Table 2.3 BigDye sequencing PCR cycling temperatures.  
Step Temperature (°C) Time  
1 95 5 min 
2 95 30 s 
3 55 10 s 
4 60 4 min 
  
Primer Direction Sequence                                                    
(5'-> 3') 
Expression cassette sequencing  Forward 1 TGGGTAACGCCAGGGTTT 
Expression cassette sequencing  Forward 2 TGGCATGGATCAATTCCG 
Expression cassette sequencing  Reverse 1 TCATGTGGTCGGGGTAGC 
Expression cassette sequencing Reverse 2 GGGCTGCAGGAATTCTCA 
Expression cassette sequencing  Reverse 3 AGCGGATAACAATTTCACAC 
pAAV-MCS PCR Forward CCCATAGAGAGGATTACAAC 
pAAV-MCS PCR Reverse TTTAGTGCGTACGCGAGAT 
pAAV-MCS sequencing Forward 1 CATCGAGAGAACCATCTCAA 
pAAV-MCS sequencing Forward 2 CTGGCCCATCACTTTGGC 
pAAV-MCS sequencing Forward 3 GACAGCCTTCCACTTCGG 
pAAV-MCS sequencing Reverse 1 TCAGGCTTTCTCGGATTGA 
pAAV-MCS sequencing Reverse 2 GAAACCCCGTCTCTACCA 
pAAV-MCS sequencing Reverse 3 CTGCAGGTCGACTCTAGA 
Step 
Temperature 
(°C) 
Time (s) Purpose 
1 95 30 Initial melting 
2 95 30 Melting 
3 55 60 Primer annealing 
4 68 60/kb Strand expansion 
6 68 300 Final strand expansion 
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2.7 Protein extraction 
2.7.1 Cell lysis 
Cell lines cultured in 6-well plates as described in section 2.2.2 and transfected 
as described in Section 2.2.3 were washed twice with sterile PBS and trypsinised 
as described in section 2.2.2. The cells were aspirated from the wells and placed 
in a 1.5 mL Eppendorf tube before being pelleted via centrifugation at 16000 x g 
for 5 min. The supernatant was discarded and the cell pellet re-suspended in 200 
µL of protein lysis buffer. Cell lysis was encouraged via repeated aspiration using 
a 28 G needle and 1 mL syringe. The samples were shaken on ice for 1 hr to 
allow for complete cell lysis and protease inhibition before any remaining debris 
was removed via centrifugation at 16000 x g for 10 min at 4 °C. The protein 
sample was transferred to a fresh 1.5 mL Eppendorf and stored at -80 °C, being 
thawed on ice as needed.  
2.7.2 Bicinchoninic acid (BCA) assay 
The BCA assay was performed using the Pierce BCA assay kit (Thermo Scientific, 
Loughborough, UK) as per the manufacturer’s instructions. Briefly, a set of 
protein standards were prepared via serial dilution of a bovine serum albumin 
(BSA) stock solution (2000 µg of protein per mL) in protein lysis buffer to 
produce a range of protein concentrations. Once prepared, 25 µL of each 
standard was pipetted in duplicate into wells of a clear, flat-bottomed 96-well 
plate. Protein lysis buffer only was used as a negative control. Next, 1, 5 and 10 
µL of each protein sample, prepared as described in section 2.7.1, was pipetted 
into wells of the same plate in duplicate. Each sample well was adjusted to a 
final total volume of 25 µL via the addition of the appropriate volume of protein 
lysis buffer (24, 20 and 15 µL, respectively). The working BCA solution was then 
prepared by mixing reagents A and B in a ratio of 49:1. Next, 25 µL of this 
working solution was added to each sample and standard well using a 
multichannel pipette before incubation of the plate in the dark at 37 °C for 30 
min. The colour intensity of the plate was then determined via absorbance 
measurement at 562 nm using a Wallac VICTOR2 plate reader (PerkinElmer, 
Wallac, Finland).  
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Protein concentration of each sample was then determined by first averaging the 
duplicates for each value and plotting the standard curve using the absorbance 
reading from the standards against the total protein in each well of the standard 
(Figure 2.2). The equation of the line was then used to determine protein 
concentration of each sample by solving for X, using the absorbance of each 
sample as Y and correcting for the volume of the sample in the well (divide by 
the volume in µL). Concentration determined for each lysate volume (1, 5 and 10 
µL) were then averaged to calculate the final protein concentration. 
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Figure 2.2 Linear relationship of protein concentration and absorbance at 562 nm in a BCA 
assay. 
Absorbance readings from a set of protein standards in a BCA assay plotted as total protein per 
well (X) against absorbance at 562 nm (Y) producing a strong linear correlation. The equation of 
the line can be used to determine protein concentration in other samples. 
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2.8 Western immunoblotting 
Protein samples, prepared and quantified as described in Sections 2.7.1 and 
2.7.2, were first diluted to equivalent concentrations in protein lysis buffer, 
with samples kept on ice throughout. Samples were then reduced by mixing 30 
µL of protein sample buffer with 10 µL of 4 x NuPAGE LDS sample buffer and 4 µL 
of NuPAGE reducing agent in a 1.5 mL Eppendorf tube. Reduction was achieved 
by heating the sample mixture for 10 min at 70 °C on a heat block. Next, 800 mL 
of 1 x NuPAGE MOPS SDS running buffer was prepared by dilution of the 20 x 
stock in H2O. The pre-cast 12-sample 4/12 % bis-tris NuPAGE gel was then 
prepared by removal of the sample comb and was assembled in a gel tank 
(Invitrogen, Paisley, UK) which was then filled with the running buffer. Once 
prepared, 20 µL of each prepared sample was loaded into the gel using gel-
loading pipette tips, with 5 µL of Seeblue protein ladder (Invitrogen, Paisley, UK) 
loaded into one well as a molecular weight reference. The gel was 
electrophoresed for 1 hr at 200 volts.  
2.8.1 Transfer 
During the electrophoresis step, the transfer buffer was prepared by diluting the 
20 x stock of NuPAGE transfer buffer to 1 x in 20 % methanol in H2O and a Novex 
polyvinylidene difluoride (PVDF) pre-cut blotting membranes with 0.45 µm pore-
size (Invitrogen, Paisley, UK) and 2 pre-cut filter papers were pre-soaked in the 
transfer buffer as were 7 sponges. Once the electrophoresis was complete, the 
gel was carefully removed from the cassette and place on top of 3 pre-soaked 
sponges and one piece of filter paper which had been stacked into the transfer 
cassette. The PVDF membrane was place on top followed by the second filter 
paper and remaining 4 sponges. The cassette was then closed, ensuring no air 
bubbles remained between any of the layers, and locked into the transfer tank, 
ensuring the current would be running perpendicular to the gel and such that the 
positive electrode was on the membrane side of the cassette, ensuring transfer 
would take place in the correct direction. The tank was then filled with the 
transfer buffer and a current applied at 40 volts for 1 hr.  
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2.8.2 Protein detection 
Two-stage protein detection was performed by first probing for the protein using 
an un-tagged antibody against the protein of interest and then probing for the 
primary antibody using a horseradish peroxidase (HRP) conjugated secondary 
antibody, making for more specific detection. After transfer, the membrane was 
removed from the cassette and a corner cut off to mark the top and protein side 
of the membrane. The membrane was blocked in 10 % milk (Marvel, Premier 
Foods, Hertfordshire) in TBS-T (0.1 % tween) for 1 hr at room temperature with 
shaking to prevent non-specific antibody binding. The primary rat anti-mouse 
IgG2b antibody [1 mg/mL stock, Abcam (ab167476), Cambridge, UK] was then 
prepared by dilution 1 in 250 in 10 % milk in TBS-T and was incubated on the 
membrane for 2 hr at room temperature with shaking. The membrane was then 
washed for 3 x 10 min in TBS-T before incubation with the secondary rabbit anti-
rat IgG HRP antibody [Dako (P0450), Cambridge, UK] diluted 1 in 1000 in 10 % 
milk in TBS-T for 2 hr at room temperature. The membrane was washed again 
for 3 x 10 min in TBS-T. The membrane was incubated with Amersham ECL prime 
solution (GE Healthcare, Buckinghamshire, UK), prepared by mixing reagents 1 
and 2 in equal volumes as per the manufacturer’s instructions, for 1 min. The 
membrane was immediately transferred to an X-ray film cassette for 
development with photographic film. 
2.9 Real-time quantitative reverse transcription PCR 
2.9.1 Reverse transcription 
Reverse transcription of RNA was performed using a reverse transcription kit 
(Invitrogen, Paisley, UK) as per the manufacturer’s instructions for a 40 µL 
reaction using 500 ng of RNA per reaction. Reactions were set up in a 96-well 
plate on ice with components per reaction as follows: 4 µL of 10x reaction 
buffer, 8.8 µL of MgCl2, 8 µL of dNTPs (2.5 mM each dNTP), 2 µL of 50 µM 
random hexamers, 0.8 µL of 20 U/µL RNAse inhibitor and 1 µL of 50 U/µL reverse 
transcriptase (multiscribe) enzyme with the total reaction volume made up to 40 
µL with the addition of nuclease-free H2O. The 96-well plate was sealed and 
centrifuged briefly to mix. The plate was placed on a PCR heat block and set for 
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the cycling conditions for the reverse transcriptase reaction as shown in Table 
2.5. Once complete, the plate was stored at -20 °C until needed.  
2.9.2 Quantitative PCR 
QPCR reactions were set up in a 384-well MicroAmp optical PCR plate 
(Invitrogen, Paisley, UK) with a total reaction volume of 10 µL on ice. Reactions 
were performed in duplicate using 1.5 µL of each RT product per reaction 
(Section 2.9.1). H2O was used as a negative control. 5 µL of TaqMan Universal 
Master Mix II (Invitrogen, Paisley, UK), containing ultra-pure AmpliTaq Gold DNA 
Polymerase, dNTPs and buffer components, was added to each well with 0.5 µL 
of the TaqMan assay containing the primer-probe combination for the specific 
gene of interest (see Table 2.4) and the total reaction volume made up to 10 µL 
with nuclease-free H2O. The plate was sealed with an optical adhesive film and 
centrifuged briefly to mix the components. QPCR was performed on a 7900HT 
Fast Real-Time PCR System (Invitrogen, Paisley, UK). Cycle threshold values (Ct) 
for each gene was normalised to that of a house-keeper gene for each sample. 
Data was expressed as fold change compared to a reference sample determined 
using the 2-∆∆Ct method (Schmittgen and Livak, 2008), where ∆∆Ct= (Ct of 
sample)-(Ct of reference sample), with the fold change represented arbitrarily 
as relative quantification (RQ).  
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Table 2.4 TaqMan gene expression assay details 
Gene Assay ID RefSeq Gene ID Label 
Agtr1a (AT1R) Mm01957722_s1  NM_177322.3  FAM 
Agtr2 (AT2R) Mm01341373_m1  NM_007429.5  FAM 
Mas 1 Mm00434823_s1 NM_008552.4  FAM 
ACE Mm00802048_m1 NP_001268748.1  FAM 
ACE2 Mm01159003_m1 NP_001123985.1  FAM 
B2m Mm00437762_m1 NM_009735.3  FAM 
GAPDH 4352339E NM_008084.2 VIC 
18S 4319413E X03205.1 VIC 
 
Table 2.5 Reverse-transcription cycling temperatures 
Step Temperature (°C) Time (min) 
1 25 10 
2 48 30 
3 95 5 
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2.10 In vivo models and physiological measurements 
2.10.1 The mouse model of myocardial infarction 
All surgical procedures were performed in accordance with the Animals Scientific 
Procedures Act (1986) and were approved by the University of Glasgow Ethical 
Review Panel and the UK Home Office. Animals were male C57BL/6 mice 
obtained from Harlan (UK) at 8 weeks of age and housed under controlled 
environmental conditions (12 hr light/dark cycle at ambient temperature and 
humidity) and maintained on a standard chow diet. Animals were allowed at 
least a 1 week acclimatisation period before being used for procedure between 
9-11 weeks of age (body weight 23-28 g).  
2.10.1.1 Theatre set-up, animal preparation and intubation 
The MI procedure was performed using sterile technique. Pre- and post-
operative analgesia was prepared and administered prior to surgery in order to 
give adequate time for the drugs to take effect. Each animal received an intra-
peritoneal injection of 0.6 μg Buprenorphrine and 0.1 mg Carprofen in 0.4 mL of 
sterile 5 % NaCl saline. Post-surgery animals received 25 µg of Temegesic 
(Buprenorphrine) delivered in soft food daily for 3 days following surgery. The 
surgical area was set up under a surgical microscope with a heat mat and 
ventilator (Figure 2.3).  
The induction box was filled with 4 % isofluorane in oxygen at a flow rate of 1 
L/min and animals placed in the box for induction. Animals were then placed on 
a facemask on the same isofluorane-oxygen mix in the preparation area and the 
hair removed from the chest. The shaven area was cleaned thoroughly using 
Hibiscrub surgical disinfectant after which the animal was transferred to a 
facemask in the surgical area. Prior to intubation, analgesia and fluids were 
administered and a sterile ocular lubricant (Lacrilube, Allergen Inc., USA) used 
to cover the eyes to prevent drying during surgery. The intubation apparatus, 
comprised of a plastic support with a suture loop attached, was prepared under 
the dissecting microscope. Animals were then intubated using a custom-made 
0.8 mm diameter, 25 mm long intra-tracheal cannula (Harvard Apparatus, Kent, 
UK, Figure 2.3) covered with a silicone cuff to prevent air leakage (Figure 2.3). 
The Y-piece of the cannula was attached to the inspiration and expiration tubes 
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of a Minivent Mouse Ventilator Type 845 (Hugo Sachs Elektronik- Harvard 
Apparatus, Germany) set at 25 μL SV and 25 strokes/min, with the flow rate 
reduced to 0.6 L/min. Correct placing of the cannula was assessed by noticeable 
synchronous rise and fall of the chest with the ventilator. After successful 
intubation, the animal was positioned on a pre-warmed heat mat (Figure 2.3), 
on their back, slightly on their right hand side with right fore- and hind-limbs 
taped to the heat mat. The left arm was suspended using a piece of tubing to 
make the left-hand side chest accessible. The remaining left hind-limb remained 
free for regular flexor withdrawal monitoring and the ventilator tubes taped 
down securely to prevent movement.  
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Figure 2.3 Animal preparation and intubation for the MI surgical procedure. 
(A) Positioning of the animal for intubation, allowing visualisation of the throat under the 
microscope for accurate insertion of the cannula. (B) The custom-made intubation cannula. (C) 
Positioning of the animal prior to surgery. (D) Positioning of equipment with ventilator proximal to 
the heat mat and the surgical surface covered in sterile drapes.  
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2.10.1.2 Thoracotomy, left anterior descending coronary artery ligation and 
recovery 
Isofluorane concentration was gradually and incrementally reduced as the 
surgical procedure progressed to 0 % by the end of the surgery. Once positioned, 
a diagonal incision was made in the skin using sharp dissection scissors running 
upward at an angle left to right. The skin was retracted using elastic blunt hook 
retractors (Harvard Apparatus, UK) which were secured in place using pin-tacks 
inserted though the retractor into cork underlying the surgical drape. Blunt 
dissection of the muscles was performed which were secured clear of the rib 
cage using the retractors. Entry into the chest was made via the fourth 
intercostal rib space by first perforating the muscle by carefully inserting the tip 
of a pair of sharp angled forceps. Full entry was made using a battery-operated 
cauterising pen (Harvard Apparatus, UK), in order to avoid substantial blood loss, 
and the ribs retracted in order to visualise the left ventricle, with care taken not 
to damage the lung.  
For sham procedures the surgery was identical, however the left anterior 
descending (LAD) coronary artery ligation was not performed and the surgery 
progressed to closing of the chest and recovery. For animals undergoing MI, 
visualisation of the LAD was achieved by increasing the magnification and light 
intensity of the microscope. The vessel was ligated using 9-0 ethilon suture 
(Ethicon, Livingston, UK) to achieve an approximately 40 % infarct of the left 
ventricle, with the suture placed as close to the vessel as possible to avoid any 
other major vessel ligation. Correct placing of the suture was immediately 
obvious due to the blanching observed in the myocardial tissue below the suture 
(Figure 2.5).  
Following ligation, the ribs were released from the retractor hooks and 3 pieces 
of non-absorbable 6-0 Prolene sutures (Ethicon, UK) placed between the 3rd and 
5th intercostal muscles. The left most suture was used to gently raise the rib 
cage while the lung was re-inflated via occlusion of the ventilator expiration 
tube by pinching until the lung reached the surgical marker points made earlier 
in the surgery. The expiration tube was placed in a beaker of tap water to 
maintain lung re-inflation by creating positive end-expiratory pressure. The 
sutures were then tied firmly to close the excision. Muscles were released from 
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the retractors and replaced before the skin was replaced and the incision closed 
using 5-6 individual stitches with absorbable 6-0 Vicryl suture (Ethicon, 
Livingston, UK) (Figure 2.4). At this stage, isofluorane level was reduced to 0 % 
and the wound cleaned well with Hibiscrub disinfectant. The animal remained on 
the ventilator at 100 % oxygen for 5 min following surgery and remained on the 
ventilator on room air thereafter until signs of consciousness became apparent. 
Upon recovery, animals were placed in a pre-heated cage lined with soft 
bedding. Animals received analgesia as described, were weighed daily for one 
week check for any substantial weight loss and were checked 3 times daily for 3 
days to assess activity levels and ensure the wound remained closed and showed 
no signs of infection. 
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Figure 2.4 Images of MI surgical procedure. 
Images of the stages of thoracotomy and closing for the MI procedure in the order performed (A-H) 
as described in the text. Scale bar= 5 mm. 
 
 
Figure 2.5 LAD ligation. 
Images showing exposed mouse heart before and after LAD ligation. Blanched myocardium visible 
below the suture indicates successful ligation of the vessel. Scale bar= 1 mm 
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2.10.2 In vivo viral vector delivery in the mouse MI model 
2.10.2.1 Adenoviral vectors 
Ad vectors were delivered directly to the myocardium during the MI procedure. 
A viral dose of 1 x 109 pfu per animal was chosen based on the literature 
(Moilanen et al., 2011; Ruixing et al., 2007; Toivonen et al., 2012). This dose 
was confirmed in initial experiments utilising RAdCMV-LacZ, a reporter gene 
expressing adenoviral vector which enabled direct visualisation of gene transfer 
efficiency in the myocardium (see Chapter 4). 
RAdAng-(1-9) or empty control virus (RAd60) were defrosted on ice and diluted 
to 1 x 109 pfu in a 50 μL volume using sterile PBS in a class II microbiological 
safety cabinet. The animals were prepared for surgery and the MI procedure 
carried out up until the LAD ligation (Section 2.10.1). Following LAD ligation, the 
sterile adenoviral vector preparation was warmed briefly to room temperature 
and loaded into a sterilised 50 µL Hamilton syringe (Hamilton Company, Nevada, 
USA) with a 30 G needle. The total volume was delivered in 5 x 10 µL injections 
distributed evenly across the border zone LV proximal to the blanched region of 
the heart. The animal was then closed and monitored post-operatively (Section 
2.10.1).  
2.10.2.2 Adeno-associated viral vectors 
AAV9 vectors were delivered to MI animals via intra-venous tail vein injection 
following MI surgery. The viral dose per animal of 1 x 1011 viral geneomes (vg) 
was chosen based on the literature (Denegri et al., 2014; Inagaki et al., 2006) 
and preliminary experiments performed using an enhanced green fluorescent 
protein (eGFP)-expressing AAV9 control virus (see Chapter 5). 
AAV was prepared and transported to the surgical theatre as described for 
adenovirus (Section 2.10.2.1), with 1 x 1011 vg prepared in a total volume of 100 
µL. The MI surgery was performed up until before recovery of the animal as 
described (Section 2.10.1). The animal’s tail was then swabbed with 70 % 
ethanol and heated using a heat lamp in order to visualise a tail vein. The AAV 
was heated briefly to room temperature and loaded into a 100 µL Hamilton 
syringe (Hamilton Company, Nevada, USA) with a 30 G needle. The needle was 
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carefully inserted into the vein and the entire volume injected. Pressure was 
immediately placed on the injection site using a sterile swab to prevent any 
leakage of the injection until no more bleeding was evident. Animals were then 
recovered and monitored post-operatively. 
2.10.3 Echocardiography 
Echocardiography was used as a means of making serial measurements of cardiac 
function in MI animals for longitudinal study. Both M-mode and Doppler 
measurements were recorded for each animal. Echocardiographic images of the 
mouse heart were obtained using a Siemens Acuson Sequoia 512 ultrasound unit 
with an 18LS probe set at a frequency of 14 MHz. Animals were anesthetised in 4 
% isofluorane mixed with oxygen. They were placed on a nose cone on a heat 
mat where the isofluorane was reduced to 1.5 % at a flow rate of 1 L/min for the 
duration of the measurements. Temperature was monitored throughout using a 
precision thermometer with flexible probe (Harvard Apparatus, Kent, UK) with 
excess heat provided using a heat lamp where required. Animals were placed on 
their back with the forelimbs retracted slightly to open the chest but so as not 
to inhibit breathing. Ultrasound gel was placed on the animal’s chest and on the 
probe and M-mode images captured in both the longitudinal and transverse axis. 
Imaging was kept consistent between animals by measurements being made just 
above where the papillary muscles could be visualised. Doppler measurements 
were made by placing the probe below the animal’s diaphragm pointed up 
towards the heart to achieve a 4 chamber view. The mitral valve was located 
using colour-flow mapping, where blood flow toward the probe appeared as red. 
Analysis was performed using ImageJ software, with measurements taken as an 
average between analyses of four separate images. Fractional shortening (FS) 
was calculated as follows: 
FS= 100-(
LVESD
LVEDD
×100) 
Where LVEDD = Left ventricular end diastolic chamber dimension, LVESD = Left 
ventricular end systolic chamber dimension and FS = Fractional shortening 
(Figure 2.6).   
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Figure 2.6 Echocardiography M-mode image analysis. 
Transverse M-mode image taken in a 4-week sham animal demonstrating the measurements 
performed for each images to asses functional parameters and cardiac remodelling. LVEDD = Left 
ventricular end diastolic chamber dimension, LVESD = Left ventricular end systolic chamber 
dimension. 
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2.10.4 Pressure-volume loop measurements 
Pressure-volume loop measurements are widely regarded as the gold-standard in 
assessing intact heart function in real-time. It is an invasive method involving 
the insertion of a miniature sensor catheter into the left ventricle of the heart 
which is able to determine ventricular pressure and true blood volume 
independent from loading conditions (Pacher et al., 2008). 
2.10.4.1 The ADVantage PV-loop system 
The ADVantage AD500 PV-loop system (Transonic Systems Inc., The Netherlands) 
is a small animal PV-loop system that uses admittance catheter-based 
technology to measure true-blood volume in real time without the need for a 
hypertonic saline bolus injection offset (see Section 2.10.4.5). Traditional 
conductance-based PV loop systems use a tetra-polar catheter placed inside the 
LV which stimulates an electrical field and measures conductance of both the 
blood pool and myocardium, over-estimating true blood volume and measuring 
only resistivity of the blood and myocardium, and not the capacitive properties 
of the cardiac tissue. Where the admittance system varies is that it is able to 
measure both conductive and capacitive properties of blood and tissue. When 
this is performed at a frequency of 20 kHz, blood has resistivity only. This allows 
separation of blood and muscle admittance by the system by modelling blood as 
only resistive and the muscle as both resistive and capacitive. Admittance 
technology uses production of an alternating electrical current which is phase-
shifted by the charge of the cardiomyocytes themselves, causing a time-delay in 
the current received by the catheter compared to the emission signal. This 
phase-shift is used to determine muscle conductance and remove it completely 
from the total measured conductance. Real-time calculations are then used to 
determine true blood volume independent from muscle. These calculations 
utilise the mathematical algorithm known as Wei’s equation (Wei et al., 2005) 
which relies on several measurements made by the catheter itself in real-time 
and some constants which are determined by other means (see Sections 2.10.4.4 
and 2.10.4.5). The catheter itself comprises 4 platinum electrode rings which 
generate the current, an electrical sensing window and a membrane pressure 
sensor (Figure 2.7). When placed in the ventricle, 4 separate parameters are 
measured: pressure (mmHg), volume (µL), phase (degrees) and magnitude (µS). 
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Phase corresponds to the muscle-derived conductance only and admittance 
magnitude corresponds to both blood and muscle-derived conductance. Both 
phase and magnitude are calculated in real time and are dependent upon in-put 
information about the myocardial permitivity and conductivity properties (see 
Section 2.10.4.5). This information is then used to calculate true blood volume 
using Wei’s equation (Scisence PV Technical Note) as follows: 
𝑉𝑜𝑙 =  
1
(1 −
𝐺𝑏
𝛾 )
𝜌𝐿2(𝐺𝑏) 
Where ρ = blood resistivity, L = measuring electrode distance, Gb = measured 
blood conductance (separated from muscle conductance using admittance phase 
measurements) and γ is the equation as follows: 
𝛾 =  
−𝑏 ± √(𝑏2 − 4𝑎𝑐)
2𝑎
 
Where: 
𝑎 = 𝑆𝑉 − 𝜌𝐿2(𝐺𝑏−𝐸𝐷 −  𝐺𝑏−𝐸𝑆) 
𝑏 =  −𝑆𝑉 ∙ (𝐺𝑏−𝐸𝐷 + 𝐺𝑏−𝐸𝑆) 
𝑐 = 𝑆𝑉 ∙ 𝐺𝑏−𝐸𝐷 ∙ 𝐺𝑏−𝐸𝑆 
Where SV = stroke volume, Gb-ES = blood conductance at end-systole and Gb-ED = 
blood conductance at end-diastole. 
SV is a constant determined independently and input into the system (see 
Section 2.10.4.4). 
2.10.4.2 PV-loop surgery 
Prior to surgery, the ADV500 system (Transonic Systems Inc., The Netherlands) 
was set up on the surgical table connected to a laptop via a 4-channel analogue 
to digital converter with Labscribe2 software (iWorx, New Hampshire, USA) 
open. Channels were connected in the correct order (1-4 for pressure, volume, 
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phase and magnitude, respectively). The 1.2 F 4.5 mm spaced PV admittance 
catheter (FTH-1212B-4517, Transonic Systems Inc., The Netherlands, Figure 2.7) 
was connected to the ADV500 box and carefully secured in a clamp stand above 
a pre-heated tissue bath set at 37 °C and soaked in warmed 5 % NaCl saline for 1 
hr prior to use so that calibration could be performed at physiological 
temperature. Upon first use, a 2 point in-built calibration specific for mouse was 
performed (Table 2.6) and recorded for each channel and the Labscribe2 file 
saved to be used for each subsequent recording. Prior to each insertion of the 
catheter into the carotid, a fine adjustment was performed to balance the 
pressure signal. 
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Figure 2.7 ADVantage PV-loop mouse admittance catheter. 
Image of the 1.2 F, 4.5 mm spaced mouse ADVantage PV-loop system catheter. 1= four platinum 
ring electrodes for absolute volume measurements, 2= Pressure membrane sensor and 3= 
electrical sensor window. Scale= 1 mm. 
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Table 2.6 Two point calibration values for mouse using ADVantage PV-loop system. 
 
Calibration value 
Output Low High 
Pressure (mmHg) 0 100 
Volume (µL) 0 150 
Phase (degrees) 0 20 
Magnitude (µS) 0 5000 
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Mice were induced and intubated as described in Section 2.10.1.1. The mouse 
was positioned upside down with its cranial end towards the surgeon (Figure 2.8) 
and placed on a homeothermic monitoring system (Harvard Apparatus, Kent, UK) 
which was used to keep body temperature at 37 °C for the duration of the 
procedure, with a heat lamp used for extra heat where required. The animal was 
laid on its back and its fore-limbs retracted gently and taped to the heat mat. 
One hind-limb was left free in order to monitor the flexor withdrawal response. 
Isofluorane concentration was reduced gradually throughout the procedure and 
measurements were taken at 1.5 %. A vertical incision was made in the skin of 
the neck which was retracted using elastic blunt hook retractors (Harvard 
Apparatus, Kent, UK). Underlying muscle was blunt dissected and retracted in 
the same manner, with care taken not to disturb the trachea. Further blunt 
dissection was performed to free the right carotid artery of surrounding tissue. 
The vessel was kept moist using warmed 5 % NaCl saline throughout the 
remainder of the procedure. The vessel was permanently occluded at the cranial 
end using a length of 6-0 silk braided suture (Pearsalls, Somerset, UK) sutured 
tightly around the vessel. The length of the suture was used to anchor the vessel 
and raise it slightly to simplify the remainder of the procedure. Two pre-tied 
single-throw sutures were positioned around the vessel and the blood flow at the 
dorsal end temporarily occluded using a weighted length of suture wrapped 
around the vessel (Figure 2.9). The prepared catheter was then moved to the 
surgical table and the receiver taped down securely. Ensuring blood flow in the 
vessel had been suspended, a small incision was made using micro-dissection 
scissors in the cranial end of the carotid artery. A small amount of blood loss 
confirmed successful perforation. The catheter was then inserted into the vessel 
and the two pre-tied sutures tightening to hold it in place, avoiding the 
electrodes and sensing windows. The temporary dorsal occlusion was then 
removed and blood flow returned to the vessel (Figure 2.10). Data recording was 
established on the ADV500 box and Labscribe2 software. The catheter was 
advanced down into the left ventricle, with successful entry confirmed with a 
drop in the end diastolic pressure reading to near 0 mmHg. Optimal positioning 
of the catheter into the centre of the ventricle was achieved initially using a 
real time pressure vs. magnitude plot and positioning the catheter so that the 
phase value read as low as possible (typically <5°) and the loop was as large as it 
could be. Once optimal placement was achieved, a baseline scan was performed 
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on the ADV500 box. This calculates blood and myocardial electrical parameters 
and applies them to Wei’s equation to generate true blood volume which 
appears as an additional channel to phase and magnitude. At this stage the loop 
can be viewed as pressure vs. volume channels and the animals temperature was 
adjusted to 37 °C and the isofluorane concentration reduced to 1.5 %. A 5 min 
acclimatisation period was then allowed before a further baseline scan followed 
by a 10 min steady state recording period.  
Following steady state, a vena cava occlusion was performed in order to assess 
left ventricular stiffness and diastolic dysfunction. An incision was made just 
below the xiphoid process through the skin and muscle, with care taken not to 
cause any excessive bleeding. The liver was depressed slightly using a clean 
cotton bud in order to visualise the vena cava behind it next to the diaphragm 
(Figure 2.11). Slow, gradual occlusion of the vessel was achieved while still 
recording the PV-loop data by gently depressing the vessel using a clean cotton 
bud, resulting in a ‘family of loops’ cause by gradual reduction of both pressure 
and volume parameters due to decreased cardiac loading. Finally, the animals 
underwent Schedule 1 via cervical dislocation. 
  
Chapter 2  98 
 
 
Figure 2.8 PV-loop surgical set up and animal positioning. 
Images showing positioning of animal as described in the text and the positioning of the ventilator 
and recording equipment in relation to the surgical area. 
 
 
Figure 2.9 PV loop surgical carotid artery dissection. 
Sequential images showing the stages of carotid dissection for insertion of the PV-loop cathter. (A) 
Visualisation of the animal neck area. (B) Vertical incision made in the skin. (C) Blunt dissection 
and retraction of the surrounding tissue and muscle. (D) Cranial permanent occlusion and dorsal 
temporary occlusion and re-positioning of the carotid artery. Scale bar= 1 cm. 
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Figure 2.10 PV-loop carotid catheter cannulation. 
Sequential images showing carotid cannulation and insertion of the PV-loop catheter. (A) Pre-tied 
suture positioned around vessel. (B) Incision made into the cranial end of the carotid (indicated by 
the arrow). (C) Insertion of the catheter through the incision and securing it in place by tightening 
sutures. (D) Advancement of catheter into the vessel down into the left ventricle. Scale bar= 1 mm. 
 
 
Figure 2.11 PV-loop vena cava occlusion. 
Image showing visualisation of the vena cava prior to occlusion.1= Xiphoid process, 2= Diaphragm, 
3= Liver and 4= vena cava. Scale bar= 1 mm. 
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2.10.4.3 PV-loop analysis 
PV-loop data was analysed offline in Labscribe2 software by generation of an 
average loop from analysis of 2 min steady-state recording and determination of 
multiple haemodynamic and contractile parameters based on this average loop. 
Stiffness was determined using the end-diastolic pressure-volume relationship 
(EDPVR) by fitting a non-linear exponential equation to the end-diastolic 
pressure and volume points generated from the family of loops produced through 
vena cava occlusion. The equation is as follows: 
EDP=Cexp
(β*EDV)
 
Where EDP= end-diastolic pressure, EDV= end-diastolic volume, C= a curve 
fitting constant and β= the diastolic stiffness coefficient (Burkhoff et al., 2005). 
2.10.4.4 Aortic flow-probe surgery 
Aortic flow probe measurements were performed using a Transonic MA1.5PSL 
mouse flowprobe and T5420 transit-time perivascular flow meter (Transonic 
Systems Inc., The Netherlands). Theatre was prepared for surgery as described 
in Section 2.10.4.2. The perivascular flow meter was positioned on the surgical 
table and connected to a laptop via an analogue to digital converter and 
Labscribe2 (iWorx, New Hampshire, USA) software opened. The flow probe was 
connected to the flow meter and soaked in clean 5 % NaCl saline warmed to 37 
°C for 1 hr prior to surgery. A 2 point calibration of the probe was then 
performed using two in-built values (0 V= 0 mL/min and 1 V= 5 mL/min). Animals 
were induced, intubated and positioned as described (Section 2.10.4.2). 
Temperature was monitored throughout using a homeothermic monitoring 
system (Harvard Apparatus, Kent, UK) and isofluorane reduced gradually 
throughout the procedure. A right-thoracotomy was performed in a similar 
fashion to the left-thoracotomy carried out for the MI procedure (Section 
2.10.1.2), however entry into the chest was made via the 2nd intercostal rib 
space. Upon entry and retraction of the ribs, the aorta became immediately 
obvious (Figure 2.12). Very careful blunt dissection around the aorta was 
performed to allow placement of the probe around the vessel, with care taken 
not to rupture any vessels or disturb the right atria. A piece of 6-0 silk braided 
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suture (Pearsalls, Somerset, UK) was looped under the vessel to aid positioning 
of the flow probe. The flow probe was prepared by drying on a clean swab and 
insertion of surgical lubricant (Savage Labs, New York, USA) into the sensing 
window to ensure no air pockets interfered with the signal. The probe body was 
then inserted into the surgical cavity and the suture loop used to gently lift the 
vessel and place it into the sensing window (Figure 2.12). More surgical gel was 
inserted around the probe once placed. Cardiac output (CO) was measured in 
Labscribe2 software and a micro-manipulator arm used to achieve optimum flow 
readings. Isofluorane concentration was reduced to 1.5 % for the duration of the 
measurements. A 5 min acclimatisation period was allowed before steady state 
measurements were taken for 5 min. Following surgery, the probe was carefully 
removed and soaked in a 1 % solution of biological enzyme (Tergazyme, Alconex, 
New York, USA) for 1 hr, rinsed thoroughly with distilled water and air-dried 
prior to storage. Data was analysed offline using Labscribe2 software. The 
average SV calculated from average CO values from a group of animals was used 
to determine true blood volume as part of Wei’s equation for PV-loop 
measurements. Flow probe measurements carried out in adult male C57BL/6 
mice demonstrated an average CO of 9± 1.29 mL/min, an average HR of 466± 
11.4 bpm and an average SV of 20± 3 µL (n= 3, Figure 2.13). Individual animal 
measurements are shown in Table 2.7. Therefore, SV was set at 20 µL for 
subsequent PV-loop measurements. This was within the normal SV range (17-30 
µL) reported elsewhere for mice anaesthetized with isofluorane (Pacher et al., 
2008).  
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Figure 2.12 Aortic flow-probe placement. 
Images demonstrating the view upon entry into the chest cavity with immediate visualisation of the 
aorta (1) and placement of the vessel into the flow probe. Scale bar= 5 mm.  
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Figure 2.13 Flow probe measurements. 
Flow probe analysis of adult C57BL/6 mice for determination of CO (A), HR (B) and SV (C), n= 3. 
Data presented as mean± SEM. CO= cardiac output, HR= heart rate, SV= stroke volume. 
 
 
Table 2.7 Individual animal flow probe measurement indices. 
Animal CO (mL/min) HR (bpm) SV (µL) 
1 11.59 459.36 25.23 
2 7.31 488.06 14.97 
3 8.35 450.35 18.53 
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2.10.4.5 Murine myocardial permittivity and conductivity measurements 
Traditional conductance-based catheter systems for the measurement of left-
ventricular blood volume rely on hypertonic saline bolus offset to differentiate 
the contribution of the parallel admittance of the myocardium to the 
conductance measurements of the blood (Raghavan et al., 2009). However, due 
to the small size of mice, the bolus significantly alters haemodynamic properties 
of the heart, making it a less than optimal approach for assessing true blood 
volume in this setting (Raghavan et al., 2009). The admittance-based catheter 
technology used here utilises an in-built offset for myocardial interference, i.e. 
contribution of the cardiac muscle conductivity to the calculation of blood 
volume, with reading of true blood volume by utilising pre-determined 
myocardial conductance properties of the murine myocardium which is used as 
part of Wei’s equation (Section 2.10.4.1) in determining blood volume. Previous 
studies (Porterfield et al., 2009) have determined conductivity: permittivity (σ: 
ε) ratios in normal and aortic-banded C57BL/6 mouse hearts using epicardial 
surface probe measurements, determining a ratio of 800 thousand units/s (K/s) 
for normal mice (Porterfield et al., 2009). It was reported that in a diseased 
state, the myocardial electrical properties are altered, with a decrease in ratio 
to 700 K/s in the hypertrophied myocardium of the aortic banded mice. In the 
ADVantage system, the ‘heart type’ or σ: ε ratio is pre-set at 800 K/s, however 
this can be modified on the system. In order to establish the heart type that 
should be used in the MI model, an epicardial surface calibration probe (FM-
1987-1H, Transonic Systems Inc., The Netherlands) was used. 
Animals were prepared for surgery, intubated and positioned as described 
(Section 2.10.4.2). Temperature was monitored throughout using a 
homeothermic monitoring system (Harvard Apparatus, UK). A left thoracotomy 
was performed identical to that described (Section 2.10.1.2). In MI animals any 
adhesive tissue was carefully dissected away to expose the left ventricular wall. 
The surface probe was connected to the ADVantage system control box and 
measurements recorded in Labscribe2 software (iWorx, New Hampshire, USA). 
To take measurements, the probes electrodes were placed on the moist 
epicardial surface of the non-infarcted LV, avoiding any major blood vessels. A 
micromanipulator was used to hold the probe in place and a steady state flow 
recording was taken. The probe was then removed, rinsed well and air dried 
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before storage. Recordings were analysed offline by averaging the steady state 
measurement in Labscribe2 software. Average ‘heart-type’ values were 
determined by averaging α:ε ratios for each group of animals. The heart type 
was determined in both 8 week sham and MI animals using permittivity probe 
measurements of the myocardium (Figure 2.14). Both sham and MI α:ε ratios 
were determined to be approximately 800 K/s with no significant differences 
between the two groups (n= 5 per group, p>0.05). Therefore, heart type 
remained at the system default setting of 800 K/s for both sham and MI animals. 
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Figure 2.14 Cardiac permittivity measurements. 
Cardiac permittivity measurements for 8 week sham and MI animals, n= 5 per group. Data 
presented as mean± SEM. 
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2.10.5 Animal post-mortem and tissue harvest 
Mice were euthanized rapidly via cervical dislocation. Organ weights were taken 
as a measure of cardiac hypertrophy and dysfunction. Hearts were rapidly 
excised and immediately washed in a beaker of ice-cold 5 % NaCl saline before 
being cannulated and perfused with the same solution. Hearts were 
photographed and dabbed dry on a swab before being weighed. All lobes of the 
lung and liver were excised, washed and dabbed dry before being weighed. All 
organ weights were normalised to tibia length. Cardiac tissue was preserved in 
paraformaldehyde for histology and snap frozen for gene expression analysis. For 
hearts taken for both uses, a longitudinal section of the heart was snap frozen in 
liquid nitrogen and stored at -80 °C, with the remainder placed in 10 % neutral 
buffered saline with 4 % paraformaldehyde (Cellstore, UK) overnight before 
being stored in 1 x PBS prior to processing. For whole hearts taken only for gene 
expression analysis, dissection was first performed to separate the hearts into 
the following regions: scar, border (peri-infarct), remainder LV, remote LV, 
septum and RV. The paleness of the scar tissue made it easily distinguished from 
non-infarcted myocardium and was removed first. A 1 mm region of tissue 
proximal to the scar region was then removed as the border region. The RV and 
septum were then separated from the LV, which was subsequently divided into 
two sections: the remote LV proximal to the atria and the remainder LV proximal 
to the border region. The remote LV was utilised for gene expression analysis. 
Dissection was performed accurately using micro dissection instruments and a 
dissection microscope.  
2.11 Histology 
2.11.1 Tissue processing 
Following fixation, tissue sample were processed on a Shandon Excelsior tissue 
processor (Thermo Scientific, Basingstoke, UK, Table 2.8) and embedded in 
paraffin wax the following day for histological use. Hearts were mounted 
longitudinally in order to visualise all cardiac structures. Tissue sections were 
prepared for IHC and histology by first chilling the paraffin blocks on a cold plate 
before using a microtome to cut sections at a thickness of 4 μm which were then 
dried on Tissue-Tek adhesion microscope slides (Sakura, Thatcham, UK) 
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overnight at 50 ºC and stored at room temperature until use. For heart tissue 
blocks, serial sections were taken every 100 µm until the chambers of both 
ventricles became evident. Sections for staining were taken at this point in an 
effort to keep the tissue depth consistent between animals. Prior to histological 
staining or IHC, sections were de-paraffinised and re-hydrated using Histoclear 
and decreasing concentration gradients of ethanol. 
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Table 2.8 Processing sequence for paraffin embedding of tissue samples. 
Solution Incubation Time 
(min) 
70 % Ethanol 30 
95 % Ethanol 30 
100 % Ethanol 30 
100 % Ethanol 30 
100 % Ethanol 45 
100 % Ethanol 45 
100 % Ethanol 60 
Xylene 30 
Xylene 30 
Xylene 30 
Paraffin Wax 30 
Paraffin Wax 45 
Paraffin Wax 45 
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2.11.2 Immunohistochemistry  
Tissue sections were cut and rehydrated as described in Section 2.11.1. 
Endogenous peroxidase activity was quenched using incubation in 3 % H2O2 in 
distilled H2O for 30 min at room temperature followed by a 5 min wash in 
distilled H2O. Sodium citrate antigen retrieval was then performed (for all 
primary antibodies apart from anti-β-galactosidase). 10 mM sodium citrate 
solution was heated until boiling. Sections were placed in a plastic rack, 
submerged in the hot solution and heated for 15 min, slides were then cooled for 
30 min to ensure correct re-folding of the antigen. Slides were washed in running 
tap water for 5 min. Blocking was performed to prevent non-specific antibody 
binding using incubation with the appropriate blocking solution (Table 2.9) for 30 
min at room temperature. Blocking solution was removed and slides incubated 
with primary antibody diluted in a reduced concentration blocking solution for 
the appropriate length of time (Table 2.9). Rabbit IgG diluted to the same final 
concentration was used as a negative control. Following primary antibody 
incubation, slides were washed for 3 x 5 min using the appropriate wash buffer 
before incubation with the appropriate secondary antibody diluted in reduced 
concentration blocking solution for the specified time (Table 2.10). Sections 
were washed for 3 x 5 min using wash buffer. For secondary antibodies 
conjugated directly to HRP, 3,3'-Diaminobenzidine (DAB) staining could be 
performed directly. For biotinylated antibodies an extra step was performed to 
attach a HRP-labelled avidin-biotin or streptavidin-biotin complex to the 
secondary antibody. Avidin and streptavidin molecules have a very high affinity 
for biotin and as such will bind to the biotinylated antibody, amplifying the 
signal. For anti-collagen III, the VECTASTAIN standard ABC reagent kit was used 
(Vector Laboratories, Peterborough, UK) as per the manufacturer’s instructions. 
Two drops of each reagent A and B were mixed in 5 mL of PBS and incubated at 
room temperature for 30 min to allow avidin-biotin complexes to form. Sections 
were then incubated with the ABC for 30 min before being washed well for 3 x 5 
min in PBS and DAB staining performed. For anti-eGFP and β-galactosidase, 
Streptavidin peroxidase (Sigma-Aldrich, Poole, UK) was used. Streptavidin was 
diluted 1: 200 in PBS/TBS and incubated on the slides for 30 min at room 
temperature before the slides were washed for 3 x 5 min and DAB staining 
performed.  
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The Vector DAB substrate kit (Vector Laboratories, Peterborough, UK) was 
prepared as per the manufacturer’s instructions (2 drops of buffer, 4 drops of 
DAB chromagen, 2 drops of H2O2 and 2 drops of nickel (optional) per 5 mL of 
distilled H2O). The prepared substrate was added to one slide and a stopwatch 
started. The slide was monitored under a microscope to look for colour 
development. As soon as the dark-brown staining became apparent the slide was 
placed in distilled H2O to stop the reaction and the time of incubation noted. All 
slides were then developed for this length of time to keep staining intensity 
consistent. This was typically between 1-5 min. Slides were washed in running 
tap water for 5 min before counter-staining of the nuclei for 30 s in Harris 
haematoxylin (Sigma-Aldrich, Poole, UK). Slides were washed for 5 min in 
running tap water before being dehydrated using the reverse of the re-hydration 
procedure. Slides were then mounted using DPX histological mounting medium 
(Merck Chemicals Ltd., Nottingham, UK) and dried overnight at room 
temperature. 
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Table 2.9 Primary IHC antibodies and reaction conditions. 
 
Table 2.10 Secondary IHC antibodies and reaction conditions. 
Protein Secondary Antibody Concentration Company & Clone number Host Species Dilution Incubation Time 
eGFP Anti-rabbit IgG biotinylated 1.5 mg/mL Vector (BA-1000) Goat 1:200 2 hr at room temperature 
β-galactosidase Anti-rabbit IgG biotinylated 1.5 mg/mL Vector (BA-1000) Goat 1:200 30 min at room temperature 
Mouse collagen I Anti-rabbit IgG HRP 0.25 mg/mL Dako (P0448) Goat 1:100 45 min at room temperature 
Mouse collagen III Anti-rabbit IgG biotinylated 1.5 mg/mL Vector (BA-1000) Goat 1:500 30 min at room temperature 
 
 
Protein Concentration Company & Clone number 
Host 
Species 
Dilution Blocking Solution Incubation Time 
eGFP 0.5 mg/mL Abcam (ab6556) Rabbit 1:200 15 % normal goat serum in TBS-T Overnight at 4 °C 
β-galactosidase 2.5 mg/mL MP-Biomedicals (8559762) Rabbit 1:350 20 % normal goat serum in PBS 1 hr at room temperature 
Mouse collagen I 1 mg/mL Abcam (ab34710) Rabbit 1:200 6 % normal goat serum in 1% BSA/PBS Overnight at 4 °C 
Mouse collagen III 1 mg/mL Abcam (ab7778) Rabbit 1:1000 2 % normal goat serum in PBS-T Overnight at 4 °C 
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2.11.3 Picrosirius red staining 
Tissue sections were re-hydrated and incubated in a 1 mg/mL solution of Sirius 
red (Sigma-Aldrich, Poole, UK) in saturated picric acid (picrosirius red stain) in 
the dark at room temperature for 90 min. Sections were washed 2 x 3 min in 
0.01 N HCl acidified water followed by dehydration in 2 x 3 min washes in 100 % 
ethanol and 2 x 7 min washes in Histoclear. Sections were mounted using DPX 
histological mounting medium (Merck Chemicals Ltd., Nottingham, UK) and dried 
overnight at room temperature. 
2.11.4 Imaging and analysis 
Once dry, IHC and picrosirius red sections were imaged on an EVOS FL colour 
imaging system (Life Technologies, Paisley, UK). Whole sections were imaged 
and captured as 8-bit TIFF files which were exported directly to an external 
memory source. Staining quantification was performed using ImageJ software. 
For whole heart sections, quantification was performed per region of the heart 
(scar, LV, RV and septum) with an equivalent apical section taken as a scar 
region in non-MI animals. For analysis, images were split into a red-green-blue 
(RGB) image stack. For DAB staining, quantification was performed on the blue 
image and for picrosirius red the green image was used. In each case a colour-
intensity threshold was set to include all positive-stained pixels in the image and 
staining quantified as the % of total pixels within the intensity threshold of a 
selected area of interest. For vessel-associated staining quantification, images 
were analysed in the same way with the region of interest limited to any vessels 
visible in the image. Scar sizing in MI animals was performed using 
measurements in picrosirius red stained sections using the following equation: 
Infarct size (%)=
EPI infarct ratio + ENDO infarct ratio
2
×100 
Where EPI ratio= epicardial infarct length/epicardial circumference and ENDO 
ratio= endocardial infarct length/ endocardial circumference. Measurements 
were performed on two sections approximately 200 µm apart per heart. The 
infarcted area was defined as where >50 % of the thickness of the myocardium 
was fibrotic tissue.  
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2.11.5 Wheat germ agglutinin staining 
Tissue sections were re-hydrated and underwent sodium citrate antigen retrieval 
as described in Section 2.11.2. Sections were blocked for 1 hr at room 
temperature with 1 % BSA in PBS and 5 % goat serum. Next, sections were 
incubated with 10 µg/mL of WGA conjugated with Alexa Fluor 555 (Life 
Technologies, Paisley, UK) diluted in the blocking solution for 1 hr at room 
temperature in the dark. Slides were washed in PBS for 2 x 5 min before being 
dabbed dry and mounted with Prolong Gold anti-fade reagent + 4',6-diamidino-2-
phenylindole (DAPI) to stain nuclei (Life Technolgies, Paisley, UK). Slides were 
dried at room temperature overnight and stored in the dark at 4 °C prior to 
imaging. 
2.11.5.1 Confocal imaging and image analysis 
Confocal images of WGA stained sections were taken using a LCI Plan-Neofluar 
25x/0.8 1 mm Korr Ph2 confocal water-immersion objective lens on a Zeiss laser 
scanning confocal microscope (LSM 510 Meta, Carl Zeiss Ltd., Cambridge, UK) 
and accompanying software. Line-scan images were obtained using Diode 405-30 
(excitation of DAPI) and HeNe 543 (excitation of WGA) lasers with a total 
exposure time of 1 min and 40 s. Images of cellular cross-sections of 
cardiomyocytes in both transverse and longitudinal axis of the LV were captured 
for each heart section and exported as 8-bit TIFF files.   
Images were exported into ImageJ where a macro setting a scale for each image 
was applied. Cell length (longitudinal images) and cell diameter (transverse 
images) was measured for each image. Two sections and two images per cellular 
orientation of the LV were analysed per animal. Cells were chosen at random 
using placement of a grid pattern overlying the image with cells selected where 
grid lines intersected. Cell length and diameter was determined for each animal 
by averaging all cell measurements. Exclusion criteria were applied for minimum 
cell length of <70 µm to account for not being able to observed the whole cell 
given the optical sectioning of the confocal microscope. 
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2.12 β-Galactosidase staining 
In order to stain for β-galactosidase activity in intact tissue samples preserved in 
paraformaldehyde, 5-bromo-4-chloro-3-indolyl-β-D-galactosidase (X-GAL) 
staining was used. X-GAL (Melford Laboratories, Ipswich, UK) was re-suspended 
in dimethylformamide (DMF) to achieve a final stock concentration of 20 mg/mL 
and stored at -20 °C and defrosted to make up the stain as needed. The X-GAL 
stain was made fresh and stored at 4 °C for a maximum of 7 days. The 
composition was as follows (final concentrations): Na2HPO4 1.54 mM, NaH2PO4 
0.46 mM, MgCl2 26.00 µM, H3Fe(CN6)6 60.00 µM, H4Fe(CN6)6 60.00 µM and 1.00 
mg/mL X-GAL. After fixation, tissue samples were washed well 2 x in PBS and 
submerged in X-GAL stain. Samples were incubated in the stain in the dark 
overnight at 37 °C and then washed 2 x in PBS. Areas of positive β-galactosidase 
expression appeared dark blue after staining. Tissue samples were photographed 
and were processed and wax-embedded as described (Section 2.11.1). 
2.13 eGFP assay 
An eGFP assay was used in order to assess transgene expression within cell 
lysates using the eGFP fluorescence intensity of a lysed tissue sample in relation 
to protein concentration. First, 25-30 mg of frozen tissue harvested in liquid 
nitrogen as described in Section 2.10.5 was placed on dry ice in a 2 mL 
Eppendorf tube. A 5 mm stainless steel bead (Qiagen, Manchester, UK) and 300 
μL of 1 x reporter lysis buffer (5 x stock diluted to 1 x in PBS, Promega, 
Southampton, UK) was added to each tube. Tissue was lysed on a Qiagen Tissue 
Lyser (Qiagen, Macnchester, UK) at 20 Hz for 3 x 90 s. Samples were shaken on 
ice for 10 min to ensure total lysis of all the tissue before remaining debris was 
removed from the samples via centrifugation in a table top centrifuge at full 
speed for 5 min. The supernatant was removed to a fresh tube and placed on ice 
and the debris and bead discarded. Next, 20 μL of each sample was pipetted into 
a well of a black 96-well plate (BD Biosciences, Oxford, UK) in duplicate and 
made up to a total volume of 100 μL by addition of 80 μL of 1 x reporter lysis 
buffer. As a negative control, 100 μL of 1 x reporter lysis buffer was used. The 
plate was incubated in the dark at room temperature for 10 min before 
fluorescence was determined on a Wallac VICTOR2 plate reader (PerkinElmer, 
Wallac, Finland) via excitation at 488 nm and emission recorded at 509 nm. 
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Fluorescence was normalised to protein concentration of each sample 
determined via BCA assay (Section 2.7.2). Fluorescence was expressed as 
relative light units (RLU) per mg of protein. 
2.14 Mouse cardiomyocyte isolation 
Single mouse ventricular cardiomyocytes were isolated from the hearts of adult 
C57BL/6 mice via constant-flow Langendorff retrograde perfusion with 
collagenase type I enzyme (Figure 2.15). This method involves cannulation of the 
aorta resulting in perfusion through the coronary system of the enzymatic 
solution which digests extracellular matrix and connective tissue, yielding single 
cardiomyocytes in the solution. 
Adult C57BL/6 mice were euthanized via cervical dislocation and the heart and 
lungs rapidly excised via thoracotomy and washed in a beaker of ice cold Krebs-
Heinseleit solution (Figure 2.15). The lungs and surrounding tissue were 
dissected in order to free and identify the aorta. The heart was cannulated using 
a 1 mm diameter catheter and secured using 6-0 silk braided suture (Pearsalls, 
Somerset, UK). The peristaltic pump was switched on in order to begin constant 
perfusion of the heart at a rate of 4 mL/min with 37 °C Krebs-Heinseleit 
solution. Blood clearing from visible vasculature on the surface of the heart was 
used as confirmation of successful cannulation. The heart was placed vertically 
in a clamp stand and perfused until the perfusate ran clear (1-2 min) before the 
addition of collagenase I (Worthington Chemicals, USA) and protease type XIV 
(Sigma-Aldrich, Poole, UK) directly to the Krebs-Heiseleit reservoir at final 
concentrations of 0.7 mg/mL and 0.07 mg/mL, respectively. Digestion times 
varied between preparations, but on average were performed for 6 min, with 
adequate digestion observed as a paling of the cardiac tissue and loss of obvious 
vessel architecture. As the digestion progressed, noticeable paling of the heart 
was observed (Figure 2.16 A and B). After adequate digestion time a 3-way tap 
was used to change the source of the perfusate to a second reservoir containing 
pre-warmed 0.5 % BSA in Krebs-Heiseleit solution. Perfusion of the BSA solution 
was continued for a further 4 min in order to deactivate the enzyme and prevent 
over-digestion. The heart was then cut down from the cannula and the atria, 
vessels and RV removed (Figure 2.16 C). The remaining LV and septal tissue was 
cut into small pieces and placed in a 15 mL Falcon tube with 5 mL of BSA 
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solution. Trituration using a flame-blunted Pasteur pipette was used to agitate 
the tissue and release the individual cells from any remaining tissue into 
suspension (Figure 2.16 D and E). Any remaining tissue was allowed to settle to 
the bottom of the tube and the cell suspension aspirated off and placed in a new 
tube. This process was repeated twice more with the remaining tissue to achieve 
a total volume of 15 mL. This was concentrated gently using a hand-operated 
centrifuge to pellet the cells. The supernatant was removed and discarded and 
the cells re-suspended in 5 mL of fresh BSA solution. The calcium concentration 
of the cellular suspension was raised gradually from 0 to 1 mM by the addition of 
1 µL/mL of 100 mM CaCl2 solution to the suspension every 5 min to prevent 
cellular hyper-contraction as a result of the calcium paradox (Chapman and 
Tunstall, 1987). This is a manifestation which occurs when cardiomyocytes are in 
a nominally Ca2+-free surrounding. The re-introduction of physiological Ca2+ 
levels immediately results in an influx of Ca2+ which binds the myofilaments and 
causes hyper-contraction and balling of the cell. Re-introducing Ca2+ gradually 
minimises this. The final cellular suspensions compromises recognisable rod-
shaped cardiomyocytes with visible striations and hyper-contracted ball-shaped 
cells which occur as a result of damage of the sarcolemma, either as a result of 
enzymatic activity or physical damage, allowing influx of Ca2+ into the cell 
(Figure 2.16 F and G).  
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Figure 2.15 Mouse cardiomyocyte isolation Langendorff set-up, heart excision and 
cannulation. 
Images showing Langendorff rig set-up (A), cannula positioned under dissection microscope with 
pre-tied suture (B) and dissection, washing and cannulation of the heart (C-E). 
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Figure 2.16 Mouse cardiomyocyte isolation collagenase I digestion. 
Images showing collagenase I digestion of the mouse heart to yield single cells. Enzyme perfusion 
of the heart results in noticeable paling of the cardiac tissue (A & B). After digestion the RV, atria 
and vessels are discarded (C) and the remaining tissue agitated to dissociate the cells (D & E). 
Rod and ball-shaped myocytes are visible in the preparation (F & G).  
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2.15 Single cardiomyocyte Ca2+-handling measurements 
2.15.1 Epifluorescence microscopy 
The use of epifluorescence microscopy to image Ca2+ in isolated cardiomyocytes 
requires the use of a Ca2+-sensitive fluorescent probe, or fluorophore. 
Ratiometric fluorophores are particularly appropriate for this purpose as they 
correct for differential dye-loading and path-lengths which may cause misleading 
[Ca2+] measurements. Differential path length and dye loading stems from 
heterogeneity in cellular morphology, meaning photons from different parts of 
the cell travel to the detector via different paths. For measurements in static 
cells this can be accounted for by normalisation to a baseline measurement, 
however as cardiomyocytes are contractile this cannot be done. Here the 
ratiometric Ca2+-sensitive fluorophore Fura-4F, with excitation at 340 and 380 
nm when bound and unbound to Ca2+, respectively, and emission at 510 nm was 
used. The dye associates and dissociates from the Ca2+ in the cytoplasm of the 
cardiomyocyte as it is released and taken back up by the SR during ECC. When 
bound, it is excited at 340 nm and when unbound at 380 nm, so as emission from 
excitation at one wavelength increases, it decreases from the other and vice-
versa. When the ratio of emission at 340 and 380 nm is calculated, the trace 
rises and falls with Ca2+ release and re-uptake (Wokosin et al., 2004).  
2.15.2 Experimental protocols 
Calcium imaging was performed on an inverted epifluorescence microscope 
positioned in a Faraday cage in a darkened room. All experiments were carried 
out at 37 °C under constant pressure perfusion with the use of a heated 
perfusion pen (Cell Microcontrols, Virginia, USA) and a peristaltic pump outflow. 
Cell stimulation was at a rate of 1 Hz and cells were loaded with Fura-4F AM 
ester ratiometric dye (Life Technologies, Paisley, UK). Experiments were carried 
out at physiological [Ca2+] (1.8 mM) and pH (7.48) with the use of a HEPES 
buffered superfusate in which all other components were diluted. SR Ca2+ 
content was determined using a 10 mM caffeine solution. Instantaneous solution 
changes were achieved by priming the system with up to 7 different solutions 
which were interchangeable via an automated pinch-valve system. 
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For all Ca2+ imaging experiments, isolated cardiomyocytes were pelleted using a 
hand-operated centrifuge and re-suspended in 5 mL of HEPES buffered 
superfusate. Cells were then loaded by the addition of 5 µL of Fura-4F to 1 mL of 
cells and followed by incubation in the dark at room temperature for 10 min, 
after which time a further 3 mL of superfusate was added to the cells to de-
esterificate the fluorophore. Cells were loaded onto a cell bath (Cell 
Microcontrols, Virginia, USA) connected to a stimulator set at 1 Hz with 2 ms 
duration voltage pulses delivered via parallel platinum wires. Cell stimulation 
simulates sarcolemmal depolarization in response to an AP. Cells were visualised 
using a 40 x oil immersion objective lens and perfusion and outflow started.  
Prior to each experimental protocol, a 20 second steady state recording of 
quiescent cell fluorescence was recorded to determine the resting cell [Ca2+], or 
Rmin. At the end of each experimental protocol, stimulation was terminated 
simultaneously with the application of the 10 mM caffeine bolus. This empties 
the SR of Ca2+ producing a caffeine-induced Ca2+-transient which can be used to 
determine SR calcium content. In a group of cells the Rmax was determined by 
perforation of the cell using a pulled glass micropipette positioned using a 
micromanipulator arm.  
2.15.3 Data acquisition and analysis 
For Ca2+ imaging, the fluorescence signal was sampled at 5000 Hz and data 
recorded in Clampex 10.3 software using an analogue to digital convertor (Axon 
Instruments, California, USA). Data was imported into Origin 6.1 software 
(Originlab, Massachusetts, USA) and the 340/380 ratio (fluorescence corrected 
for artefact) determined for the trace. A timing signal was generated based on 
the sampling frequency and a steady-state recording of 12 transients used to 
calculate an average transient using a macro written by Prof. Godfrey Smith, 
University of Glasgow. Exponential decay functions were calculated using the 
software’s own programmes. Fluorescence ratio could be converted into [Ca2+]i 
using the following equation: 
[Ca2+]=Kd×β(R-Rmin)/(Rmax-R) 
Where Kd= the dissociation constant of the dye (0.77 µM for Fura-4F)(Wokosin et 
al., 2004), β= the relative change in fluorescence between 0 and saturating 
Chapter 2  122 
 
[Ca2+] at 380 nm, R= the ratio signal, Rmin= the minimum ratio before stimulation 
(0 [Ca2+]) and Rmax= is the maximum signal (saturating [Ca2+]). β was measured by 
Dr. Chris Loughrey during system set-up and calibration, with Kdβ= 2.8 x 10-6 for 
Fura-4F.  
2.15.4 Fractional shortening measurements 
Cell shortening was measured simultaneously with Ca2+ imaging using edge-
detection imaging equipment (IonOptix, Dublin, Ireland) and accompanying 
software (Ionwizard 6.0) which measured the change in cell length during 
stimulation. Data was sampled at 2000 Hz and traces were exported as text files 
to be analysed in Origin 6.1 software. An equivalent length of trace to Ca2+ 
transient analysis was averaged (12 contractions) and a timing signal generated 
using a macro. Diastolic cell length was taken immediately before stimulation 
(L0) and used to calculate fractional shortening as the average % reduction from 
L0. 
2.16 Statistical analysis 
Data are represented as mean values ± the standard error of the mean (SEM) 
unless otherwise stated. qRT-PCR data was expressed as relative quantification 
(RQ) with each sample normalised to a control. qRT-PCR error was expressed as 
rqmax, which is calculated based on the maximum expression level that 
represents a 95 % confidence interval of the mean RQ value according to 
Students T-test and represents the standard error of the mean expression level. 
Paired student’s T-test was performed for direct comparisons and one-way 
analysis of variance (ANOVA) with Tukey’s post-test was performed for multiple 
comparison, with a P value <0.05 considered statistically significant.  
For animal groups in in vivo studies, n-numbers are indicated for each figure. 
Data for echocardiography was analysed using repeated measures ANOVA with 
Tukey’s post-test. A P value <0.05 was considered statistically significant. All 
statistical analysis was carried out using Graphpad Prism 4 software (GraphPad 
Software Inc., California, USA). 
 
  123 
 
Chapter 3: Characterisation of a mouse MI model 
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3.1 Introduction 
3.1.1 The mouse model of coronary artery ligation 
Two-thirds of human patients who develop HF do so as a result of myocardial 
infarction caused by coronary artery disease (Ho et al., 1993; Klocke et al., 
2007). Therefore a desirable animal model for the development of potential 
therapeutics for cardiac contractile dysfunction post-MI is one which mimics the 
same injury and disease processes, such as in the mouse MI model. Mouse models 
in general are extremely popular in biological research for a variety of reasons. 
They share 99 % of their genes with humans and have similarities in all major 
organ systems; they are small, docile, cheap and easy to maintain and breed; 
they are easy to genetically manipulate and a variety of ‘humanising’ 
experimental procedures have been developed to mimic human conditions 
(Rosenthal and Brown, 2007). Although the MI procedure is performed in large 
animal models such as dog or pig there can be a high incidence of ventricular 
tachycardia and ventricular fibrillation (Hood et al., 1967; Iwanaga et al., 2004) 
as well as incurring significantly higher maintenance, infrastructure and 
purchase costs. Mice are also extremely well suited to adenoviral-vector 
administration for the assessment of gene therapy based therapeutics as they 
can be administered with high viral doses without an apparent toxicity response 
(Curiel and Douglas, 2002). C57BL/6 mice have a non-observable adverse effect 
level (NOAEL) dose of 2.4 x 109 pfu/m2 for Ad vectors compared to that of 1.7 x 
109 pfu/m2 for hamsters and 1.2 x 107 pfu/m2 for humans which is advantageous 
for experimental purposes but may be problematic from a translational aspect 
(Curiel and Douglas, 2002). Due to their small size lower vector load is required 
per animal compared to that of a pig or dog. This makes mice a more 
economical choice in terms of vector production for the use of viral gene 
therapy and allows assessment of gene therapy approaches for the treatment of 
remodelling post-MI. 
The CAL MI model was selected for the present study as it matches the aetiology 
of the disease by mimicking acute occlusion of the coronary artery in acute MI, 
resulting in ischemia of the myocardium while also permitting control over the 
time and site of the occlusion allowing for reproducibility (Klocke et al., 2007). 
The CAL MI model was first described in mice in 1977 (Zolotareva and Kogan, 
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1978) and has since been increasingly used to investigate underlying mechanisms 
contributing to cardiac dysfunction in MI in both wild type and transgenic mice. 
Small animals are suited to determination of cardiac functional parameters and 
infarct sizes using techniques such as echocardiography, as well as for 
electrophysiological characterisation using ex vivo preparations on Langendorff 
apparatus (Kuhlmann et al., 2006). Cardiac haemodynamic parameters have also 
been well characterised in the model at various time points and remodelling 
severities using pressure-volume relationships (Patten et al., 1998; Shioura et 
al., 2007). This has been made possible due to the popularity of the mouse as an 
experimental model leading to the development of advanced technologies which 
are able to make accurate measurements on such a small scale. 
3.1.2 Study of the RAS in the mouse MI model 
The mouse MI model has been used extensively to study the role of the RAS in 
cardiac remodelling and dysfunction post-MI and its therapeutic potential, with 
the role of the angiotensin receptors being particularly well investigated (Harada 
et al., 1999; Yang et al., 2002a). The role of the AT1R in remodelling post-MI was 
demonstrated using global AT1R knock-out mice (Harada et al., 1999). AT1R KO 
mice have been shown to have increased survival rate, decreased expression of 
foetal, collagen and TGFβ-1 genes, attenuation of HF (as measured via activity 
levels and right ventricular to body weight ratio) and decreased left ventricular 
dilation and increased fractional shortening (as measured using 
echocardiography following infarction). This demonstrated that the AT1R is a 
major contributor to cardiac remodelling and progression to heart failure 
following MI (Harada et al., 1999). Conversely, transgenic mice which over-
express the AT2R specifically in the heart have significantly decreased end 
systolic volume indices and preserved EF as determined via MRI versus wild type 
groups, highlighting the dramatically converse effects of Ang II signalling via its 
different receptors (Yang et al., 2002b). The use of AT2R knock-out mice has also 
demonstrated that the cardio-protective effects seen by valsartan (an AT1R 
antagonist)-mediated AT1R blockade are in part mediated by the AT2R. 
Decreases in left ventricular dimensions and decreased lung to body-weight ratio 
was observed in wild-type mice treated with valsartan post-MI. This attenuation 
was not observed in the AT2R knock-out animals when administered with 
valsartan (Oishi et al., 2006). Despite the positive results observed in transgenic 
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animals with regards to the therapeutic potential of the AT2R, the mouse MI 
model has also been used to show that a synthetic small molecule agonist 
(compound 21; C21) of the AT2R does not have the same effect as AT2R over-
expression (Jehle et al., 2012). C21 administered via minipump, or the AT1R 
antagonist candesartan, delivered via drinking water, was given to mice 
following MI. Cardiac function was assessed at 28 days using CMR and only the 
candesartan group had  preserved left ventricular EF, showing that direct 
stimulation of the AT2R does not have the same beneficial effects as AT1R 
blockade or AT2R over-expression following MI (Jehle et al., 2012). 
The effects and mechanisms of ACE inhibition have also been well studied in the 
model. ACEi administered 1 month after MI in wild-type mice has been shown to 
have a beneficial effect on cardiac structural and functional remodelling, with 
echocardiography measurements showing decreased LVDD, increased LV EF and 
increased FS, and histological analysis showing reduced cardiac hypertrophy and 
fibrosis (Liu et al., 2002). These beneficial effects were found to be mediated by 
eNOS which was increased due to the inhibition of Ang II synthesis as a result of 
ACEi. The effects seen as a result of ACEi were absent or reduced in eNOS knock-
out animals following MI (Liu et al., 2002). The model has also been used to 
demonstrate that ACE inhibition using enalapril or AT1R blockade using Losartan 
have equivalent effects on reducing cardiac hypertrophy and ANP and collagen 
type I gene expression following MI (Patten et al., 2003). 
The therapeutic potential of the counter-regulatory RAS has been less well 
studied in the mouse MI model, however it has been demonstrated that 
subcutaneous injection of Ang-(1-7) following MI increased left ventricular 
pressure measured via LV catheter, reduced LV and RV hypertrophy and 
decreases BNP and collagen type I expression. These effects were associated 
with an increase in VEGF and c-kit positive cells in the infarcted hearts, 
suggesting Ang-(1-7) may enhance cardiac recovery post-MI through stimulation 
of bone-marrow derived progenitor cells which migrate to the myocardium 
(Wang et al., 2010a).  
These findings highlight the utility of the MI model for studying the therapeutic 
potential of the RAS and unravelling some of the mechanisms underlying the 
effects seen.  
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3.2 Aims 
The aims of this chapter were to: 
 Learn how to surgically induce MI in the mouse. 
 Characterise the mouse MI model for functional, haemodynamic, 
histological and gene expression parameters, particularly with respect to 
the RAS. 
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3.3 Results 
3.3.1 MI surgery mortality 
MI-associated incidence and cause of mortality was monitored for an 8-wk period 
following MI in male C57BL/6 mice (Figure 3.1). Kaplan-Meier survival curves 
plotting mortality rates of all MI-animals successfully recovered from procedure 
demonstrated a significant reduction in survival of MI animals vs. sham (n= 53 
and 46, respectively, P<0.01) over an 8 wk period, with 15 % of MI animals dying 
within the first wk following surgery (Figure 3.1 A). The main cause of death for 
animals which survived the MI procedure was cardiac rupture, accounting for 
33.3 % of all procedure-related mortality, with 4.2 % dying of an unknown cause 
post-operatively which could not be determined by post-mortem analysis. The 
remainder of deaths were associated with intra-operative complications (Figure 
3.1 B). A change in mortality was associated with gaining experience in the MI 
procedure, with an inverse relationship observed between the number of MI 
procedures performed and the number of deaths resulting from procedural 
complications, increasing overall survival rates from 30 % at its lowest to 67 % at 
its highest (Figure 3.1 C). 
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Figure 3.1 MI-surgery related mortality. 
(A) Kaplan-Meier plot of MI vs. sham mortality following recovery from procedure over an 8 wk 
period.  **= P<0.01, n= 53 and 46 for MI and sham, respectively. (B) Cause of MI-mortality, both 
intra-operatively and post-recovery. (C) Relationship of intra-operative associated death, cardiac 
rupture rates and overall survival to the number of procedures performed. 
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3.3.2 Haemodynamic and functional measurements in the MI 
model 
3.3.2.1 Echocardiography 
Serial echocardiography measurements were performed on sham and MI animals 
on a weekly basis for 4 wks. A separate cohort of animals were taken to 8 wks 
post-MI for comparison (Figure 3.2).  
At 1 wk post-MI there was a significant drop in FS in MI animals compared to 
sham (49.9± 0.2 vs. 30.4± 0.3 %, 1 wk sham (n= 12) vs. 1 wk MI (n= 12); P<0.001; 
Figure 3.2 A-ii). The significant reduction in the MI group was maintained at all 
time-points, with a gradual further reduction in FS from 1 wk to 8 wks post-MI by 
15.2 % (30.4± 0.3 vs. 25.8± 0.9 %, 1 wk MI (n= 12) vs. 8 wk MI (n= 6); P<0.05). FS 
was unchanged throughout the 8 wk period in the sham group (Figure 3.2 A-ii). 
The reduction observed in FS was associated with increases in both LVEDD and 
LVESD in the MI group compared to sham animals and gradually increased from 1 
wk to 8 wk post-MI. At 1 wk, LVEDD in MI was significantly increased to 120.6 % 
of sham animals (4.1± 0.03 vs. 3.4± 0.02 mm, 1 wk MI (n= 12) vs. 1 wk sham (n= 
12); P<0.00; Figure 3.2 A-iii). LVEDD gradually increased throughout the study, 
with a significant increase in the 8 wk MI group to 140.1 % of sham animals (4.6± 
0.2 vs. 3.3± 0.04 mm, 8 wk MI (n= 6) vs. 8 wk sham (n= 6); P<0.001), however 
LVEDD in 1 wk animals was not significantly different at 8 wks post-MI (Figure 3.2 
A-ii). A similar pattern was seen in LVESD with a significant increase at 1 wk post 
MI of 164.0 % of sham (1.7± 0.02 vs. 2.8± 0.02 %, 1 wk sham (n= 12) vs. 1 wk MI 
(n= 12); P< 0.001; Figure 3.2 A-iv) which gradually increased until 8 wks, 
reaching 200 % of sham animals (P<0.001). LVESD significantly increased between 
1 and 8 wks post MI, with a further expansion at 8 wks to 121.4 % of 1 wk post-MI 
animals (2.8± 0.2 vs. 3.4± 0.1 mm, 1 wk MI (n= 12) vs. 8 wk MI (n= 6); P<0.05; 
Figure 3.2 A-iii). Sham LVESD and LVEDD were unchanged throughout the 8 wks. 
LV posterior wall thickness was unchanged between sham and MI at all time-
points (Figure 3.2 A-v & vi). 
E/A wave ratios were determined using mitral valve Doppler measurements 
(Figure 3.2 B). E/A wave showed no significant difference between sham and MI 
animals at 4 and 8 wks following procedure or between 4 and 8 wk post-MI 
animals (Figure 3.2 B-ii).   
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Figure 3.2 Effect of MI on FS, LV wall-thickness and E/A ratio assessed by 
echocardiography. 
(A-i.) Example M-mode images for 4 wk and 8 wk sham and MI animals. Scale bars= 5 mm and 1 
second. Serial FS (ii.), LVEDD (iii.), LVESD (vi.) and posterior LV wall thickness measurements 
from M-mode echocardiography images for MI and sham groups from 1 to 8 wks post-MI. ***= 
P<0.05 vs. sham, #= P<0.05 vs. 1 wk MI. (B-i.) Example E/A wave Doppler measurements for 4 wk 
and 8 wk sham and MI animals. Scale= 0.2 m/s and 20 mm. (ii.) Average E/A ratio measurements 
for the mitral valve determined using echocardiography Doppler for 4 and 8 wk sham and MI 
animals. n= 12 and 6 for 4 and 8 wk data sets, respectively. Data presented as mean± SEM. FS= 
fractional shortening, LVEDD= left-ventricular end-diastolic dimension, LVESD= left-ventricular 
end-systolic dimension, E= early wave and A= after wave.   
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3.3.2.2 PV-loop 
The effects of MI on LV haemodynamic indices were assessed using closed chest 
PV-loop measurements in 4 and 8 wk MI and sham animals (Figure 3.3 & Table 
3.1). It was shown that MI had a significant effect on a range of systolic, 
diastolic and volume indices at both 4 and 8 wks following MI.  
Systolic measurements demonstrated a significant reduction in ESP between 
sham and MI groups at each time point, with MI ESP reduced to 76.2 % and 81.7 % 
of time-matched shams for 4 and 8 wk groups, respectively (P<0.001; Table 3.1). 
There was no significant difference between 4 and 8 wk MI ESP (Figure 3.3 A & 
B-i). Similarly, dP/dtmax was significantly reduced in MI animals compared to 
sham at each time point, with a reduction to 53.2 % and 67.0 % of sham for 4 
and 8 wk MI, respectively (P<0.001). There were no differences between MI 
groups at any time-point (Figure 3.3 B-ii). EF was also significantly reduced in MI 
to 62.8 % and 57.5 % of sham animals at the 4 and 8 wk time-points, respectively 
(P<0.01 at 4 wks; P<0.001 at 8 wks). Although there was no significant difference 
in EF between 4 and 8 wk MI, there was a trend towards a reduction at the 8 wk 
time point (Figure 3.3 B-iii). CO was shown to be unchanged between all 4 
groups (Figure 3.3 B-iv).  
Diastolic measurements showed no significant change in EDP between sham and 
MI groups at either time-point (Figure 3.3 C-i). However, dP/dtmin was 
significantly reduced in MI groups at both time points to 54.8 % (P<0.01) and 66.1 
% (P<0.001) of sham for 4 and 8 wk groups, respectively (Figure 3.3 C-ii). Tau 
was also significantly increased in the MI groups at both time-points, with 
increases to 154.2 % at 4 wks (P<0.001) and 140.0 % at 8 wks (P<0.05) of sham 
(Figure 3.3 C-iii). EDPVR measurements were not significantly different between 
sham and MI at the 4 wk time-point. At 8 wks there was a significant difference 
between sham and MI groups, with MI animals having a EDPVR 3 times greater 
than that of sham animals (P<0.001; Figure 3.3 B-iv).  
Volume parameters demonstrated a significant difference in EDV in 4 wk MI 
animals, increasing to 228.7 % of sham animals (P<0.01) (Figure 3.3 D-i). This 
was also the case at 8 wks, where MI EDV was significantly increased to 203.0 % 
of sham animals (P<0.05). The same pattern was seen in ESV, with significant 
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increases in MI animals of 345.6 % (P<0.01) and 292.7 % (P<0.01) for 4 and 8 wk 
groups, respectively (Figure 3.3 D-ii). 
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Table 3.1 Effect of MI on haemodynamic LV PV-loop indices. 
  
4 wk 8 wk 
  
Sham MI Sham MI 
HR (bpm) 600.9 ± 15.0 581.1 ± 6.0 604.3 ± 8.5 571.5 ± 7.5 
ESP (mmHg) 104.7 ± 3.1 79.6 ± 3.6 *** 103.5 ± 1.6 84.7 ± 2.7 *** 
EDP (mmHg) 7.7 ± 1.8 12.7 ± 1.1 6.3 ± 1.3 7.2 ± 1.2 
Developed pressure (mmHg) 96.92 ± 2.3 66.7 ± 5.3 *** 97.3 ± 0.4 77.5 ± 2.5 *** 
dp/dtmax (mmHg/min) 10920.8 ± 450.0 5761.1 ± 376.8 *** 10719.9 ± 732.6 7219.5 ± 443.8 *** 
dp/dtmin (mmHg/min) 8664.2 ± 717.6 4749.6 ± 314.7 *** 8343.1 ± 669.3 5517.5 ± 409.1 ** 
Tau (ms) 5.9 ± 0.5 9.1 ± 0.3 *** 5.5 ± 0.3 7.7 ± 0.7 ** 
EDPVR 0.03 ± 0.02 0.08 ± 0.01  0.03 ± 0.00 0.11 ± 0.01 ** 
ESV (µL) 12.3 ± 2.3 42.5 ± 8.5 ** 16.5 ± 0.5 48.3 ± 7.1 ** 
EDV (µL) 28.2 ± 3.4 64.5 ± 8.2 *** 33.4 ± 1.2 67.8 ± 9.4 * 
CO (µL/min) 9948.0 ± 1095.4 12722.8 ± 610.6  10190.9 ± 475.3 10880.9 ± 1550.5  
EF (%) 58.1 ± 3.7 36.5 ± 4.0 ** 50.4 ± 0.9 29.0 ± 1.7 ***  
 
HR= heart rate, ESP= end systolic pressure, EDP= end diastolic pressure, dp/dt max= maximal rate of rise of pressure, -dp/dt min= maximum rate of fall in pressure, 
Tau= time relaxation constant, EDPVR= end diastolic pressure-volume relationship stiffness constant, ESV= end systolic volume, EDV= end diastolic volume, CO= 
cardiac output, EF= ejection fraction. *= P<0.05, **= P<0.01, ***= P<0.001 vs. time-matched sham. 
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Figure 3.3 Effect of MI on LV haemodynamic indices as determined by PV-loop 
measurements. 
LV haemodynamic measurements for 4 and 8 wk sham and MI animals determined using the 
ADVantage PV-loop system with true blood volume calculated using Wei’s equation (A) Example 
PV-loop relationships for sham, 4 wk MI and 8 wk MI animals. (B) Systolic functional indices of 
ESP (i.), dP/dtmax (ii.), EF (iii.) and CO (vi.); (C) Diastolic functional indices of EDP (i.), dP/dtmin (ii.), 
Tau (iii.) and EDPVR (vi.); and (D) Volume indices of EDV (i.) and ESV (ii.). *= P<0.05, **= P<0.01, 
***=P<0.001 vs. time-matched sham. n= 7, 6, 5 and 9 for 4 wk sham and MI and 8 wk sham and 
MI, respectively. Data presented as mean± SEM. 
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3.3.3 Post-mortem and Histological Analysis 
3.3.3.1 Organ weights 
Examination of excised hearts during post-mortem analysis demonstrated 
progressive scar thinning and increase in heart size in MI animals compared to 
sham at each time point (Figure 3.4 A). No significant change in HW: TL is 
evident between sham and MI groups at 3 days, 1 wk and 4 wks following surgical 
procedure (Figure 3.4 B). However, at 8 wks post-MI HW:TL in the MI group was 
significantly increased to 125 % of sham (8.8± 0.6 vs.10.9± 0.4, 8 wk sham (n= 6) 
vs. 8 wk MI (n= 6); P<0.05; Figure 3.4 B). No significant difference in LuW:TL and 
LiW:TL was evident between sham and MI groups at any of the time points 
studied (Figure 3.4 C and D). 
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Figure 3.4 Effect of MI on post-mortem organ weights. 
(A) Example images of MI and sham hearts for each of the studied time points. HW:TL (B), LiW:TL 
(C) and LuW:TL (D) ratios for sham and MI animals at 3 days, 1, 4, and 8 wks following surgical 
procedure *= P<0.05. n= 6, 5, 7 and 6 for 3 day, 1, 4 and 8 wk groups, respectively. Data is 
presented as mean± SEM. Scale bar= 5 mm. TL= tibia length, HW= heart weight, LuW= lung 
weight and LiW= liver weight.  
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3.3.3.2 Cardiomyocyte sizing 
WGA staining of heart sections from 4 and 8 wk sham and MI animals was used to 
quantify average cardiomyocyte cell length and diameter as a measure of 
cardiomyocyte hypertrophy. Exclusion criteria were applied to cells below a 
minimum threshold length of 70 µm (Figure 3.6 A). 
Average cell diameter was shown to be significantly increased in both MI groups 
compared to the corresponding time-matched sham group (15.0± 0.3 vs. 18.2± 
0.4 µm, 4 wk sham (n= 9) vs. 4 wk MI (n= 9); P<0.01; 15.1± 0.3 vs. 20.2± 0.5 µm, 
8 wk sham (n= 10) vs. 8 wk MI (n= 10); P<0.001; Figure 3.5 A-i & ii). Cell 
diameter was also significantly increased between 4 and 8 wk MI groups 
(P<0.001; Figure 3.5 A-ii). Average cell length was shown to be unchanged 
between sham and MI animals across both time points (Figure 3.5 B-i & ii).  
When mean cell length was correlated to dilation as measured via PV-loop for MI 
animals, a significant relationship between increasing cell length and EDV was 
observed (P<0.01; Figure 3.6 B). 
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Figure 3.5 Quantification of cardiomyocyte size post-MI. 
Example images of cellular cross-sections in both transverse (A-i.) and longitudinal (B-i.) axis are 
shown for 4 and 8 wk sham and MI animals, with cellular membranes stained red and cellular 
nuclei in blue. Magnification= 25x, scale= 100 µm. B-i zoom image insert scale= 50 µm. 
Determination of left-ventricular cardiomyocyte diameter (A-ii. n= 126, 126, 144 and 139 cells for 4 
wk sham and MI and 8 wk sham and MI groups, respectively) and length (B-ii. n= 105, 92, 99 and 
89 cells for 4 wk sham and MI and 8 wk sham and MI groups, respectively) in the hearts of 4 and 8 
wk sham and MI animals using WGA staining. ***= P<0.001 vs time-matched sham, ###= P<0.001 
vs.4 wk MI. n= 9 and 10 animals for 4 and 8 wk groups, respectively. Data presented as mean± 
SEM with the average cell-size for each animal taken as the average of a group of cells evenly 
distributed across the left ventricle.   
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Figure 3.6 Cell length histogram and EDV vs. cardiomyocyte length relationship.  
(A) Cell length frequency histogram showing 70 µm minimum threshold indicated by dashed line. 
(B)Cardiomyocyte length vs. EDV from PV-loop measurements for 4 and 8 wk MI animals. Each 
point indicates one animal. EDV= end diastolic volume. 
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3.3.3.3 Regional fibrosis, collagen expression and scar size 
At 4 wks, % fibrosis as measured by picrosirius red staining in the scar region of 
MI animals was significantly increased compared to sham (2.6± 0.5 vs. 72.4± 5 %, 
4 wk sham (n= 9) vs. 4 wk MI (n= 9); P<0.001; Figure 3.7 B-i). This was 
predominantly due to deposition of collagen I, which was also significantly 
increased in 4 wk MI scars (14.9± 1.48 vs. 31.7± 7.6 %, 4 wk sham (n= 9) vs. 4 wk 
MI (n= 9); P<0.05; Figure 3.8 B-i), with no change in collagen III expression 
(Figure 3.9 B-i). By 8 wks total fibrosis had increased further to 88.2± 2.7 % of 
the myocardium, and was significantly increased compared to both 8 wk sham 
(P<0.001) and 4 wk MI animals (P<0.01; Figure 3.7 B-i), however there was no 
change in collagen I or III expression. In the left ventricle, total fibrosis was 
significantly increased in the MI groups at both the 4 wk and 8 wk time points in 
comparison to time-matched sham groups (8.5± 1.2 vs. 1.1± 0.4 %, 4 wk MI (n= 9) 
vs. 4 wk sham (n= 9); P<0.001; 7.5± 0.5 vs. 1.8± 0.5 %, 8 wk MI (n= 10) vs. 8 wk 
sham (n= 10); P<0.001; Figure 3.7 B-ii). However, there was no significant 
difference between LV fibrosis between 4 and 8 wk MI groups (P>0.05; Figure 3.7 
B-ii). There was no change in collagen I or III expression in the LV at either time-
point. In the septum, MI fibrosis was significantly increased at 4 and 8 wks 
compared to time-matched sham groups (P<0.01; Figure 3.7 B-iii). Fibrosis was 
also significantly increased at 8 wks post-MI compared to the 4 wk time-point (4 
wk MI= 4.6± 0.8, 4 wk sham= 0.7±0.2, 8 wk MI= 23.2± 5.9 and 8 wk sham= 2± 0.4 
%; P<0.01; Figure 3.7 B-iii). The increased fibrosis at 8 wks was due to significant 
increases in collagen I only compared to sham (3.9± 1.6 vs. 15.7± 4.2 %, 8 wk 
sham (n= 10) vs. 8 wk MI (n= 10); P<0.05; Figure 3.8 B-iii) and 4 wk MI groups (4 
wk MI= 3.9± 1.3 %; P<0.05; Figure 3.8 B-iii). Fibrosis % of the right ventricle was 
significantly increased in MI groups vs. the corresponding sham group at both 
time points (P<0.01), with a significant increase at 8 wks compared to 4 wks 
post-MI (4 wk MI= 3.2± 0.6, 4 wk sham= 1±0.3, 8 wk MI= 10.4± 2.6 and 8 wk 
sham= 0.7± 0.1 %; P<0.05; Figure 3.7 B-iv). At 8 weeks, collagen I was 
significantly increased in the RV region compared to sham (10.0± 2.0 vs. 35.9± 
4.5 %, 8 wk sham (n= 10) vs. 8 wk MI (n= 10); P<0.001; Figure 3.8 B-vi) and 4 wk 
MI groups (4 wk MI= 12.2± 3.3 %; P<0.001; Figure 3.8 B-vi). Collagen III was also 
significantly increased in 8 wk MI RV compared to both sham (2.2± 1.1 vs. 7.7± 
1.7 %, 8 wk sham (n= 10) vs. 8 wk MI (n= 10); P<0.05; Figure 3.9 B-vi) and 4 wk 
MI groups (4 wk MI= 1.2± 0.5 %; P<0.01; Figure 3.9 B-vi).  
Chapter 3  142 
 
Scar sizes, determined as a % of the LV, were shown to be unchanged between 4 
wk and 8 wk MI groups (Figure 3.7 C-i). There was also no significant difference 
in scar thickness between 4 and 8 wk MI groups (Figure 3.7 C-ii).  
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Figure 3.7 Cardiac regional fibrosis quantification and scar sizing following MI. 
(A) Example images of picrosirius red staining of 4 and 8 wk sham and MI heart sections. (B) 
Quantification of total cardiac fibrosis of the scar (i.), left ventricle (ii.), right ventricle (iii.) and 
septum (iv.) regions of 4 and 8 wk sham and MI animals. **= P<0.01, ***= P<0.001 vs time-
matched sham, #= P<0.05, ##= P<0.01 for 4 wk vs. 8 wk MI. (C) Scar size (i) and thickness (ii) 
comparison of 4 and 8 wk MI animals. Scar size was determined as a % of the total myocardial 
area. n= 9 and 10 for 4 and 8 wk groups, respectively. Data presented as mean± SEM. 
Magnification= 1.25x, scale= 1 mm.  
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Figure 3.8 Cardiac regional collagen I quantification following MI. 
(A) Representative images of heart regions showing distribution of DAB staining for collagen I 
expression in 4 and 8 wk sham and MI animals. Negative IgG used as a control for antibody 
specificity. Magnification= 10x, scale bar= 500 µm. (B) Quantification of DAB staining for positive 
collagen I expression in cardiac regions of scar (i.), LV (ii.), septum (iii.) and RV (iv.) as a 
percentage of the total region for 4 and 8 wk sham and MI animals. *= P<0.05, ***P<0.001 vs. time-
matched sham, #=P<0.05, ###P<0.001 for 4 wk MI vs. 8 wk MI, n= 9 and 10 for 4 and 8 wk groups, 
respectively. Data presented as mean± SEM.   
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Figure 3.9 Cardiac regional collagen III quantification following MI. 
(A) Representative images of heart regions showing distribution of DAB staining for collagen III 
expression in 4 and 8 wk sham and MI animals. Negative IgG used as a control for antibody 
specificity. Magnification= 10x, scale bar= 500 µm. (B) Quantification of DAB staining for positive 
collagen III expression in cardiac regions of scar (i.), LV (ii.), septum (iii.) and RV (iv.) as a 
percentage of the total region for 4 and 8 wk sham and MI animals. *= P<0.05 vs. time-matched 
sham, ##P<0.01 for 4 wk MI vs. 8 wk MI, n= 9 and 10 for 4 and 8 wk groups, respectively. Data 
presented as mean± SEM.   
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3.3.3.4 Perivascular fibrosis and collagen expression 
At the 4 wk time point there was no significant difference in perivascular fibrosis 
between MI and sham groups (Figure 3.10 B). However, the 8 wk MI group 
demonstrated a significant increase in perivascular fibrosis compared to both the 
8 wk sham group (15.8± 1.1 vs. 23.7± 1.9 %, 8 wk sham (n= 10) vs. 8 wk MI (n= 
10); P<0.01; Figure 3.10 B) and 4 wk MI group (4 wk MI=15.8± 1.6 %; P<0.01; 
Figure 3.10 B). This was due to significant increases in perivascular collagen I 
expression compared to sham (5.8± 0.4 vs. 9.4± 1.0, 8 wk sham (n= 10) vs. 8 wk 
MI (n= 10); P<0.01; Figure 3.11 B) and 4 wk MI groups (4 wk MI= 6.4± 1.0 %; 
P<0.05; Figure 3.11 B), as well as a significant increase in perivascular collagen 
III expression compared to sham (4.3± 0.7 vs. 8.05± 0.6 %, 8 wk sham (n= 9) vs. 8 
wk MI (n= 9); P<0.01; Figure 3.12 B) and 4 wk MI groups (4 wk MI= 4.2± 0.6 %; 
P<0.001; Figure 3.12 B). 
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Figure 3.10 Cardiac perivascular fibrosis quantification following MI. 
(A) Representative images of left-ventricular localised vessels and associated picrosirius red 
staining for 4 and 8 wk sham and MI heart sections. Magnification= 20x, scale= 100 µm. (B) Total 
perivascular cardiac fibrosis quantification of 4 and 8 wk sham and MI animals. **= P<0.01 vs. 
time-matched sham, ##= P<0.01 for 4 wk vs. 8 wk MI. n= 9 and 10 for 4 and 8 wk groups, 
respectively. Data presented as mean± SEM.  
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Figure 3.11 Cardiac perivascular collagen I quantification following MI. 
(A) Representative images of cardiac vessels and associated DAB staining for collagen I 
expression for 4 and 8 wk sham and MI heart sections. Negative IgG used as a control for antibody 
specificity. Magnification= 20x, scale= 200 µm. Insert zoom image scale= 100 µm. (B) 
Quantification of DAB staining for perivascular collagen I expression in heart sections of 4 and 8 wk 
sham and MI animals. **= P<0.01 vs time-matched sham, #= P<0.05 for 4 wk vs. 8 wk MI. n= 7 
and 10 for 4 wk and 8 wk groups, respectively. Data presented as mean± SEM.  
  
Chapter 3  149 
 
 
Figure 3.12 Cardiac perivascular collagen III quantification following MI. 
(A) Representative images of cardiac vessels and associated DAB staining for collagen III 
expression for 4 and 8 wk sham and MI heart sections. Negative IgG used as a control for antibody 
specificity. Magnification= 20x, scale= 200 µm. (B). Quantification of perivascular DAB staining for 
collagen III expression in heart sections of 4 and 8 wk sham and MI animals. **= P<0.01 vs time-
matched sham, ###= P<0.001 for 4 wk vs. 8 wk MI. n= 9 for each group. Data presented as mean± 
SEM. 
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3.3.4 Gene expression analysis 
3.3.4.1 Selection of a stable housekeeping gene for normalisation 
In order to identify a suitable housekeeping gene for use in gene expression 
analysis in mouse MI tissue, qRT-PCR was performed for 3 housekeeping genes 
(GAPDH, 18s and B2m) (Figure 3.13). With only 0.3 Ct difference between 
average MI and sham values, GAPDH was the most stable between the two 
groups, therefore GAPDH was used as the housekeeping control gene for 
normalisation of data in all other gene expression analysis.  
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Figure 3.13 Stability of house-keeping genes for use in qRT-PCR in sham and MI heart 
tissue. 
Global gene expression of 3 common house-keeping genes (GAPDH, 18s and B2m) in the cardiac 
tissue of 8 wk sham and MI animals as determined by qRT-PCR. n= 4 per group. Data presented 
as mean Ct± SEM. Ct= cycle threshold. 
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3.3.4.2 RAS Receptor Gene Expression 
Regional expression of the main RAS receptors, AT1R, AT2R and Mas, was 
determined using qRT-PCR in sham and MI heart tissue at 3 days, 1, 4 and 8 wks 
post-MI (Figure 3.14). Gene expression was normalised to GAPDH and MI 
expression relative to the corresponding time- and region-matched sham 
expression. Hearts were separated into 4 regions; scar, border, remote LV and 
RV, with a proximal apical region of sham hearts taken as the scar region.  
AT1R expression was significantly reduced following MI at all time-points except 
the 1 wk post-MI time-point. At 3 days post-MI, expression was significantly 
reduced in all MI regions (P<0.05), with the most pronounced reduction in 
expression evident in the scar region, with a 6.6-fold reduction in expression 
corresponding to a doubling of the normalised Ct value (3.6± 0.01 vs. 6.4± 0.2 
Ct, 3 day sham scar (n= 3) vs. 3 day MI scar (n= 3); P<0.05). At 4 wks there was a 
trend towards reduced expression in the scar and remote-LV regions, and a 
significant reduction in the border region (P<0.05). At 8 wks post-MI, expression 
in all regions was significantly reduced by 2-4 fold in each region compared to 
sham (P<0.05; Figure 3.14 A). AT2R expression was significantly up-regulated 
specifically in the scar region but this gradually reduced to sham levels as the 
time post-MI increased (Figure 3.14 B). At 3-days post-MI, expression in the scar 
region was increased approximately 17-fold compared to the corresponding sham 
region (RQ= 16.7± 0.6, P<0.001). Expression was increased 7-fold in the scar 
region one week post MI compared to sham (RQ= 6.9± 2.2, P<0.05). At 4-wks 
post-MI, there was a 20-fold increase in AT2R expression in the scar region. At 8-
wks post-MI there was still a small but significant increase in AT2R expression in 
the scar region (RQ= 3.9± 0.03, P<0.001; Figure 3.14 B). Mas receptor expression 
was unchanged in all regions at all time-points post-MI in comparison to 
corresponding sham animal regions and time-points (Figure 3.14 C).  
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Figure 3.14 RAS-receptor regional cardiac gene expression in MI and sham animals. 
qRT-PCR-determined gene expression quantification of AT1R (A), AT2R (B) and Mas (C) receptors 
in the scar, border, remote-LV and RV regions of 3 day, 1, 4 and 8 wk sham and MI hearts. *= 
P<0.05, **= P<0.01, ***= P<0.001 vs. time-matched sham region. n= 3 per time-point. Data 
presented as RQ± rqmax. Normalisation of expression to a housekeeper (GAPDH) was performed 
for all samples. MI gene expression was normalised to equivalent time-matched sham region 
expression, therefore sham expression was arbitrarily set at a RQ= 1. RQ= relative quantification, 
LV= left ventricle, RV= right ventricle.  
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3.3.4.3 ACE and ACE2 Expression 
Next, regional expression of ACE and ACE2 was determined (Figure 3.15). ACE 
expression showed a region-specific expression pattern, with significant up-
regulation in the scar region of MI animals at all time-points with the exception 
of 3 days post-MI. Expression levels were increased in the MI scar region from 1 
wk post-MI onwards, with levels increased 4.2± 0.3 (P<0.01), 4.6± 0.2 (P<0.01) 
and 4.2± 0.9 (P<0.05) fold compared to sham scar for 1, 4 and 8 wk MI 
respectively (Figure 3.15 A). Conversely, ACE2 expression was down-regulated, 
but in a region-specific manner, primarily at acute time-points following MI. The 
most pronounced change was observed 3 days post-MI, with a significant 
decrease in expression in the scar and border regions (RQ= 0.29± 0.05 and 0.66± 
0.04, respectively; P<0.05). A significant reduction was also seen in the border 
region 4 wks post-MI (RQ= 0.7± 0.03, P<0.05). At 8 following MI, ACE2 expression 
had normalised to sham levels (Figure 3.15 B).  
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Figure 3.15 ACE and ACE2 regional cardiac gene expression in MI and sham animals. 
qRT-PCR-determined gene expression quantification of ACE (A) and ACE2 (B) enzymes in the 
scar, border, remote-LV and RV regions of 3 day, 1, 4 and 8 wk sham and MI hearts. *= P<0.05, 
**= P<0.01 vs. time-matched sham region. n= 3 per time-point. Data presented as RQ± rqmax. 
Normalisation of expression to a housekeeper (GAPDH) was performed for all samples. MI gene 
expression was normalised to equivalent time-matched sham region expression, therefore sham 
expression was arbitrarily set at a RQ= 1. RQ= relative quantification, LV= left ventricle, RV= right 
ventricle. 
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3.4 Discussion 
Here, the permanent CAL mouse MI model was characterised for both functional, 
structural and gene expression parameters, primarily at 4 and 8 wk post-MI time-
points, to assess its suitability as a model of cardiac dysfunction and 
remodelling. The data demonstrated adverse changes to both cardiac function 
and structure following MI, including reduced LV systolic indices and increased 
fibrosis and hypertrophy, which were associated with changes to RAS receptor 
and enzyme expression. 
It is well established that the mouse LAD permanent ligation model is associated 
with high incidence of mortality (Gehrmann et al., 2001; Lutgens et al., 1999; 
Patten et al., 1998), consistent with what was observed here, where the main 
cause of reduced survival, other than procedural-associated mortality, was 
cardiac rupture, which occurred within the first week following recovery. 
Cardiac rupture has been shown to occur primarily between a few hours up to 6 
days following procedure, and found to be accountable for between 12.5-26.4 % 
of total published mortality (Barandon et al., 2003; Gehrmann et al., 2001; 
Patten et al., 1998). Cardiac rupture can occur in 10 % of human patients who 
have suffered a transmural MI, accounting for approximately a third of total MI 
patients (Kumar and Cannon, 2009; Oliva et al., 1993). The mouse MI model is 
thought to be the only experimental animal model to mimic this (Gao et al., 
2010). In the present study only a small number of deaths occurred outside the 
rupture-risk time frame (≤ 7 days post-MI) in the MI group. Sudden death at later 
time-points have also been reported elsewhere in the model, with mortalities 
recorded from 2 wks up to 6 months following MI (Patten et al., 1998; Yang et 
al., 2002a). Both rupture-related and later sudden deaths have been reported to 
be potentially associated with large infarcts incorporating >48 % of the left 
ventricle (Patten et al., 1998). This is due to greater collagen degradation during 
the scar healing phases leading to enhanced wall-thinning and increased wall 
stress being exerted on the surviving myocardium and more severe ventricular 
remodelling and progression to HF (Patten et al., 1998). 
Echocardiography in MI animals demonstrated an acute and progressive 
reduction in cardiac contractility following MI. Using echocardiography, it has 
been demonstrated that significant LV dilation and reduced wall movement 
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leads to a significantly reduced FS in MI as early as 1 wk following infarction 
(Gao et al., 2000; Gehrmann et al., 2001; Patten et al., 1998), consistent with 
observations here. Early LV dilation is a result of acute scar expansion in the 
infarcted region, with expansion of the non-infarcted LV occurring in the more 
chronic remodelling phase (Trueblood et al., 2001). Trans-mitral Doppler 
analysis using echocardiography allows assessment of diastolic filling patterns as 
a measurement of diastolic dysfunction and ventricular compliance (Hoit and 
Walsh, 1997). Here, no difference was observed between sham and MI E/A wave 
isoform ratios at either 4 or 8 wks following MI. In failing MI hearts, an increased 
E/A ratio is normally evident due to impairment of LV relaxation (Krishnamurthy 
et al., 2006; Liu et al., 2010b). However, it was previously reported that to 
identify parameters to distinguish HF and non-failing mouse MI hearts at 2 weeks 
post-MI a significant decrease in mitral valve Doppler velocity was only 
detectable in mice with large infarcts (>40 %) (Finsen et al., 2005). Therefore 
the results observed here may be as a result of smaller infarct sizes. Moreover, 
no significant alteration in E/A ratio in mouse MI animals up to 90 days post-MI, 
despite obvious fibrotic tissue accumulation and evidence of reduced myocardial 
performance, has also been observed (Benavides-Vallve et al., 2012).  
LV hypertrophy was not evident in MI animals from echocardiography 
measurements, however cardiac hypertrophy was identified from post-mortem 
heart weight and histological analysis. It is possible that hypertrophy was not 
evident in M-mode images due to limited spatial resolution when used on the 
rapidly beating mouse heart as a result of the low transducer frequency 
available here (Doevendans et al., 1998; Hoit and Walsh, 1997). WGA staining 
demonstrated that the LV hypertrophy in MI animals was due to concentric 
hypertrophy, or cell thickening, rather than eccentric hypertrophy, or cell 
lengthening, at both time-points. This increase in cross-sectional area is 
consistent with that observed by Yang et al., (2002) where myocyte cross-
sectional area of the non-infarcted region of mouse MI hearts was assessed at 
various time-points, with a significant increase evident from as early as 1 wk 
post-MI, with progressive increases until 6 months post-MI (Yang et al., 2002a). 
Concentric hypertrophy has been shown to be more commonly associated with 
cardiac functional compensation, with a transition to eccentric hypertrophy 
being associated with decline of cardiac function and progression to heart failure 
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(Francis and Chu, 1995; Gerdes, 1997; Lemmens et al., 2007; Scherrer-Crosbie et 
al., 2001). This is another indication that the MI hearts at 4 and 8 weeks are still 
well compensated. Although concentric hypertrophy is beneficial for LV dilation 
and systolic function, it can still be associated with diastolic dysfunction (Jain et 
al., 2002). However, the presence of ventricular dilation, as evidenced by PV-
loop measurements at both 4 and 8 wks post-MI, in the absence of non-infarcted 
wall thinning suggests there may also be eccentric hypertrophy occurring. In 
fact, when EDV was plotted against cell length for MI animals here there was a 
significant relationship between increasing cell length and EDV, suggested 
greater cell lengthening in a small sub-set of MI animals with more advanced 
dilation. It has been demonstrated that both eccentric and concentric 
hypertrophy occurs following MI as a result of the combined increase in volume 
and pressure load on non-infarcted myocardium (Force and Molkentin, 2006; 
Opie et al., 2006; Runge and Patterson, 2007).  
PV loop measurements demonstrated the development of systolic and diastolic 
dysfunction in the mouse MI model. Systolic dysfunction combined with 
ventricular dilation resulted in a significantly reduced EF, with a tendency to be 
more severe at 8 wks. EDPVR measurements, which assess ventricular 
compliance independent of load, demonstrated a significant increase at 8 wks 
post-MI, but not at 4 wks, suggesting increasing ventricular stiffness over time. 
However, between 4 and 8 wks post-MI, haemodynamic parameters did not 
change significantly, with equivalent levels of dysfunction at each time-point in 
the MI group. This is consistent with previous observations in this model (Shioura 
et al., 2007). Using the mouse MI model a comparison of closed-chest 
haemodynamic properties in mice 2, 4, 6 and 10 wks post-MI was performed and 
demonstrated an early decline in systolic function which declined gradually with 
increased time, with diastolic dysfunction declining gradually and only reaching 
significance by 10 wks. Hearts at 4 and 6 wks post-MI were found to be well 
compensated, thought to be as a result of hypertrophy and scar stabilisation, 
with decompensation evident at 10 wks post-MI (Shioura et al., 2007). In the 
study presented here the only notable difference between 4 and 8 wk post-MI 
animals was an increased EDPVR at the 8 wk time-point compared to 4 wks. 
Increased EDPVR indicates dysfunctional relaxation of the ventricle following 
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contraction due to stiffening, primarily as a result of interstitial fibrosis and 
collagen deposition (Tsuda et al., 2003).   
This increased EDPVR at 8 wks post-MI was consistent with histology assessing 
total fibrosis and collagen deposition, which demonstrated a significant increase 
in total fibrosis of the scar, LV, septum and RV of 4 and 8 wk MI hearts, which 
was significantly worse at the 8 wk time point, as was perivascular fibrosis, 
suggesting the majority of fibrosis at 4 wks is interstitial with a mix of both 
interstitial and perivascular fibrosis at 8 wks. When looking specifically at 
different collagen isoform expression, there was no significant change in either 
collagen I or III expression in the LV of either MI group at either time-point. 
However, at 4 wks the scar region shows a significant increase in collagen I 
expression. This reduced to equivalent levels as sham animals by 8 wks. The 
increase in total fibrosis seen in the septum, RV and in the perivascular region of 
the 8 wk animals corresponded to an increase in both collagen I and collagen III 
isoforms in these regions. In general collagen I was more highly expressed than 
collagen III in all regions. The extent of interstitial and perivascular fibrosis and 
the enhanced collagen deposition in the non-infarcted myocardial regions is 
consistent with previous reports in the mouse MI model (Doevendans et al., 
1998; Takeshita et al., 2004). ECM deposition and fibroblast proliferation is 
dynamically regulated by MMPs in response to myocardial injury and 
inflammation (Jugdutt, 2003; Shioura et al., 2007), with ECM proteins 
undergoing rapid synthesis and breakdown (Trueblood et al., 2001). The dynamic 
nature of collagen expression may account for the differences in collagen 
isoforms observed between 4 and 8 wks post-MI. Isoform expression has been 
identified to be time-specific following MI, with myofibroblast proliferation and 
collagen synthesis occurring while the scar is forming, which, once complete, 
triggers collagen expression to be down-regulated and stimulates apoptosis of 
most of the myofibroblasts (Sutton and Sharpe, 2000). The dynamic nature of 
collagen expression has been demonstrated in the rat MI model, where collagen I 
and III expression was dramatically altered in different heart regions at different 
times, with collagen III found to be associated with the more acute remodelling 
phase but being down-regulated at later time-points, while collagen I levels 
were elevated at 4 days post-MI and remained up-regulated at 90 days (Cleutjens 
et al., 1995a). This may help explain the reduction in collagen and the increase 
Chapter 3  160 
 
in fibrotic area observed in the scar region at 8 wks. With collagen and 
myofibroblasts mainly being associated with necrotising myocytes (Sutton and 
Sharpe, 2000), it could be assumed that by 8 wks there are far fewer myocytes 
remaining in the infarcted area and the scar is fully formed, therefore collagen 
is down-regulated. Collagen I and collagen III isoforms are the two most common 
collagen isoforms found in the heart and have been shown to have different 
physical properties (Janicki et al., 1988). An increase in collagen I: collagen III 
ratio has been found in hearts from patients with CHF (Bishop et al., 1990) and it 
has also been shown that the collagen I: collagen III ratio is increased in both the 
LV and RV of the rat MI HF model, consistent with changes in haemodynamic 
measurements and the development of ventricular dysfunction (Wei et al., 
1999). This is consistent with observations in the mouse MI model here. 
The haemodynamic changes following MI suggests that although considerable LV 
remodelling had taken place, the hearts had not reached failure stage and 
cardiac function was still compensated. The rat MI model has previously been 
characterised to present with similar pathophysiological manifestations as 
human CHF patients, such as depressed CO and elevated left ventricular filling 
pressure (Pfeffer et al., 1979), and therefore is an accepted animal model of 
CHF. In contrast, CO has been shown to be preserved in this model even up to 12 
months following MI (Pons et al., 2003). CHF is developed in the model providing 
a sufficiently large infarct is induced (>40 % of the LV) (Finsen et al., 2005; 
Kinugawa et al., 2000; Li et al., 2006b). Animals with infarcts above 50 % 
demonstrate a high mortality rate within the first 2 wks following surgery, while 
mice with infarcts of less than 30 % show very little adverse remodelling 
compared to sham animals (Bayat et al., 2002). However, large infarct also has 
the disadvantage of leading to an increased rupture rate (Patten et al., 1998). In 
the present study, infarct size was consistently <40 %; there was no alteration in 
E/A ratio; the hypertrophic response was found to be predominantly concentric; 
CO, SV and EDP was unaltered and there was no indication of pulmonary 
oedema, all of which suggest the mouse MI model in this setting was a model of 
compensated left-ventricular dysfunction rather than one of CHF. 
Gene expression analysis of RAS components following MI have previously been 
reported primarily in the rat MI model (Savoia et al., 2011; Sun et al., 1998; 
Yang et al., 1998). The changes in AT2R receptor levels in this study are 
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consistent with what has been reported in the rat, with it being shown that AT2R 
expression levels are extremely low in the normal rodent heart (Schluter and 
Wenzel, 2008), but are found to be up-regulated in pathological conditions, 
including MI (Savoia et al., 2011). However, AT1R levels have been demonstrated 
to be up-regulated in rat hearts immediately following global ischemia (Yang et 
al., 1998) and in the rat MI model (Sun et al., 1998). The discrepancy seen here 
may be the result of AT1R regulation by Ang II. It has been shown that following 
acute Ang II up-regulation, AT1R receptor expression increases in the associated 
tissue. However, upon chronic Ang II exposure, AT1R will be down-regulated due 
to a negative feedback loop (Kim et al., 2005). Furthermore, the expression 
pattern of both the AT1R and AT2R seen here is similar to that seen in biopsies 
performed in hearts from patients with CHF, where AT1R expression has been 
shown to be down-regulated in the atrial and LV tissue in comparison to the AT2R 
(Tsutsumi et al., 1998).  
ACE and ACE2 gene expression was shown in the present study to be 
dysregulated in a region-specific manner, with expression only changing within 
the scar and, in some instances, the border region. ACE levels were unchanged 
in the acute phase immediately following MI, however by 1 wk post-MI it was 
found to be significantly up-regulated in the scar region. This up-regulation then 
remained stable at the later time-points studied. Conversely, ACE2 was 
significantly down-regulated during the acute phase following MI, with this 
change evident in the scar at 3 days post-MI and in the scar and border regions 4 
wks post-MI, with levels returning to that of sham at the more chronic 8 wk 
time-point. Again, any comparable data on ACE and ACE2 expression following MI 
has been performed in the rat. Two such studies have shown almost identical 
changes in ACE expression in the rat as seen here in the mouse, with up-
regulation evident from 3 days- 1 wk post-MI and maintained up until at least 8 
wks post-MI (Burrell et al., 2005; Ocaranza et al., 2006). However, the pattern 
of ACE2 expression reported does not match what has been observed here, with 
it reported as being up-regulated in the LV during the acute phase but down-
regulated at later time points (Ocaranza et al., 2006). ACE2 has also been 
reported to be up-regulated in both infarcted and non-infarcted regions in both 
acute and chronic phases following MI (Burrell et al., 2005). Global cardiac ACE 
and ACE2 expression in the rat 4 wks following MI demonstrated no changes in 
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expression of either enzyme (Ishiyama et al., 2004). The discrepancies seen in 
these studies compared to this work could potentially be the result of species 
variation or the region of the heart in which expression was assessed. It is also 
likely that infarct size and resulting severity of remodelling, level of contractile 
compensation and region of expression are all key in affecting ACE and ACE2 
expression levels, especially as they have been associated with decline and 
improved cardiac contractility, respectively (Crackower et al., 2002; Zhao et al., 
2010).  
In human heart disease, ACE and ACE2 are found up-regulated in the LV in cases 
of ischemic HF, with ACE found to be increased 3 fold compared to controls 
(Goulter et al., 2004; Studer et al., 1994; Zisman et al., 2003). Up-regulation of 
ACE2 in this setting has been proposed to be a compensatory mechanism for 
counter-acting chronic activation of the RAS through degradation of Ang II 
(Ferreira et al., 2010b; Wang et al., 2012). This increase in ACE expression in LV 
seen in human MI is consistent with the increased ACE expression seen here in 
the mouse scar region. Similarly, in advanced stages post-MI in human MI, LV 
AT1R expression is found to be down-regulated while AT2R expression remains 
unchanged following an initial increase during the acute post-MI phase (Haywood 
et al., 1997). A very similar pattern of expression is observed here in the MI 
model, with a global decrease in AT1R expression associated with reduction of 
AT2R expression by 8 weeks post-MI.  
3.5 Summary 
These data have demonstrated that the mouse MI model is a suitable model of 
compensated left-ventricular dysfunction that presents with measurable 
structural and functional cardiac remodelling changes comparable to that 
previously reported. Furthermore, the model shows changes in RAS component 
gene expression that are comparable to that seen in hearts of patients with 
cardiac dysfunction and which have previously not been demonstrated in the 
mouse MI model. Therefore, it is a suitable model in which to study the effects 
of a potential RAS-targeted therapeutic on these adverse remodelling changes.  
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Chapter 4: Assessment of the effects of Ad-
mediated delivery of Ang-(1-9) in the mouse MI 
model 
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4.1 Introduction 
4.1.1 Ad 
Adenoviruses (Ad) are non-enveloped, medium-sized viruses carrying a linear, 
double stranded genome of 30-40 Kb in an icosahedral nucleocapsid between 70-
100 nm in diameter (Graham and Prevec, 1991; Kennedy and Parks, 2009). They 
were first isolated from human adenoid tissue in 1953 (Rowe et al., 1953). Over 
51 human Ad serotypes have since been identified, with human Ad5 the most 
extensively characterised (Russell, 2009). Serotyping was the original 
classification used on the basis of the virus’s ability to be neutralised by specific 
animal antisera. They can be further classified into 6 species, A-F, based on 
their ability to agglutinate erythrocytes. Members of a particular species tend to 
show similarities in tissue tropism and clinical manifestations (Borriello et al., 
2005). Human Ad infection is prevalent in the population, however it is generally 
not associated with severe disease. Species C, such as Ad5, cause mild 
respiratory infection when inhaled, with some serotypes (e.g. species F) 
associated with gastrointestinal infection (Duncan and Hutchison, 1961) and 
others with conjunctivitis (e.g. species B and D) when they come into contact 
with the eye (Lichtenstein and Wold, 2004). Ad4 and Ad14 have been identified 
as having the potential to induce acute respiratory distress (ARD) upon 
inhalation, although this occurs more commonly in immunocompromised 
individuals (Russell, 2009). 
Different Ad serotypes are reasonably well conserved, however they do show 
differences in their host and tissue tropism (Kennedy and Parks, 2009). 
Determination of tissue tropism and host species of Ad5 vectors has been shown 
to be determined by fibre and penton base domains which dictate cell receptor 
interactions (Havenga et al., 2002). This has been elegantly demonstrated 
through the development of fibre chimeric Ad5 vectors which are engineered to 
express the fibre proteins of a different serotype, thus altering its tropism. For 
example, an Ad5 vector expressing an Ad16 fibre shows more efficient 
transduction of vascular endothelial and smooth muscle cells than Ad5 (Havenga 
et al., 2001). Due to the ubiquitous nature of coxsackie Ad receptor (CAR), 
tissue targeting of Ad vectors is problematic. Ad delivered systemically will 
disseminate throughout the body, potentially causing off-target effects. This can 
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be controlled through the route of administration, such as direct injection to 
target tissues rather than systemic delivery (Johnson et al., 2006), as well as 
through direct modification of viral fibre molecules, viral conjugation or 
chemical polymer modifications (Mizuguchi and Hayakawa, 2004). Iv delivery 
results in sequestration of the virus primarily to the liver through interaction 
with FX in the blood (Kalyuzhniy et al., 2008; Waddington et al., 2008). 
4.1.1.1 Adenoviral structure, infection and DNA replication 
The development of advanced X-ray crystallography and microscopy techniques 
enabled determination and assignment of the main Ad structural proteins (Saban 
et al., 2005; Stewart et al., 1993)(Figure 4.1). The basic capsid structure is 
composed of 240 homotrimeric hexon proteins composing the faces and edges of 
the capsid, and penton base proteins which are located on the 12 apices of the 
capsid and are attached to the fibres which are composed of 3 distinct regions; 
the tail, shaft and knob (Russell, 2009). There are also several minor proteins 
(IIIa, VI, VIII and IX) associated with the capsid and thought to be required for 
capsid stabilisation (Smith et al., 2010; Vellinga et al., 2005). In the virus core 
there are 6 other proteins, 5 of which are associated with the genome [V, VII, 
Mu, IVa2 and the terminal protein (TP)], with the sixth being the virion protease, 
which is essential in the assembly of new viral particles (Russell, 2009).   
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Figure 4.1 Ad capsid and core structure. 
Schematic of an Ad capsid cross-section identifying the location of the major and minor capsid and 
core proteins (Russell, 2009). 
  
Chapter 4  167 
 
Upon infection the first stage of virus internalisation into the cell has been found 
to be through receptor binding of the fibre knob (Zhang and Bergelson, 2005). 
Species C Ad5 is the best characterised with it identified in vitro and during 
local infection in many tissues to utilises the immunoglobulin coxsackie Ad 
receptor (CAR) for cell entry, which is found on many different cell types 
(Bergelson et al., 1997; Noutsias et al., 2001). Other species have been shown to 
utilise other receptors, e.g. some members of the species D family utilise sialic 
acid (Arnberg et al., 2002), whereas most of the species B serotypes bind to 
CD46 (Gaggar et al., 2005; Marttila et al., 2005). Following receptor attachment, 
entry into the cell is facilitated by the interaction of the RGD motif located on 
the penton base with cellular αV integrins, which triggers viral internalisation via 
endocytosis into an endosome through clathrin-coated pit formation and 
rearrangement of the cytoskeleton (Mathias et al., 1994). Once internalised, a 
step-wise disassembly of the viral capsid begins with release of the fibre 
proteins and dissociation of the penton bases. The core and minor capsid 
proteins are then shed or degraded (Greber et al., 1993). Endosome membrane 
disruption is then brought about by the activity of the endosomalytic protein VI 
(Wiethoff et al., 2005), releasing the partially un-coated capsid into the 
cytoplasm where it translocates via microtubules towards the nucleus into which 
it releases its genome by docking at a nuclear pore (Russell, 2009). 
Once the genome has entered the nucleus Ad replication occurs (Figure 4.2). 
This can be separated into two main phases; the early stage and DNA 
replication, and the late stage (Paul Thomas and Mathews, 1980). Each stage 
involves expression of particular genes; the early genes (E1A, E1B, E2B, E3 and 
E4) and late genes (L1-L5) which encode for functions specific to each stage. 
Host cell proteins are also utilised by the virus for successful replication (Cann, 
2001; Davison et al., 2003; Hay, 1985; Van der Vliet, 1995).  
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Figure 4.2 Ad DNA replication 
Schematic showing the process of Ad DNA replication following host cell invasion. ITR= inverted 
terminal repeat, ORI= origin of replication, TP= terminal protein, E= early, L= late, TP= terminal 
protein, pTP= pre-cursor terminal protein, NFI= nuclear factor I, OctI/NFIII= nuclear factor III.  
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4.1.2 Ad as a gene therapy vector 
Human Ad5 is currently the most commonly used vector for clinical gene therapy 
applications (Dormond et al., 2009). Its relative ease of construction, ability to 
infect post-mitotic cells, be produced in high titres in complementing cell lines 
(Kamen and Henry, 2004), and its high transduction rates in a variety of cells in 
vitro and in vivo (Schiedner et al., 1998) make them ideal vectors for gene 
therapy research. The late 1990’s saw a dramatic increase in research 
surrounding the clinical application of Ad gene therapy vectors, however this 
suffered a severe blow in 1999 when 18 year old Jesse Gelsinger tragically died 
as a result of taking part in an Ad5 gene therapy trial for ornithine 
transcarbamylase (OTC) deficiency as a result of fatal systemic inflammatory 
response syndrome in response to transduction with the virus (Raper et al., 
2003).  
Modification of the Ad genome for gene therapy application initially saw the 
generation of replication-deficient vectors through the deletion of E1A and E1B 
regions of the genome, inhibiting viral replication but allowing propagation in 
cell lines, such as 293 cells, which encode the E1 genes in trans necessary for 
Ad5 replication (Kozarsky and Wilson, 1993). However, first generation rAd 
vectors, with only E1 deletions, retain a high level of cytotoxicity and have a 
cloning capacity of only 5.2 kb (Graham et al., 1977), making them unsuitable 
for many gene therapy uses (Benihoud et al., 1999). Second generation rAds 
have multiple deletions in the viral genome, with the E1 deletion combined with 
either E2, E3 or E4 deletions, which further improves their safety profile, 
reduces the host inflammatory response and increases transgene capacity 
(Rauschhuber et al., 2012). Second generation vectors superceded by third 
generation rAd vectors are also termed gutless vectors, in that all viral genes 
have been removed excluding the ITRs and viral packaging signal. They therefore 
require helper viruses for replication in vitro (Benihoud et al., 1999). These 
vectors have the added benefits of being able to carry a transgene up to 36 kb in 
size, and further improved safety profile due to the absence of the viral genes 
and, as they do not express viral antigens, they do not elicit a host immune 
response (Parks et al., 1996; Rauschhuber et al., 2012). The production of a 
large quantity of clinical grade rAd vectors is extremely important for their pre-
clinical and clinical use (Kamen and Henry, 2004). This has driven the 
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development of new methods for virus quantitation, complementary cell line 
cultivation and viral purification, with a move from traditional small-scale CsCl 
gradient purification to more efficient chromatography methods, making 
production of first generation rAds on an industrial scale feasible (Kamen and 
Henry, 2004). 
The use of first generation rAds in a clinical setting is made problematic mainly 
due to the onset of host immunity limiting the time-frame of transgene 
expression and preventing the further vector administration, as well as the 
prevalence of pre-existing immunity in the population to the predominantly 
utilised human serotype 5 virus (Chirmule et al., 1999). Host immunity is thought 
to be an important determinant of clinical outcome when using Ad as a gene 
therapy vector (Hedman et al., 2003), with expression of the viral transgene 
only being transient due to clearance of the virus between 2-4 wks and 
administration of a second dose usually ineffective (Laitinen et al., 1997). This 
has been demonstrated in the rat heart, where Ad expression was detectable up 
until 21 days post-delivery. However, animals that had been previously exposed 
to the virus showed a dramatic drop in expression after 48 hr and complete 
clearance by 6 days post-delivery due to immune mediated clearance 
(Gilgenkrantz et al., 1995). High proportions of most populations already have 
pre-existing immunity to Ad5 vectors due to natural exposure, mainly through an 
antibody response to the capsid hexon antigens (Barouch et al., 2004; Sumida et 
al., 2005). In one study, a cohort of patients being screened for Ad5 immunity 
found all subjects possessed Ig for Ad5, 55 % of which were neutralising 
(Chirmule et al., 1999). In order to circumvent this, research into the safe use of 
alternative serotypes that are rarer in humans has been pursued along with the 
development of chimeric Ad5 vectors carrying hexon antigens from other 
serotypes. For example, Ad35 has shown to be effective in the presence of pre-
existing Ad5 immunity, making it a candidate as an alternative vector (Barouch 
et al., 2004). Similarly, synthesis of chimeric Ad5 vectors which have had the 
immunogenic hexon epitopes replaced by those of Ad48 have also been shown 
not to be repressed by pre-existing Ad5 immunity (Roberts et al., 2006).  
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4.2 Aims 
Despite the drawbacks of Ad use, they remain powerful tools for gene-based 
research and therapy. In the present study they have been used to investigate 
the therapeutic potential of Ang-(1-9) in an animal model of cardiac dysfunction. 
The aims of this chapter were to: 
 Optimise Ad-mediated gene delivery to the mouse myocardium in vivo and 
demonstrate efficient transduction in sham and MI animals. 
 Utilise intra-cardiac delivery of an Ad serotype 5 vector expressing Ang-(1-
9) in order to assess its effect on structural and functional cardiac 
remodelling in the mouse model of MI. 
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4.3 Results 
4.3.1 Ad titration 
Batches of RAdAng-(1-9), RAd60 and a β-galactosidase expressing vectors (RAdβ-
gal) were prepared and titered using both limiting dilution assay on 293 cells to 
determine infectious plaque forming units per mL titre (pfu/mL) and micro-BCA 
assay to determine total viral particles per mL titre (VP/mL) (Table 4.1).  
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Table 4.1 Ad preparation plaque-forming unit titres. 
Virus Batch 
Titre (Plaque 
forming units/ml) 
Titre (VP/mL) Ratio pfu:VP 
RAd-β-gal 
1 1.88 x 1010 9.79 x 1011 1 : 52.0 
2 2.95 x 1011 8.66 x 1012 1 : 29.4 
RAd60 1 5.176 x 1011 7.59 x 1012 1 : 15.1 
RAd-Ang-(1-9) 1 1.11 x 1011 2.90 x 1012 1 : 26.1 
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4.3.2 RAd-Ang-(1-9) generation 
The design of the transgene inserted into the Ad5 vector utilised in this study to 
over-express Ang-(1-9) was first described by Methot et al., in 2001 (Methot et 
al., 2001). It is a fusion protein sequence encoding for a biological peptide pump 
that enables the synthetic production of Angiotensin peptides without the need 
for the peptide precursors of the RAS system (Figure 4.3 A). The protein core is 
composed of four regions; a signal peptide from human pro-renin, the mouse 
heavy chain constant of IgG2B, a portion of human pro-renin pro-segment and 
Ang-(1-9). The signal peptide targets the protein to the endoplasmic reticulum 
of the cell to ensure eventual peptide secretion, while the mouse IgG segment 
provides sufficient molecular weight to ensure efficient production of the 
protein. The pro-renin pro-segment contains a protease cleavage site at its 
carboxyl terminus which has been modified so that it is cleaved by furin- a 
protease located in the Golgi network of the secretory pathway in a broad range 
of cell types (Methot et al., 2001). Following cleavage, the active Ang-(1-9) 
peptide is released and secreted from the cell. 
Successful expression of the fusion protein from the Ad vector was confirmed in 
vitro by transduction of HeLa cells of either the Ang-(1-9) expressing 
recombinant adenoviral vectors [RAdAng-(1-9)] or an empty control Ad5 vector 
(RAd60) for 48 hr by western immunoblotting for the mouse IgG2B region of the 
fusion protein revealing an un-cleaved fusion protein band visible in RAdAng-(1-
9) transduced cells only at approximately 32 KDa (Figure 4.3 B).  
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Figure 4.3 Ang-(1-9) Ad expression cassette structure and expression. 
(A) Schematic showing the structure of the Ang-(1-9) fusion peptide expressed from the RAdAng-
(1-9) encoded expression cassette. (B) Western blot of HeLa cell lysates transduced with RAdAng-
(1-9) or RAd60 MOI 50 and 100 or untransduced and probed for the mouse Fc IgG2B fragment.  
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4.3.3 Optimisation of in vivo Ad delivery 
4.3.3.1 Ad delivery to the mouse myocardium 
Prior to use of the RAdAng-(1-9) in the mouse MI model, optimisation 
experiments to ensure sufficient transgene expression would be achieved in vivo 
were performed using RAd-β-gal delivered in non-infarcted mouse hearts via 
direct intra-cardiac injection. A range of viral doses were assessed and 
expression determined at 5 days post-vector delivery (Figure 4.4). Increasing 
viral dose from 1 x 109 through to 5 x 109 produced increasing cardiomyocyte 
transduction measured by X-Gal staining (Figure 4.4 A i-iii) and immunostaining 
for β-gal (Figure 4.4 B i-iv).  
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Figure 4.4 Ad transduction of the mouse heart. 
Transduction of the mouse heart by RAd-β-gal following intramyocardial delivery of 1 (i.), 4 (ii.) and 
5 x 109 pfu (iii.) of virus per heart. (A) Gross fixed hearts stained using X-gal, identifying regions of 
virus expression as blue. (B) & (C) DAB staining for β-Gal expression on sections from wax 
embedded hearts. Negative IgG was used as a control for antibody specificity. (D) Quantification of 
DAB staining as a % of the total myocardial area. n= 3 for 1 x 109 pfu, n= 2 for 4 and 5 x 109 pfu. 
Data presented as mean (± SEM where n>2). Magnification= 1.25 x and 20 x, scale= 1 mm and 10 
µm, respectively. 
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4.3.3.2 Ad delivery in MI 
Following successful transduction of non-infarcted mouse hearts, transduction of 
infarcted mouse hearts was assessed using viral injection in the border zone 
region immediately following infarction. Transduction was assessed at 5 days 
post-virus delivery of either the high (5 x 109 pfu) or low (1 x 109 pfu) viral dose 
(Figure 4.5). Blue X-gal staining or β-gal immunopositivity was evident in both 
hearts at both doses just above the site of ligation but not in the scar, as 
indicated by the white arrows (Figure 4.5 A-i & ii). As the 1 x 109 pfu dose 
produced efficient transgene expression it was selected for further studies.  
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Figure 4.5 Ad transduction of the infarcted mouse heart. 
Transduction of the infarcted mouse heart by RAd-β-gal following intramyocardial delivery of 1 (i.) 
and 5 x 109 pfu (ii.) of virus post-infarction in the infarct border region. (A) Gross fixed hearts 
stained using X-gal, identifying regions of virus expression as blue. White arrows indicate areas of 
positive X-gal staining. (B) & (C) DAB staining for β-Gal expression on sections from wax 
embedded hearts. Black arrows indicate areas of infarct tissue, white arrows indicate areas of 
positive staining. (C) Quantification of DAB staining as a % of the total myocardial area. n= 2 for 
each dose. Data presented as mean values. Magnification= 1.25 x and 20 x, scale= 1 mm and 10 
µm, respectively.   
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4.3.4 Study design and mortality rates 
Following confirmation of sufficient viral transduction of the myocardium, 
therapeutic gene transfer was assessed in 4 groups [sham, MI, MI+RAd60 and 
MI+RAdAng-(1-9)] (Figure 4.6 A).  
A Kaplan-Meier survival plot for mortality of all animals recovered from 
procedure in each group demonstrated that no deaths occurred in the sham 
group. Each of the MI groups demonstrated a high incidence of mortality 
following the MI procedure (MI= 50, MI+RAd60= 55.56, MI+RAdAng-(1-9)= 35.7 %; 
Figure 4.6 B & C). Within the first 7 days following surgery all deaths were due 
to cardiac rupture. In the MI and MI+RAd60 groups there were a small number of 
deaths from unknown causes out with the first 7 days following procedure. This 
accounted for 22.2 % and 11.1 % of total mortality in MI and MI+RAd60 groups, 
respectively (Figure 4.6 C). Overall, the MI+RAdAng-(1-9) group demonstrated 
the lowest overall mortality rate of the MI groups at 4 wk post-procedure, with 
no significant difference compared to sham animals and no deaths recorded past 
7 days post-surgery. MI and MI+RAd60 group mortality was significantly increased 
compared to the sham group (P<0.05; Figure 4.6 B & C).   
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Figure 4.6 Study design and procedure-associated mortality. 
(A) Study design showing time-frame of measurements over the 4 wk study period. (B) Kaplan-
Meier plot of mortality following recovery from procedure for each animal group (sham, MI, 
MI+RAd60, MI+RAdAng-(1-9)) over the 4 wk study period. *= P<0.05, **= P<0.01 vs. sham. n= 9, 
18, 18 and 14 for sham, MI, MI+RAd60 and M+RAdAng-(1-9), respectively. (C) % survival and 
cause of mortality for each animal group following recovery from procedure.   
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4.3.5 Haemodynamic and functional measurements 
4.3.5.1 Echocardiography 
Serial echocardiography measurements were used in order to perform functional 
and structural cardiac measurements. E/A wave ratios were determined using 
mitral valve Doppler measurements. At 1 wk post-MI there is was significant 
reduction in FS in MI animals compared to sham, with the significant decrease 
maintained at each time-point and progressively declining from 1 to 4 wks 
(Figure 4.7 A-ii). This was associated with a significant increase in LVEDD and 
LVESD at all time-points (Figure 4.7 A-iii & iv), with no changes in sham FS, 
LVEDD or LVESD across the 4 wk period. The changes in FS observed in the RAd60 
group was almost identical to that observed in the MI group, being significantly 
reduced compared to sham at 1 wk post-MI (52± 0.6 vs. 28.7± 0.9 %, 1 wk sham 
(n= 6) vs. 1 wk MI+RAd60 (n= 6); P<0.05), with FS progressively declining from 1 
to 4 wks post-MI, with a 10.1 % reduction in FS at 4 wks compared to 1 wk post-
MI (Figure 4.7 A-ii). Again, this was associated with a significant increase in 
LVEDD and LVESD compared to sham at all time-points. By 4 wks post-MI, LVEDD 
had significantly increased to 136 % of sham (3.4± 0.1 vs. 4.6± 0.3 mm, 4 wk 
sham (n= 6) vs. 4 wk MI+RAd60 (n= 6); P<0.05) and LVESD had significantly 
increased to 207 % of sham (1.7± 0.1 vs. 3.4± 0.3 mm, 4 wk sham (n= 6) vs. 4 wk 
MI+RAd60 (n= 6); P<0.05; Figure 4.7 A-iii & iv). In the MI+RAdAng-(1-9) group, a 
significant attenuation in the reduction in FS was observed at 1 wk post-MI 
compared to that of MI and MI+RAd60 groups, with FS increased to approximately 
141 % of MI and MI+RAd60 groups (MI+RAdAng-(1-9)= 40.1± 0.9; P<0.05). This 
significant attenuation was maintained from 1 to 4 wks, with the MI+RAdAng-(1-
9) group having a FS of approximately 145.6 % of MI and MI+RAd60 at 4 wks post-
MI (MI= 24.6± 1.7, MI+RAd60= 25.8± 1.7, MI+RAdAng-(1-9)= 36.4± 2.1; P<0.05; 
Figure 4.7 A-ii). There was no significant difference in LVEDD in any of the MI 
groups at any time-point, however at 1 and 4 wks post-MI, LVESD in the 
MI+RAdAng-(1-9) group was significantly reduced compared to that of MI and 
MI+RAd60 groups (Figure 4.7 A-iii & iv). There was no significant difference in 
posterior LV wall thickness between any of the groups at any time-point (Figure 
4.7 A-v & vi). E/A wave ratios for each group demonstrated no significant 
difference between any of the groups at 4 wks post-procedure (P>0.05; Figure 
4.7 B-i & ii).  
Chapter 4  183 
 
 
Figure 4.7 Effect of RAdAng-(1-9) on FS, wall thickness and E/A ratio in MI as assessed by 
echocardiography. 
(A-i.) Example M-mode images for each animal cohort at 4 wks. Scale= 0.2 m/s and 20 mm. Serial 
FS (ii.), LVEDD (iii.), LVESD (iv.) and posterior LV wall thickness (v.) measurements from M-mode 
echocardiography images for sham, MI, MI+RAd60 and MI+RAdAng-(1-9) animal cohorts from 1 to 
4 wks post-procedure. (B-i.) Example E/A wave Doppler measurements for each animal group at 4 
wks post-procedure. Scale= 5 mm and 1 second. (ii.) Average E/A ratio measurements for the 
mitral valve determined using echocardiography Doppler for sham, MI, MI+RAd60 and 
MI+RAdAng-(1-9) animal groups. n=6 for each group. Data presented as mean± SEM FS= 
fractional shortening, LVEDD= left-ventricular end-diastolic dimension, LVESD= left-ventricular 
end-systolic dimension, E= early wave, A= after wave.*= P<0.05 vs. sham; #= P<0.05 vs. MI and 
MI+RAd60.  
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4.3.5.2 PV loop measurements 
The effect of RAdAng-(1-9) on LV haemodynamics following MI was assessed via 
closed-chest PV loop measurements (Table 4.2). Similarly to the 
echocardiography data, the MI+RAd60 group demonstrated almost identical 
changes in haemodynamic parameters as the MI group in comparison to sham 
(Figure 4.8). Systolic parameters in the MI+RAd60 animal groups were decreased 
significantly to 75.0, 64.2 and 63.2 % of sham for ESP, dP/dtmax and EF, 
respectively (P<0.05; Figure 4.8 B i-iii). CO in the MI+RAd60 was not significantly 
changed compared to sham (Figure 4.8 B iv). Diastolic differences in the 
MI+RAd60 groups showed a significant decrease in dP/dtmin to 58.4 % of sham 
(P<0.01) and a significant increase in Tau to 152.5 % of sham (P<0.01). No 
significant difference was evident between any of the groups for EDP and EDPVR 
(Figure 4.8 C i-iv). Volume parameters showed a significant increase in both EDV 
and ESV to 239.4 and 370.7 % of sham, respectively (P<0.05; Figure 4.8 D i-iii), 
however SV remained unchanged.  
In the MI+RAdAng-(1-9) group, the reductions in ESP, dP/dtmax and EF seen in the 
MI and MI+RAd60 groups were significantly attenuated. ESP and EF were 
significantly increased to 122.8 and 148.1 % of both MI and MI+RAd60 groups, 
respectively (P<0.05). The EF of the MI+RAdAng-(1-9) was essential normalised to 
sham levels. Dp/dtmax was still significantly reduced to 75.3 % of sham, however 
this was a significant increase in comparison to the MI group. CO in the 
MI+RAdAng-(1-9) group was significantly increased to 139.3 % of sham (P<0.05; 
Figure 4.8 B-i-iv). 
The diastolic parameters dP/dtmin and Tau in the MI+RAdAng-(1-9) animals 
remained unchanged compared to the other two MI groups, with EDP and EDPVR 
remained unchanged compared to sham (Figure 4.8 C i.-vi.). SV, ESV and EDV 
values for the MI+RAdAng-(1-9) group were not significantly different from either 
the sham group or the MI and MI+RAd60 groups (P>0.05; Figure 4.8 D-i-iii).  
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Table 4.2 Effect of RAdAng-(1-9) on haemodynamic LV PV-loop indices in MI.  
        
  
  MI 
  
Sham MI only +RAd60 +RAdAng-(1-9) 
HR (bpm) 600.9 ± 15.0 583.1 ± 5.3 577.6 ± 12.7 586.1 ± 12.3 
ESP (mmHg) 104.7 ± 3.1 79.6 ± 3.6 *** 79.0 ± 5.1 *** 97.1 ± 2.5 ## 
EDP (mmHg) 7.7 ± 1.8 12.7 ± 1.1 12.5 ± 1.2 12.3 ± 0.8 
Developed pressure (mmHg) 96.92 ± 2.3 66.7 ± 5.3 ** 66.6 ± 6.1 ** 85.9 ± 2.6 
dp/dtmax (mmHg/min) 10920.8 ± 450.0 5761.1 ± 376.8 *** 7014 ± 430.6 *** 8222.5 ± 314.9 *** ~~ 
dp/dtmin (mmHg/min) 8664.2 ± 717.6 4749.6 ± 314.7 *** 5062.4 ± 774.2 ** 5505.6 ± 325.5 ** 
Tau (ms) 5.9 ± 0.5 9.1 ± 0.3 ** 9.0 ± 1.0 ** 9.2 ± 0.5 ** 
EDPVR 0.03 ± 0.02 0.08 ± 0.01  0.07 ± 0.01 0.06 ± 0.01 
ESV (µL) 12.3 ± 2.3 42.5 ± 8.5 * 45.6 ± 11.6 * 25.9 ± 4.7 
EDV (µL) 28.2 ± 3.4 64.5 ± 8.2 ** 67.5 ± 10.5 ** 45.4 ± 4.6 
SV (µL) 15.9 ± 1.5 22 ± 1.0 22.0 ± 1.8 23.5 ± 1.7 
CO (µL/min) 9948.0 ± 1095.4 12722.8 ± 610.6  12208.0 ± 1018.1 13857.5 ± 1192.8 * 
EF (%) 58.1 ± 3.7 36.5 ± 4.0 * 36.7 ± 7.2 * 54.2 ± 5.4 # 
 
HR= heart rate, ESP= end systolic pressure, EDP= end diastolic pressure, dp/dtmax= maximum rate of rise of pressure, -dp/dtmin= maximum rate of fall in pressure, 
Tau= time relaxation constant, EDPVR= end diastolic pressure-volume relationship stiffness constant, ESV= end systolic volume, EDV= end diastolic volume, SV= 
stroke volume, CO= cardiac output, EF= ejection fraction. *= P<0.05, **= P<0.01, ***= P<0.001 vs. sham; #= P<0.05, ##= P<0.01 vs. MI and MI+RAd60; ~~= P<0.01 
vs. MI only. 
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Figure 4.8 Effect of RAdAng-(1-9) on LV haemodynamic indices in MI as determined by PV-
loop measurements. 
LV haemodynamic measurements for sham, MI, MI+RAd60 and MI+RAdAng-(1-9) animals 4 wks 
post-procedure determined using the ADVantage PV-loop system with true blood volume 
calculated using Wei’s equation. (A) Example PV-loop relationships for each animal group at 4 
wks. (B) Systolic functional indices of ESP (i.), dP/dtmax (ii.), EF (iii.) and CO (iv.); (C) Diastolic 
functional indices of EDP (i.), dP/dtmin (ii.), Tau (iii.) and EDPVR (iv.); and (D) Volume indices of SV 
(i.), EDV (ii.) and ESV (iii.). *= P<0.05, **= P<0.01, ***= P<0.001 vs. sham; #= P<0.05, ##= P<0.01 
vs. MI and MI+RAd60; ~~= P<0.01 vs. MI only. n= 7, 6, 5 and 7 for, sham, MI, MI+RAd60 and 
MI+RAdAng-(1-9), respectively. Data presented as mean± SEM. 
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4.3.6 Post-mortem and histological analysis 
4.3.6.1 Organ weights 
Analysis of organ weights found an increase in HW:TL ratio of the MI+RAd60 
group equivalent to that of the MI group, both of which were significantly 
increased to approximately 125.6 % of sham (sham= 7.8± 0.2, MI=9.9± 0.6, 
MI+RAd60= 9.8± 0.4; P<0.01). HW:TL ratio for the MI+RAdAng-(1-9) group was not 
significantly different to that of the other 3 groups (Figure 4.9 B). There was no 
significant difference between LuW:TL and LiW:TL ratios between any of the 4 
groups (Figure 4.9 C & D).  
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Figure 4.9 Effect of RAdAng-(1-9) on post-mortem organ weights in MI. 
(A) Example images of hearts for each animal group at 4 wks. n= 7, 6, 5 and 7 for, sham, MI, 
MI+RAd60 and MI+RAdAng-(1-9), respectively. HW:TL (B), LuW:TL (C) and LiW:TL (D) ratios for 
sham, MI, MI+RAd60 and MI+RAdAng-(1-9) groups at 4 wks post-surgery. **= P<0.01 vs. sham.  
Data presented as mean± SEM. Scale bar= 5 mm. TL= tibia length, HW= heart weight, LuW= lung 
weight and LiW= liver weight. 
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4.3.6.2 Cardiomyocyte sizing 
Average cell diameter, assessed using WGA staining, was significantly increased 
in MI and MI+RAd60 groups compared to sham (sham= 15.0± 0.3, MI= 18.2± 0.4, 
MI+RAd60= 18.7± 0.4 µm; P<0.001; Figure 4.10 A-ii). However, average cell 
diameter of the MI+RAdAng-(1-9) group was significantly reduced compared to 
the 2 control MI groups (MI+RAdAng-(1-9)= 16.0± 0.3 µm; P<0.001; Figure 4.10 A-
ii). Cell length was not significantly altered across any of the animal groups 
(Figure 4.10 B-ii).  
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Figure 4.10 Effect of RAdAng-(1-9) on cardiomyocyte size following MI. 
Example images of cellular cross-sections in both transverse (A-i.) and longitudinal (B-i.) axis are 
shown for each animal group, with cellular membranes stained red and cellular nuclei blue. Main 
image magnification= 25x, scale= 50 µm and 100 µm, inset zoom image scale= 25 µm and 50 µm 
for A-i. and B-i., respectively. Determination of left-ventricular cardiomyocyte diamater (A-ii. n= 126, 
126, 109 and 124 cells for sham, MI, MI+RAd60 and MI+RAdAng-(1-9), respectively) and length 
(B-ii. n= 105, 92, 78 and 84 cells for sham, MI, MI+RAd60 and MI+RAdAng-(1-9), respectively) in 
the hearts of sham, MI, MI+RAd60 and MI+RAdAng-(1-9) animals using WGA staining. ***= 
P<0.001 vs sham, ###= P<0.001 vs. MI and MI+RAd60. n= 9, 9, 8 and 9 animals for sham, MI, 
MI+RAd60 and MI+RAdAng-(1-9), respectively. Data presented as mean± SEM with the average 
cell-size for each animal taken as the average of a group of cells evenly distributed across the LV.   
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4.3.6.3 Regional fibrosis, collagen expression and scar sizing 
The scar region of all 3 MI groups was found to be the most fibrotic region within 
the MI hearts, with positive fibrosis staining significantly increased to 
approximately 268 % of sham in the MI and MI+RAd60 groups (sham= 2.7± 0.5, 
MI= 72.9± 4.5, MI+RAd60= 72.0± 5.1 %; P<0.001; Figure 4.11) and to 239 % of 
sham in the MI+RAdAng-(1-9) group (2.7± 0.5 vs. 64.6± 4.9 %, sham (n= 9) vs. 
MI+RAdAng-(1-9) (n= 9); P<0.001; Figure 4.11), with no significant difference 
between the % of staining in the scar region between any of the 3 MI groups 
themselves. Collagen expression was not significantly different in MI animals 
compared to sham, however there was a non-significant increase in both 
collagen I and III in the scar region of all MI animals, with collagen I most 
abundant (Figure 4.12 and Figure 4.13). LV fibrosis quantification was 
significantly increased in the MI and MI+RAd60 groups compared to sham (sham= 
1.34± 0.4, MI= 9.1± 1.2, MI+RAd60= 10.7± 1.5 %; P<0.001). However, LV fibrosis 
in the MI+RAdAng-(1-9) group was significantly reduced to approximately 54 % of 
MI and MI+RAd60 LV fibrosis (P<0.05) and unchanged compared to sham. Again, 
there were no significant changes in the expression of either collagen isoform in 
the LV, but a non-significant trend towards increase in both isoforms (Figure 
4.12 and Figure 4.13). Quantification of fibrosis in the septum region only 
showed a significant increase in the % of staining in the MI group compared to 
sham (1.1± 0.3 % vs. 3.5± 0.7 %, sham (n= 9) vs. MI (n= 9); P<0.01), with no other 
differences between groups. This appeared to be predominantly a result of 
increased collagen I expression which was increased but not significantly altered 
(Figure 4.12). Collagen III expression remained unchanged (Figure 4.13). 
Quantification of the RV demonstrated a very similar change in fibrosis 
expression as seen in the LV, with MI and MI+RAd60 groups % fibrosis equivalent 
and increased significantly to approximately 800 % of sham (sham= 0.9± 0.2 %, 
MI= 6.1± 1.7 %, MI+RAd60= 6.7± 1.7 %; P<0.05). Again, collagen staining 
suggested this was predominantly a result of collagen I expression, which again 
was increased in MI and MI+RAd60 groups but not significantly different (Figure 
4.12). Collagen III expression remained unchanged (Figure 4.13). MI+RAdAng-(1-
9) RV fibrosis was not significantly different to any of the other 3 groups (Figure 
4.11 B). Average scar size and scar thickness was not significantly different 
between the 3 MI groups (Figure 4.11 C & D).  
Chapter 4  192 
 
 
Figure 4.11 Effect of RAdAng-(1-9) on regional fibrosis and scar size following MI. 
(A) Example images of picrosirius red staining of heart sections for each animal group. Data 
presented as mean± SEM. Magnification= 1.25x, scale= 2 mm. Zoom insert image scale= 0.5 mm. 
(B) Quantification of total cardiac fibrosis of the scar, left ventricle, right ventricle and septum 
regions of sham, MI, MI+RAd60 and MI+RAdAng-(1-9) hearts. *= P<0.05, **= P<0.01 vs sham 
region; #= P<0.05 vs. MI and MI+RAd60 region. (C) Scar size for each MI group, determined as a 
% of the total myocardial area. (D) Average scar thickness for each MI groups. n= 9, 9, 8 and 9 for 
sham, MI, MI+RAd60 and MI+RAdAng-(1-9), respectively.   
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Figure 4.12 Effect of RAdAng-(1-9) on regional cardiac collagen I expression following MI.  
(A) Representative images of heart sections showing the distribution of DAB staining for collagen I 
expression in each of the animal groups. Negative IgG was used as a control for antibody 
specificity. Magnification= 10x, scale bar= 500 µm. (B) Quantification of DAB staining for positive 
collagen I expression in the cardiac regions of scar, LV, septum and RV as a percentage of the 
total region for sham, MI, MI+RAd60 and MI+RAdAng-(1-9) groups. n= 9, 9, 8 and 8 for sham, MI, 
MI+RAd60 and MI+RAdAng-(1-9) groups, respectively. Data presented as mean± SEM. 
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Figure 4.13 Effect of RAdAng-(1-9) on regional cardiac collagen III expression following MI.  
(A) Representative images of heart sections showing distribution of DAB staining for collagen III 
expression in each animal group. Negative IgG used as a control for antibody specificity. 
Magnification= 10x, scale bar= 500 µm. (B) Quantification of DAB staining for positive collagen III 
expression in the cardiac regions of scar, LV, septum and RV as a percentage of the total region 
for sham, MI, MI+RAd60 and MI+RAdAng-(1-9) animals. n= 9, 9, 8 and 9 for sham, MI, MI+RAd60 
and MI+RAdAng-(1-9) groups, respectively. Data presented as mean± SEM.  
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4.3.6.4 Perivascular fibrosis and collagen expression 
Quantification demonstrated no significant difference in the % of positive fibrosis 
staining associated with the cardiac vasculature between any of the animal 
groups (Figure 4.14). Perivascular collagen I levels were not significantly altered 
between sham, MI and MI+RAd60 groups (Figure 4.15). However, staining in the 
MI+RAdAng-(1-9) group was significantly reduced compared to the MI group (6.4± 
0.9 % vs. 3.1± 0.5 %, MI vs. MI+RAdAng-(1-9), P<0.05; Figure 4.15). There was no 
significant difference in perivascular collagen III levels between all 4 groups 
(Figure 4.16). 
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Figure 4.14 Effect of RAdAng-(1-9) on cardiac perivascular fibrosis following MI. 
(A) Representative images of left-ventricular localised vessels and associated picrosirius red 
staining of heart sections for each animal group. Magnification= 20x, scale= 100 µm. Insert zoom 
image scale= 50 µm. (B) Total perivascular cardiac fibrosis quantification for sham, MI, MI+RAd60 
and MI+RAdAng-(1-9) hearts. n= 9, 9, 8 and 9 for sham, MI, MI+RAd60 and MI+RAdAng-(1-9), 
respectively. Data presented as mean± SEM. 
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Figure 4.15 Effect of RAdAng-(1-9) on perivascular cardiac collagen I expression following 
MI. 
(A) Representative images of cardiac vessels and associated DAB staining for collagen I 
expression for heart sections of each animal group. Negative IgG used as a control for antibody 
specificity. Magnification= 20x, scale= 200 µm. Insert zoom image scale= 100 µm. (B) 
Quantification of DAB staining for perivascular collagen I expression in heart sections of sham, MI, 
MI+RAd60 and MI+RAdAng-(1-9) animals. *= P<0.05 vs sham and MI. n= 7, 7, 6 and 8 for sham, 
MI, MI+RAd60 and MI+RAdAng-(1-9), respectively. Data presented as mean± SEM 
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Figure 4.16 Effect of RAdAng-(1-9) on perivascular cardiac collagen III expression following 
MI. 
(A) Representative images of cardiac vessels and associated DAB staining for collagen III 
expression in heart sections for each group. Negative IgG used as a control for antibody specificity. 
Magnification= 20x, scale= 200 µm. Insert zoom image scale= 100 µm. (B) Quantification of 
perivascular DAB staining for collagen III expression in heart sections of sham, MI, MI+RAd60 and 
MI+RAdAng-(1-9) animals. n= 9, 9, 8 and 9 for sham, MI, MI+RAd60 and MI+RAdAng-(1-9), 
respectively. Data presented as mean± SEM. 
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4.3.7 Gene expression analysis 
qRT-PCR analysis revealed ACE expression was unchanged in the MI and 
MI+RAdAng-(1-9) groups compared to sham. However, expression was 
significantly increased in the MI+RAd60 group relative to sham (RQ= 2.0± 0.2, 
P<0.05; Figure 4.17 A). ACE2 expression was not significantly altered between 
any of the groups, nor was AT1R gene expression (Figure 4.17 B & C). AT2R gene 
expression was found to be significantly increased in all the MI groups. 
Expression was significantly increased 3-4 fold in the MI groups compared to 
sham (RQ= 4.5± 3.0, 3.4± 0.7 and 3.5± 0.2 for MI, MI+RAd60 and MI+RAdAng-(1-
9), respectively; P<0.05; Figure 4.17 D). Mas receptor gene expression was 
unchanged in MI and MI+RAdAng-(1-9) groups, however it was significantly down-
regulated in the MI+RAd60 group (RQ= 0.75± 0.04; P<0.05; Figure 4.17 E).   
Chapter 4  200 
 
 
 
Figure 4.17 Effect of RAdAng-(1-9) on RAS receptor and enzyme gene expression following 
MI. 
qRT-PCR-determined gene expression quantification of ACE (A), ACE2 (B), AT1R (C), AT2R (D) 
and Mas (E) in the hearts of sham, MI, MI+RAd60 and MI+RAdAng-(1-9) animals. *= P<0.05, **= 
P<0.01, ***= P<0.001 vs. sham. Data presented as RQ± rqmax. n= 3 per group. Normalisation of 
expression to a housekeeper (GAPDH) was performed for all samples. MI gene expression was 
normalised to sham expression, therefore sham expression was arbitrarily set at a RQ= 1. RQ= 
relative quantification. 
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4.4 Discussion 
In this chapter, efficient transduction of the infarcted mouse heart has been 
demonstrated using direct injection of a rAd vector. When this approach was 
utilised in order to over-express Ang-(1-9), an attenuation in the depressed 
cardiac contractility observed following MI was demonstrated in response to Ang-
(1-9), with improved FS and normalised EF. Moreover, a reduction in interstitial 
fibrosis and an anti-hypertrophic effect was observed following RAdAng-(1-9) 
delivery. 
Efficient transduction of cardiomyocytes in infarcted and non-infarcted mouse 
myocardium was demonstrated using direct intramyocardial injection of Ad-β-gal 
at doses of 1 and 5 x 109 pfu per animal. Direct injection as a means of 
transducing the myocardium with Ad has been previously reported as a safe and 
efficient method of achieving transient cardiomyocyte transgene expression in 
the rat and mouse heart (Guzman et al., 1993). The doses selected for testing 
were based on what has been reported elsewhere, with doses used for direct 
intramyocardial injection of the mouse heart in the literature ranging from 1 x 
107 to 1 x 1010 pfu per animal, with transduction efficiencies ranging from 6 to 
20 % of LV cardiomyocytes transduced (Agah et al., 1997; Chen et al., 2012; 
Ruixing et al., 2007; Toivonen et al., 2012; Vassalli et al., 2003). This is 
consistent with the transduction efficiencies seen here of between 7-15 % of the 
total myocardium transduced, depending on dose.  
The post-operative rupture rate seen in the MI and MI+RAdAng-(1-9) groups of 
38.9 % and 35.7 %, respectively, were consistent with the high mortality rate 
associated with the MI model as reported elsewhere and discussed previously 
(Gehrmann et al., 2001; Lutgens et al., 1999; Patten et al., 1998). However, the 
50 % mortality seen in the MI+RAd60 group was much higher than what is 
generally reported. With the two main determinants of cardiac rupture in the 
murine model having been reported as infarct size and post-infarct inflammation 
(Gao et al., 2010), it is feasible that one of these determinants is responsible for 
the increased rate of rupture observed in this group. In the acute phase post-
infarction, MMP levels and activity dramatically increases, (Fang et al., 2007; 
Matsumura et al., 2005), there is significant neutrophil and macrophage 
infiltration into the myocardium in order to clear away necrotic myocytes as 
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well as increased Toll-like receptor signalling, increased chemokine and cytokine 
expression and an increase in circulating inflammatory cells (Frangogiannis, 
2012; Gao et al., 2010; Tao et al., 2004). This inflammatory response is thought 
to to promote scar formation and avoid adverse remodelling (Frangogiannis, 
2012). Prolongation of the inflammatory response can be detrimental to cardiac 
healing, promoting further apoptosis of cardiomyocytes and preventing efficient 
collagen deposition, further reducing the tensile strength of the scar 
(Frangogiannis, 2012). This is potentially as a result of increased MMP activity, 
which has been shown to break down the fibrillary network and extracellular 
matrix molecules post-MI, weakening the scar (Fang et al., 2007), all of which 
can increase risk of rupture.  
As Ad delivery is associated with an increase in inflammatory mediators and 
recruitment of inflammatory cells into transduced tissue (Liu and Muruve, 2003), 
including the rodent heart resulting in significant myocardial inflammation (Chu 
et al., 2003), it is possible the Ad delivery was responsible for this increased 
rupture rate, which was perhaps being attenuated to an extent by Ang-(1-9) in 
the RAdAng-(1-9) transduced hearts. As Ang II acting via the AT1R is known to be 
pro-inflammatory in cardiovascular disease, with blockade via ACE-I and ARBs 
exerting anti-inflammatory effects, it is possible that activation of the counter-
regulatory RAS via Ang-(1-9) could have similar anti-inflammatory effects 
(Ferrario and Strawn, 2006). In fact, activation of the Mas receptor via Ang-(1-7) 
has been shown to be anti-inflammatory in experimental models of arthritis (da 
Silveira et al., 2010). As scar size was slightly reduced in the RAd60 group, it is 
unlikely that large infarct sizes contributed to the increased rupture rate. 
Although increased or prolonged inflammation caused by Ad delivery is a 
potential explanation for the increased rupture rate, this remains to be 
clarified. As there is already extensive inflammation present post-MI 
(Frangogiannis, 2012), this may not necessarily be affected by a great degree by 
Ad administration. Determination of expression and duration of expression of 
various inflammatory mediators such as TNF-α, IL-1 and IL-6 in MI and MI+Ad 
hearts would help to resolve this (Nian et al., 2004). Deaths out with the rupture 
time-period in the mouse MI model is usually attributed to acute pump failure, 
ventricular arrhythmia or development of HF (Gao et al., 2000; Hattori et al., 
2004). The absence of post-rupture phase deaths and lower overall deaths in the 
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MI+RAdAng-(1-9) groups may support its cardio-protective effects and may also 
indicate a possible anti-arrhythmogenic effect. However, as only a small number 
of animals died suddenly in the MI and MI+RAd60 groups after the rupture risk 
period this is not conclusive and requires further work.  
This study has been the first to show a beneficial effect of Ang-(1-9) on cardiac 
function in the mouse MI model. Delivery of RAdAng-(1-9) directly to the non-
infarcted myocardium in infarcted hearts demonstrated a completely normalised 
EF, as well as increased FS and improved LV systolic indices as measured by 
invasive PV loop measurements. No changes in diastolic parameters were 
observed. The improved function was associated with increased pressure 
generation and decreased volume indices in the RAdAng-(1-9) transduced hearts.  
There is currently only one other study reported in the literature assessing the 
role of Ang-(1-9) on cardiac function post-MI in the rat model (Ocaranza et al., 
2010). In this instance, systemic delivery of the peptide via minipump was used 
and cardiac function was assessed via echocardiography measurements. 
Echocardiography parameters demonstrated significantly reduced LV dimensions 
and volumes in Ang-(1-9)-infused animals compared to MI controls and revealed 
a reduction in wall-thickness, suggesting an anti-hypertrophic effect and 
reduced LV expansion, but no change was observed in functional parameters of 
EF and FS between infarcted rats being treated with Ang-(1-9) and controls 
(Ocaranza et al., 2010). There are many reasons why the results observed in this 
study are not necessarily consistent with what has been shown here. Previously 
echocardiography measurements did show alterations in volume and LV 
dimensional parameters, this was never corroborated using a more sensitive 
technique such as PV loops and did not translate into increased FS or EF 
(Ocaranza et al., 2010). The method of peptide delivery is the most likely 
explanation as here, the peptide has been expressed locally within the heart, 
most likely at high concentrations compared to previously where delivery via 
minipump involves its slow release into the blood where it is likely to reach the 
heart at far lower concentrations. Moreover, it has been suggested that the 
effects of a RAS component produced locally in a tissue may differ from those 
observed from the same RAS component present systemically. The local RAS 
involves the formation of RAS peptides within tissues and is independent from 
peptide formation within the circulation, with the local RAS thought to act 
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specifically in one cell or tissue in order to orchestrate tissue specific functions, 
whereas the systemic RAS is thought to facilitate more acute effects (Lee et al., 
1993). These differential effects can be seen when comparing local Ang II 
production in the heart to systemic Ang II delivery, with acute cardiac 
remodelling only observed when the peptide is infused systemically (Mercure et 
al., 2008; van Kats et al., 2001), however the exact mechanisms underlying 
these differences remain to be clarified. It is therefore possible that systemic 
delivery of Ang-(1-9) via minipump may not exert the same effect on the heart 
as production of that peptide from the myocytes themselves as a result of viral 
gene delivery. Examples of this have also been seen with regards to the study of 
Ang-(1-7) and its effects on cardiac function and remodelling. A study comparing 
the effect of circulating and cardiomyocyte-produced Ang-(1-7) on cardiac 
function in the rat MI model found that only circulating Ang-(1-7) appeared to 
exert a beneficial effect on cardiac function 3 wks post-MI, with no effect 
observed where Ang-(1-7) was locally produced in the heart (Wang et al., 
2010a).  This is consistent with an earlier study which utilised transgenic rats 
which over-expressed Ang-(1-7) specifically in the heart. They found that the 
over-expression of Ang-(1-7) had no effect on functional cardiac parameters or 
BP in response to Ang II infusion, although seemed to have anti-hypertrophic and 
anti-fibrotic effects (Mercure et al., 2008). Comparatively, when delivered 
systemically via minipump infusion in the rat MI model, Ang-(1-7) appears to 
exert beneficial effects on cardiac function, restoring ventricular pressure and 
preventing progression to HF (Loot et al., 2002a). Moreover, this perhaps 
suggests that effects external to the myocardium, such as in the vasculature, are 
required for the beneficial effects of Ang-(1-7) which are only exerted when it is 
delivered systemically. An exception to this was illustrated in a study where 
lentiviral delivery of Ang-(1-7) was utilised in the rat model of MI. The viral 
vectors were delivered directly to the left ventricle resulting in over-expression 
of Ang-(1-7) specifically in the heart. In this instance, a beneficial effect was 
seen on cardiac function (Qi et al., 2011). This conflicting evidence suggests that 
method of delivery as well as location of expression of RAS peptides can have 
dramatic opposing effects on the outcome with regards to its effects on cardiac 
function and remodelling, and also supports independent activity of Ang-(1-7) 
and Ang-(1-9).  
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In vitro and in vivo evidence has suggested Ang-(1-9) signals via the AT2R (Flores-
Muñoz et al., 2012; Flores-Muñoz et al., 2011; Flores-Munoz et al., 2012; 
Ocaranza et al., 2014), and although direct stimulation of the AT2R by Ang-(1-9) 
has not been associated with improved cardiac function to date, the receptor 
itself has been implicated in functional improvements. It is therefore possible 
that Ang-(1-9) may be exerting its effects via the AT2R in this setting, thereby 
counter-acting Ang II-induced cardiac remodelling. Although Ang-(1-9) has not 
been directly implicated in improved cardiac function post-MI prior to this study, 
there is evidence suggesting that the counter-regulatory RAS is a promising 
therapeutic target for maintenance of cardiac function post-MI, specifically the 
ACE2-Ang-(1-7)-Mas axis (Santos et al., 2008). Ang-(1-7) acting via Mas has been 
shown to exert beneficial effects on Ang II induced remodelling (Grobe et al., 
2006) and to exert beneficial effects on LV haemodynamic parameters when 
infused or delivered lentiviral vectors following MI in the rat (Loot et al., 2002a; 
Qi et al., 2011). ACE2 has also been demonstrated to be crucial in cardiac 
remodelling post-MI, with ACE2 deficient mouse hearts demonstrating 
exacerbated remodelling post-MI, with increased MMP activation, inflammation 
and ROS production, all of which are accompanied with increased circulating Ang 
II and decreased Ang-(1-7) (Kassiri et al., 2009). Further cardioprotective effects 
of ACE2 were demonstrated using an ACE2 inhibitor, C16, in the rat MI model, 
where FS was decreased and scar size increased in animals treated with the 
inhibitor (Kim et al., 2010). Although there is enough evidence to suggest Ang-
(1-9) exerts independent biological effects, there is a possibility that when 
produced locally in vivo Ang-(1-9) undergoes conversion to Ang-(1-7) via ACE 
activity, which has been shown here to be elevated in MI hearts, and could then 
act via Mas, exerting further beneficial effects. Synergistic therapeutic effects 
of both Ang-(1-9) and locally produced Ang-(1-7) may therefore provide dual 
benefit in MI, however this remains to be assessed. 
Histological analysis of MI hearts revealed scar size of between 30-40 %. Despite 
similar scar sizes, RAdAng-(1-9) transduced hearts demonstrated reduced total 
fibrosis in the LV region of the heart, which appeared to be primarily interstitial. 
Anti-fibrotic effects of Ang-(1-9) have previously been demonstrated in vivo in 
the SHRSP via AT2R signalling (Flores-Munoz et al., 2012). The AT2R again has 
been associated with anti-fibrotic effects in models of cardiac dysfunction, with 
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direct stimulation using C21 shown to reduced cardiac fibrosis and collagen 
deposition again through MMP regulation (Lauer et al., 2014; Rehman et al., 
2012). There is also a well-established role for Ang-(1-7) and the Mas axis in 
exerting anti-fibrotic effects on the myocardium with ACE2 over-expression and 
Ang-(1-7) signalling both inhibiting collagen deposition and fibroblast 
proliferation (Grines et al., 2003; Grobe et al., 2007; Iwata et al., 2005; 
McCollum et al., 2012). This suggest Ang-(1-9) could be exerting this anti-fibrotic 
effect through direct signalling via the AT2R and/or through conversion to Ang-
(1-7).  
A trend towards an anti-hypertrophic effect was seen in MI hearts transduced by 
RAdAng-(1-9) through both heart weight and direct cell sizing measurements. 
This is consistent with the anti-hypertrophic effects already reported for Ang-(1-
9) in in vitro and in vivo models of Ang II induced hypertrophy and in the rat MI 
model (Flores-Muñoz et al., 2012; Flores-Muñoz et al., 2011; Ocaranza et al., 
2010). Although initially adaptive, chronic cardiac hypertrophy has been 
demonstrated to be maladaptive following MI, eventually leading to the 
depression of cardiac contractility, increased LV dilation and increased cardiac 
fibrosis (Pfeffer and Braunwald, 1990). Similarly to cardiac fibrosis, 
cardiomyocyte hypertrophy is also associated with increased ROS production and 
MMP activity (Miura et al., 2003; Murdoch et al., 2006; Takimoto and Kass, 
2007), with AT2R over-expression or stimulation also being associated with 
reduced wall thickening and reduced expression of pro-hypertrophic genes 
(Rehman et al., 2012; Yang et al., 2002b). As Ang-(1-7) acting via Mas has also 
been demonstrated to be anti-hypertrophic (Keidar et al., 2007; Loot et al., 
2002a; Tallant et al., 2005), this again suggests an AT2R and/or conversion to 
Ang-(1-7) mediated anti-hypertrophic effect of Ang-(1-9) in this setting. 
In the previous chapter, regional changes in RAS receptor and enzyme gene 
expression was demonstrated at 4 wks post-MI in relation to sham. Some of those 
changes were evident when whole heart gene expression was analysed in this 
study, such as the increase in AT2R expression, which is consistent with what has 
been reported in the rat MI model elsewhere (Savoia et al., 2011). However, 
other changes in MI hearts discussed previously, such as decreased ACE2 and 
AT1R gene expression and increased ACE, have not been seen here, although 
there were small trends towards these changes. This is most likely due to the 
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regional nature of these changes shown previously. There were also no obvious 
changes in gene expression in the RAdAng-(1-9) transduced hearts. This again 
may be the result of the changes being region specific and therefore 
undetectable in whole heart lysates or alternatively due to the transient nature 
of Ad-mediated transgene expression. As the Ad would have been cleared from 
the animals by 4 wks following administration (Laitinen et al., 1997), it is 
possible that there were changes in RAS gene expression during peak expression 
of the virus transgene that were lost upon clearance.  
The primary finding of this chapter was the protective functional effects exerted 
by RAdAng-(1-9) delivery, which was shown to completely normalise cardiac EF. 
This suggests an effect on inotropy of the heart is being exerted in order to 
maintain force of contraction. One possible hypothesis is that Ang-(1-9) is able 
to exert direct effects on cardiomyocyte Ca2+-handling, increasing 
cardiomyocyte contractility. This is explored further in a later chapter.  
4.5 Summary 
Efficient transduction of the myocardium in both sham and MI animals can be 
achieved using direct intra-myocardial delivery of an Ad vector. When this 
approach was used to deliver an Ad vector expressing an Ang-(1-9) fusion protein 
in the mouse MI model, the peptide was found to confer both structural and 
functional cardio-protective effects compared to control Ad, including improved 
LV systolic indices and contractility, decreased total cardiac fibrosis and 
decreased cardiomyocyte hypertrophy. These findings provide proof of concept 
for the utility of Ang-(1-9) therapeutic delivery in the heart via gene transfer. 
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Chapter 5: Assessing the effects of adeno-
associated virus serotype 9-mediated Ang-(1-9) 
delivery in the mouse MI model 
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5.1 Introduction 
5.1.1 Adeno-associated virus 
Adeno-associated virus (AAV) was first discovered in 1965 when it was identified 
as a contaminant in a simian adenovirus preparation (Atchison et al., 1965). AAV 
were described as small, DNA-containing particles that behaved as ‘defective 
viruses’ (Atchison et al., 1965). At approximately 260 Å in diameter, the AAV 
family are very small, non-enveloped viral particles with an icosahedral capsid 
which carries a 4.7-4.9 Kb single-stranded DNA (ssDNA) genome (Agbandje-
McKenna and Kleinschmidt, 2011; Day et al., 2014; DiMattia et al., 2012). As of 
2014, 12 AAV serotypes (AAV1 to AAV12) had been isolated from humans and 
non-human primates (Chahal et al., 2014; DiMattia et al., 2012), with AAV2 
perhaps the most well characterised and the serotype most often utilised in 
clinical trials to date (Kotterman et al., 2015). Initially, different AAV serotypes 
were distinguished based on their susceptibility to serological neutralisation and 
the absence of cross-reactivity indicating no shared antigens on the viral 
surface. These antigenic differences also dramatically affect the vector tropism 
and interaction with the host immune system (Gao et al., 2004). However, as 
more serotypes have been discovered, genome similarities and antigenic cross-
reactivity of certain serotypes has allowed them to be sub-divided into 8 
different clades or classes, A-F, with AAV4 and AAV5 existing currently as clonal 
isolates (Agbandje-McKenna and Kleinschmidt, 2011). For example, AAV1 and 
AAV6 both belong to clade A, with members of each clade sharing between 60-99 
% genome identity, with AAV4 and AAV5 being the most genetically different 
from each other and all other serotypes (Agbandje-McKenna and Kleinschmidt, 
2011). 
Unlike Ad, AAV infection of humans is not associated with any known pathology 
(Day et al., 2014). Despite this, infection with AAVs in the population is 
common, therefore so is the presence of neutralising antibodies, with antibodies 
to AAV2 being the most commonly occurring, followed closely by AAV1 (Calcedo 
et al., 2009). The ‘defective virus’ property of AAV is due to the dependency of 
AAV on co-infection with a helper virus, such as Ad or herpes simplex virus 
(HSV), in order to replicate (Day et al., 2014). 
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5.1.1.1 AAV structure and genome 
The AAV genome is comparatively simple compared to that of Ad, containing 
only 3 distinct open reading frames (ORFs); rep, cap and a nested alternative 
reading frame within the cap gene. The 3 ORFs are flanked by ITRs (145 bp for 
AAV2) at either end of the genome which form tight T-shaped hairpin structures 
essential for viral packaging (Day et al., 2014). It is the cap gene which encodes 
for the 3 structural proteins which compose the viral capsid; VP1, VP2 and VP3, 
through alternative splicing of the cap mRNA (Agbandje-McKenna and 
Kleinschmidt, 2011). The full length mRNA encodes for the largest protein VP1 
(87 KDa). Encoding from an alternative start codon produces the mRNA for VP2 
(73 KDa), and VP3 (61 KDa) is encoded from a downstream ATG sequence 
(Agbandje-McKenna and Kleinschmidt, 2011). The rep ORF encodes for the 4 
genes required for viral replication (Rep40, Rep52, Rep68 and Rep72), with the 
third nested ORF within the cap gene encoding for a chaperone protein required 
for localisation of capsid proteins during viral assembly, which will be discussed 
later (Sonntag et al., 2010). 
The AAV capsid is composed of 60 copies of the VP proteins arranged with T= 1 
icosahedral symmetry, the structure of which has been determined to 3 Å 
resolution using X-ray crystallography (Xie et al., 2002). The VP proteins exist in 
a predicted ratio of 1:1:10 for VP1, VP2 and VP3, respectively, with VP3 
accounting for 90 % of the capsids protein content and being the most well-
conserved protein across the AAV serotypes (Agbandje-McKenna and 
Kleinschmidt, 2011; DiMattia et al., 2012). Each VP has a core composed of an 8-
strand β-barrel motif and an α-helix, which is conserved throughout the 
serotypes. Nine surface-exposed variable regions (VRs) are located on the loops 
connecting the β-strands (Walters et al., 2004). It is these VRs that are 
responsible for the variation in tissue tropism and immunogenicity among the 
different serotypes (DiMattia et al., 2012). 
5.1.1.2 AAV cell transduction and replication 
AAV cellular transduction bares many similarities to that already discussed for 
Ad, requiring the same basic steps of cell surface receptor binding, 
internalisation, virus trafficking through an endosomal compartment, endosomal 
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escape, trafficking to the nucleus, viral uncoating and replication (Ding et al., 
2005). Many cell surface receptors have been identified for AAV cell entry 
(Johnson and Dudleenamjil, 2012). For AAV2 its primary receptor has been 
identified as heparan sulfate proteoglycan (HSPG) (Summerford and Samulski, 
1998) which it binds using specific arginine residues located in its capsid VRs 
(Opie et al., 2003). It is also thought to bind other co-receptors including αVβ5 
integrin (Summerford et al., 1999), human fibroblast growth factor receptor 1 
(FGFR-1) (Qing et al., 1999) and hepatocyte growth factor receptor (c-Met) 
(Kashiwakura et al., 2005), which are thought to stabilise viral attachment and 
facilitate internalisation. Other receptors and co-receptors identified for other 
serotypes include various glycoprotein sialic acid residues for AAV1, AAV4, AAV5, 
AAV6 and AAV12 (Kaludov et al., 2001; Schmidt et al., 2008; Walters et al., 
2001; Wu et al., 2006), platelet-derived growth factor receptor for AAV5 (Di 
Pasquale et al., 2003), FGFR-1 for AAV3 (Blackburn et al., 2006) and the 37/67 
KDa laminin receptor for AAV2, AAV3, AAV8 and AAV9 (Akache et al., 2006). 
Cell transduction of AAVs has been most extensively studied for AAV2. Upon 
receptor binding, AAV2 particles are taken up into an endosome through 
dynamin-dependent, clathrin-mediated endocytosis (Bartlett et al., 2000). This 
requires activation of Rac1, which in turn activates the phosphatidylinositol-3 
kinase pathway required for subsequent trafficking of the AAV to the nucleus via 
the cellular microtubules (Sanlioglu et al., 2000). AAV escape from the 
endosome is thought to be triggered by the acidification of the endosome during 
maturation and potentially facilitated by phospholipase A2 (PLA2) activity seen 
at the N-terminus of VP1 of AAV2 after transduction of HeLa cells (Girod et al., 
2002). However, this cell entry and release process appears to vary between cell 
types, with high transduction efficiency in cells such as skeletal muscle, neurons 
and hepatocytes, but very limited transduction efficacy in vascular endothelial 
cells (Denby et al., 2005). This is thought to be attributed to two factors; 
sequestration of the virus to the ECM due to high expression of the AAV2 HSPG 
receptor competing for virus binding thus inhibiting cell entry (Pajusola et al., 
2002) and impaired intracellular processing of internalised viral particles 
resulting in targeting of the viral proteasome for degradation (Nicklin et al., 
2001; Yan et al., 2004). Following escape, the viral particles translocate to the 
nucleus and enter the nuclear pore. This process is thought to be facilitated by 
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putative nuclear translocation signals located at the N-terminus of VP2 (Johnson 
et al., 2010). Both the PLA2 and nuclear translocation motifs are found to be 
highly conserved between AAV serotypes. Moreover, they are located on the 
interior of the capsid structure during assembly and are inaccessible to 
antibodies, but appear to be translocated to the capsid exterior during the 
infection process as a result of a conformational change (Sonntag et al., 2006). 
During the infection process viral un-coating occurs. Whether this occurs 
primarily outside or inside the nucleus is unknown (Xiao et al., 2002), however it 
has been demonstrated that intact capsids can enter the nucleus (Johnson and 
Samulski, 2009). Following un-coating and entry into the nucleus, the ssDNA 
genome is converted into a double-stranded molecule (Thomas et al., 2004).  
AAV vectors have a bi-phasic life-cycle. Following cell transduction, either the 
lytic or lysogenic life-cycle will progress depending on whether a helper virus is 
present or absent. In cells co-infected with either an Ad or HSV, AAV will follow 
its lytic life-cycle of viral replication. If it infects alone however, it will follow 
its lysogenic life-cycle, whereby its gene expression is repressed and latency is 
established by integration of its own genome into that of the host cell 
(Goncalves, 2005). Latency occurs through preferential integration into a 
specific site on human chromosome 19, 19q13.3q-ter, known as AAVS1, mediated 
by Rep78 and Rep68 (Kotin et al., 1991). A variety of helper functions have been 
identified as being required for the completion of AAV replication, as well as 
functions provided by the host DNA replication machinery (Janik et al., 1981; 
Weindler and Heilbronn, 1991), including transcriptional activation, mRNA 
maturation, translational enhancement, modulation of the host cell cycle and 
roles in DNA replication (Ferrari et al., 1996; Ward and Kerr, 2005; Weindler and 
Heilbronn, 1991). Following successful DNA replication and translation of the VP 
structural proteins, AAV assembly occurs in the nucleus, with new capsids first 
detectable in the nucleoli. Assembly only requires the cap genes via expression 
of the chaperone virus assembly protein, which targets newly synthesised VP 
proteins to the nucleolus (Sonntag et al., 2011; Sonntag et al., 2010).  
5.1.2 AAV as a gene therapy vector 
The use of recombinant AAV vectors (rAAV) for gene therapy applications was 
first explored in 1980 with the development of infectious molecular clones of 
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AAV2 (Carter, 2004), with this leading to the development of the first rAAV 
vectors some years later (Hermonat and Muzyczka, 1984; Tratschin et al., 1985). 
Refinement of rAAV design and of the trans-complementation system over the 
following two decades has resulted in an explosion in the interest of AAV as a 
gene therapy vector for a variety of target diseases (Carter, 2004). 
The production of rAAV vectors involves the deletion of the full rep and cap 
ORFs, leaving only the flanking inverted terminal repeat (ITR) regions intact, 
allowing a possible transgene insert size of up to approximately 5 Kb (Dong et 
al., 1996). This is possible as the ITRs are the only cis-acting regions required for 
AAV genome rescue, replication and packaging (Carter, 2004; Schwartz et al., 
2009). Even with the removal of the majority of AAV genes, the small viral 
particle size of AAV restricts the packaging capacity thus precluding the 
modification of the vector for diseases requiring larger genes, especially 
compared to that of rAds which have a packaging capacity of between 8-40 Kb, 
compared to only 4.7 Kb for AAV (Duan et al., 2001). Production of rAAV vectors 
requires the use of a producer cell line, co-transfected with a plasmid carrying 
the rAAV genome, composed of the transgene flanked by the ITRs under the 
control of a promotor, and a second helper plasmid expressing Ad helper 
function genes as well as the AAV viral rep and cap genes in trans (Lai et al., 
2002). The presence of the viral replication genes and the Ad helper functions 
subject the rAAV genome to the wild-type lytic cycle by rescuing it from the 
plasmid backbone, replicating then packaging it into pre-formed AAV viral 
capsids (Goncalves, 2005). The development of rAAVs has mainly utilised AAV2, 
however any transgene expression cassette flanked by the 145 bp ITR regions of 
AAV2 can be packaged into any of the other serotype capsids (Nonnenmacher 
and Weber, 2012). The absence of the rep genes in the rAAV vector genome 
means integration into the AAVS1 site of the host genome does not occur as it 
does for wild-type AAV (Goncalves, 2005).  
The use of rAAVs as a gene therapy vector has several advantages over the use of 
rAds. They exhibit sustained transgene expression with no associated pathologies 
and the various serotypes exhibit a variety of tropisms allowing for efficient 
tissue specificity. The sustained transgene expression exhibited by rAAV vectors 
is perhaps one of the qualities which makes them such an attractive prospect as 
a gene therapy vector, with rAAV particles found to still be detectable in retinal 
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cells 6 years after the initial delivery (Stieger et al., 2008). As mentioned, rAAVs 
do not site-specifically integrate into the host cell genome. Experiments 
performed in mice in vivo demonstrated that only approximately 10 % of 
transduced viruses integrating at random sites into the host cell chromosomes 
(Nakai et al., 2001). It is now accepted that the majority of rAAV DNA persists in 
an extrachromosomal capacity as episomal circular genomes (Yang et al., 1999) 
from which the majority of transgene expression occurs (Nakai et al., 2001). This 
is thought to explain the stability of rAAV genomes in cells such as hepatocytes, 
myofibers, cardiomyocytes and neurons, which have a low or absent mitotic 
activity (Alexander et al., 2008).  
The induction of a strong cell-mediated immune response to a vector is 
extremely disadvantageous with regards to gene therapy, such as occurs with Ad 
vectors, as it limits the duration of transgene expression by clearance of virally 
transduced cells (Brockstedt et al., 1999; Daya and Berns, 2008). However, due 
to the absence of all viral genes in rAAV vectors, there is a very limited innate 
immune response by the host as the transgene and capsid remain the only 
antigens (Lai et al., 2002; Nayak and Herzog, 2009), with it demonstrated in 
mice that intramuscular delivery does not elicit a cellular-mediated immune 
response at all (Brockstedt et al., 1999). However, this lack of response tends to 
be route of administration and transgene-specific, with a cytotoxic T-cell 
response to viral capsid proteins evident in mice where rAAV was administered iv 
and ip (Brockstedt et al., 1999). The extent of this response also appears to be 
serotype-specific, with recent clinical trials utilising AAV8 vectors for treatment 
of haemophilia resulting in the production of AAV8-capsid-specific peripheral T-
cells and increased liver enzymes requiring glucocorticoid treatment to avoid 
complete clearance of virally transduced cells (Nathwani et al., 2011; 
Tuddenham, 2012). However, where a chemokine and cellular immune response 
is triggered, this has been demonstrated to be to a far lesser extent than that 
induced by an Ad vector as AAV interacts with TLR-9, which induces only 
transient cytokine production and cell infiltration (Zaiss et al., 2002; Zhu et al., 
2009). Ad delivery has also been demonstrated to induce a strong type I 
interferon response, which is absent upon AAV delivery (McCaffrey et al., 2008). 
The main host immune response to AAV is humoral as its interaction with the 
complement system is primarily through the classical pathway and is antibody-
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dependent (Nayak and Herzog, 2009), resulting in the production of neutralising 
antibodies (Sun et al., 2003). Again, the magnitude of this response tends to be 
route of administration dependent, with neutralising antibodies produced when 
the virus is delivered im or iv, but not when administered intranasally in non-
human primate models (Hernandez et al., 1999). Other factors affecting the 
extent of response include virus serotype, target organ and the transgene being 
expressed (Nayak and Herzog, 2009). Neutralising antibodies to the common 
serotypes AAV1 and AAV2 have been reported in up to 80 % of the population, 
with antibodies to the less common serotypes such as AAV4, AAV7 and AAV8 
being far lower (Blacklow et al., 1968; Calcedo et al., 2009). Avoiding pre-
existing immunity may be possible by utilising the less common serotypes in 
vector design and considering the route of administration carefully (Nayak and 
Herzog, 2009). 
Of the identified AAV serotypes, AAV1-AAV9 have been evaluated for in vivo 
transduction and have been demonstrated to show distinct tissue tropisms (Table 
5.1) (Zincarelli et al., 2008). Therefore, selective use of certain serotypes can 
help target gene therapies more specifically to tissues (Lai et al., 2002). As well 
as this innate tropism, rAAV tissue transduction can be further modified to 
expand or reduce tissue specificity. Cross-packaging approaches can be utilised 
in order to expand the tissue tropism of AAV. For example, an AAV2 genome 
packaged into an AAV5 capsid (AAV2/5) will transduce both photoreceptors and 
retinal pigment epithelial (RPE) cells of the eye, whereas AAV2 alone will only 
transduce the photoreceptor cells (Auricchio et al., 2001).  
One limitation of the use of rAAV as a gene therapy vector compared to rAd is its 
unique pattern of transgene expression. Whereas rAd transgene expression will 
be detectable within 24 hr, it has been demonstrated that expression following 
rAAV delivery increases gradually following transduction with the vector, 
requiring approximately 2-6 wks before a plateau is reached, depending on the 
serotype (Zincarelli et al., 2008). This has been attributed to 2 rate-limiting 
steps; inefficient AAV trafficking in certain tissues (Hauck et al., 2004) and 
second strand synthesis of the ssDNA genome (Ferrari et al., 1996).  
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Table 5.1 AAV serotype tissue tropism. 
Virus Tissue Tropism 
AAV1 SM, CNS, retina, pancreas, heart 
AAV2 VSMC, SM, CNS, liver, kidney 
AAV3 Hepatocarcinoma, SM 
AAV4 CNS, retina 
AAV5 SM, CNS, lung, retina 
AAV6 SM, heart, lung 
AAV7 SM, retina, CNS 
AAV8 Liver, SM, CNS, retina, pancreas, heart 
AAV9 Liver, heart, brain, SM, lungs, pancreas, kidney 
 
SM= smooth muscle, CNS= central nervous system, VSMC= vascular smooth muscle cells. 
Modified from (Nonnenmacher and Weber, 2012).  
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5.1.2.1 AAV serotype 9 
AAV9 is a novel serotype first isolated from primate tissue using a PCR-based 
molecular rescue method (Gao et al., 2002). It was isolated from human tissue 2 
years later and was found to be serologically distinct from all other known 
serotypes at that time allowing it to be grouped into its own clade, clade F (Gao 
et al., 2004). It has received particular attention as a potential gene therapy 
vector since its identification as it has the potential to be used as a global gene 
delivery vector, disseminating into all tissues of the body with a single iv dose 
(Bostick et al., 2007). In particular it has been shown to have an affinity for 
lung, skeletal muscle and heart when delivered intravenously (Ghosh et al., 
2007; Inagaki et al., 2006; Pacak et al., 2006). In fact, it has been demonstrated 
that a low dose of 1 x 1011 vp of AAV9 delivered iv in the mouse will transduce 
over 80 % of cardiomyocytes within the heart, with 100 % transduction possible 
when the dose is increased (Inagaki et al., 2006). Moreover, it has been shown 
that transduction efficiency is un-altered when the vector is delivered directly 
into the myocardium via direct injection (Bostick et al., 2007). Not only does 
AAV9 have the strongest tropism towards the heart of all known cardio-tropic 
AAV serotypes in mice (Bish et al., 2008), it has also been determined to be part 
of the ‘high-expression’ and ‘rapid-onset’ AAV groups. It has the most varied 
tissue transduction capability and highest transgene protein expression levels 
out of serotypes 1-9 and its transgene expression is detectable in mice just 7 
days following iv delivery, whereas other serotypes such as AAV2 and AAV3 may 
not have detectable expression levels until 4 wks post-delivery (Zincarelli et al., 
2008). More recently, mutagenesis of the AAV9 capsid surface VRs has allowed 
the generation of liver-detargeted vectors, allowing more specific targeting to 
the heart and skeletal muscle (Pulicherla et al., 2011). AAV9s ability to cross the 
blood-brain barrier also makes it an ideal vector for targeting the brain and CNS 
(Forsayeth and Bankiewicz, 2011; Manfredsson et al., 2009). The unique 
properties of AAV9 therefore make it an ideal candidate vector for gene therapy 
applications, especially for the targeting of cardiac disease. Here, AAV9 has 
been utilised to study the potential therapeutic properties of Ang-(1-9) for 
cardiac remodelling in the mouse MI model.  
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5.2 Aims 
The aims of this chapter were to: 
 Clone an expression cassette into an AAV shuttle vector for the production 
of AAV9 vectors expressing the Ang-(1-9) fusion protein and demonstrate 
successful transgene expression from the cassette. 
 Optimise AAV9 delivery in the mouse MI model using systemic tail vein 
delivery and show successful myocardial transduction. 
 Utilise systemic delivery of the Ang-(1-9) expressing AAV9 vector in order 
to assess its effect on structural and functional cardiac remodelling in the 
mouse model of MI. 
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5.3 Results 
5.3.1 Cloning of the AAV expression cassette 
5.3.1.1 Plasmid maps, ligation and recombination 
The pBluescript SK+ parental plasmid encoding the Ang-(1-9) fusion protein 
transgene sequence, as described in Chapter 4, had been previously been cloned 
into the MCS of the plasmid using HinDIII and EcoRI restriction sites (Figure 5.1 
A-i). In order to produce an AAV9 vector expressing this fusion protein, the full 
transgene sequence was excised from the pBluescript SK+ plasmid at ClaI and 
BamHI sites and inserted at the corresponding sites into the plasmid pAAV-MCS 
(Figure 5.1 A-ii). This inserted the sequence between the CMV promotor and 
poly-A sequences, flanked by the AAV2 ITR sequences.  
ClaI and BamHI restriction endonuclease digests were performed on both 
plasmids and the Ang-(1-9) encoding insert band at 1 Kb and the pAAV-MCS 
backbone at 4.6 Kb were excised from the gel and the DNA purified (Figure 5.1B-
i). A ligation reaction was performed and subsequently transformed into 
competent E.coli and resultant colonies screened for the successfully ligated 
pAAV-MCS containing the inserted Ang-(1-9) DNA sequence (Figure 5.1 B-ii, 
positive colonies indicated by the black arrows). 
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Figure 5.1 Ang-(1-9) expression cassette plasmid maps, purification of vector and insert 
DNA and clone screening. 
(A-i.) pBluescript parental plasmid carrying the original Ang-(1-9) fusion protein sequence in the 
MCS. (ii.) The empty pAAV-MCS AAV shuttle plasmid, into the MCS of which the Ang-(1-9) fusion 
protein sequence was to be inserted. MCS= multiple cloning site. (B-i.) Ethidium bromide agarose 
gel showing separation of DNA fragments from the double ClaI and BamHI digests of the 
pBluescript and pAAV-MCS plasmids following gel purification of the desired vector and insert 
fragments. (ii.) Ethidium bromide agarose gel of clone screening using double ClaI and BamHI 
digests following ligation of insert and vector DNA. Positive clones are indicated by the black 
arrows and show the excised insert. L= 1 Kb ladder. 
 
  
i. A ii. 
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5.3.1.2 Expression of the Ang-(1-9) fusion protein from the AAV expression 
cassette 
Expression of the transgene was confirmed in vitro via RT-PCR following 
transfection into H9c2 cells. Following electrophoresis a band present at 710 bp 
indicated successful mRNA expression from the transgene (Figure 5.2 A-i & ii).  
Following confirmation of successful transgene mRNA expression, protein 
expression was confirmed via western immunoblotting with probing for the 
mouse heavy chain IgG2B fragment of the fusion protein in transfected HeLa cell 
lysates performed, revealing a band at approximately 32 KDa confirming 
successful expression of the protein (Figure 5.2 B). 
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Figure 5.2 Confirmation of fusion protein transcription and protein expression from the 
pAAV-MCS expression cassette. 
(A-i.) Ethidium bromide agarose gel showing separation of DNA fragments from a PCR reaction 
carried out on cDNA synthesised from RNA extracted from H9c2 cells transduced with 5 or 7.5 ng 
of pAAV-MCS plasmid DNA or control DNA. (ii.) Ethidium bromide agarose gel loaded with no-RT 
control wells of the PCR reactions to control for DNA contamination and negative PCR control 
reactions to check for primer specificity. L= 1 Kb ladder, UT= untransfected cells, -ve= negative 
control plasmid DNA transduced, PB= pBluescript parental plasmid transduced, +ve= positive 
control plasmid for PCR reaction. (B) Western blot carried out on HeLa cell lysates transfected with 
5 or 7.5 ng of pAAV-MCS or negative control plasmid DNA and probed for the mouse Fc IgG2B 
fragment. P= polymer transfection control.  
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5.3.2 Optimisation of AAV in vivo delivery 
5.3.2.1 AAV transgene expression in MI 
Transduction of infarcted myocardium was first assessed using AAVGFP to 
optimise transgene expression. Following infarction but prior to recovery, 1 x 
1011 vg were delivered intravenously via tail vein. Hearts were harvested at 1, 2 
and 8 wks following viral delivery. (Figure 5.3). GFP expression was detectable 
at 1 wk post-delivery in the infarcted mouse heart. This was shown to increase 
between wks 1 and 2 by approximately 5-fold, with higher expression maintained 
up until the 8 wk time-point (Figure 5.3 A). 
Via IHC, GFP expression was evident in the cardiomyocytes of the AAVGFP 
transduced infarcted hearts at 1, 2 and 8 wks post-virus delivery. GFP expression 
was visibly more extensive at the 2 and 8 wk post-delivery time-points, 
consistent with the GFP assay results and demonstrating efficient global 
transduction of the heart by the AAV9 vector (Figure 5.3 B). 
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Figure 5.3 AAV9 transduction of the infarcted mouse heart. 
Transduction of the infarcted mouse heart by AAVGFP following tail vein delivery of 1 x 1011 vg per 
animal post-infarction. Expression was assessed at 1, 2 and 8 wks following virus delivery (A) 
Quantification of GFP expression in transduced mouse heart lysates using a GFP assay. 
Fluorescence was normalised to both negative control heart tissue basal fluorescence and protein 
concentration of the lysate. n= 2 per time-point. Data presented as mean values. (B) DAB staining 
for GFP expression in sections from wax-embedded hearts transduced with AAV-GFP for 1, 2 and 
8 wks. GFP -positive lung tissue, GFP-negative heart tissue and IgG were used to confirm antibody 
specificity. n= 2. Magnification= 4x and 40x, scale= 100 µm.  
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5.3.3 Mortality 
Following confirmation of successful AAV-mediated transduction of the 
myocardium in the mouse MI model, the effect of AAVAng-(1-9) on structural and 
functional remodelling post-MI was assessed. Four animal groups were utilised; 
sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) (Figure 5.4 A).  
A Kaplan-Meier plot of mortality for all animals recovered from procedure 
demonstrated that total mortality in each of the 3 MI groups occurred within the 
first 7 days following procedure due to rupture. The % mortality was 
approximately equivalent in the MI and MI+AAVGFP groups, however only 
MI+AAVGFP mortality was significantly increased compared to sham animals 
(MI+AAVGFP= 33.3 %; P<0.05). Mortality was reduced in the MI+AAVAng-(1-9) 
group and was not significantly different to sham animals (sham= 100, MI= 26.7, 
and MI+AAVAng-(1-9)= 9.1 %; P>0.05; Figure 5.4 B). 100 % of these deaths were 
attributable to cardiac rupture as determined by post-mortem analysis (Figure 
5.4 C). The sham group demonstrated a 100 % survival rate.  
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Figure 5.4 Study-design and procedure-associated mortality. 
(A) Study design showing time-frame of measurements over the 8 wk study period. (B) Kaplan-
Meier plot of mortality following recovery from procedure for each animal group (sham, MI, 
MI+AAVGFP, MI+AAVAng-(1-9)) over the 8 wk study period. *= P<0.05 vs. sham. n= 10, 15, 15 
and 11 for sham, MI, MI+AAVGFP and M+AAVAng-(1-9), respectively. (C) % of survival and cause 
of mortality for each animal group following recovery from procedure.   
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5.3.4 Haemodynamic and functional measurements 
5.3.4.1 Echocardiography 
A significant reduction in FS was seen from 1 wk post-MI onwards in the MI and 
MI+AAVGFP groups, with a progressive decrease in FS with time from 1 to 8 wks 
post-MI (Figure 5.5 A-i & ii). This was associated with increases in LVESD in both 
groups at all time-points and a trend towards increase in LVEDD at each time-
point (Figure 5.5 A-iii & iv). Delivery of AAVAng-(1-9) resulted in a significant 
attenuation of this reduced FS at all time-points. At the 8 wk time-point, 
MI+AAVAng-(1-9) FS, although significantly reduced to 78.4 % of sham (49.1± 1.6 
vs. 38.5± 1.9 %, sham (n= 6) vs. MI+AAVAng-(1-9) (n= 6); P<0.05), was 
significantly increased compared to both the MI and MI+AAVGFP groups (MI= 
25.8± 2.2, MI+AAVGFP= 26.6± 0.7 %; P<0.05 vs. MI+AAVAng-(1-9)). Overall, FS in 
the MI+AAVAng-(1-9) FS remained stable from 1 wk onwards, with no progressive 
decline as seen in the other 2 MI groups (Figure 5.5 A-ii). There was no 
difference in LVEDD in the MI+AAVAng-(1-9) group compared to the MI and 
MI+AAVGFP groups (Figure 5.5 A-iii). There was also no significant difference in 
LVESD, except at the 1 wk time-point where MI+AAVAng-(1-9) LVESD was 
significantly reduced compared to MI+AAVGFP only (2.5± 0.1 vs. 3.0± 0.1 mm, 
MI+AAVAng-(1-9) (n= 6) vs. MI+AAVGFP (n= 6); P<0.05). For the remaining time-
points, there was a trend towards a decrease in LVESD in the MI+AAVAng-(1-9) 
group compared to the other 2 MI groups (Figure 5.5 A-iv). No significant changes 
in posterior LV wall thickness was detectable between groups at any time-points 
(Figure 5.5 A-v & iv). E/A wave ratio measurements demonstrated no significant 
changes between animal groups (Figure 5.5 B i & ii).  
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Figure 5.5 Effect of AAVAng-(1-9) on FS, wall thickness and E/A ratio in MI as assessed by 
echocardiography. 
(A-i.) Example M-mode images for each animal cohort at 8 wks Scale= 5 mm and 1 second. Serial 
FS (ii.), LVEDD (iii.), LVESD (iv.) and posterior LV wall thickness (v.) measurements from M-mode 
echocardiography images for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) animal cohorts from 1 
to 8 wks post-procedure. *= P<0.05 vs. sham; #= P<0.05 vs. MI and MI+AAVGFP; ~= P<0.05 vs. 
MI+AAVGFP only. (B-i.) Example E/A wave Doppler measurements for each animal group at 8 wks 
post-procedure. Scale= 0.2 m/s and 20 mm. (B-ii.) Average E/A ratio measurements for the mitral 
valve determined using echocardiography Doppler for sham, MI, MI+AAVGFP and MI+AAVAng-(1-
9) animal groups at 8 wks post-procedure. n= 6 per group. Data presented as mean± SEM. FS= 
fractional shortening, LVEDD= left-ventricular end-diastolic dimension, LVESD= left-ventricular 
end-systolic dimension E= early wave and A= after wave.  
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5.3.4.2 PV loops 
In the MI+AAVAng-(1-9) group, a significant attenuation in the changes to the 
systolic indices seen in the MI and MI+AAVGFP groups following PV loop 
measurements was evident (Table 5.2 & Figure 5.6). There were significant 
increases in ESP (P<0.001), EF (P<0.001) and CO (P<0.05) to approximately 113, 
163 and 178 % of both MI and MI+AAVGFP groups, respectively. Moreover, EF was 
normalised to that of the sham group, with CO significantly increase when 
compared to sham levels (P<0.05). DP/dtmax was still significantly reduced to 
78.5 % of sham (P<0.001), which was not significantly altered compared to the 
other 2 MI groups (Figure 5.6 B-i-iv). 
AAVAng-(1-9) delivery appeared to have no significant effect on LV diastolic 
parameters (Figure 5.6 C). EDP was not significantly changed across any groups. 
DP/dtmin was significantly decreased in the MI+AAVAng-(1-9) group to 79.6 % of 
sham, with Tau increased significantly to 138.2 % of sham (P<0.05). This was 
similar to what was observed in the MI and MI+AAVGFP groups (Figure 5.6 C-i-iii). 
However, where EDPVR in the MI and MI+AAVGFP groups was significantly 
increased to 363.3 % and 400 % of sham, respectively, MI+AAVAng-(1-9) EDPVR 
remained unchanged compared to sham (P<0.05).  
MI and MI+AAVGFP EDV was significantly increased compared to sham. 
MI+AAVAng-(1-9) EDV was also increased, however this was not significant 
compared to sham (Figure 5.6 D-i). ESV was significantly increased to 
approximately 282 % of sham in the MI and MI+AAVGFP groups (P<0.01). ESV for 
the MI+AAVAng-(1-9) group was not significantly different of that of sham and 
was reduced compared to the 2 MI groups (Figure 5.6 D-ii). SV was significantly 
increased in the MI+AAVAng-(1-9) group to approximately 188 % of sham and 160 
% of the other 2 MI groups (P<0.05; Figure 5.6 D-iii). 
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Table 5.2 Effect of AAVAng-(1-9) on haemodynamic LV PV-loop indices in MI. 
        
  
  MI 
  
Sham MI only +AAVGFP +AAVAng-(1-9) 
HR (bpm) 604.3 ± 8.5 571.5 ± 7.5 558.0 ± 4.6 583.1 ± 13.5 
ESP (mmHg) 103.5 ± 1.6 84.7 ± 2.7 *** 85.1 ± 2.0 *** 95.9 ± 1.4 * ## 
EDP (mmHg) 6.3 ± 1.3 7.2 ± 1.2 6.1 ± 0.7 6.9 ± 1.8 
Developed pressure (mmHg) 97.3 ± 0.4 77.5 ± 2.5 *** 78.9 ± 2.1 89.0 ± 1.8 
dp/dtmax (mmHg/min) 10719.9 ± 732.6 7219.5 ± 443.8 *** 7144.8 ± 340.8 *** 8415.3 ± 471.0 *** 
dp/dtmin (mmHg/min) 8343.1 ± 669.3 5517.5 ± 409.1 *** 5635.8 ± 276.4 *** 6637.2 ± 546.8 ** 
Tau (ms) 5.5 ± 0.3 7.7 ± 0.7 * 7.3 ± 0.2 7.6 ± 0.6 * 
EDPVR 0.03 ± 0.00 0.109 ± 0.01 ** 0.12 ± 0.01 ** 0.07 ± 0.01 ~ 
ESV (µL) 16.5 ± 0.5 48.3 ± 7.1 ** 45.3 ± 3.6 ** 32.9 ± 5.2 
EDV (µL) 33.4 ± 1.2 67.8 ± 9.4 * 65.5 ± 3.5 * 64.8 ± 10.8 
SV (µL) 16.9 ± 0.8 19.5 ± 2.6  20.2 ± 1.0 31.9 ± 5.7 *# 
CO (µL/min) 10190.9 ± 475.3 10880.9 ± 1550.5  10869.2 ± 578.1 19335.7 ± 3859.6 *# 
EF (%) 50.4 ± 0.9 29.0 ± 1.7 ***  31.5 ± 2.2 *** 48.8 ± 1.4 ### 
 
HR= heart rate, ESP= end systolic pressure, EDP= end diastolic pressure, dp/dt max= maximal rate of rise of pressure, -dp/dt min= maximum rate of fall in pressure, 
Tau= time relaxation constant, EDPVR= end diastolic pressure-volume relationship stiffness constant, ESV= end systolic volume, EDV= end diastolic volume, SV= 
stroke volume, CO= cardiac output, EF= ejection fraction. *= P<0.05, **= P<0.01, ***= P<0.001 vs. sham; #= P<0.05, ##= P<0.01, ###= P<0.001 vs. MI and 
MI+AAVGFP; ~= P<0.05 vs. MI+AAVGFP only. n= 9, 9, 9 and 8 for, sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively. 
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Figure 5.6 Effect of AAVAng-(1-9) on LV haemodynamic indices in MI as determined by PV-
loop measurements. 
LV haemodynamic measurements for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) animals 8 
wks post-procedure determined using the ADVantage PV-loop system with true blood volume 
calculated using Wei’s equation. (A) Example PV-loop relationships for each animal group at 8 
wks. (B) Systolic functional indices of ESP (i.), dP/dtmax (ii.), EF (iii.) and CO (iv.); (C) Diastolic 
functional indices of EDP (i.), dP/dtmin (ii.), Tau (iii.) and EDPVR (iv.); and (D) Volume indices of 
EDV (i.), ESV (ii.) and SV (iii.). *= P<0.05, **= P<0.01, ***= P<0.001 vs. sham; #= P<0.05, ##= 
P<0.01, ###= P<0.001 vs. MI and MI+AAVGFP; ~= P<0.05 vs. MI+AAVGFP only. n= 9, 9, 9 and 8 
for, sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively. Data presented as mean± SEM. 
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5.3.5 Post-mortem and histological analysis 
5.3.5.1 Organ weights 
HW:TL ratio was significantly increased in all MI groups to 121, 118 and 125 % of 
sham for MI, MI+AAVGFP (P<0.05) and MI+AAVAng-(1-9) (P<0.01) groups, 
respectively (Figure 5.7 A & B). LuW:TL and LiW:TL ratios remained unchanged 
across all 4 groups (Figure 5.7 C & D).  
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Figure 5.7 Effect of AAVAng-(1-9) on post-mortem organ weights in MI. 
(A) Example images of hearts for each animal group at 8 wks. Scale bar= 5 mm. TL= tibia length, 
HW= heart weight, LuW= lung weight and LiW= liver weight.HW:TL (B), LuW:TL (C) and LiW:TL 
(D) ratios for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) groups at 8 wks post-procedure. *= 
P<0.05, **= P<0.01 vs. sham. n= 10, 10, 9 and 8 for, sham, MI, MI+AAVGFP and MI+AAVAng-(1-
9), respectively. Data presented as mean± SEM.  
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5.3.5.2 Cardiomyocyte sizing 
Cell diameter was significantly increased in all 3 MI groups to 128.2, 119.0 and 
123.9 % of sham for MI, MI+AAVGFP and MI+AAVAng-(1-9) animal groups, 
respectively (sham= 15.1± 0.3, MI=20.9± 0.9, MI+AAVGFP= 19.4± 0.4, MI+AAVAng-
(1-9)= 20.1± 0.4 µm; P<0.001; Figure 5.8 A-ii). There was no significant 
difference in cell length between any groups (Figure 5.8 B-ii). 
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Figure 5.8 Effect of AAVAng-(1-9) on cardiomyocyte size following MI. 
Example images of cellular cross-sections in both transverse (A-i) and longitudinal (B-i) axis are 
shown for each animal group, with cellular membranes stained red and cellular nuclei blue. Main 
image magnification= 25x, scale= 50 µm. Inset zoom image scale= 12.5 µm for A-i., 50 µm for B-i. 
Determination of left-ventricular cardiomyocyte diameter (A-ii. n= 144, 139, 127 and 112 cells for 
sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively) and length (B-ii. n= 99, 89, 69 and 66 
for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively) in the hearts of sham, MI, 
MI+AAVGFP and MI+AAVAng-(1-9) animals using WGA staining. ***= P<0.001 vs sham. n= 10, 
10, 9 and 8 animals for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively. Data 
presented as mean± SEM with the average cell-size for each animal taken as the average of a 
group of cells evenly distributed across the LV.   
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5.3.5.3 Regional fibrosis and collagen expression 
The scar regions of all 3 MI groups were significantly more fibrotic in comparison 
to proximal sham apical tissue, with over 80 % of the area positive for fibrosis. 
However fibrosis in the scar area of the MI+AAVAng-(1-9) group was significantly 
reduced compared to the corresponding region in the MI+AAVGFP group (86.9± 
1.0 vs. 92.4± 1.0 %, MI+AAVAng-(1-9) (n= 10) vs. MI+AAVGFP (n=9); P<0.01). 
Fibrosis in the LV region was significantly increased in all 3 MI groups compared 
to sham (P<0.01). Fibrosis was significantly increased in the septum in the MI and 
MI+AAVGFP groups compared to sham, however it was significantly reduced in 
the MI+AAVAng-(1-9) group (MI= 10± 2.4 , MI+AAVGFP= 6.3± 0.4 , MI+AAVAng-(1-
9)= 3.4± 0.6 %; P<0.01). Similarly in the RV, fibrosis was significantly increased in 
MI and MI+AAVGFP (P<0.01), however it was not significantly different to any 
other group in MI+AAVAng-(1-9) animals (Figure 5.9 A & B). 
Scar size was consistent between all 3 MI groups (MI= 35.9± 2.8, MI+AAVGFP= 
35.2± 2.1, MI+AAVAng-(1-9)= 36.9± 2.5 %; Figure 5.9 C). MI and MI+AAVGFP scar 
thickness was found to be 329± 25 µm and 276± 3.9 µm, respectively. 
MI+AAVAng-(1-9) group scar thickness was 383± 14 µm, significantly increased 
compared to the MI+AAVGFP group (P<0.05), however not compared to the MI 
group (Figure 5.12 D). 
There were no significant differences in the extent of collagen I in the scar or LV 
regions across any groups. However, in the septum collagen I levels in the MI 
group only was significantly increased compared to sham (3.9± 1.6 vs. 15.7± 4.2 
%, sham (n= 10) vs. MI (n= 10), P<0.001). The MI+AAVAng-(1-9) group had 
significantly less collagen I than the MI septum region (MI+AAVAng-(1-9)= 3.4± 
1.0 %; P<0.05 vs. MI). In the RV, collagen I in the MI group was significantly 
increased compared to sham (10.0± 2.0 vs. 35.9± 4.5 %, sham (n= 10) vs. MI (n= 
10); P<0.001). While the MI+AAVGFP RV region showed no significant difference 
compared to other groups, MI+AAVAng-(1-9) collagen I levels were significantly 
reduced to 37 % of MI (P<0.001) (Figure 5.10 A & B). There were no significant 
differences in collagen III expression in any of the regions between any groups 
(Figure 5.11 A & B). 
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Figure 5.9 Effect of AAVAng-(1-9) on regional fibrosis and scar size following MI. 
(A) Example images of picrosirius red staining of heart sections for each animal group. Data 
presented as mean± SEM. Magnification= 1.25x, scale= 1 mm. Zoom inset image scale= 0.5 mm. 
(B) Quantification of total cardiac fibrosis of the scar, left ventricle, right ventricle and septum 
regions of sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) hearts. *= P<0.05, **= P<0.01, ***= 
P<0.001 vs sham region; #= P<0.05, ##= P<0.01 vs. MI and MI+AAVGFP region. (C) Scar size for 
each MI group, determined as a % of the total myocardial area. (D) Average scar thickness for 
each MI groups. n= 10, 10, 9 and 8 for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), 
respectively.   
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Figure 5.10 Effect of AAVAng-(1-9) on regional cardiac collagen I expression following MI.  
(A) Representative images of heart sections showing the distribution of DAB staining for collagen I 
expression in each of the animal groups. Negative IgG was used as a control for antibody 
specificity. Magnification= 10x, scale bar= 500 µm. (B) Quantification of DAB staining for positive 
collagen I expression in the cardiac regions of scar, LV, septum and RV as a percentage of the 
total region for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) groups.*= P<0.05, ***= P<0.001 vs. 
sham; #= P<0.05, ###= P<0.001 vs. MI. n= 10, 10, 9 and 8 for sham, MI, MI+AAVGFP and 
MI+AAVAng-(1-9) groups, respectively. Data presented as mean± SEM.   
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Figure 5.11 Effect of AAVAng-(1-9) on regional cardiac collagen III expression following MI.  
(A) Representative images of heart sections showing distribution of DAB staining for collagen III 
expression in each animal group. Negative IgG used as a control for antibody specificity. 
Magnification= 10x, scale bar= 500 µm. (B) Quantification of DAB staining for positive collagen III 
expression in the cardiac regions of scar, LV, septum and RV as a percentage of the total region 
for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) animals. n= 10, 10, 9 and 8 for sham, MI, 
MI+AAVGFP and MI+AAVAng-(1-9) groups, respectively. Data presented as mean± SEM.   
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5.3.5.4 Perivascular fibrosis and collagen expression 
Total perivascular fibrosis in the MI and MI+AAVGFP groups was significantly 
increased to approximately 152 % of sham (P<0.01). This increase was 
significantly attenuated in the MI+AAVAng-(1-9) group (MI= 23.7± 1.9, 
MI+AAVGFP= 24.7± 2.3, MI+AAVAng-(1-9)= 18.1± 1.3 %; P<0.05; Figure 5.12 A & 
B). Perivascular collagen I expression was only significantly increased in the MI 
group compared to sham (5.8± 0.4 vs. 9.4± 1.0 %, sham (n= 10) vs. MI (n= 10); 
P<0.05; Figure 5.13 A & B), whereas perivascular collagen III expression was 
significantly increased in the MI+AAVGFP group only compared to sham (4.3± 0.7 
vs. 8.6± 1.4 %, sham (n= 10) vs. MI+AAVGFP (n= 8); P<0.05; Figure 5.14 A & B).  
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Figure 5.12 Effect of AAVAng-(1-9) on cardiac perivascular fibrosis following MI. 
(A) Representative images of left-ventricular localised vessels and associated picrosirius red 
staining of heart sections for each animal group. Magnification= 20x, scale= 200 µm. Zoom inset 
images scale= 100 µm. (B) Total perivascular cardiac fibrosis quantification for sham, MI, 
MI+AAVGFP and MI+AAVAng-(1-9) hearts. **= P<0.01 vs. sham; #= P<0.05 vs. MI and 
MI+AAVGFP. n= 10, 10, 9 and 8 for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively. 
Data presented as mean± SEM.  
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Figure 5.13 Effect of AAVAng-(1-9) on perivascular cardiac collagen I expression following 
MI. 
(A) Representative images of cardiac vessels and associated DAB staining for collagen I 
expression for heart sections of each animal group. Negative IgG used as a control for antibody 
specificity. Magnification= 20x, scale= 200 µm. (B) Quantification of DAB staining for perivascular 
collagen I expression in heart sections of sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) animals. 
*= P<0.05 vs sham. n= 10, 10, 9 and 8 for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), 
respectively. Data presented as mean± SEM.  
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Figure 5.14 Effect of AAVAng-(1-9) on perivascular cardiac collagen III expression following 
MI. 
(A) Representative images of cardiac vessels and associated DAB staining for collagen III 
expression in heart sections for each group. Negative IgG used as a control for antibody specificity. 
Magnification= 20x, scale= 200 µm. (B) Quantification of perivascular DAB staining for collagen III 
expression in heart sections of sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) animals. *= P<0.05 
vs. sham. n= 10, 10, 9 and 8 for sham, MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively. Data 
presented as mean± SEM.  
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5.3.6 Gene expression analysis 
Cardiac gene expression of the main RAS components following MI was 
determined using qRT-PCR (Figure 5.15). ACE expression was significantly 
increased in all 3 MI groups relative to sham, with a 1.5-2 fold increase in 
expression (RQ= 1.9± 0.1, 1.3± 0.02 and 1.4± 0.04 for MI, MI+AAVGFP and 
MI+AAVAng-(1-9), respectively; P<0.05; Figure 5.15 A). ACE2 expression 
remained unchanged across the groups (Figure 5.15 B). AT1R expression was 
significantly decreased in all 3 MI groups relative to sham by approximately 1.5 
fold (RQ= 0.7± 0.01, 0.7± 0.03 and 0.6± 0.02 for MI, MI+AAVGFP and MI+AAVAng-
(1-9), respectively; P<0.05; Figure 5.15 C). There was no significant difference in 
AT2R expression in MI and MI+AAVGFP groups relative to sham, however 
expression in the MI+AAVAng-(1-9) group was significantly increased 4 fold in 
comparison to both sham and the 2 MI groups (RQ= 1.4± 0.1, 1.2± 0.1 and 4.5± 
1.0 for MI, MI+AAVGFP and MI+AAVAng-(1-9), respectively; P<0.05; Figure 5.15 
D). Similarly, Mas levels remained unchanged in MI and MI+AAVGFP groups 
relative to sham, however were significantly decreased 1.4 fold in the 
MI+AAVAng-(1-9) group compared to sham and MI only (RQ= 1.0± 0.02 and 0.6± 
0.03 for MI and MI+AAVAng-(1-9), respectively; P<0.05; Figure 5.15 E). 
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Figure 5.15 Effect of AAVAng-(1-9) on RAS receptor and enzyme gene expression following 
MI. 
qRT-PCR-determined gene expression quantification of ACE (A), ACE2 (B), AT1R (C), AT2R (D) 
and Mas (E) in the hearts of sham, MI, MI+AAVGFP and MI+AAVAng-(1-9) animals. *= P<0.05, **= 
P<0.01, ***= P<0.001 vs. sham, #= P<0.05 vs MI and MI+AAVGFP, ~~= P<0.01 vs. MI only. n= 3 
per group. Data presented as RQ± rqmax. Normalisation of expression to a housekeeper (GAPDH) 
was performed for all samples. MI gene expression was normalised to sham expression, therefore 
sham expression was arbitrarily set at a RQ= 1. RQ= relative quantification. 
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5.4 Discussion 
In this chapter, AAV9 demonstrated efficient transduction of the infarcted 
mouse myocardium using iv systemic delivery. AAVAng-(1-9) was shown to 
mediated cardio-protective effects following MI in the mouse, with 
improvements observed in cardiac contractility and EF, reduced ventricular 
stiffness and reduced fibrosis, all of which occurred in parallel with increased 
cardiac AT2R expression. 
AAV transduction and transgene expression in the mouse infarcted myocardium 
was demonstrated to be efficient and homogeneous with AAVGFP when delivered 
systemically at a dose of 1 x 1011 vg. Transgene expression was detectable at 7 
days post-delivery, with maximal expression detected by 2 wks. The pattern of 
expression observed is consistent with that reported previously (Zincarelli et al., 
2008). AAV9 is reported to have strong tropism for the heart when delivered iv in 
the mouse (Ghosh et al., 2007; Pacak et al., 2006), with as high as 80 % 
transduction of cardiomyocytes observed (Inagaki et al., 2006). Detectable 
expression as early as 1 wk post-delivery has also been demonstrated, with AAV9 
classed as having ‘rapid-onset’ of expression compared to other AAV vectors, 
e.g. AAV2 and AAV3 where expression may not be detectable until 4 wks post-
delivery (Zincarelli et al., 2008). Iv delivery was selected over direct myocardial 
injection as non-invasive delivery is a more attractive translational approach as 
it minimises physical damage to the myocardium. Furthermore, direct injection 
of AAV9 to the myocardium has been shown to provide no further benefit in 
transduction efficiency over iv delivery (Inagaki et al., 2006). 
Rupture rates in MI and MI+AAVGFP groups were found to be consistent with 
previous reports, however MI rupture rate was less in the MI+AAVGFP and not 
significantly different to sham (Gehrmann et al., 2001; Lutgens et al., 1999; 
Patten et al., 1998). The rupture rate in the MI+AAVAng-(1-9) group was lower 
than the other 2 MI groups and out with the reported 12.6-26.4 % mortality that 
would be expected in this model (Gehrmann et al., 2001), despite scar sizes 
being consistent between groups. The overall rupture rate in MI animals was far 
lower in the present study compared to the previous chapter, therefore it is 
difficult to directly compare the effects of Ad vs. AAV delivery on rupture rate. 
The decreased rupture rate in MI+AAVAng-(1-9) animals was reduced compared 
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to the MI+AAVGFP group, providing further indication that Ang-(1-9) expression 
may prevent cardiac rupture, potentially by promoting thicker scar formation, or 
alternatively through modulation of the inflammatory response. As discussed in 
the previous chapter, a prolongation of the inflammatory response post-MI can 
increase the risk of rupture by reducing the tensile strength of the scar 
(Frangogiannis, 2012). AAV vectors are reported to invoke negligible cell-
mediated immune responses, although this can depend on tissue and serotype 
utilised (Lai et al., 2002; Nayak and Herzog, 2009; Nicklin et al., 2001). In fact, 
direct comparison of AAV and Ad in rat heart demonstrated significant 
inflammatory cell infiltrate into the myocardium in response to Ad transduction, 
which is completely absent in AAV transduction (Chu et al., 2003). Therefore, if 
Ang-(1-9) exerts an anti-inflammatory effect it may reduce the inflammatory 
response post-MI and reduce the rupture rate. However, as the transgene 
expression levels from AAV9 within the rupture time-frame is unknown and the 
mortality rate differences were not significant, the reduced rupture rate in the 
MI+AAVAng-(1-9) group needs to be explored further in future studies. 
AAVAng-(1-9) transduced hearts demonstrated improvements in cardiac 
contractility and systolic LV hemodynamic indices which are consistent with the 
effects seen following Ad-mediated delivery. Ang-(1-9) also reduced LV stiffness 
at the 8 wk post-MI time-point. The potential pathways associated with this 
improved function are discussed in detail in the previous chapter. However, 
differences in echocardiography and PV-loop measurements between the 2 
studies were evident. In the previous study, there was strong evidence for a 
reduction in LVESD following Ang-(1-9) delivery, indicating increased 
contraction, however this effect was less pronounced following AAV-Ang-(1-9) 
delivery. Increased LV dilation was also evident in the AAVAng-(1-9) group, 
reflected by the increased EDV found using PV loop measurements. However, 
regardless of dilation, the MI+AAVAng-(1-9) hearts consistently had greater 
contraction and blood ejection, as reflected in the dramatically increased CO 
and SV and normalised EF, showing that regardless of the extent of dilation, 
function was maintained. The exact mechanism by which Ang-(1-9) is promoting 
this increased contraction is unclear. One possibility is modulation of 
cardiomyocyte inotropy which is explored further in the next chapter.   
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Total fibrosis in the RV and septum regions in the AAVAng-(1-9) transduced 
hearts was found to be significantly reduced compared to that of the other two 
MI groups, with this appearing to be primarily as a result of a decrease in 
collagen I expression, but not collagen III, with greater collagen I expression in 
the control MI groups. This is consistent with findings that in the rat MI model, 
elevated collagen III expression is commonly associated with the acute phase 
following MI, with down-regulation at later time-points, whereas collagen I 
levels stay elevated (Cleutjens et al., 1995a). An increase in collagen I: collagen 
III ratio in the heart, as seen in control MI animals here, is found in human 
patients with CHF and in the rat HF model, and is associated in the rat with 
changes to haemodynamic properties of the ventricle and the development of 
severe LV dysfunction such as elevated LVEDP (Bishop et al., 1990; Wei et al., 
1999). The different properties of the two collagen isoforms accounts for the 
different effects they exert on the heart. Collagen I forms thick, rigid fibre 
bundles which significantly contribute to ventricle stiffening, whereas collagen 
III forms thin isolated fibres with a much greater extent of laxity (Friedman et 
al., 1993), therefore reduced expression of collagen I in the AAVAng-(1-9) 
transduced hearts may help account for the improved haemodynamic properties 
observed and the reduced stiffness coefficient demonstrated from the PV loop 
measurements. This is not the first study to demonstrate effects of Ang-(1-9) on 
cardiac collagen expression, with the effects seen here consistent with what has 
been seen in the SHRSP, where minipump infusion of Ang-(1-9) demonstrated a 
significant decrease in cardiac collagen I deposition with no change in collagen 
III, thus decreasing the collagen I: collagen III ratio in an AT2R dependent manner 
(Flores-Munoz et al., 2012). The anti-fibrotic effects evident in this study 
contrast with that observed following Ad-mediated delivery of Ang-(1-9) where 
the anti-fibrotic effects were focussed in the LV. Here, a more global effect was 
seen, primarily in the RV and septum. This could perhaps be attributed to the 
differential fibrosis seen here between the 4 and 8 wk time-points post-MI, 
where there was less fibrosis at 4 wks therefore an effect was not detectable, or 
alternatively as a result of the distribution of the viral vectors. As discussed, iv 
delivery of AAV9 provides global cardiac transduction, compared to direct Ad 
injection which transduces smaller regions proximal to injection sites. AAV9-Ang-
(1-9) may therefore have a more potent effect than Ad gene transfer in regions 
other than the LV.  
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Due to the more advanced time-point post-MI compared to the previous study, 
total perivascular fibrosis was increased in MI and MI+AAVGFP groups, which 
appeared to be as a result of a combination of both collagen I and collagen III 
deposition. This appeared to be attenuated in AAVAng-(1-9) transduced hearts 
which showed significantly reduced total perivascular fibrosis and no significant 
increase in collagen I or collagen III perivascular deposition. Unlike fibrosis as 
part of the scar healing process, which occurs in response to cell loss, 
perivascular fibrosis occurs in response to inflammation (Swynghedauw, 1999), 
with adventitial fibroblast proliferation shown to be mediated by Ang II- AT1R 
interaction (McEwan et al., 1998). This also has the additional effects of 
inhibiting MMP-1 and thus preventing collagen break-down (Brilla et al., 1994). 
As discussed, maladaptive ventricular fibrosis and collagen deposition 
contributes to ventricular stiffening and progression to HF (Kania et al., 2009). 
The use of low-dose anti-inflammatory drugs post-MI in the rat has demonstrated 
attenuation of perivascular fibrosis, however this was not associated with 
improvements in diastolic function of the heart, whereas inhibition of combined 
interstitial and perivascular fibrosis was (Van Kerckhoven et al., 2000). This is 
similar to what has been found here, where despite an anti-fibrotic effect, 
diastolic LV haemodynamic indices appear largely unchanged, with only some 
small, non-significant trends towards improvement.  
Activation of the counter-regulatory RAS has also been shown to exert anti-
fibrotic effects, with Ang-(1-7) attenuating cardiac perivascular fibrosis in the 
rat DOCA-salt model of hypertension (Grobe et al., 2006) and Ang-(1-9) acting 
via the AT2R being associated with reduced cardiac fibrosis in the SHRSP and 
inhibition of fibroblast proliferation in vitro (Flores-Munoz et al., 2012). 
Moreover, the effects of Ang-(1-9) in the study by Flores-Munoz et al., (2012) 
were thought to be in part mediated by increased NO bioavailability and Nox-4 
expression in endothelial cells (Flores-Munoz et al., 2012). As AT2R signalling is 
associated with regulation of MMPs and decreased ROS production (Dandapat et 
al., 2008; Namsolleck et al., 2014), which in turn is associated with decreased 
expression of inflammatory mediators due to the reduced activity of NADPH 
oxidase, it is possible that modulation of these pathways is a potential 
mechanism for the effects seen in the present study and which could be 
investigated in future. 
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Unlike in the previous study, there were no anti-hypertrophic effects evident in 
the AAVAng-(1-9) transduced hearts. This may also be explained by the 
differences in viral vectors used. When assessed in vitro, the anti-hypertrophic 
effects seen by Ang-(1-9) peptide are dose-dependent (Flores-Muñoz et al., 
2011). As AAV-mediated transgene expression is lower than Ad (Wright et al., 
2001) and as angiotensin peptides have very short half-lives (circa 2 min in the 
circulation) in vivo (Chappell et al., 1998) it is possible AAV-mediated Ang-(1-9) 
delivery does not reach a high enough concentration to have the same effect as 
seen when expressed by Ad. However, without determination of the exact 
concentration of Ang-(1-9) being produced by each vector in vivo, the reason for 
this disparity between the two studies still remains unclear. Alternatively, it 
could be attributed to the later time-point at which hypertrophy was assessed (8 
wks compared to 4 wks) however this also remains to be assessed. 
Increased ACE and decreased AT1R expression were observed via qRT-PCR at 8 
weeks. In Chapter 3 it was demonstrated that AT2R expression was increased 
acutely following MI, but reduced to sham levels by 8 wks post-MI. This has been 
reported in other models of MI (Savoia et al., 2011; Schluter and Wenzel, 2008). 
However, here Ang-(1-9) delivery maintained elevated AT2R expression to 8 wks. 
As the AT2R is associated with a variety of cardio-protective effects, including 
reduced remodelling and improved function post-MI (Kaschina et al., 2008; 
Kaschina et al., 2014; Namsolleck et al., 2014; Oishi et al., 2003; Yang et al., 
2002b) and the regulation of MMPs and resulting anti-fibrotic effects in the heart 
(Kaschina et al., 2008; Lauer et al., 2014), increased AT2R expression may 
mediate these cardioprotective effects. The decrease in Mas expression 
observed in AAVAng-(1-9) transduced hearts is relatively difficult to explain. Mas 
receptor expression is usually associated with ACE2 activity, with increased ACE2 
producing increased Ang-(1-7) levels and in turn increased Mas expression (Zhang 
et al., 2014). The reverse is also true, where decreased ACE2 and increased ACE 
activity decreases Ang-(1-7) levels, thus decreasing Mas expression (Lakshmanan 
et al., 2011). Therefore more detailed analysis of protein levels and receptor 
function is required. 
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5.5 Summary 
Iv delivery of AAV9 in the mouse MI model is an efficient method of globally 
transducing the mouse myocardium. AAV9 mediated delivery of Ang-(1-9) in the 
mouse MI model conferred cardio-protective effects. These effects included 
increased LV systolic indices, EF and CO, decreased LV stiffness and decreased 
total fibrosis and collagen I expression. This was also associated with an increase 
in AT2R gene expression. These results suggest Ang-(1-9) may be a promising 
therapeutic target for functional and structural remodelling post-MI. 
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Chapter 6: The effect of renin-angiotensin system 
peptide hormones on mouse cardiomyocyte Ca2+-
handling 
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6.1 Introduction 
6.1.1 The use of isolated cardiomyocytes in understanding ECC 
The use of isolated, single adult cardiomyocytes has proved an invaluable tool in 
the study and understanding of electrophysiological properties of the heart and 
the role of the electrical and contractile dysregulation of individual 
cardiomyocytes on overall heart function (Roth et al., 2014). The use of isolated 
cardiomyocytes has the advantage over whole organs of allowing selection of 
cardiomyocytes from a particular area of the heart, ease of visualisation of 
internal cellular structures, suitability for immunohistochemical applications and 
ease of imaging (Louch et al., 2011). Moreover, it provides the opportunity to 
study the mechanisms underlying cardiomyocyte contractility and Ca2+-handling 
in the single cell and how this is affected by different pharmacological 
interventions as well as changes that occur in health and disease (Despa et al., 
2012; Helmes et al., 2003; Touchberry et al., 2013). The successful isolation of 
adult rat cardiomyocytes using enzyme digestion was first described in 1969 
(Kono, 1969), with enzyme digestion using retrograde Langendorff perfusion via 
aortic cannulation described a year later (Berry et al., 1970). Prior to this, only 
embryonic and neonatal cardiomyocytes had been isolated with any success 
(Farmer et al., 1983). However, neonatal cardiomyocytes differ considerably in 
their morphological and Ca2+-handling properties (Kato et al., 1996; Katsube et 
al., 1996; Smolich et al., 1989; Wetzel et al., 1993), as do immortalised 
cardiomyocyte cell lines such as HL-1, which lack many of the structural and 
physiological properties associated with freshly isolated cells (Claycomb and 
Palazzo, 1980). Moreover, culturing of adult cardiomyocytes results in cell 
transformation in order to adapt to the culture conditions, with cell rounding 
and shortening (Leach et al., 2005), loss of T-tubule density (Pavlović et al., 
2010), prolongation of the cellular AP (Schackow et al., 1995), decrease in 
systolic peak Ca2+ (Banyasz et al., 2008) and the loss of synchronous SR Ca2+ 
release (Mitcheson et al., 1996). Therefore, for electrophysiological and Ca2+-
handling measurement purposes, acutely isolated adult cardiomyocytes are the 
most physiologically relevant to the living organism (Louch et al., 2011). 
Compared to rat, mouse cardiomyocyte isolation has proved more problematic, 
with direct application of methods that proved successful in other species failing 
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to produce high quality cells when applied to mouse hearts (O’Connell et al., 
2007). This is thought to be due to an increased susceptibility to 
hypercontracture compared to other species (Li et al., 2014). Successful 
protocols developed for mouse isolation require particular attention to be paid 
to timing of digestion protocols, appropriate collagenase enzyme batch 
selection, water quality and to ensure that all perfusion solutions remain 
nominally Ca2+ free (O’Connell et al., 2003; O’Connell et al., 2007; Wolska and 
Solaro, 1996). 
6.1.1.1 Ca2+ paradox 
Early isolation of adult rat cardiomyocytes encountered the issue of the Ca2+ 
paradox; that is the ‘rounding up’ or hypercontracture of cardiomyocytes 
isolated using Ca2+-free solutions upon exposure to physiological Ca2+ 
concentrations (Farmer et al., 1983; Powell and Twist, 1976). This results from a 
large Ca2+ overload of the cells following a period in Ca2+-free conditions, 
resulting in continuous cellular contraction, disruption of the sarcolemma, loss 
of mechanical and electrical activity, depletion of phosphate stores and release 
of the intracellular contents and enzymes (Liu et al., 2006; Piper, 2000). This 
phenomenon is similar to the processes observed in I/R injury of whole hearts, 
where reperfusion of ischemic myocardium results in further irreversible 
myocardial damage as a result of reintroduction of physiological Ca2+ 
concentrations (Zimmerman and Hülsmann, 1966). In mouse ventricular 
cardiomyocytes, Ca2+ entry following Ca2+ restoration is thought to be primarily 
through the transient receptor potential canonical (TRPC) channels, which 
mediate signals in response to PLC-coupled receptors and are activated as a 
result of SR Ca2+ depletion during the period in Ca2+-free conditions (Kojima et 
al., 2010; Soboloff et al., 2007). Other causal mechanisms of Ca2+-overload 
which have been suggested include disruption of sarcolemmal mechanical 
stability making it permeable to Ca2+ and activation of reverse-mode NCX due to 
Na+ overload (Piper, 2000). It is thought that Na+ overload is a result of depletion 
of both Ca2+ and Mg+ during the Ca2+-free period resulting in permeability of the 
L-type Ca2+ channel to Na+ (Ashraf, 1979; Chapman et al., 1984; Rodrigo and 
Chapman, 1991). Upon restoration of physiological Ca2+, reverse-mode NCX is 
activated and there is an influx of Ca2+. However, this is not thought to be the 
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case in all instances of Ca2+ overload (Jansen et al., 1998; Van Echteld et al., 
1998).  
6.1.2 Ca2+ imaging 
Ca2+ is crucial in the regulation of cardiomyocyte ECC (Bers, 2002), hypertrophy 
(Hunton et al., 2002) and apoptosis (Atsma et al., 1995), therefore its 
homeostasis is of vital importance for cardiomyocyte function. The development 
of methods to allow Ca2+ imaging in single cardiomyocytes has played a vital role 
in the study of electrophysiological properties of the heart and the study of ECC 
for decades. It was this technique which was used to discover CICR as the 
precise mechanism behind ECC (Fabiato and Fabiato, 1979), and since the 
development of ratiometric Ca2+ sensitive dyes and epifluorescent Ca2+ imaging 
techniques in the 1980’s (Bright et al., 1989; Grynkiewicz et al., 1985), it has 
been utilised for a variety of mechanistic studies into the dysregulation of ECC 
and Ca2+ handling in disease (Gomez et al., 1997). 
Ca2+ handling measurements indirectly assess the function of the various Ca2+ 
handling proteins during ECC (Bers, 2001). Measuring the average Ca2+ transient 
amplitude assesses SR-mediated Ca2+ release (the culmination of L-type Ca2+ 
channel activity, sensitivity of the RyR to Ca2+ and SR Ca2+ content). The Tau of 
the transient, defined as the time required for the transient to decay by 1/e 
(i.e. 36.8 %), allows assessment of the main Ca2+ extrusion mechanisms, the NCX 
and SERCA. Finally, the use of a rapidly applied bolus of high concentration 
caffeine as a means of emptying the SR Ca2+ store allows an estimation of SR 
Ca2+ content, and the Tau of the caffeine-induced Ca2+-transient allows an 
estimation of NCX activity only (Bers, 2002).  
6.1.2.1 Myofilament sensitivity 
Ca2+ homeostasis is not the only regulator of cardiomyocyte contractile force as 
modification of myofilament Ca2+ sensitivity is an alternative mechanism. This is 
determined through the minimum threshold Ca2+ concentration required for 
activation of contraction (Stoehr et al., 2014). Modification of myofilament 
sensitivity occurs via β-adrenergic stimulation, where the myofilaments become 
desensitized in order to accelerate relaxation (Janssen, 2010). Increased 
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sensitivity and force generation can be brought about by the use of Ca2+-
sensitising drugs and myosin activators (Janssen, 2010). Therefore, an increased 
Ca2+-transient may not always be sufficient for increased contractility. The 
opposite is also true, with a positive inotropic effect may be induced without the 
presence of a change in Ca2+-handling, making it important that cell shortening 
measurements are also performed.    
6.1.3 The effects of RAS peptides on cardiomyocyte Ca2+-
handling 
6.1.3.1 Ang II 
The effect of Ang II on cardiomyocyte Ca2+-handling and contractility has been 
extensively studied. There have been various studies identifying a positive 
ionotropic effect of Ang II on cardiomyocytes, however the mechanism of this 
has, too, been conflicting. In rabbit cardiomyocytes, a positive AT1R-mediated 
ionotropic effect has been demonstrated in response to Ang II, with increase 
myofibrillar sensitivity thought to be a potential mechanism (Fujita and Endoh, 
1999; Ikenouchi et al., 1994). However, although these two studies 
demonstrated similar effects on cardiomyocyte contractility, one demonstrated 
no change to the Ca2+-transient or L-type current, suggesting only a change to 
myofibrillar Ca2+ sensitivity occurred in response to Ang II (Ikenouchi et al., 
1994). The second study demonstrated an increased Ca2+-transient and an 
increase in NCX and reverse mode NCX activity, suggesting alterations to Ca2+-
handling also had a role in the positive ionotropic effects being exerted. The 
increase in the Ca2+-transient observed in this study was proposed to be due to 
activation and modulation of the NCX as well as sensitization of the 
myofilaments to Ca2+ as a result of AT1R-stimulation (Fujita and Endoh, 1999). 
Reverse-mode NCX facilitates influx of extracellular Ca2+ into the cytoplasm as 
opposed to forward mode NCX which facilitates Ca2+ extrusion following CICR 
(O'Rourke, 2008). The mode in which the NCX acts is dependent on Ca2+ and Na+ 
sarcolemma gradients (O'Rourke, 2008). Studies on isolated cat cardiomyocytes 
have also identified a positive ionotropic effect of Ang II, with increased Ca2+-
transient amplitude and an increase in L-type Ca2+ current (Petroff et al., 2000; 
Salas et al., 2001). A negative lusitropic effect was also associated with a 
decrease in NCX, mediated by PKC signalling, with increased intracellular Ca2+ as 
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a result of reduced extrusion via the NCX and prolongation of the AP (Salas et 
al., 2001). A later study, also in isolated cat cardiomyocytes, again identified an 
increased Ca2+-transient and positive ionotropic effect of Ang II, mediated by 
AT1R signalling. However, in contrast, NCX activity was found to be increased 
and reverse mode NCX activated. This was found to be due to an Ang II-
dependent increase in ET-1 signalling which stimulated ROS production thus 
activating the NCX (Cingolani et al., 2006). Ang II, via the AT1R, also has a 
positive iontropic effect on isolated dog ventricular cardiomyocytes. 
Interestingly, in cells isolated from dogs with pacing-induced CHF, Ang II elicited 
a negative inotropic effect, with cells exhibiting depressed contraction (Cheng 
et al., 1996). A mechanism proposed for these varying effects was activation of 
IP3 and PKC by Ang II, resulting in modulation of Ca2+-handling, changes to 
myofilament Ca2+-sensitivity and activation of NCX, producing a positive 
inotropic response in healthy cardiomyocytes. In CHF cardiomyocytes, activation 
of the same pathways may exacerbate the existing dysfunctional Ca2+-handling 
(Cheng et al., 1996) 
Other studies have also found Ang II to exert a negative inotropic effect on 
isolated cardiomyocytes. In cells isolated from normal and hypertrophied rat 
myocardium, Ang II resulted in reduced cellular contractility which was 
accompanied by reduced peak systolic Ca2+ (Meissner et al., 1998), although a 
later study also in rat cardiomyocytes found that the negative ionotropic effect 
they observed was not associated with a change in the Ca2+-transient, but was 
rather a result of reduced myofilament sensitivity which was thought to be 
modulated by PKC activation of p38 MAPK (Palomeque et al., 2006). In mouse 
ventricular cardiomyocytes a similar effect was observed in response to Ang II, 
with a PKC-mediated reduction in cellular contractility observed in the absence 
of a change in the Ca2+-transient (Sakurai et al., 2002). PKC/p38 MAPK can 
modulate contractility either through modulation of intracellular pH or through 
direct phosphorylation of the contractile apparatus such as TnI, with modulation 
of phosphorylation proposed to be the mechanism of action of Ang II in both of 
these studies (Palomeque et al., 2006; Sakurai et al., 2002). As well as this 
conflicting evidence, it has also been demonstrated in cardiomyocytes isolated 
from rat, guinea pig, humans and infarcted rat myocardium that Ang II in a 
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concentration range of 1 nM to 10 µM has no effect on inotropy or Ca2+-handling 
(Lefroy et al., 1996; Touyz et al., 1996).  
6.1.3.2 Ang-(1-7) 
There is limited evidence for a direct effect of Ang-(1-7) on isolated 
cardiomyocyte inotropy and Ca2+-handling. A single study looking at the direct 
application of 10 nM Ang-(1-7) on isolated WT mouse cardiomyocytes 
demonstrated no effect of the peptide on Ca2+-handling parameters (Dias-
Peixoto et al., 2008), which was confirmed in ventricular cardiomyocytes 
isolated from transgenic rats overexpressing circulating Ang-(1-7) (Gomes et al., 
2010). However, both of these studies had interesting caveats. In the former, 
Ca2+-handling was also assessed in cardiomyocytes isolated from Mas receptor 
knock-out mice, which were demonstrated to have slower Ca2+-transients, 
reduced peak systolic Ca2+ and reduced SERCA expression (Dias-Peixoto et al., 
2008). As these animals have been demonstrated to have reduced cardiac 
function in vivo, this altered Ca2+-handling was proposed as a potential 
mechanism (Santos et al., 2006). In the second study, although the 
cardiomyocytes isolated from the transgenic rats overexpressing Ang-(1-7) did 
not show any altered Ca2+-handling parameters, they were found to be resistant 
to the decrease in Ca2+-transient amplitude induced by Ang II in a potential 
NO/guanosine 3’,5’-cyclic monophosphate–dependent pathway (Gomes et al., 
2010). Interestingly, ventricular cardiomyocytes isolated from transgenic rats 
with cardiac over-expression of an Ang-(1-7) fusion protein demonstrated an 
increase in Ca2+-transient amplitude, faster transient kinetics and increased 
SERCA2a protein expression, which the authors stated was consistent with the 
improved cardiac function observed in these animals in response to isoproterenol 
in vivo (Ferreira et al., 2010a).  
To date, no studies have been reported on the assessment of the effects of Ang-
(1-9) on single cardiomyocyte Ca2+-handling properties. In the present study, the 
effects of the RAS peptides Ang-(1-7), Ang-(1-9) and Ang II, on isolated mouse 
cardiomyocyte Ca2+-handling and inotropy was assessed using epifluorescent 
microscopy and cell shortening measurements.   
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6.2 Aims 
The aims of this chapter were to: 
 Optimise the Langendorff single mouse cardiomyocyte isolation protocol. 
 Assess the effects of the peptides Ang II, Ang-(1-7) and Ang-(1-9) on 
inotropy and Ca2+-handling in isolated mouse cardiomyocytes using 
epifluorescent microscopy and cell shortening measurements. 
 Investigate the mechanism of action of the peptides in this setting using 
RAS receptor antagonists. 
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6.3 Results 
6.3.1 Mouse cardiomyocyte isolation optimisation and study 
design 
6.3.1.1 Collagenase I enzyme batch selection 
Prior to the isolation of single mouse cardiomyocytes for study purposes, a 
suitable collagenase I enzyme to yield good-quality, Ca2+-tolerant cells suitable 
for experimental procedure was required to be identified. The total yield of 
cells from each enzyme batch at 0 mM Ca2+ was not significantly altered 
between enzyme batches, and as expected was not changed upon increasing the 
Ca2+ concentration, with a consistent yield of approximately 1.5-2 million cells 
per heart from LV and septum tissue (Figure 6.1 A). However, there were 
noticeable differences in the % of surviving rod-shaped cardiomyocytes between 
the enzyme batches. At 0 mM Ca2+, the 275 U/mg batch preparations contained 
a far greater % of rod-shaped cardiomyocytes compared to both the 370 and 390 
U/mg enzymes (270 U/mg= 14.2± 9.6 %, 270 U/mg= 7.3± 4.5 %, 390 U/mg= 5.5± 
0.8 %). Overall the cells isolated using each enzyme were Ca2+-tolerant, with 
only a small loss in the % of rod-shaped cells (Figure 6.1 B).  
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Figure 6.1 Collagenase I enzyme batch selection. 
(A) Total cell number counts from mouse cardiomyocyte isolations performed using different 
collagenase I enzyme batches in 0 and 1 mM Ca2+ solutions. (B) Rod-shaped cardiomyocyte 
counts represented as a % of the total cardiomyocytes in each isolation performed using different 
collagenase I batches in 0 and 1 mM Ca2+ solutions. n= 3 per batch. Data presented as mean± 
SEM.  
  
Chapter 6  262 
 
6.3.1.2 Experimental design and cardiomyocyte isolation 
Due to its better rod yield, the 275 u/mg batch was selected to take forward for 
experiments. Once digestion times and conditions had been optimised with this 
enzyme batch, the average total cell yield per isolation was approximately 2 
million, with approximately 30 % of these being rod-shaped at 1 mM Ca2+ (Figure 
6.2).  
In order to investigate the effects of RAS peptides on cardiomyocyte Ca2+ 
handling, 4 different protocols were employed (Figure 6.3): 
 Peptide pre-treatment: Cells were incubated with 1 µM of Ang-(1-7), Ang-
(1-9) or Ang II for 15 min prior to 2 min stimulation at 1 Hz. Perfusate was 
supplemented with 1 µM of appropriate peptide, with water used as a 
control (Figure 6.3 A). 
 Peptide pre-treatment + double caffeine: For estimation of L-type Ca2+ 
channel activity the peptide pre-treatment protocol was combined with a 
10 mM caffeine bolus prior to initiating stimulation. The amplitude of the 
first transient produced, referred to the L-type Ca2+-transient hence-
forth, was used to estimate Ca2+ entry via the L-type Ca2+ channel (Eisner 
et al., 2000; Elliott et al., 2013) (Figure 6.3 B).  
 Peptide perfusion: A 2 min steady-state cell stimulation was recorded for 
control solution. The solution was then switched to either a second 
control solution or a 100 or 500 nM solution of either Ang-(1-9) or Ang II 
for a further 1 min (Figure 6.3 C). 
 Antagonist pre-treatment + peptide perfusion: The peptide perfusion 
approach was combined with pre-treatment of cells for 15 min prior to 
stimulation with either 1 µM Losartan (AT1R antagonist) or 500 nm 
PD123319 (AT2R antagonist) in order to investigate the actions of the 
peptides. Perfusate was supplemented with the appropriate antagonist 
throughout (Figure 6.3 D). 
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A 10 mM caffeine bolus was applied simultaneously with the cessation of 
stimulation at the end of each protocol in order to assess SR Ca2+ content. Cell 
shortening measurements were recorded simultaneously with Ca2+-transient 
measurements.  
  
Chapter 6  264 
 
 
Figure 6.2 Experimental cardiomyocyte isolation cell yields. 
Average cell yields and rod % from cardiomyocyte isolations performed for experimental work 
using the 275 u/mg batch of collagenase I enzyme. Count performed at 1 mM Ca2+, n= 7. Data 
presented as mean± SEM.  
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Figure 6.3 Ca2+ imaging experimental protocols. 
Schematics showing the various protocols employed to study the effects of the RAS peptides Ang II, Ang-(1-7) and Ang-(1-9) on Ca2+-handling protein activity and to 
investigate the mechanisms of action of these peptides. The white arrow indicates the start of stimulation and the black arrow the end. 
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6.3.2 Peptide pre-treatment 
6.3.2.1 Ca2+-transient analysis 
Using protocol A (Figure 6.3), the effect of pre-treatment of mouse 
cardiomyocytes with 1 µM of either Ang-(1-7), Ang-(1-9) or Ang II (Fukuta et al., 
1996; Fukuta et al., 1998; Gunasegaram et al., 1999) on Ca2+-transient amplitude 
and Tau was determined (Figure 6.4). Ca2+-transient amplitude was found to be 
unaltered between control and Ang-(1-7) treated cells (Figure 6.4 B-i). However, 
the average amplitude of Ang-(1-9) treated cells was significantly increased to 
177 % of control cells (549.3± 71.5 vs. 972.0± 100.6 nM, control (n= 31) vs. Ang-
(1-9) (n= 34); P<0.05; Figure 6.4 B-ii). The amplitude of Ang II treated cells was 
also significantly increased to 174.7 % of control cells (549.3± 71.5 vs. 959.3± 
146.1 nM, control (n= 31) vs. Ang II (n= 24); P<0.05; Figure 6.4 B-iii). Tau of the 
Ca2+-transient was not significantly altered across all the treatment groups 
(Figure 6.4 C-i-iii).  
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Figure 6.4 The effects of 1 µM of RAS peptides on mouse cardiomyocyte Ca2+-transient 
amplitude and tau. 
(A) Example Ca2+-transient traces for each cell treatment group. Red trace indicates 1 Hz 
stimulation. Average Ca2+-transient amplitude (B) and Tau (C) for isolated mouse cardiomyocytes 
untreated or pre-treated with 1 µM of Ang-(1-7) (i.), Ang-(1-9) (ii.) or Ang II (iii.). *= P<0.05 vs. 
control. n= 31, 26, 34 and 24 for control, Ang-(1-7), Ang-(1-9) and Ang II, respectively. Data 
presented as mean± SEM.  
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6.3.2.2 L-type Ca2+-transient analysis 
Using protocol B (Figure 6.3), the effect of the peptides on the L-type Ca2+ 
transient was assessed. Average amplitudes of the L-type Ca2+-transient was 
unchanged in Ang-(1-7) and Ang II treated cells compared to control (Figure 6.5 
B-i & iii). However, Ang-(1-9) treated cells showed a significantly increase L-type 
Ca2+-transient amplitude, which was increased to 250 % of control (70.8± 15.9 vs. 
187.1± 23.5, control (n= 11) vs. Ang-(1-9) (n= 14); P<0.01; Figure 6.5 B-ii).  
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Figure 6.5 The effects of 1 µM of RAS peptides on mouse cardiomyocyte L-type Ca2+-
transient amplitude. 
(A) Example L-type Ca2+-transient traces for each cell treatment group. (B) Average L-type Ca2+-
transient amplitude for isolated mouse cardiomyocytes untreated or pre-treated with 1 µM of Ang-
(1-7) (i.), Ang-(1-9) (ii.) or Ang II (iii.). ***= P<0.001 vs. control. n= 11, 12, 14 and 10 for control, 
Ang-(1-7), Ang-(1-9) and Ang II, respectively. Data presented as mean± SEM. 
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6.3.2.3 Caffeine-induced Ca2+-transient analysis 
The effects of 1 µM of Ang-(1-7), Ang-(1-9) and Ang II on SR Ca2+ content and 
extrusion of Ca2+ via the NCX was assessed using a 10 mM caffeine bolus applied 
following stimulation, with resulting transient correlating to release of Ca2+ via 
the RyR. Caffeine-induced Ca2+-transient amplitude was unchanged compared to 
control cells in cells treated with Ang-(1-7) and Ang II (Figure 6.6 B-i & iii). 
However, caffeine-induced Ca2+-transient amplitude was significantly increased 
in Ang-(1-9) treated cells to 160 % of control cells (1076.1± 132.1 vs. 1792.6± 
288.9, control (n= 28) vs. Ang-(1-9) (n= 30); P<0.05; Figure 6.6 B-ii). Caffeine-
induced Ca2+-transient Tau was unaltered in all treatment groups (Figure 6.6 C-i-
iii).  
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Figure 6.6 The effects of 1 µM of RAS peptides on mouse cardiomyocyte caffeine-induced 
Ca2+-transient amplitude and tau. 
(A) Example caffeine-induced Ca2+-transients for each cell treatment group. Average caffeine-
induced Ca2+-transient amplitude (B) and Tau (C) for isolated mouse cardiomyocytes untreated or 
pre-treated with 1 µM of Ang-(1-7) (i.), Ang-(1-9) (ii.) or Ang II (iii.).*= P<0.05 vs. control. n= 28, 23, 
30 and 20 for control, Ang-(1-7), Ang-(1-9) and Ang II, respectively. Data presented as mean± 
SEM.   
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6.3.2.4 Cell shortening measurements 
The effect of 1 µM of Ang-(1-7), Ang-(1-9) or Ang II on cell shortening was 
measured simultaneously with Ca2+-handling measurements. Shortening was 
presented as the average % reduction in diastolic cell length during contraction. 
Resting cell length was shown to be consistent across all treatment groups at 
approximately 150 µm (Figure 6.7 B-i-iii). Cell shortening was not significantly 
altered compared to control in Ang-(1-7) and Ang II treated groups (Figure 6.7 C-
i & iii). However, cell shortening measurements were significantly increased in 
Ang-(1-9) treated cells to 166.9 % of control (6.8± 0.9 vs. 10.2± 1.1 %, control 
(n= 17) vs. Ang-(1-9) (n= 22); P<0.05; Figure 6.7 C-ii).   
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Figure 6.7 The effects of 1 µM of RAS peptides on mouse cardiomyocyte length and FS. 
(A) Example cell shortening traces for each cell group. Red trace indicates 1 Hz stimulation 
Average cell length (B) and cell shortening (C) measurements for isolated mouse cardiomyocytes 
untreated or pre-treated with 1 µM of Ang-(1-7) (i.), Ang-(1-9) (ii.) or Ang II (iii.). *= P<0.05 vs. 
control. n= 17, 19, 22 and 16 for control, Ang-(1-7), Ang-(1-9) and Ang II, respectively. Data 
presented as mean± SEM.   
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6.3.2.5 Spontaneous rises in intracellular Ca2+ 
The effect of Ang-(1-7), Ang-(1-9) and Ang II on spontaneous rises in intracellular 
Ca2+ compared to un-treated cells during the 2 min stimulation period was 
determined by counting the number of spontaneous Ca2+ releases throughout the 
trace and expressing the value as spontaneous rises in intracellular Ca2+ per 
second. Example Ca2+-transient traces from Ang II treated cells showed the 
presence of spontaneous Ca2+ release as anomalies in the trace, independent of 
cell stimulation (Figure 6.8 A). Only Ang II treatment was shown to significantly 
increase the frequency spontaneous Ca2+ release compared to control cells 
reaching 400 % of control (0.02± 0.01 vs. 0.08± 0.02 Ca2+ release/s, control (n= 
31) vs. Ang II (n= 26); P<0.01; Figure 6.8 B-iii). Neither Ang-(1-7) nor Ang-(1-9) 
produced a significant increase in spontaneous Ca2+-rise frequency compared to 
control cells (Figure 6.8 B–i & ii).   
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Figure 6.8 The effects of 1 µM of RAS peptides on mouse cardiomyocyte spontaneous rise 
in intracellular Ca2+ frequency. 
(A) Example of Ca2+-transient traces from an Ang II-treated cells. Spontaneous Ca2+ release is 
indicated by the red arrows. Red trace indicates 1 Hz stimulation. (B) Average spontaneous Ca2+ 
release frequency for isolated mouse cardiomyocytes untreated or pre-treated with 1 µM of Ang-(1-
7) (i.), Ang-(1-9) (ii.) or Ang II (iii.). **= P<0.01 vs. control. n= 31, 26, 34 and 26 for control, Ang-(1-
7), Ang-(1-9) and Ang II, respectively. Data presented as mean± SEM.  
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6.3.3 Peptide perfusion 
6.3.3.1 Ca2+-transient analysis 
Following demonstration of the modulating effects on Ca2+-handling properties 
using 1 µM of Ang-(1-9) and Ang II incubated on cells, both peptides were further 
investigated for their effects using lower concentrations (100 and 500 nM) on 
separate cohorts of cells to determine if the response observed was dose-
dependent or whether other differences between the actions of the peptides 
became apparent. For this, protocol C (Figure 6.3) was utilised. Data was 
presented as the % increase in transient amplitude and % decrease in Tau within 
the same cell between control solution and peptide. Control cells were also 
subjected to a solution change mid-stimulation, however in this case there was 
no peptide present. Application of 100 or 500 nM of Ang-(1-9) or Ang II produced 
a significant increase in the Ca2+-amplitude by 17-25 % (P<0.001; Figure 6.9 A). A 
similar trend was observed with the Tau changes where all peptide 
concentrations produced a significant decrease in Tau by 7-12 % (P<0.05; Figure 
6.9 B).  
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Figure 6.9 The effects of RAS peptide perfusion on mouse cardiomyocyte Ca2+-transient 
amplitude and Tau. 
Average % change in Ca2+ transient amplitude (A) and Tau (B) for isolated mouse cardiomyocytes 
perfused with control solution followed by further perfusion with a second control solution or with 
100 or 500 nM of an Ang-(1-9) or Ang II solution. *=P<0.05, **=P<0.01, ***= P<0.001 vs. control.  
n= 11, 8, 20, 9 and 11 for control, Ang-(1-9) 100 nM, Ang-(1-9) 500 nM, Ang II 100 nM and Ang II 
500 nM, respectively. Data presented as mean % change± SEM.   
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6.3.3.2 Caffeine-induced Ca2+-transient analysis 
Next, the effect of Ang-(1-9) and Ang II on SR Ca2+ content and NCX-mediated 
Ca2+ extrusion was assessed using 10 mM caffeine as described previously. There 
was no significant difference in either caffeine-induced Ca2+-transient amplitude 
or Tau any of the treatment groups (Figure 6.10 A & B).   
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Figure 6.10 The effects of 100 and 500 nM of RAS peptides on mouse cardiomyocyte 
caffeine-induced Ca2+-transient amplitude and tau. 
Average caffeine-induced Ca2+-transient amplitude (A) and Tau (B) for cells perfused with 100 or 
500 nM of Ang-(1-9) or Ang II or control solution. n= 5, 7, 7, 14 and 4 for control, 100 nM Ang-(1-9), 
100 nM Ang II, 500 nM Ang-(1-9) and 500 nM Ang II, respectively. Data presented as mean± SEM.   
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6.3.3.3 Cell shortening measurements and spontaneous rises in intracellular 
Ca2+ frequency analysis 
Both the 100 and 500 nM Ang-(1-9) produced a significant increase in cell 
shortening compared to control solution. When 100 or 500 nM of Ang-(1-9) was 
applied cell shortening was increased by 33.0± 5.7 % and 32.5± 7.8 %, 
respectively (P<0.05). A similar trend was seen with application of a 100 or 500 
nM Ang II producing an increase in cell shortening by 54.1± 16.6 % and 33.7± 10.4 
%, respectively (P<0.05; Figure 6.11 A). The frequency of spontaneous rises in 
intracellular Ca2+ was unaffected by switching between control solutions. 
Application of either concentration of Ang-(1-9) or Ang II also had no significant 
effect. However application of either concentration of Ang II produced a trend 
towards an increase in the frequency of spontaneous Ca2+ release during 
stimulation (Figure 6.11 B).  
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Figure 6.11 The effects of 100 and 500 nM of RAS peptides on mouse cardiomyocyte cell 
shortening and spontaneous rises in intracellular Ca2+ frequency. 
Average % change in cell shortening (A) and spontaneous Ca2+ release frequency pre and post-
peptide perfusion (B) for cells perfused with 100 or 500 nM of Ang-(1-9) or Ang II or control 
solution. *= P<0.05, **= P<0.01 vs. control. n= 5, 7, 7, 14 and 4 for control, 100 nM Ang-(1-9), 100 
nM Ang II, 500 nM Ang-(1-9) and 500 nM Ang II, respectively. Data presented as mean± SEM.  
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6.3.4 Peptide inhibitor studies 
6.3.4.1 Ca2+-transient analysis 
In order to establish whether the effects Ang-(1-9) and Ang II were dependent on 
the AT1R or AT2R, incubation and perfusion of the mouse cardiomyocytes with 
the AT1R antagonist Losartan and/or the AT2R antagonist PD123319 was 
performed in combination with perfusion of the peptides as per protocol D 
(Figure 6.3).  
For Ang-(1-9), the change in Ca2+-transient amplitude seen previously was 
unaltered in the presence of either antagonist, with both Ang-(1-9) 
concentrations inducing a significant increase in Ca2+-transient amplitude by 21-
29 % after peptide application, regardless of antagonist (Figure 6.12 A-i; P<0.05). 
An almost identical change was seen in Tau, with Ang-(1-9) application 
significantly decreasing Tau by 8-10 % (P<0.05; Figure 6.12 A-ii). 
For Ang II, the low dose of 100 nM was assessed with either Losartan, PD123319 
or a combination of both. In this instance, the change in amplitude seen in the 
cells treated with Losartan or Losartan and PD123319, which was increased by 
approximately 12 %, was found to be significantly reduced compared to the 37 % 
increase seen in the cells treated with PD123319 only (P<0.05; Figure 6.12 B-i). 
The % decrease in Tau observed followed similar pattern. The Losartan and 
Losartan/PD123319 combination groups Tau was significantly decreased by 8.6± 
1.7 % and 10.7± 2.0 % for Losartan and Losartan + PD123319 combination, 
respectively (P<0.05). The decrease in Tau by 13.1± 6.4 % in the PD123319 group 
was larger, however this was not significantly different to control cells (Figure 
6.12 B-ii).   
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Figure 6.12 The effects of RAS inhibitors on Ang-(1-9) and Ang II- induced Ca2+-transient 
amplitude and Tau changes in mouse cardiomyocytes.  
(A) Average % change in Ca2+-transient amplitude (i.) and rate of decline (ii.) for isolated mouse 
cardiomyocytes pre-treated with 1 µM of Losartan or 500 nM of PD123319 and perfused with 
control solution followed by further perfusion with control or with 100 or 500 nM of an Ang-(1-9) 
solution. *=P<0.05, **=P<0.01 vs. control. n= 4, 12, 7, 5 and 8 for control, 100 nM + Losartan, 500 
nM + Losartan, 100 nM + PD123319 and 500 nM + PD123319, respectively. Data presented as 
mean % change± SEM. (B) Average % change in Ca2+-transient amplitude (i.) and rate of decline 
(ii.) for isolated mouse cardiomyocytes pre-treated with 1 µM of Losartan, 500 nM of PD123319 or 
a combination of both and perfused with control solution followed by further perfusion with control 
or with 100 nM of an Ang II solution. *P<0.05, **=P<0.01 vs. control; #=P <0.05 vs. Ang II+ 
PD123319.  n= 4, 14, 5 and 6 for control, +Losartan, + Losartan and PD123319 and + PD123319, 
respectively. Data presented as mean % change± SEM.  
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6.3.4.2 Caffeine-induced Ca2+-transient analysis 
The effect of the combined peptide and antagonist treatment on SR Ca2+ content 
and NCX mediated Ca2+ extrusion via NCX was assessed using 10 mM caffeine. No 
experimental condition appeared to have a significant effect on caffeine-
induced Ca2+-transient amplitude or Tau compared to the control cell group 
(Figure 6.13 A-i & ii & B-i & ii).   
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Figure 6.13 The effects of RAS inhibitors on Ang-(1-9) and Ang II- induced caffeine-induced 
Ca2+-transient amplitude and Tau changes in mouse cardiomyocytes. 
(A) Average caffeine-induced Ca2+-transient amplitude (i.) and Tau (ii.) for isolated mouse 
cardiomyocytes pre-treated with 1 µM of Losartan or 500 nM of PD123319 and perfused with 100 
or 500 nM of an Ang-(1-9) solution. n= 4, 12, 7, 5 and 8 for control, 100 nM + Losartan, 500 nM + 
Losartan, 100 nM + PD123319 and 500 nM + PD123319, respectively. Data presented as mean± 
SEM. (B) Average Ca2+-transient amplitude (i.) and Tau (ii.) for isolated mouse cardiomyocytes pre-
treated with 1 µM of Losartan, 500 nM of PD123319 or a combination of both and perfused with 
100 nM of an Ang II solution. n= 4, 14, 5 and 6 for control, +Losartan, + Losartan and PD123319 
and + PD123319, respectively. Data presented as mean± SEM.  
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6.3.4.3 Cell shortening measurements and spontaneous rise in intracellular 
Ca2+ frequency analysis 
Next, the effects of combined peptide and antagonist treatment on cell 
shortening and spontaneous Ca2+ release was assessed. The pre-treatment of 
cells with either Losartan or PD123319 produced no effect on the changes 
observed upon application of 500 or 100 nM of Ang-(1-9), with a significant 
increase in cell shortening produced following Ang-(1-9) application by 33.6± 3.8 
%, 51.0± 3.8 %, 80.9± 27.1 % and 74.7± 35.9 % for 500 and 100 nM Ang-(1-9) + 
Losartan and 500 and 100 nM Ang-(1-9) + PD123319, respectively (Figure 6.14 A-
i). Again, there were no changes observed in the frequency of spontaneous rises 
in intracellular Ca2+ in response to Ang-(1-9) application and this was not altered 
by pre-treatment with the receptor antagonists (Figure 6.14 A-ii).  
The pre-treatment of cells with Losartan or a combination of Losartan and 
PD123319 reduced the increase in cell shortening response previously seen in 
response to 100 nM of Ang II (AngII+Losartan= 20.3± 8.0 %, 
AngII+Losartan+PD123319= 24.3± 13.7 %), which was significantly reduced 
compared to cells pre-treated with PD123319 only, which showed a significant 
increase in cell shortening of 69.5± 23.7 % of control solution (P<0.05) (Figure 
6.14 B-i). Again, there was no significant difference in the frequency of 
spontaneous intracellular rises in Ca2+ between control solution and upon 
application of 100 nM of Ang II, however there was a trend towards an increase 
in frequency in cells pre-treated with PD123319 only (Figure 6.14 B-ii).   
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Figure 6.14 The effects of RAS inhibitors on Ang-(1-9) and Ang II- induced cell shortening 
and spontaneous rises in intracellular Ca2+ frequency changes in mouse cardiomyocytes. 
(A) Average % change in cell shortening (i.) and average spontaneous Ca2+ release frequency pre 
and post-peptide perfusion (ii.) for isolated mouse cardiomyocytes pre-treated with 1 µM of 
Losartan or 500 nM of PD123319 and perfused with 100 or 500 nM of an Ang-(1-9) solution. *= 
P<0.05, **= P<0.01 vs. control. n= 4, 12, 7, 5 and 8 for control, 100 nM + Losartan, 500 nM + 
Losartan, 100 nM + PD123319 and 500 nM + PD123319, respectively. Data presented as mean± 
SEM. (B) Average % change in cell shortening (i.) and average spontaneous Ca2+ release 
frequency pre and post-peptide perfusion (ii.) for isolated mouse cardiomyocytes pre-treated with 1 
µM of Losartan, 500 nM of PD123319 or a combination of both and perfused with 100 nM of an 
Ang II solution. *= P<0.05 vs. control; #= P<0.05 vs. PD123319. n= 4, 14, 5 and 6 for control, 
+Losartan, + Losartan and PD123319 and + PD123319, respectively. Data presented as mean± 
SEM.   
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6.4 Discussion 
The present study assessed the effects of Ang-(1-7), Ang-(1-9) and Ang II on 
single mouse cardiomyocyte Ca2+-handling and dissected their mechanisms of 
action. No effect on any Ca2+-handling parameters was detected using Ang-(1-7), 
however both Ang-(1-9) and Ang II exerted a positive inotropic effect on mouse 
cardiomyocytes, increasing Ca2+-transient amplitude and cell contractility at 1 
µM, 500 nM and 100 nM. The response was instantaneous upon exposure of the 
cells to the peptide. NCX and SERCA activity appeared to be not significantly 
altered in response to pre-treatment of cells with 1 µM of both Ang-(1-9) and 
Ang II, however incubation of cells with Ang-(1-9) appeared to increase SR Ca2+-
content and suggested a role for increased L-type Ca2+ channel activity, which 
was absent in cells treated with Ang II. Ang II also resulted in an increased 
frequency of diastolic Ca2+ waves which was absent in cells treated with Ang-(1-
9). The effects of Ang II were found to be mediated by the AT1R, however the 
actions of Ang-(1-9) on the Ca2+-transient appeared to be AT2R-independent.  
This is the first study to show a direct effect of Ang-(1-9) on mouse 
cardiomyocyte Ca2+-handling. The lack of effect seen here through Ang-(1-7) 
treatment, however, is consistent with previous reports (Dias-Peixoto et al., 
2008) (Gomes et al., 2010). Despite this, there is some evidence for Ang-(1-7) to 
have a protective effect on Ca2+-handling properties in cells which have 
undergone treatment to modify Ca2+-handling parameters, such as isoproterenol 
(Ferreira et al., 2010a) or Ang II stimulation (Gomes et al., 2010), suggesting it 
may be beneficial in cells isolated from remodelled hearts. As the 
cardiomyocytes used here were isolated from healthy, WT mouse hearts and 
were used without prior stimulus or treatment the data agree with previous 
findings.   
In the present study, a positive inotropic effect was observed for Ang II. The 
results seen here in response to Ang II treatment has shown an increased Ca2+-
transient amplitude when incubated on cells at a concentration of 1 µM, 
consistent with several other studies which have reported a similar effect (De 
Mello and Monterrubio, 2004; Petroff et al., 2000; Salas et al., 2001). In the 
majority of these studies the primary receptor thought to be mediating the 
effects of Ang II was the AT1R, which was identified through the use of the AT1R 
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antagonist Losartan used in similar doses ranges to what was utilised here 
(Cheng et al., 1996; Cingolani et al., 2006; Fujita and Endoh, 1999). However, in 
these previous studies a complete inhibition of the effects of Ang II was seen 
when used in combination with Losartan, in contrast to what was observed here 
in the present study. Here the use of Losartan in combination with Ang II brought 
about a trend towards normalisation back to control levels for Ca2+-transient 
amplitude and cell shortening, but not a complete inhibition of the effects. This 
suggests the effects seen here are at least in part mediated by the AT1R, with 
potential incomplete blocking of the receptor being the most reasonable 
explanation for the partial reversal. As there was no effect of PD123319 and an 
equivalent effect of combined Losartan and PD123319 to Losartan only, this 
suggests no role for the AT2R in the effects seen.  
Previous data exploring the mechanisms of action of Ang-(1-9) has identified the 
AT2R as the mediator of its effects using the AT2R antagonist PD123319 in similar 
concentrations utilised here (Flores-Muñoz et al., 2012; Flores-Muñoz et al., 
2011; Flores-Munoz et al., 2012; Ocaranza et al., 2010). However, in the present 
study neither Losartan or PD123319 appeared to abrogate the positive inotropic 
effects observed in response to Ang-(1-9) on the mouse cardiomyocytes. This 
suggests that Ang-(1-9) is possibly eliciting its effects via an alternative 
mechanism to Ang II and via an unidentified receptor. Alternatively, it is possible 
the AT2R receptor was not completely inhibited by PD123319. Moreover, 
although PD123319 is a very commonly used AT2R antagonist, recently there 
have been some concerns identified with its selectivity (Henrion, 2012). 
The main differences observed between the effects seen in response to 1 µM Ang 
II and Ang-(1-9) incubation was the increased SR Ca2+-content and L-type Ca2+ 
channel observed in cells pre-treated with Ang-(1-9) and the increased incidence 
of spontaneous rises in intracellular Ca2+ seen in Ca2+-transient traces from cells 
exposed to Ang II. The increase in SR Ca2+ content combined with the increased 
L-type current seen in cells pre-treated with Ang-(1-9) suggests that the 
increased Ca2+-influx is resulting in loading of the SR. This increased SR content 
may be sensitising the RyR, allowing for more Ca2+ to be released during CICR, 
thus leading to the increased transient. The absence of this increase in Ang II 
pre-treated cells may be due to the absence of increased Ca2+ entry via the L-
type, with the increased transient potentially primarily a result of increased RyR 
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sensitivity. The increased frequency of spontaneous rises in intracellular Ca2+ 
seen in response to Ang II incubation is similar to the effects reported for Ang II 
treatment in human atrial cells, where it was found to significantly increase 
spontaneous Ca2+ spark frequency in an AT1R-depdendent manner. In vivo, 
spontaneous Ca2+ release, or Ca2+-leak from the RyR is common in patients with 
HF and can lead to fatal ventricular arrhythmia (Farr and Basson, 2004; 
Venetucci et al., 2008). In fact, early positive inotropic agents such as 
catecholamines and PDE-I’s investigated for the potential treatment of HF 
enhanced this problem by increasing cytosolic Ca2+ concentration, thus 
increasing the propensity for spontaneous Ca2+ release (Du Toit et al., 1999). 
There are several potential mechanism by which Ang II could be exerting this 
effect. As mentioned, Ang II could potentially be modifying RyR sensitivity. 
Moreover, the increased spontaneous Ca2+ release and lack of increased SR Ca2+ 
content in the Ang II pre-treated cells may be associated as diastolic Ca2+ leak 
from the SR is not only known to be a cause of arrhythmia, but is also associated 
with depleted SR Ca2+ (Bers et al., 2003). 
The spontaneous rises in intracellular Ca2+ observed in Ang II treated cells 
occurred as early-after depolarisations (EADs) rather than delayed after 
depolarisations (DADs), both of which have distinct mechanisms (Levy and 
Wiseman, 1991). DADs occur in instances of Ca2+ overload as a result of the 
generation of a transient inward current, attributed to NCX, which can lead to a 
second depolarisation of the cell (Sipido et al., 2007). EADs occur when the AP is 
prolonged, allowing time for Ca2+ entry via reactivation of the L-type Ca2+ which 
reverses repolarization (Qu et al., 2013). DADs occur late into or after full 
repolarization of the cell, whereas EADs occur during plateau or at the beginning 
of repolarization (Levy and Wiseman, 1991). Both can trigger propagation 
impulses via spontaneous CICR from the SR, as was observed in some instances in 
Ang II treated cells (Levy and Wiseman, 1991). This suggests that the 
mechanisms for the increased spontaneous Ca2+ release observed in response to 
Ang II involves the modulation of the AP and/or L-type Ca2+ function, however 
this requires further investigation.  
The positive inotropic effect induced by Ang-(1-9) was associated with increased 
L-type Ca2+-transient amplitude and an increase in SR Ca2+ content when cells 
were pre-treated with 1 µM of the peptide. The increase in L-type Ca2+-transient 
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observed suggests a possible increase in L-type Ca2+-channel activity or 
expression and may account for the overall increased Ca2+-transient amplitude, 
with more Ca2+ entering the cell during each AP (Berridge et al., 2003). The L-
type Ca2+ channel has been demonstrated to be regulated by PKC- and PKA-
mediated pathways, with multiple G-protein coupled receptors in the heart 
acting through cAMP/PKA pathways (Kamp and Hell, 2000), therefore it is 
possible Ang-(1-9) is acting through a similar pathway in this setting. Increased 
SR Ca2+ content can also increase Ca2+ release during CICR by increasing the 
luminal sensitisation of the RyR (Bers, 2002), which is consistent with the 
increased SR Ca2+-content seen in cells pre-treated with Ang-(1-9) here. The 
increased Ca2+-transient amplitude resulted in the increased cell shortening 
observed.  
There were a number of differences found between peptide incubation and 
perfusion experiments. Transient amplitude and FS were the only parameters 
found to be equivalently altered upon both pre-incubation and perfusion of Ang-
(1-9) and Ang II. Ca2+-transient Tau was unaltered in pre-incubation experiments 
but was found to be significantly reduced in perfusion experiments. This may be 
explained by the more sensitive nature of the perfusion experiments, where 
changes were being detected within one cell, allowing smaller changes to be 
more easily identified. Increased SR Ca2+ content was observed in cells pre-
treated with Ang-(1-9) but not in perfusion experiments. This perhaps indicates 
that an extended period of Ang-(1-9) exposure is required to allow sufficient 
time to load the SR. The increase in spontaneous rises in intracellular Ca2+ were 
only observed in cells pre-treated with Ang II and not in perfusion experiments. 
Again, this may be to do with the time of exposure to the peptide. The different 
concentrations of the peptide may also explain some of these differences 
however this required further investigation. L-type Ca2+-transient was not 
measured in the perfusion experiments and it is therefore unclear as to its 
activity in these conditions.   
The exact receptor interactions and mechanisms underlying the actions of the 
peptides in this setting still remain to be clarified. Larger n-numbers for the 
lower dose groups would be advantageous in detecting more subtle changes to 
Ca2+-handling due to the variation in parameters from cell to cell. More direct 
methods of measuring the L-type Ca2+ channel, such as patch clamping, could 
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also be employed and the effect of the peptides on the cell AP may also provide 
further information on the mechanism.  
6.5 Summary 
Retrograde Langendorff perfusion of a collagenase I enzyme is an efficient way 
of isolating single, Ca2+-tolerant mouse cardiomyocytes. The peptides Ang-(1-7), 
Ang-(1-9) and Ang II have varying effects on single mouse cardiomyocyte Ca2+-
handling properties and inotropy as assessed using epifluorescence microscopy 
and cell shortening measurements. Ang-(1-7) exerted no measurable effects. 
Ang-(1-9) and Ang II exerted positive inotropic effects associated with increased 
Ca2+-transient amplitude and increased cell shortening. Ang II only was 
associated with an increase in spontaneous SR-mediated Ca2+ release events. 
Ang-(1-9) was associated with an increase in L-type Ca2+ transient amplitude and 
an increase in SR Ca2+ content when pre-treated with a 1 µM dose, suggesting a 
possible mechanism of action. The effects seen in response to Ang II were 
mediated, in part, by the AT1R. The receptor interaction for Ang-(1-9) remains 
to be determined. This is the first time Ang-(1-9) has been associated with a 
positive inotropic effect in isolated mouse cardiomyocytes.  
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Chapter 7: General discussion 
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7.1 Overall summary 
Activation of the RAS hormonal cascade following infarction contributes 
significantly to the pathophysiological changes which drive the decline in cardiac 
function post-MI, contributing to eventual HF (Carey and Siragy, 2003). Targeting 
of the counter-regulatory axis of the RAS is emerging as a potential novel 
therapeutic strategy to attenuate adverse cardiac remodelling and preserve 
cardiac function (McKinney et al., 2014). Therefore, the primary aim of this 
thesis was to assess the potential therapeutic effects of the counter-regulatory 
RAS peptide Ang-(1-9) in MI using a viral-mediated gene transfer approach.  
Firstly, the mouse MI model, selected as a suitable animal model for cardiac 
remodelling and dysfunction, was characterised for structural, functional and 
gene expression changes. Following MI at both 4 and 8 weeks, it was 
demonstrated that there was a significant expansion of the LV and decline in 
cardiac contractility. Changes to the cardiac structure were also evident, with 
the development of cardiomyocyte hypertrophy and the deposition of collagen I 
and collagen III in interstitial and perivascular areas, which was more enhanced 
at 8 weeks post-MI, and as such hearts at 8 weeks post-MI also demonstrated 
significantly increased ventricular stiffening. Gene expression changes in RAS 
components were also evident, with increased ACE and AT2R expression, and 
decreased AT1R and ACE2. The structural and functional changes that occurred 
in this animal model resemble the main pathophysiological changes which occur 
in human hearts following MI (Sutton and Sharpe, 2000), and therefore made it 
suitable for assessment of the therapeutic potential of Ang-(1-9). 
Next, optimisation of a viral-vector mediated delivery of Ang-(1-9) was 
performed. Initially, a rAd5 vector was utilised for delivery. Successful 
transduction of 7-14 % of the myocardium was achieved using direct myocardial 
injection using a β-gal expressing rAd and assessing myocardial transduction at 5 
days post-delivery. A second study was also carried out utilising a rAAV9 vector. 
Efficient transduction across approximately 80 % of the myocardium was 
achieved using a single iv injection of rAAV9, which was assessed using an eGFP 
expressing vector. Both candidate therapeutic viral vectors expressed identical 
Ang-(1-9) fusion proteins to facilitate the successful expression and cellular 
secretion of the peptide (Methot et al., 2001). 
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The first of the two in vivo studies utilised rAd gene transfer and assessed the 
effects of Ang-(1-9) on cardiac remodelling over a 4 week period. It was found 
that Ang-(1-9) successfully preserved cardiac function following MI, with 
enhanced contractility, EF and ESP compared to control groups. Cardio-
protective effects were evident in cardiac structure, with a small decrease in 
hypertrophy and regional interstitial fibrosis observed. Moreover, this 
demonstrated that with expression of a potent secreted transgene product 
significant, whole-heart effects were observed even when only a small 
proportion of cardiomyocytes (approximately 7-14 % of the myocardium) had 
been transduced. Clinical trials have utilised Ad vectors to express pro-
angiogenic factors in ischaemic hearts for this reason, with increased protein 
levels detectable in areas of the myocardium remote from the original rAd 
injection site observed in animals models (Grines et al., 2002; Grines et al., 
2003; Hedman et al., 2003; Mack et al., 1998; Magovern et al., 1996; Stewart et 
al., 2006). Therefore it could be anticipated a similar effect occurred in the 
current study, however this remains to be demonstrated. The second study 
utilising the rAAV9 vector allowed assessment of the effects of Ang-(1-9) at a 
later time-point due to the longevity of transgene expression. The rAAV9 vector 
also targets a greater proportion of cardiomyocytes and therefore achieves 
enhanced homogeneous delivery compared to rAd, making it the preferred 
choice for clinical gene therapy applications (Bajgelman et al., 2015; Byrne et 
al., 2008; Hajjar et al., 2008; Jaski et al., 2009; Kawase et al., 2011; Kawase et 
al., 2008; Zsebo et al., 2014). Similarly to the first study, cardiac function in MI 
animals was preserved by Ang-(1-9) from 1 week post-MI, which was unexpected 
due to the delay in transgene expression onset displayed by AAV vectors 
(Zincarelli et al., 2008). However, further investigation demonstrated that rAAV9 
transgene expression was detectable in the mouse heart as soon as 1 wk 
following delivery. Similarly to the rAd study, Ang-(1-9) when delivered by rAAV9 
demonstrated improved contractility, normalised EF and increased ESP. The 
advancement of the time-point from 4 to 8 wk resulted in increased ventricular 
stiffening and dilation in the MI model, however Ang-(1-9) reduced ventricular 
stiffness and produced a significantly increased CO even compared to sham due 
to the increased dilation but maintained EF. The more advanced interstitial and 
perivascular fibrosis at 8 weeks was also significantly attenuated by Ang-(1-9), 
primarily through decreased deposition of collagen I, the isoform associated with 
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development of severe LV dysfunction (Wei et al., 1999). These cardioprotective 
effects were also associated with significantly increased AT2R expression. Unlike 
in the previous study, there was no obvious anti-hypertrophic effect seen at 8 
weeks using AAV9-mediated delivery. The reason for this has not been 
determined in this study, however it is possible that LV hypertrophy is inherent 
at this stage in the model and cannot be overcome, although there is a 
stabilisation of remodelling in the adaptive phase where improved cardiac 
function is maintained. This stabilisation may be advantageous as it may prevent 
progression to maladaptive remodelling and HF, however this remains to be 
investigated in longer-term studies.  
An accompanying study was performed in order to try and elucidate the 
mechanisms by which Ang-(1-9) acts in cardiomyocytes utilising Ca2+-handling 
measurements on isolated mouse cardiomyocytes. Ca2+-handling is impaired in 
hearts post-MI, with this thought to contribute to a decline in cardiac function 
(Gwathmey et al., 1987). Therefore, it was proposed that the beneficial effects 
exerted by Ang-(1-9) in the mouse MI model perhaps involved the direct 
modulation of cardiomyocyte Ca2+-handling. The effect of the application of 
endogenous Ang-(1-9) peptide on isolated mouse cardiomyocyte Ca2+-handling 
was compared to that of Ang-(1-7) and Ang II using epifluorecence microscopy. It 
was found that both Ang-(1-9) and Ang II exerted a positive inotropic effect on 
mouse cardiomyocytes, with increased Ca2+-transient amplitude and increased 
cell shortening. Ang-(1-7) had no effect. The effects mediated by Ang-(1-9) were 
found to potentially be mediated by increased L-type Ca2+ channel activity and 
increased SR Ca2+ content. Moreover, Ang II treatment was associated with an 
increased propensity for spontaneous rises in intracellular Ca2+, whereas this was 
not observed with Ang-(1-9). Identification of the receptor through which each 
peptide was exerting its effects was investigated using the AT1R and AT2R 
receptor antagonists Losartan and PD123319. It was found that the effects of 
Ang II were at least in part being mediated by the AT1R, however the Ang-(1-9) 
mediated effects appeared AT2R-independent under these experimental 
conditions. Further studies are required to clarify if indeed this is the case. 
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7.2 Future perspectives 
This study is the first to demonstrate a functional cardioprotective effect of Ang-
(1-9) post-MI using gene transfer. One other previous study has reported a 
beneficial functional effect of Ang-(1-9) on the heart in a model of dilated 
cardiomyopathy and also demonstrated using the Mas receptor antagonist A-779 
that the effects observed were completely independent of conversion to Ang-(1-
7) (Zheng et al., 2015). However, the present study has not used receptor 
antagonists in order to investigate the in vivo receptor by which Ang-(1-9) is 
exerting its effects. There are now a multitude of studies which have 
demonstrated the independent biological activity of Ang-(1-9) via the AT2R 
(Flores-Muñoz et al., 2012; Flores-Muñoz et al., 2011; Flores-Munoz et al., 2012; 
Zheng et al., 2015), therefore the assumption could be made that in the current 
studies Ang-(1-9) is mediating its effects via the AT2R. However, in the complex 
in vivo environment, and especially following MI where cardiac ACE expression is 
elevated, the partial or complete conversion of Ang-(1-9) to Ang-(1-7) is highly 
likely. This however may be advantageous as the beneficial effects of Ang-(1-9) 
signalling via the AT2R may be further enhanced by conversion to Ang-(1-7) and 
subsequent signalling via the Mas receptor, which is well established to exert 
cardioprotective effects in models of MI and HF (Loot et al., 2002b; Marques et 
al., 2012; Patel et al., 2012; Qi et al., 2011; Wang et al., 2010a; Zhao et al., 
2013). What is unclear in this study is the extent this possible conversion is 
contributing to the effects seen. In order to address this, subsequent studies 
could utilise minipump infusion of A-779, Losartan or combination into viral 
vector transduced MI animals in order to identify the contribution of each 
peptide to the effects seen in this setting. Peptide levels could also be measured 
directly from cardiac lysates using techniques able to differentiate between the 
similar peptide structures, such as mass-spectrometry, high-performance liquid 
chromatography and enzyme-linked immunosorbent assays. 
The mouse MI model has previously been demonstrated to be a suitable model 
for severe cardiac remodelling (Klocke et al., 2007; Zolotareva and Kogan, 
1978). However, this remodelling, consistent with what has been observed here, 
generally remains in the compensated LV dysfunction phase for an extended 
period of time following MI without a further decline in cardiac function, with 
preserved CO observed up to 12 months following infarction (Pons et al., 2003). 
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Therefore in the current study the cardioprotective capacity of Ang-(1-9) 
treatment has been assessed only in the compensatory phase of remodelling and 
not in the more severe de-compensatory phase leading to HF. Therefore in the 
future the therapeutic potential of Ang-(1-9) could be assessed in a more severe 
cardiac dysfunction model, such as the rat CHF model which develops similar 
pathophysiological manifestations as human HF patients including depressed CO 
and elevated LV filling pressure (Pfeffer et al., 1979) or a large-infarct mouse MI 
group (Finsen et al., 2005; Kinugawa et al., 2000). Moreover, the AAV-vector 
mediated delivery approach used here would be particularly well suited for a 
long-term study into the effects of Ang-(1-9) on HF due to the extended 
transgene expression potential (Stieger et al., 2008), allowing for a time-course 
of the protective effects of Ang-(1-9) to be determined without requiring re-
administration of the vector. As well as the development of the biological pump 
described here which enables the peptides to be utilised using a gene therapy 
approach (Methot et al., 2001), oral formulation of RAS peptides, including Ang-
(1-7) and Alamandine, have already been developed and efficacy demonstrated. 
Although these oral formulations demonstrate short half-lives following 
absorption they still demonstrate that promising advances are being made to 
take RAS peptides closer to be utilised therapeutically in a clinical setting 
(Lautner et al., 2013; Marques et al., 2012). Similarly, the oral agonist of the 
AT2R, C21, has demonstrated promising pre-clinical therapeutic effects in MI and 
stroke (Joseph et al., 2014; Kaschina et al., 2008). Moreover, Ang-(1-7) is 
currently being utilised clinically for a variety of purposes. Ongoing clinical trials 
include the use of the active peptide analogue NorLeu-A(1-7) which has been 
shown to clinically accelerate diabetic wound healing when applied topically 
through modulation of cellular proliferation, angiogenesis, and dermal repair 
(Balingit et al., 2012; Rodgers et al., 2011; Rodgers et al., 2003) and in cancer 
therapy, delivery of Ang-(1-7) following chemotherapy promotes reconstitution 
of the haematopoietic system by promoting proliferation of bone marrow 
progenitor cells (Ellefson et al., 2004; Heringer-Walther et al., 2009; Rodgers 
and Xiong, 2003; Rodgers and Oliver, 2006). 
Following the identification of a beneficial functional effect of Ang-(1-9) peptide 
in vivo a potential mechanism by which this occurred was explored in vitro using 
Ca2+-handling studies as abnormal cardiomyocyte Ca2+-handling is known to be a 
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contributing factor to the decline in cardiac function post-MI (Gwathmey et al., 
1987). The present study has identified for the first time that Ang-(1-9) is able to 
enhance the contraction of mouse cardiomyocytes by increasing the cellular 
Ca2+-transient, possible in a L-type Ca2+ channel-dependent manner. However, as 
Ca2+-handling measurements only indirectly assess the function of the main Ca2+-
handling proteins, more direct measurements are required to confirm what has 
been observed (Bers, 2001). Whole cell patch clamp is a technique which allows 
the study of a single ion channel species on a cell membrane and could be used 
to directly measure any changes in L-type Ca2+ channel activity in response to 
Ang-(1-9) (Sakmann and Neher, 1984). Changes to expression levels of the ion 
channel could also be assessed using qRT-PCR and western blot approaches, 
although large changes in expression would be unexpected within a short 
incubation period. Moreover, there is no evidence in the present study to 
suggest alterations in Ca2+-handling are contributing to the improved cardiac 
function observed in vivo. Further studies could be undertaken to investigate 
this further and potentially establish a link between what has been seen in the 
in vivo and in vitro studies. By performing the Ca2+-handling measurements on 
cells isolated from MI animals transduced with either an Ang-(1-9) expressing 
vector or control vector, any differences in Ca2+-handling could be identified and 
directly correlated with the improved cardiac function observed. In the present 
study the effects of Ang-(1-9) on Ca2+-handling were only assessed in healthy 
cardiomyocytes, an interesting study would be to assess its effects on cells with 
dysfunctional Ca2+-handling, such as those subjected to hypoxia (Kang et al., 
2006; Saini and Dhalla, 2005). Moreover, as rodent ECC differs from that of 
humans with regards to the AP and the extrusion of Ca2+ (Bers, 2002; Hove-
Madsen and Bers, 1993) studies could also be performed in cardiomyocytes 
isolated from a species with more similar ECC properties to humans, such as 
rabbit. Additionally, a receptor through which Ang-(1-9) was exerting the 
positive inotropic effect observed in vitro was not identified. To date, the 
primary receptor through which Ang-(1-9) has been reported to interact has 
been the AT2R (Flores-Muñoz et al., 2011). This work has primarily been done 
through using the antagonist PD123319, also utilised here in these studies, but 
however failed to block the effects of Ang-(1-9). However, there have been 
concerns raised over the selectivity of PD123319, with off-target effects being a 
possibility (Henrion, 2012). Therefore, the AT2R-deficient transgenic mouse 
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(Ichiki et al., 1995) would provide the ideal way to investigate and clarify the 
involvement of the AT2R for Ang-(1-9) function.  
Interestingly, when compared to Ang II, Ang-(1-9) failed to elicit an increase in 
spontaneous rises in intracellular Ca2+ to the same degree. This perhaps warrants 
further investigation into the possible anti-arrhythmogenic effects of the 
peptide. This could be performed in a variety of ways. In vivo arrhythmogenesis 
could be continuously monitored post-MI using telemetry probe implantation and 
continuous ECG recording, with differences between Ang-(1-9) treated and 
untreated animals assessed (Stilli et al., 2001). Whole-heart Langendorff ECG 
recording could also be utilised to assess its potential anti-arrhythmogenic 
effects in a different pro-arrhythmogenic model, such as I/R injury, with the 
effects on Ang-(1-9) infusion assessed on the incidence to reperfusion 
arrhythmias. A similar approach has previously been utilised for Ang-(1-7), where 
there is already evidence that it exerts anti-arrhythmogenic effects (De Mello, 
2004; Ferreira et al., 2001; Ferreira et al., 2010b; Santos et al., 2004). 
Therefore it is possible that Ang-(1-9) acts in a similar way or that in vivo its 
possible conversion to Ang-(1-7) also mediates anti-arrhythmogenic effects, 
however this remains to be clarified. The whole-heart approach would also allow 
measurements of pressure changes in response to Ang-(1-9), providing further 
information on its positive inotropic effects at the whole-organ level (Skrzypiec-
Spring et al., 2007).  
There are a variety of other potential effects Ang-(1-9) exerts on the heart 
following MI that have not been explored here. One interesting aspect to assess 
would be any change in the inflammatory response brought about by Ang-(1-9) 
following MI. In both in vivo studies there was a trend towards a reduced rupture 
rate in Ang-(1-9) treated animals, although this did not reach significance. As a 
prolonged or severe post-MI inflammatory response can be detrimental to post-
infarct myocardial healing, resulting in reduced tensile strength of the scar and 
promotion of cardiac rupture (Frangogiannis, 2012), it is possible Ang-(1-9) was 
exerting an anti-inflammatory effect. This is a possibility as not only is 
stimulation of the AT2R associated with anti-inflammatory effects post-MI 
(Kaschina et al., 2008), but in a recent study Ang-(1-9) infusion in the rat STZ 
model of dilated cardiomyopathy was shown to reduce expression of the pro-
inflammatory mediators TNF-α and IL-1β within the myocardium (Zheng et al., 
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2015). Other aspects which could be investigated are the effects of Ang-(1-9) on 
angiogenesis and apoptosis. In both in vivo studies there was again a trend 
towards increased scar thickness, potentially indicating 2 things; improved scar 
healing and collagen deposition or improved survival of the myocardium within 
the infarct area. If the latter were true it is possible that enhanced angiogenesis 
within the infarct or reduced cardiomyocyte apoptosis occurred. There is 
currently no evidence to suggest Ang-(1-9) affects either of these parameters 
within the heart, however Ang-(1-7) signalling via Mas has been demonstrated to 
be essential for angiogenesis during the infarct healing process post-MI in the rat 
through increasing expression of VEGF-D and MMP-9 (Zhao et al., 2013). 
Therefore it is possible that over-expression of Ang-(1-9) enhanced angiogenesis 
in MI hearts through conversion to Ang-(1-7) or independently through other 
mechanisms. Cardiomyocyte apoptosis is thought to be mediated by activation of 
the AT1R, with Ang II induced activation of the Ras/Raf/MAPK pathway found to 
induce apoptosis (Bucher et al., 2001; Cigola et al., 1997; Kajstura et al., 1997). 
As AT2R stimulation is generally thought to counter-act the effects of Ang II and 
is associated with the expression of phosphatases that inhibit the MAPK signalling 
pathway (Kaschina and Unger, 2003), it is possible that if Ang-(1-9) is signalling 
via the AT2R in this setting that it may have exerted an anti-apoptotic effect, 
however this requires further investigation. A disparity observed in the present 
studies to what has been reported previously about Ang-(1-9) is the lack of a 
potent anti-hypertrophic response, with only a small effect seen with rAd 
treatment and no effect seen with rAAV. Previous studies, including Ang-(1-9) 
infusion in the rat MI model, have reported reduced HW and pro-hypertrophic 
marker expression, including ANP, BNP, β-MHC and MLC, both in vivo and in vitro 
in response to Ang-(1-9) (Flores-Muñoz et al., 2011; Ocaranza et al., 2010). In 
the present studies, hypertrophy was assessed only using HW measurements and 
WGA staining. In order to more accurately establish whether a hypertrophic 
response in present or not, hypertrophic marker expression analysis could be 
performed. As mentioned, the differences observed here and in the rat MI model 
may be attributed to the difference in peptide administration (circulatory vs. 
tissue-derived). 
The present study has not investigated any specific signalling pathways involved 
in the effects exerted by Ang-(1-9), however there are several pathways which 
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could be investigated in future studies. One such pathway which warrants 
further investigation is the ROS signalling pathway. As discussed previously, Ang 
II raises ROS levels in the heart through increased expression of NADPH oxidase 
and H2O2 generation (Garrido and Griendling, 2009; Li et al., 2006a). This has 
the effect of modulating Ca2+-handling protein channels through redox 
modification, activating the PKC and MAPK pathways and increasing NF-κB 
expression, which increases expression of NO-synthase and promotes increased 
production of ROS, and through direct modulation of ion channel expression 
(Akki et al., 2009; Palomeque et al., 2006; Shang et al., 2008). Recent studies 
have identified an anti-oxidative effect of Ang-(1-9), with it found to depress 
NADPH oxidase expression thus reducing ROS in the heart in hypertensive and 
cardiomyopathy models (Ocaranza et al., 2014; Zheng et al., 2015). Moreover, 
Ang-(1-9) also appears to inhibit the Ang II-induced increase in NF-κB expression, 
subsequently leading to decreased CTGF, collagen I, fibronectin and MMP-2 
expression in the heart, thus attenuating fibrosis development (Johar et al., 
2006; Thakur et al., 2014; Zheng et al., 2015). Through modulation of the ROS 
signalling pathway, Ang-(1-9) could be inducing the anti-fibrotic and improved 
contractile properties of the heart as observed here in vivo as well as 
modulating Ca2+-handling protein activity as observed in vitro and therefore this 
warrants further investigation.  
7.3 Conclusion 
In summary, the data from this thesis have demonstrated for the first time that 
gene delivery of Ang-(1-9) can confer functional cardio-protective effects in a 
mouse model of MI, combined with an attenuation in adverse myocardial fibrosis 
and ventricular stiffening. Moreover, accompanying studies have identified a 
potential novel role of Ang-(1-9) in exerting a positive inotropic effect on 
isolated cardiomyocytes through an increased Ca2+-transient amplitude. Overall, 
this study highlights the potential of Ang-(1-9) as a therapeutic agent for adverse 
structural and functional cardiac remodelling post-MI and provides impetus for 
further future development of Ang-(1-9) as a potential therapy in this setting. 
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